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Abstract 
Although RT-qPCR is the recommended method for monitoring responses to TKI 
therapy, it might not be the best assay for patients with deep responses considered for 
treatment discontinuation. The current consensus is that therapy discontinuation is 
followed by relapse in at least 50% of patients and that persisting LSCs with low BCR-
ABL1 expression or quiescent LSC with no BCR-ABL1 expression are the source of 
the relapse.  Therefore, identifying a sensitive method for detecting and accurately 
quantifying residual disease would help identify patients with the lowest likelihood of 
relapse, and predict those who are at a higher risk of disease recurrence while off 
therapy. 
In the era of rapid technological advances and their deployment in molecular 
diagnostics labs, we sought to investigate the potential of some of these technologies 
in improving the current clinical management of CML. Digital PCR is a recently 
developed method of absolute molecular quantification that has the potential for 
complementing RT-qPCR not only in monitoring MRD while in deep molecular 
remission or during therapy discontinuation, but also in simplifying the 
standardization efforts. NGS, on the other hand, has the potential for increasing the 
sensitivity of TKD mutation detection. Unlike the case in other diseases such as 
virology and solid tumours, the clinical value of these technologies is not yet known in 
CML. Therefore, the focus of this Ph.D. thesis was to develop protocols and proof-of-
principle data facilitating the implementation of these methodologies in routine testing 
and consequently investigating their clinical significance in the routine management of 
CML patients. 
In chapter two, we investigated an NGS-assisted DNA-based dPCR approached for 
detecting and quantifying low levels of BCR-ABL1 positive disease. When applied to 
samples with undetectable disease by RT-qPCR, DNA-based dPCR provided a 
marked improvement in sensitivity, not only over RT-qPCR, but also compared to 
real-time qPCR and to RT-dPCR. Although more sensitive, this method is not yet 
ready for the immediate implementation in routine testing. The impact of residual 
disease level as assessed by DNA-based dPCR at the time of treatment withdrawal on 
outcome is currently being investigated within the UK based DESTINY clinical trial. 
If validated in clinical trials of stopping TKI, the technique will permit a more 
personalised approach to recommendations for dose reduction or drug cessation in 
individual patients, ensuring that therapy is withdrawn only from patients with the 
highest chance of long-term remission. In addition, it will allow timely therapeutic 
intervention to prevent the occurrence of overt relapse after therapy discontinuation. 
RT-qPCR remains the gold-standard for monitoring residual disease in CML despite 
of its various limitations including the compromised precision at the lower end of the 
calibration curve, in addition to the laborious requirement of continuous assay 
validation. Therefore, efforts to improve on the current gold-standard are appreciated.  
IX 
 
In chapters three and four, we sought to investigate the performance of the E.A.C. 
assay on different RT-dPCR platforms and found that false positive signals detected in 
the negative controls limit the accurate quantification of residual disease in samples 
classified below MMR. We also showed that the performance of the RainDrop
®
 RT-
dPCR platform had excelled compared to the other two RT-dPCR platforms allowing 
a sensitivity of at least 5-logs on the IS. The false positivity detected on the three RT-
dPCR platforms using the E.A.C. assay, albeit at different levels, indicated that the 
noise is most likely platform and/or assay design related. Therefore, further work is 
required to eliminate false positivity before RT-dPCR could be adopted for the routine 
monitoring of BCR-ABL1 transcript levels in response to TKI therapy.  
Mutations in the BCR-ABL1 TKD are the most studied cause of resistance to different 
TKI therapies and play a crucial role in planning patients’ management. In chapter 
five, we validated an amplicon deep sequencing approach on the Ion Torrent PGM 
next generation sequencing platform followed by the application of the method for the 
prospective testing of referral sample over a period of one year. The aim was to 
evaluate the performance of the platform and assess the practical need for replacing 
the current gold-standard with NGS, notwithstanding its potential technical 
superiority. From technical point of view, we demonstrated that the platform has an 
LoQ and LoD of 5% and 1%, respectively. Low-level contamination occurring during 
the runs came as a persisting problem, dictating a cautious interpretation of mutations 
below 5%. Although NGS demonstrated superior sensitivity compared to the current 
gold-standard, we didn’t find enough evidence that supports an immediate need for 
replacing the gold-standard in routine clinical testing, except when performed after 
TKI resistance with the aim of guiding therapeutic intervention. 
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1. Introduction 
 
 
1.1. CML History 
Chronic myeloid leukaemia (CML) was recognized as a clinical entity characterized 
by splenomegaly and leukocytosis in the early 19
th
 century [1-3]. Almost 100 years 
later, in 1960, Nowell and Hungerford described a consistent abnormality of the G 
group of chromosomes in the cells of CML patients, which was subsequently termed 
the Philadelphia (Ph) chromosome [4]. In 1973, Janet Rowley [5] using G-banding 
technology, showed that the Ph chromosome was the result of a reciprocal 
translocation between chromosomes 9 and 22. However, it was not until the 1980s, 
that the resulting oncogenic fusion of the BCR and ABL1 genes was identified [6-8]. 
The associated fusion protein is a constitutively active tyrosine kinase, responsible for 
the disease phenotype [9]. The BCR-ABL1 protein was quickly recognized as a 
potential drugable target and led to the development of the ABL1 tyrosine kinase 
inhibitors (TKIs) which have completely changed the course of CML. A one-time fatal 
disease is now a condition with a life expectancy not much different from the normal 
population [10].   
CML is a tri-phasic disease which usually presents in an indolent chronic phase (CP) 
marked by over-production of mature granulocytes (with <10% blasts in peripheral 
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blood (PB) and bone-marrow (BM)). Left untreated, it develops over time into a fatal 
blast crisis (BC; blasts >20%, myeloid or lymphoid in nature) through an intermediate 
accelerated phase (AP; blasts <20%) [11], although a small proportion of patients may 
present in overt blast crisis, more frequently myeloid. 
 CML has a world-wide annual incidence of 1–2 per 100,000 with a slight male 
predominance and accounts for 15% of all new cases of adult leukaemia [12] in the 
western world. It occurs at any age, but with a median around 60 [13-14].  
1.2. Molecular Pathogenesis 
Karyotyping is used to confirm the diagnosis of CML where t(9;22) is detected in 95% 
of cases. Other chromosomal rearrangements such as complex translocations or 
insertions, detectable by conventional and/or molecular cytogenetics account for 
another 5% of chromosomal abnormalities in CML patients ([15-16]. The t(9;22) is 
also seen in 25–30% of adult and 5–10% of paediatric cases of acute lymphoblastic 
leukaemia (ALL) [17-18]. 
The molecular hallmark of the disease is the exchange of genetic material between the 
long arms of chromosomes 9 and 22, termed t(9;22)(9q34.1;22q11.2) resulting in the 
fusion of two genes: 5’BCR (~138.5Kbp; 23 exons) on chromosome 22 and 3’ABL1 
(~174Mbp; 11 exons) on chromosome 9 to form the fusion oncogene BCR-ABL1 [19] 
(Figure 1.1). The breakpoint on the ABL1 gene is usually confined to the 150kb 
intronic region between the two alternate first exons (1b and 1a). In exceptional cases 
the breakpoint occurs upstream of exon 1b or downstream of exon 1a [20-22]. The 
10 
 
breakpoint in the BCR gene varies albeit clustering within three main breakpoint 
cluster regions: the major (M-bcr) (8), minor (m-bcr) [23-24] and micro (µ-BCR) [25] 
regions. The M-BCR is associated with two major transcripts, the e13a2 (b2a2) (p210 
KDa) and e14a2 (b3a2) (p210 KDa). The exons within the M-BCR region previously 
numbered b1–5 were later renamed e12-e16 after the successful mapping of the entire 
BCR gene [26]. m-BCR is associated with the minor transcript, the e1a2 (190 KDa) 
denoting the involvement of ABL1 exon 1 [27]. The rarer e19a2 (p230 KDa) [28] 
transcript has increased kinase activity compared to other transcripts [29] and is 
associated with the µ-bcr cluster region. Other rarer transcripts occur and are referred 
to as ‘ν’ for variant: e6a2 (p195) [30], e8a2 (p200) [25, 31] e18a2 (p225) [32]. 
Breakpoints in ABL1 can occasionally occur upstream of exon 3, rather than exon 2, 
leading to a BCR-a3 fusion type [33] (Figure 1.1).  
The fusion gene encodes for a constitutively active tyrosine kinase and relocates the 
BCR-ABL1 protein to the cytoplasm [34].  Continuous kinase signalling allows homo-
dimerization, auto-tyrosine phosphorylation and activation of the adjacent ABL1 
protein [35-36]. Constitutive activation due to the translocation activates a number of 
key downstream pathways including cell adhesion, DNA repair, survival, proliferation 
and differentiation that eventually drive leukaemogenesis [37-38]. 
1.3. BCR-ABL1 in Normal Individuals 
Chromosomal translocations and gene fusions are not sufficient to generate 
malignancies, rather a combination of factors is necessary [39]. Several investigators 
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have shown that BCR-ABL1 fusion transcripts can be detected at very low levels in 
haematologically normal individuals who do not develop leukaemia.  [39-41]. One 
explanation could be that the translocation in these cells produces truncated proteins 
incapable of conferring a proliferative advantage [42]. Another explanation would be 
the degree of cellular differentiation of the cell in which the translocation occurs. Cells 
committed to terminal differentiation without the potential for repopulation and 
renewal will be eliminated; therefore the expression of the fusion product will not be 
enough on its own to provide survival advantage [42]. Alternatively, the translocation 
may occur in a haematopoetic stem cell (HSC) in an environment not supportive of 
leukaemic transformation, including an effective immune surveillance able to suppress 
or eliminate the neoplastic clone [43]. 
1.4. Cell of Origin & Natural History of CML 
CML is a clonal HSC disease originating in the BM and populating the blood. It is 
speculated that the cell of origin for the leukaemogenesis is different from the one that 
drives disease progression. Broadly, the hypothesis suggests that there are up to three 
cellular compartments in CML patients: Leukaemic Stem Cells (LSC), Leukaemic 
Progenitors cells (LP) and Transformed Leukaemic Blasts (TLB). LSC are 
characterised by low BCR-ABL1 expression, self-renewal ability, differentiation and 
multi-lineage repopulation.  LP are characterised by high BCR-ABL1 expression 
levels, inability to self-renew and the ability to grow and differentiate, in addition to 
several differentially activated survival pathways. TLBs are characterised by impaired 
differentiation, differentially activated self-renewal pathways, ability to proliferate and 
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the presence of additional chromosomal and genomic lesions. There are two 
transformation events in CML: leukaemic transformation and blastic transformation. 
Leukaemic transformation denotes the conversion of a normal HSC into an LSC via 
the acquisition of genomic changes initiating leukaemia. Blastic transformation 
denotes the process in which a relatively functional differentiated LP gains stem cell-
like properties, loses its differentiation and begins the uncontrolled proliferation that 
usually is associated with aggressive stages of the disease. 
In CML, evidence suggests that the Ph translocation occurs in a HSC that maintains 
the ability for self-renewal and terminal differentiation. This cell has low BCR-ABL1 
expression and is not oncogene-dependent for its survival [44-45]. Its survival 
signalling is inherent to its stem cell status. After a cell acquires a Ph translocation, 
two types of primitive cells co-exist in the BM: HSC and LSC. These populations 
drive two concurrent forms of haematopoiesis, one from the normal HSC 
compartment and the other from the LSCs harbouring the Ph chromosome. In the 
latter, BCR-ABL1 signalling leads to the immature migration of early LPs to the PB 
where their survival becomes oncogene-dependent. In this population, BCR-ABL1 
mediated signalling via key survival pathways such as JAK/STAT, PI3K/AKT, PI3K 
/mTOR and RAS/MEK pathways [43, 46] is responsible for the persistence of these 
cells. These LPs characterise the CP of CML and have high BCR-ABL1 expression 
and differentially activated survival pathways.  
Left untreated, CP CML progresses after 3–5 years to an aggressive acute leukaemia 
that is fatal within 6 months. It is speculated that the advanced disease originates from 
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a persisting LP, which due to its continuous BCR-ABL1 signalling and prolonged 
survival, increases the chance of accumulating additional genetic lesions that support 
the transformation. The time taken for progression to BC in the absence of treatment 
matches, if not exceeds, the time taken for normal cells to acquire neoplastic mutations 
under stress conditions. Another observation that supports this hypothesis is that the 
successful elimination of the LP population via TKIs has led to the almost complete 
elimination of disease progression [43]. When the inhibitor is withdrawn, leukaemic 
expansion frequently resumes, demonstrating the persistence of LSCs even during 
apparent remission [44-45].  
It has been argued that BCR-ABL1 is necessary but not sufficient for the pathogenesis 
of CML. The cell of origin and its degree of differentiation coupled with the signals 
received from the homing microenvironment are equally instrumental. Conversely, 
BCR-ABL1 is sufficient for the persistence of LP and their transformation to acute 
leukaemia. Continuous kinase signalling and the prolonged lifespan of these 
progenitors facilitate the accumulation of additional genomic lesions necessary to 
drive acute leukaemia. In advanced phase disease, the additional genomic lesion 
accumulated during transformation might become capable of sustaining acute 
leukaemia independently of BCR-ABL1.  
In summary, LSC survival is independent of BCR-ABL1, the young LP is oncogene-
dependent, the advanced LP can acquire genomic instability and TLBs are BCR-ABL1 
independent and therefore refractory to TKI therapy.  
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1.5. CML Clinical Overview 
1.5.1. Diagnosis and Staging 
The two commonly used systems to define CML and its phases are those proposed by 
the World Health Organisation (WHO) [47] and by the European Leukaemia Net 
(ELN) [48]. Both systems are largely dependent on the proportion of blasts in the PB 
or BM. Detailed definitions based on each system are reviewed in a recent publication 
[49]. A third definition set by the Centre for International Blood and Marrow 
Transplant Research (CIBMTR) is often used in the context of transplant outcome. 
The ELN criteria are more frequently used in the TKI era than those of the WHO or 
CIBMTR. 
Chronic Phase CML (CP-CML) usually has an insidious onset and the main clinical 
findings include an enlarged spleen, fatigue, night sweats and weight loss. The PB 
shows leukocytosis predominantly owning to neutrophils in different stages of 
maturation, together with basophilia and eosinophilia. Blasts usually represent <2% of 
the white blood count (WBC). The platelet count is normal or increased.  
Accelerated phase (AP-CML) is an intermediate stage of CML evolution when the 
disease starts to become refractory to therapy. It is characterized by an increase in the 
spleen size and in total WBC, blasts comprising 10–19% of the WBC, >20% 
circulating basophils, persistent thrombocytopenia and/or the appearance of new 
clonal cytogenetic abnormalities.  
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Blast Crisis (BC-CML) is considered the final stage of CML which may or may not be 
preceded by AP. Patients experience worsened performance status, and symptoms 
related to neutropenia, thrombocytopenia, anaemia and increased splenomegaly. The 
WHO criteria for the diagnosis of BC include: blasts in excess of 20% in the PB or 
BM; and/or large foci or clusters of blasts in BM histological sections. The phenotype 
of BC can be of myeloid (50%) or lymphoid (25%) lineage with a further 25% 
manifesting as biphenotypic or undifferentiated [43, 49-50].  In addition to maturation 
arrest, transformation is associated with secondary chromosome changes, observed in 
around 80% of patients [51-52]. The majority (75%) of these show the so-called 
“major route” changes, including an extra copy of the Ph chromosome, trisomy 8, 
trisomy 19 and/or an isochromosome 17q. The less common “minor route” aberrations 
include 5 numerical changes (-Y, -7, -17, +17 and +21) as well as structural 
rearrangements involving the MECOM gene at 3q26 as part of the translocation, 
t(3;21)(q26;q22). 
Karyotyping is used to confirm the diagnosis of CML [53] where t(9;22) is detected in 
95% of CML cases. Other chromosomal rearrangements such as complex 
translocations or insertions, detectable by conventional and/or molecular cytogenetics 
account for another 5% of CML patients [15-16]. In complex translocations, also 
referred to as variant, one or more additional chromosome region is involved in the 
translocation [54-56]. Thus, BCR-ABL1 is the hallmark biomarker for the diagnosis 
and monitoring response to therapy in CML. In a small proportion of cases (1–2%), 
the BCR-ABL1 fusion can be cryptic (or masked) by conventional cytogenetics due to 
16 
 
direct insertion of chromosome 9 sequences into chromosome 22 or vice versa. In 
these cases, the Ph chromosome is confirmed by fluorescent-in-situ-hybridisation 
(FISH), or RT-qPCR. 
1.5.2. Clinical Management 
The introduction of TKI has dramatically improved the outcome of CML patients. 
Prior to TKI, the median survival of CML patients after diagnosis was approximately 
5–7 years [43, 53, 57]. Today, the life expectancy of CML patients is similar to that of 
a normal population provided the therapy is administered indefinitely. Important 
aspects of modern therapy management of CML include the identification of 
prognostic markers for risk stratification, the establishment of milestones for response 
to therapy, the management of resistance and intolerance and quantitative molecular 
monitoring of residual disease. All these aspects are briefly touched on in the next 
section while focusing particularly on the aspects of resistance and minimal residual 
disease (MRD) monitoring as they are at the core of this Ph.D. thesis. 
1.5.2.1.Therapy 
CML was first treated with cytotoxic agents with the aim to control symptoms. 
Allogenic Stem Cell Transplantation (allo-SCT) provided an option for “cure”, but it 
was associated with high morbidity and mortality.  
The first TKI, imatinib forever changed the survival for these patients [49]. Today, 
imatinib is unequivocally the first-line therapy for the majority of CML patients, with 
an 80% survival rate at 8 years [58]. For patients who develop resistance to imatinib, 
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second and third-generation TKIs such as dasatinib, nilotinib, bosutinib and ponatinib 
have been developed [49, 59-60]. We review in this section, the developmental history 
and current status of available and therapies licenced by the U.S. Food and Drug 
Administration (FDA) and the European Medicenes Agency (EMA) for CML. 
1.5.2.1.1. Pre-TKI 
Early therapy focused on treating the symptoms of CML, with no impact on the 
disease. Arsenic-containing compounds, splenic irradiation, the alkylating agent 
busulfan and the ribonucleotide reductase inhibitor, hydroxycarbamide, all improved 
blood counts and provided symptomatic relief, but could not delay or prevent disease 
progression. In the 1970s, the introduction of interferon-α (IFN-) and stem cell 
transplantation (SCT) marked the first era when survival noticeably improved for a 
proportion of patients [53, 57]. Compared to cytotoxic agents, IFN- increased the 
median life expectancy by about 12–18 months to 6–7 years [57, 61-62], but side 
effects and the need for continuous subcutaneous administration affected its long-term 
use in most patients [49]. Later, IFN-in combination with cytosine arabinoside 
(ARA-C), improved survival rates [63], but at the cost of increased toxicity. The 
mechanism of action for IFN- is not fully understood, but an immunomodulatory 
role has been postulated.  
1.5.2.1.2. Stem Cell Transplantation (SCT) 
Allo-SCT is the only known curative therapy for CML. However, most patients are 
ineligible because of advanced age and/or associated comorbidities or a lack of 
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suitable matched donor [64]. Allo-SCT was first introduced in CML in the 1970s in 
the context of syngeneic donors [65] and was soon followed by sibling [66] and 
unrelated donor [67] grafting. Early attempts to improve the outcome of allo-SCT for 
CML involved the removal of donor T-lymphocytes from the transplant product in 
order to reduce the incidence and severity of the allo-immune mediated graft versus 
host disease (GVHD). Unfortunately, this procedure increased the risk of relapse [68] 
as removal of T cells impaired the graft versus leukaemia (GVL) therapeutic effect. 
Remissions were restored in patients who relapsed after T-cell depleted transplants by 
the infusion of additional donor lymphocytes [69-71]. Allo-SCT became the first-line 
treatment for all eligible patients in CP or AP in the 1980s [49]. In patients presenting 
in BC, intravenous chemotherapy combination was used to restore a second CP before 
Allo-SCT. However, in the TKI era, allo-SCT has become a third or subsequent-line 
therapy restricted to the patients who failed several lines of TKI, or who presented in 
AP or BC [49]. 
1.5.2.1.3. TKI Therapy 
1.5.2.1.3.1. First-Generation TKI 
In the late 1990s, STI-571 (imatinib, Gleevec/Glivec) was identified by Novartis in 
high-throughput screening for tyrosine kinase inhibitors. In-vitro studies demonstrated 
superior anti-proliferative activity against BCR-ABL1 positive cell lines [72-73]. Phase 
I and II clinical trials also showed clinically useful activity, even in advanced phase 
disease [74-75] paving the way to the accelerated approval for imatinib in 2002. The 
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eight year update from the Phase III International randomized study of interferon and 
cytarabine versus STI571 (IRIS) in newly diagnosed patients reported event-free 
(EFS) and progression-free survivals (PFS) of 81% and 92%, respectively [58]. This 
study established imatinib as the first-line therapy for all newly diagnosed CML 
patients regardless of disease stage. Imatinib functions by selectively binding to the 
inactive conformation of the ABL1 protein forming hydrogen and Van-der-Waal’s 
bonds with different tyrosine kinase domaine (TKD) residues and competing with 
Adenosine Triphosphate (ATP) at its binding pocket. Blocking ATP binding inhibits 
phosphorylation and casuse cell death [76]. Other kinase targets include also Able-
related gene (ARG), platelet-derived growth factors (PDGFRα/β), KIT (or CD117) 
and FMS kinases [76].  
Despite the unprecedented success of imatinib in treating CML-CP patients, 
subsequent reports showed that imatinib is discontinued in 37% and 45% at 5 and 8 
years, respectively [58].  The main reasons for discontinuation varied from 
commercial availability to primary resistance, acquired resistance, and/or intolerance 
to therapy [49]. The most commonly studied mechanism for acquired resistance is 
mutations in the BCR-ABL1 TKD, which are observed in 25–30% of early CP and 70–
80 % of BC patients [77].  
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1.5.2.1.3.2. Second-Generation TKI 
The identification of ABL1 TKD mutations as the most frequent cause of resistance 
(discussed below) lead to the development of more potent TKIs with specific efficacy 
against certain mutations.  
Dasatinib (BMS-354825, Sprycel, Bristol-Myers Squibb) is a dual Src-ABL1 kinase 
inhibitor that is structurally unrelated to imatinib and is capable of binding to and 
inhibiting both active and inactive conformations of the ABL1 TKD [78-79]. The 5 
year overall survivals (OS) of imatinib resistant and intolerant patients receiving 
dasatinib were 78% and 82%, respectively. Despite good responses in many patients, 
only 30-35% of patients remain on dasatinib at 5 years due to side effects and toxicity 
[80]. 
Nilotinib (MN107, Tasigna, Novartis Pharmaceutical Corporation, NJ, USA) is an 
orally active aminopyrimidine which was developed by crystallographic analysis of 
compounds binding to imatinib resistant BCR-ABL1 mutations [81]. It binds to the 
inactive conformation of the ABL1 kinase and it is extremely effective in phase I and 
II clinical trials in patients resistant and/or intolerant to imatinib, comparable to that of 
dasatinib (for OS and PFS) [82-83].  
Bosutinib (SKI-606) is also an oral dual Src-ABL1 kinase inhibitor. Estimated OS and 
PFS at two years were 83% and 73%, respectively in a population of patients resistant 
to more than one TKI, and 88% and 98% in imatinib resistant and intolerant 
populations, respectively [84].  
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The use of second-generation TKIs as a front-line agent was investigated subsequently 
in several international phase III randomised clinical trials against imatinib: 
DASISION [85] for dasatinib, ENESTnd [86] for nilotinib and BELA [87] for 
bosutinib.  A U.S. and Canadian intergroup also trialled dasatinib [88]. The most 
prominent outcome of all three trials was that the second-generation TKIs induced 
deeper molecular responses quicker compared to imatinib. They all had similar rates 
for complete cytogenetic response (CCyR) ranging from 68% to 86% and they all 
induced higher rates of deeper responses compared to imatinib at 2 and 3 years follow-
up [49]. Despite achieving milestones quicker and reducing the rate of progression, 
these drugs did not have an impact on OS with a follow-up of three, three and one 
years for dasatinib, nilotinib and bosutinib, respectively [89-93]. Discontinuation rates 
were also similar at about 30% at 3 years for all drugs [94]. 
1.5.2.1.3.3. Third-Generation TKI 
Third-generation TKI, ponatinib (formerly AP24534) is the only TKI with proven 
clinical activity against the pan-resistant T315I mutation (discussed below). The phase 
II PACE trial included patients in all disease stages, and subdivided each stage based 
on the presence or absence of the T315I mutation. Efficacy was shown in all sub-
groups. Ponatinib then entered phase III development as a first-line therapy but the 
study was put on hold due to safety concern related to increased incidence of arterial 
thrombotic events thought to be due to vascular endothelial growth factor (VEGF) 
inhibition. Regulatory approval was reinstated for patients with refractory Ph-positive 
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(ph
+ve
) leukaemia harbouring T315I mutations or for whom no other TKI was 
indicated. 
1.5.2.2.Response to TKI Therapy 
The response to TKI therapy is defined by morphological, cytogenetic and molecular 
parameters alongside the time taken to achieve these milestones [48, 95-96]. The ELN 
expert panel in Europe, The WHO and the National Comprehensive Cancer Network 
(NCCN) commonly used in the U.S.A. produce periodically updated guidelines for 
licensed TKIs. Nonetheless, the most widely adopted recommendations are the ELN 
guidelines [104]. Cytogenetic responses by 12–18 months are defined as: no 
Cytogenetic response (no CyR), partial (PCyR) and complete cytogenetic response 
(CCyR) based on the presence of >95%, >35% or 0%, respectively ph
+ve
 cells in a 
minimum of 20 metaphases. CCyR indicates a reduction of tumour burden of at least 
one hundred fold, otherwise referred to as a 2-logs reduction. 
Molecular responses are expressed on the International Scale (IS)(discussed later in 
the “Monitoring Response to TKI therapy” section) as the percentage ratio of BCR-
ABL1 transcripts to those of a control gene (CG) multiplied by a lab specific 
conversion factor. Ratios ≤10%, ≤1%, ≤0.1%, ≤0.01%, ≤0.0032%, and ≤0.001% 
correspond to a ≤1, ≤2, ≤3, ≤4, ≤4.5, and ≤5 log reductions in tumour burden 
compared to diagnosis (Figure 1.2) [93, 97]. The response abbreviations MR
3
, MR
4
, 
MR
4.5 
and MR
5
 correspond to ≤0.1%, ≤0.01%, ≤0.0032% and ≤0.001% detectable 
disease. The ability to measure deep responses in BCR-ABL1 negative samples is 
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dependent on the number of control gene transcripts quantified where MR
4
, MR
4.5 
and 
MR
5
 can only be reported if the ABL1 or GUSB control gene transcripts were > 
10,000, >32,000 and >100,000 (ABL1) or >24,000, >77,000 and >240,000 (GUSB), 
respectively [98]. 
The use of response ‘milestones’ requires that the depth of response is interpreted in 
relation to the time in which the patient has been receiving TKI treatment. The ELN 
classifies patients into three groups based on the cytogenetic and/or molecular 
milestones: optimal response, failure and warning. The choice of 6 and 12 months as 
therapeutic milestones is consistent with the fact that very few patients who do not 
show cytogenetic responses at these time points will subsequently achieve Ph 
cytogenetic negativity [11]. Optimal response is defined as transcript levels of ≤10% 
at 3 month, ≤1% at 6 month and ≤0.1% at 12 month. Equally, optimal response is 
defined as partial cytogenetic remission (PCyR) at 3 month and complete cytogenetic 
remission (CCyR) at 6 month. Failure is defined as >10% and >1% of transcript levels 
at 6 and 12 month, as well as no cytogenetic remission (no-CyR), >PCyR and >CCyR 
at 3, 6, and 12 month, respectively. Warning is the definition for suboptimal response 
falling between optimal response and failure. Patients in this category would require 
closer monitoring and flexibility in treatment strategies. For patients with an optimal 
response, the current recommendation is to remain on therapy indefinitely with 
continuous monitoring. 
Imatinib, remains the most common first-line therapy worldwide, despite the 
observation that dasatinib and nilotinib induce deep molecular responses in a higher 
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proportion of patients and more rapidly compared to imatinib. This is due to the 
incidence of serious side effects associated the second and third generation TKIs such 
as cardiac toxicity and pleural effusion. The ready adoption of imatinib as first-line 
therapy is also related to its ease of use (once daily oral therapy), good tolerability and 
the immediate prospect of generic products.   For those patients who fail to respond 
durably, or develop serious adverse events, bosutinib, dasatinib, nilotinib and 
ponatinib are all alternatives. 
In patients with sustained deep molecular responses, consideration has recently been 
given to the possibility of therapy discontinuation. The French STIM trial evaluated 
the consequences of TKI cessation in patients who achieve durable molecular 
responses compatible with a 5-log reduction in tumour bulk (MR
5
) [99-100]. This was 
rapidly followed by several other small studies [101-105] in addition to trials that are 
still ongoing such as the EURO-SKI and DESTINY. The common agreement within 
these trials was that 40–60% of patients relapse after therapy discontinuation due to 
persistence of therapy resistant, undetectable, redidual disease. Rigorous, accurate and 
sensitive molecular monitoring is therefore required not only to ensure good response 
to current drug, but also to identify patients suitable for treatment cessation and to 
detect early disease recurrence. Continuous monitoring, data collection and research 
are key strategies towards the ultimate goal of tailoring personalized therapies 
according to the risk profile of individual patients. 
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1.5.2.3.Resistance to TKI Therapy 
Resistance to TKI therapy can be classified as primary resistance, (i.e. failure to 
achieve pre-defined response) and acquired resistance (i.e. loss of previous responses). 
Primary resistance is most commonly observed in patients presenting with advanced 
phase disease. Resistance can be further defined as due to BCR-ABL1 ‘dependent’ or 
BCR-ABL1 ‘independent’ mechanisms. 
Although a number of mechanisms of resistance have been extensively studied, such 
as drug bioavailability [106-109], plasma protein binding rate [110] and efflux 
(MDR1) and influx proteins (hOCT-1) expression levels [111-112], none has 
translated into a robust marker for predicting response or resistance. In contrast, 
mutations in the BCR-ABL1 tyrosine kinase domain (TKD) explain resistance to TKI 
in some cases [113]. 
1.5.2.3.1. LSC Resistance 
Three types of LSCs should be distinguished as discussed in the ‘cell of origin’ 
section. Primitive LSCs with inherent stem cell characteristics in the BM, LP in the 
BM and/or PB with lineage-committed characteristics and TLB in the BM and/or PB 
with acquired stem cell-like characteristics including differentiation arrest, ability to 
self-renewal, growth, division and apoptosis evasion. Each type of cell is most 
probably responsible for a different type of resistance in association with a different 
disease stage.  While very effectively targeting the second population, imatinib and 
also the more potent TKIs are incapable of eradicating both the former and the latter 
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types of cells for different reasons. Quiescence, low BCR-ABL1 expression, survival 
or homing signals from the microenvironment niche where they reside, may all 
contribute to their survival independently of the oncogene activity. This cellular 
population is rare, 0.5% of the CD34+ population at diagnosis accounting for 5 x 10
7
 
cells [114], and forms the reservoir for disease regeneration in the absence of therapy. 
As discussed later, it is not known if resistance mechanisms other than being quiescent 
and primitive exist in this population.  They express low or no drug influx proteins. 
Chomel and colleagues  undertook a systematic analysis of the bone marrow stem cell 
compartment in patients selected on the ground of their sustained molecular remission 
(≥3 years) [115].  Using clonogenic assays they demonstrated variable expression 
levels of BCR-ABL1 in the in-vitro LTC-IC compartment which represents the 
HSC/LSC compartment in-vivo. This observation supported the fact that LSCs 
resistant to TKI do exist at remission and are capable of persistence even in the 
presence of targeted therapy. Conversely, TLBs are associated with advanced phase 
disease and have genomic instability in association with increased BCR-ABL1 
expression and TKD mutations [116]. They also have increased levels of drug efflux 
protein expression [112, 117]. Although they have high BCR-ABL1 expression levels, 
their survival is dependent on BCR-ABL1-independent signalling pathways as the 
result of oncogene activation or tumour-suppressor gene inactivation.  
Resistance to TKI therapy, similar to resistance to any drug, is multifactorial and 
disease stage dependent. TLBs are BCR-ABL1 independent where they gain stem cell-
like characteristics and proliferate depending on alternative pathways. Therefore, they 
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would be naturally TKI resistant unlike cells at the CP which are oncogene addicted 
for survival, in which, resistance would most probably involve mechanisms affecting 
drug availability or interaction with the target oncogene. Despite the multifactorial 
nature of resistance, TKD mutations remain the best studied mechanism for resistance 
to TKI. 
1.5.2.3.2. Imatinib Resistance 
Since the first mutation was detected in the BCR-ABL1 TKD [118], more than 100 
different mutations involving 57 different amino acids have been reported [96]. Only a 
subset of these mutations, are frequent, have their in-vitro half maximal inhibitory 
concentrations (IC50) identified and are associated with TKI failure [119-122]. Those 
with a clearer association with resistance are: M244V, G250E, Y253F/H, E255K/V, 
V299L, T315I/A, F317L/I, M351T, E355G, F359V/I/C, H396R/P, E450G/V and 
E459K which account for 70% to 80% of all mutations (Figure 1.3) [11, 123].  
The most common mutations cluster to one of four hot spots within the TKD: 1) the P-
loop where ATP binds (aa 248-256), 2) the TKI binding region (aa 315-317), 3) the C-
loop catalytic domain (aa 350-363) and 4) the A-loop activation domain (aa 381-402) 
(124). They can affect TKI efficacy in 3 ways: 1) by directly affecting TKI binding to 
the TKD via hydrogen bonds (for example Thr315, Met290, Glu286, Lys271, Asp381, 
Met318); 2) by inducing conformational changes via van-der-Waals bonds formed 
between the TKI and the TKD (for example F317, V289, M351, I313, F382, V256, 
28 
 
Y253, L370); 3) by inducing changes to intra-TKD regulatory interactions (for 
example H396, E450, E459) [125-126]. 
1.5.2.3.3. Second and Third Generation TKI Resistance 
Dasatinib and nilotinib are more potent and have lower IC50 values for each BCR-
ABL1 mutant form as the consequence of their different chemical structures and 
binding modality (127). Approximately 14–33% of CML patients treated with second-
generation TKI
 
as second-line develop new BCR-ABL1 mutations [128-131]. Patients 
treated with dasatinib can develop V299L, T315I, T315A, T317L/V/I/C and M351T 
mutations [85-86, 88, 132] whereas nilotinib exerts selection for p-loop mutations 
such as Y253H, E255K/V, F359V/I/C [86, 132-134]. The study of mutations in 
bosutinib treated patients is less extensive but they appear to overlap with other 
second-generation TKIs (M244V, L248V, G250E, V299L, F317L, M351T, F359V/C) 
[135-136]. The T315I mutation shows resistance to all types of TKI except ponatinib 
[137-140]. However, in-vitro studies have shown that ponatinib is less able to 
eradicate clones with compound mutations (i.e. multiple mutations in the same clone) 
[131, 141-146], with the most resistant of these being combination of T315I/F359V 
and T315I/E255V [146-148]. In clinical use however, ponatinib has proved effective 
against compound, double (polyclonal) as well as single mutations (including T315I) 
[141, 149-150]. 
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1.5.2.3.4. Alterations in TKD Other Than Point Mutations 
Additional molecular variations within the BCR-ABL1 TKD have been described as 
possible mechanisms of resistance other than single nucleotide variations (SNVs). 
These include alternatively spliced products [131, 151-152] such as those with the 
entire loss of exon 4, 7, 8 [152], small InDels such as S385_L445del, 
M318_T319delinsL, R326fs, L248_C475del [124, 131, 152] and some duplications 
[152]. For example, an in-frame insertion of 42bps has been reported [153-154] which 
results in a functional oncoprotein with an in-frame insertion of 15 new amino acids. 
Another example is an in-frame insertion of 12bps conserving the open reading frame 
of the protein after adding four AA residues between I293 and K294 [155]. The 
clinical significance of such alternations has not been fully investigated. However, 
many are predicted to produce BCR-ABL1 protein variants that lack kinase activity. 
Some have even suggested that these alternatively spliced transcripts may be acting as 
dominant-negative suppressors of the intact BCR-ABL1 transcript [156].  
Three of the aberrantly spliced isoforms are relatively more frequent and pose greater 
potential for resistance. These are: 1) the in-frame (p.L248_K274del) deletion, where 
the point mutation c.742C>G (p.L248V) activates a cryptic splice donor site within 
exon 4 causing 81bp to be spliced out at the end of the exon [156-159]. This deletion 
removes part of the ATP binding pocket which suggests that this spliced version may 
be catalytically inert [157]. The point mutation itself is also thought to be involved in 
resistance independent of the deletion as it has a high IC50 value to imatinib [160]. 2) 
The frame-shift 35bp intronic insertion at the exon 8/9 junction just after amino-acid 
30 
 
C474 (c.1423_1424ins35 (p.C475Yfs*45)), which is also seen within the ABL1 TKD 
of non-CML individuals [152, 154, 161-163].  This results in a truncated BCR-ABL1 
adding 11 amino-acid residues to the protein sequence before introducing a stop codon 
[162, 164].  This insertion could be mediated by an underlying point mutation that 
introduces this intronic sequence to the splicing machinery. The creation of an intronic 
splicing enhancer or the loss of intronic splicing silencer within exon 8 is also 
possible. 3) The in-frame c.864_917del (p.V289_T306del18) deletion, leading to 54bp 
spliced out of the exon eight. The silent mutation c.864A>G (p.A288A) creates a 
putative exon splicing enhancer at this site which leads to the skipping of the first half 
of exon 8 generating an in-frame deletion. 
1.5.2.3.5. Natural History of Mutations 
TKI therapy has changed the natural history of CML pathophysiology by effectively 
eliminating the cell compartment capable of driving the disease into an uncontrolled, 
aggressive stage. At the same time, it has introduced the concept of resistance via the 
acquisition of mutations. Until very recently, it was not clear whether the mutated 
clones pre-existed treatment with TKI as a surrogate marker of genomic instability and 
later get selected via therapy, or whether they develop de novo during TKI therapy, 
induced by the therapy itself [11, 124]. There is little evidence to support the former 
scenario particularly in early CP, as the LSCs which are not BCR-ABL1 dependent, are 
drug insensitive and they could be in a non-proliferating dormant state. Therefore, 
there is no pressure on the cell to acquire a mutated TKD.  
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However, mutations must occur in a sufficiently primitive cell that retains a full self-
renewal capacity to pose a clinical threat. Otherwise, a mutation appearing in a cell 
terminally committed to differentiation is destined to vanish [160]. The same logic is 
used to explain the harmless presence of low-level BCR-ABL1 transcripts in non-CML 
individuals. Conversely, the idea of pre-existing mutations detected at advanced phase 
disease holds ground as disease transformation occurs due to accumulated genomic 
instability. Hence, mutations found at acquired resistance most probably accumulate 
gradually over the course of the disease, until a resistant clone dominates in response 
to the therapy pressure [153, 165-167]. 
It has been suggested that TKD mutations occur as part of the natural disease 
evolution irrespective of TKI therapy by either affecting TKD activity or facilitating 
transformation as part of a wider genomic instability within the cell [125]. In this 
context, it has been suggested that some mutations may be gain-of-function or loss-of-
function leading to biological changes rather than drug resistance [125, 168-169]. 
Investigating the effect of different mutations on transforming ability, kinase activity 
and substrate specificity, it was found that cellular transforming potency did not 
always correlate with kinase activity with some mutations increasing or decreasing 
TKD activity while others had no effect at all, or minimum effect [167-168]. 
Nonetheless, the TKI pressure may facilitate the outgrowth of gain-of-function 
mutations such as p-loop mutation [125, 138, 170].  
Several investigations tried to trace the origin of mutations by preforming mutation 
analysis at different disease stages including at diagnosis, while in sustained CCyR, at 
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loss of primary response (secondary or acquired resistance to imatinib), before 
switching to a second-generation TKI, at second resistance to TKI and at advanced 
phase disease. At diagnosis and while in remission, results were contradictory. Some 
[159, 171-172] have failed to identify any mutations while others [119, 153, 172-176] 
identified mutations which did not correlate with subsequent failure. And yet, other 
investigations [120-121, 138, 140, 159, 171, 177] found that a proportion of patients 
(while in CCyR) developed TKD mutations that subsequently led to a loss of 
response. This suggests that TKD mutations are not always associated with resistance 
and do not always lead to relapse [48, 127, 178-181]. This controversy persisted with 
the deployment of more sensitive methods for mutation testing including cloning [143-
144], mass spectrometry [182] and Next Genenration Sequencing (NGS) [113, 148], 
which added an extra level of complexity by revealing the presence of low-level 
mutations but with no clear prognostic implications. As a consequence, the prognostic 
significance of mutations identified while in CCyR before overt relapse remains 
unclear. Despite being ultra-sensitive, these methods failed to produce any evidence 
for the presence of mutations at diagnosis [146, 148]. Although not conclusive in the 
clinical setting, deep sequencing in the clinical trials of second-generation TKIs 
(dasatinib and nilotinib) shed light on the architecture and evolution of resistant clones 
in a way that was not previously achievable. 
Deep sequencing showed that low-level mutations detected at the time of poor 
response, while on imatinib, formed the reservoir for subsequent resistance to 
treatment with second-generation TKI [148, 182]. In addition, compound mutations 
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have been detected when patients resistant to imatinib switched to second-generation 
TKI [86, 131-132]. The nature of these compound mutations reflected prior drug 
exposure, i.e. if a patient was treated with dasatinib after imatinib resistance, the 
compound mutation consisted of a dasatinib resistant mutation in addition to another 
mutation. This suggests that additional mutations originate from a clone that carried 
low-level second-generation TKI resistant mutation at the time of drug switch [144, 
148].  
Cloning and sequencing experiments led to further observations. 1) Sequencing 
multiple clones from one individual showed the presence of low-level mutations, not 
necessarily selected by the drug that could be more accurately classified as passenger 
mutations without any growth advantage [138, 158, 183-186]. These were more often 
transition and silent mutations; yet their increased incidence may still abrogate TKD 
function [143-144]. 2) Compound mutations coexisted with separate polyclonal 
mutations suggesting that the primary clone (with compound mutations) subsequently 
evolved to acquire additional mutations through evolution [143-144]. Furthermore, in 
some individuals, it was found that mutations affecting different bp of the same codon 
were present in different clones, suggesting a multi-clonal model of disease 
progression rather than a monoclonal process in which a single resistant clone 
successively acquires different point mutations [143-144].  
Recent findings from whole genome sequencing (WGS) approaches also support the 
concept of a multi-clonal process [187-189]. At the time of resistance, WGS found 
several clones with different low-level mutations or a combination of mutations 
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composing a reservoir for subsequent TKI resistance. Therefore, once a mutation is 
detected patients are more likely to develop new clones on subsequent TKI. Accurate 
characterization of the mutational profile of individual patients may prove valuable in 
selecting the most effective treatment.  
1.5.2.3.6. Clinical Relevance of Mutation Testing in CML Patients 
The most recent ELN guidelines recommend mutation testing in 4 situations where the 
result might affect drug selection [96]: 1) at primary resistance or failure, 2) in 
acquired resistance 3) if the response of the patient is classified as “warning” and 4) at 
progression to an advanced stage.  
1.5.2.3.7. TKD Mutation Testing 
There is a range of methodologies available for BCR-ABL1 TKD mutation testing 
[113, 183]. Factors such as analytical sensitivity, specificity and precision, fragment 
length, ability to quantify in addition to turn-around time and cost dictate which would 
be of most use in a clinical setting.  Capillary electrophoresis sequencing (CES), with 
a limit of detection of 15–20%, (also known as Sanger sequencing, direct sequencing, 
BigDye
®
 xterminator sequencing or cycle sequencing) remains the most widely used 
and recommended technique for BCR-ABL1 TKD mutation testing [127]. 
Pyrosequencing, sometimes used instead of, or in addition to, CES [130, 190] is based 
on detecting light emitted following a series of enzymatic reactions triggered by the 
pyrophosphate released on nucleotide incorporation. The amount of light is 
proportional to the number of nucleotides incorporated and is translated into a digital 
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output as a nucleic acid sequence. However, prior knowledge of the mutation under 
investigation is required as nucleotide dispensation is directed by the sequence the 
operator wants to analyse [119, 159]. Short amplicon length is another limiting factor 
as only one or maximum two mutations can be investigated at a time.  
Recent new technologies with higher sensitivity including mass spectrometry [182, 
191], NGS amplicon deep sequencing [113, 146, 192-193] and nanofluidics 
methodologies such as digital PCR [194], are capable of detecting mutations as low as 
1%. NGS combines several characteristics in one platform including: sensitivity, 
quantification, detection of known and novel mutations (including InDels) and the 
ability to distinguish compound vs polyclonal mutations [113]. Chapter VI expands 
further on these technologies.  
1.5.2.4.Monitoring Response to TKI Therapy 
Sensitive and accurate monitoring of BCR-ABL1 transcript levels is essential for 
clinical management with RT-qPCR performed every 3 months until major molecular 
response (MMR or MR
3
) is achieved, then every 3 or 6 months thereafter, depending 
on the clinician’s preference or clinical trial protocol.  In the case of a patient in the 
‘warning’ category, more frequent RT-qPCR assessments are required together with 
TKD mutation testing to facilitate timely therapeutic intervention [195]. 
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1.5.2.4.1. RT-qPCR Assay Standardization, The International Scale (IS) and  
Conversion Factors (CF) 
The introduction of RT-qPCR to measure MRD in leukaemia was a turning point in 
patient management. However, it was evident from earlier on that RT-qPCR had 
inherent limitations and dictated assay standardization and protocol uniformity to 
ensure reliable, meaningful and comparable results between laboratories. These 
limitations include: 1) Variations in efficiency of RNA extraction, reverse 
transcription (RT) and cDNA synthesis; 2) Variations in assays, chemistries, master 
mixes and platforms used; 3) Variations in the values assigned to serial dilution points 
of the standard curve often generated using inaccurate quantification methods; 4) Loss 
of quantification precision at the lower range of the standard curve. 
RT-qPCR was employed by investigators in the IRIS trial to complement the 
haematological and cytogenetic tests in patients who reached CCyR. In this study, the 
majority of patients reached CCyR within 12 months, and thus there was a need for a 
more sensitive and earlier method of monitoring the kinetics of the BCR-ABL1 clone 
[196]. RT-qPCR of BCR-ABL1 fusion transcripts was therefore employed using BCR 
as a control gene (CG) to normalize measurements. Results were expressed as a ratio 
of BCR-ABL1 over BCR and values were expressed in percentage. For the purpose of 
standardizing the results between the three testing labs (Adelaide, Seattle and 
London), a set of 30 samples collected in London from CML patients prior to therapy 
were distributed and quantified in each of the centres [196]. The calculated median 
value was considered the baseline to assess log reduction in follow-up samples. The 
use of log reduction allowed alignment of results between the three labs, while 
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eliminating the need to know the baseline value in each patient to calculate molecular 
response [91].  The IRIS trial introduced the first molecular milestone, MMR. The 
adoption of this milestone by CML centres elsewhere meant that interested labs had to 
establish their own baseline that was compatible to the one used in the IRIS trial. 
Meanwhile, between 1999 and 2002, a standardization effort was embarked upon by 
the international Europe Against Cancer (E.A.C.) program, which included 26 
laboratories from 10 EU countries. The aims were: 1) to identify robust assays for 
MRD quantification of fusion genes associated with leukaemia including the BCR-
ABL1 fusion gene; 2) to standardize protocols applicable in clinical settings; 3) to 
standardise RT-qPCR procedures; 4) to identify the best control genes for 
normalization of results [198-200]. The E.A.C. assay designed and standardized as a 
result of this initiative became the standard assay for BCR-ABL1 MRD quantification 
and ABL1 was recommended as the control gene for normalizing results [198]. ABL1 
was chosen over other genes (GAPDH, B2M, 18S rRNA and GUSB) because: 1) it 
showed high to medium expression, 2) had a stable and uniform expression between 
leukaemic and non-leukaemic samples, 3) had similar expression between PB and BM 
specimens and 4) had no known pseudogenes [198]. In addition, a highly significant 
correlation between cytogenetic measurements and RT-qPCR data was shown using 
ABL1 despite the fact that the ABL1 assay could amplify transcripts from the 
translocated as well as the normal allele, simultaneously. In 2006, GUSB was declared 
to be another suitable internal CG through a similar effort conducted later in the 
U.S.A. including members of the Association for Molecular Pathology and the 
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College of American Pathology (CAP) [201-202]. Thus, although ABL1 is currently 
the most widely used CG, BCR and GUSB are also used. Despite the extensiveness of 
the E.A.C. effort, its recommendations were not binding and it was impossible to 
enforce platforms, chemistries and CGs across many laboratories world-wide. The 
consequence of this was that no one standardized protocol was universally adopted. 
The need for an alternative means to ensure cross-laboratories uniformity remains a 
major challenge to date [200, 203].  
Together, the lack of a standardized protocol for performing RT-qPCR, the lack of an 
accurate and precise baseline value for transcript levels at diagnosis and the lack of 
independent reference material lead to the birth of the International Scale (IS) [123]. 
The IS for BCR-ABL1 transcript measurements was introduced at a meeting of CML 
experts held in Bethesda in October 2005 [123]. In this meeting, an agreement was 
reached to assign the value of 100% to the standardized baseline calculated from the 
30 pre-treatment samples within the IRIS trial. MMR was defined as 3 log reduction 
from this baseline or the equivalent to 0.1% on the IS [123]. With effective TKI, 
deeper molecular responses were identified including complete molecular remission 
(CMR) defined as the absence of detectable BCR-ABL1 transcripts measured by RT-
qPCR. It was established that the test has the ability to detect 1 copy of BCR-ABL1 in 
10,000, 32,000 or 100,000 copies of ABL. This defined the 4, 4.5 or 5 log reduction 
from the IRIS standardized baseline or 0.01%, 0.0032% and 0.001%, respectively on 
the IS [48, 95, 204-206]. This was further revised in 2014 to introduce the concept of 
deep molecular remission as defined above in the ‘response to TKI therapy’ section. 
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Reporting on IS scale is now a requirement for any laboratory performing BCR-ABL1 
quantification. To this aim, each laboratory needs to obtain a unique conversion factor 
(CF) established through a process of sample exchange with the designated reference 
lab which holds material directly linked to the original pool of the 30 IRIS pre-treated 
samples [196, 207]. Reference labs are Mannheim in Germany and Adelaide in 
Australia [92, 208]. 
Although the IS method is useful and has provided a mean for standardized results 
alignment and interpretation, it is labour intensive, needs to be checked annually or 
when changes are introduced in the methodology [93, 207-208] and is only applicable 
for samples ≤ 10%IS [209] in laboratories using ABL1 as CG (as both the translocated 
and wild-type ABL1 alleles are amplified and therefore can skew ratios when ABL1 is 
used) [198]. Hence, efforts to develop external controls with predefined transcript 
levels were required to unify lab-specific measurements of BCR-ABL1 to a common 
standardized scale [208].  
1.5.2.4.2. Reference Materials 
The International Standardization Group worked on developing two types of reference 
material, primary and secondary. The generation of primary reference material is 
laborious and therefore, it was made in limited quantities, tested, and validated 
rigorously and accredited by the WHO. The accredited primary material would then be 
exclusively distributed to manufacturers to use as calibrators for the generation of 
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secondary reference material that can be produced in large quantities and made 
available for individual testing labs.  
It was agreed that cells would be the best primary material because they are more 
comparable to a ‘live’ patient sample. Cells would control for all steps of RT-qPCR 
and aliquots can be lyophilised [210]. BCR-ABL1 naïve (HL60) and BCR-ABL1 
containing (k562) cells were mixed together at four different ratios, then concentrated 
and lyophilized [209]. HL60 was chosen because it expresses the three most widely 
used control genes (ABL1, GUSB and BCR) at comparable levels to normal leukocytes 
[209]. The panel of four dilutions was distributed to participating labs with established 
CFs for BCR-ABL1 quantification on the IS. The mean values obtained from these labs 
were assigned to the reference dilution with values of 10%, 1%, 0.1% and 0.01% on 
the IS [209, 211]. Only four dilutions ≤10% were included because of the nonlinearity 
of ABL1 CG when disease levels are >10% [212-214]. The reference material was 
accredited by the WHO expert committee on biological standardization in 2009 as the 
first WHO International Genetic Reference Panel for the quantification of BCR-ABL1 
mRNA [209, 211].  After accreditation, the WHO primary material became available 
for the production of secondary reference materials although in very limited quantity. 
Following their success as calibrators in the fields of infectious diseases and oncology 
[215-216], armoured RNA Quant (ARQ)(Asuragen) technology was used to develop 
robust synthetic ARQ calibrator panel of four points (10%, 1%, 0.1%, 0.01%) 
calibrated to the mean IS percent ratios of the WHO primary standards. ARQ 
constructs contained four synthetic transcript sequences corresponding to the exonic 
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sequences of the major BCR-ABL1 transcripts (e13a2 and e14a2, in addition to ABL1 
exons 2-11 and BCR exons 14–22 [217]. The ARQ panel was evaluated in a large 
international pilot study across 29 labs in 15 countries, followed by an accuracy 
validation across eight laboratories within seven countries. These studies demonstrated 
the compatibility of the ARQ panel with different RT-qPCR methods applying seven 
different RNA extraction protocols and 13 different platforms, highlighting the 
potential for ARQ as a secondary calibrator [217].  
The ERM
®
-AD623 is a certified reference material developed according to ISO Guide 
34:2009 standards [218]. Fragments of e14a2 BCR-ABL1 fusion transcripts, BCR and 
GUSB were amplified and cloned into the pUC18 plasmid to generate the plasmid 
pIRMM0099. Six different linearized plasmid dilutions were then produced with 
certain copy number concentrations assigned using digital PCR (dPCR) and tested in 
63 BCR-ALB1 testing labs each with their own CF. The ERM standard was certified 
by the European commission and available for distribution worldwide via the Institute 
for Reference Materials and Measurements (IRMM) in Belgium and several other 
distributors authorized by the commission. It is important to note that the use of ERM-
AD623 itself does not produce results on the IS, but it helps the calibration of in-house 
prepared reference materials to improve the accuracy of results before conversion. The 
availability of such a standard is of great value to improve the compatibility of results 
between testing labs. Nonetheless, the acquisition of CF still remains the most widely 
implemented method in the absence of certified secondary reference materials on the 
IS or external quality control schemes. 
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1.5.2.4.3. External Quality Controls 
External quality assessment programs that are independent and broadly accessible are 
crucial to improving the comparability of BCR-ABL1 results. Such an effort has been 
initiated through a scheme launched by the United Kingdom National External Quality 
Assessment Service (NEQAS) [201, 219]. 
1.5.2.4.4. Molecular Monitoring and Treatment Interruption 
With the introduction of the second and third generation TKIs and the achievement of 
deeper and faster reduction in disease levels [86, 151], greater is the chance of CML 
patients to achieve and maintain deep molecular response [100]; thereby become 
classified as ‘operationally cured’ and candidates for therapy interruption [100, 220-
227). The French Stop Imatinib (STIM) clinical trial was the first evaluating the 
consequences of TKI cessation in patients who achieve durable molecular responses of 
MR
5
 within the context of a clinical trial [99-100]. The STIM trial was rapidly 
followed by several other small trials such as TWISTER [101], a small Japanese study 
[103], A-STIM (104), HOVON (105), in addition to ongoing trials such as the EURO-
SKI and DESTINY (UK). All these studies recruited patients in MR
4
 (DESTINY has 
recruited a control group in MR
3
) or deeper sustained molecular responses for 1–2 
years, and monitored them for up to 24 months or longer. General conclusions so far 
were that (Table 1.1): 1) all studies showed 50–60% relapse rates, 2) all relapses were 
molecular not haematological and sensitive to reintroduction of imatinib, 3) none of 
the relapses developed TKD mutations, 4) the vast majority of the relapses were 
within the first 6 months of therapy discontinuation with fewer late relapses also 
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occurring (23–24 month), 5) some patients retained low-level molecular positivity 
while stopping therapy without relapsing, and 6) risk factors for relapse were: imatinib 
duration and dose prior to interruption, Sokal score at diagnosis, time to first MMR, 
time in MMR before discontinuing the therapy [228].  
Although RT-qPCR is the recommended method for monitoring responses to TKI, it 
might not be the best assay for patients with deep responses considered for treatment 
discontinuation. The current consensus is that therapy discontinuation is followed by 
relapse in at least 50% of patients and that persisting LSCs or LP with low BCR-ABL1 
expression or quiescent LSC with no BCR-ABL1 expression are the source of relapse.  
However, not all low-level RT-qPCR positivity is associated with relapse. Identifying 
a sensitive method for detecting and accurately quantifying residual disease might help 
address the question of whether disease levels before therapy discontinuation are 
associated with relapse. It would also help to establish a threshold for positivity that 
could predict those who are at a higher risk of relapse after therapy discontinuation to 
guide therapeutics re-intervention. 
In the era of rapid technological advances and their deployment in molecular 
diagnostics labs, we sought to investigate the potential of these technologies in 
improving the current clinical management of CML. Digital PCR is a recently 
developed method of absolute molecular quantification that has the portenial for 
complementing RT-qPCR not only in monitoring MRD while in deep molecular 
remission or during therapy discontinuation, but also in simplifying the 
standardization efforts. NGS, on the other hand, has the potential for increased 
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sensitivity of TKD mutation detection. Unlike the case in other diseases such as 
virology and solid tumours, the clinical value of these technologies is not yet known in 
CML. Therefore, the focus of this Ph.D. thesis was to develop protocols and proof-of-
principle data facilitating the implementation of these methodologies in routine testing 
and consequently investigating their clinical significance in the routine management of 
CML patients.  
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1.6. Aims and Objectives 
The broad aims of this project are to assess the benefits of implementing state of the 
art methodologies to the routine clinical investigation of CML, validate their use in 
routine diagnostic testing and molecular quantification of MRD, highlight critical 
points that may be relevant to the design of future clinical trials and produce data to 
support a role for such methodologies in understanding disease biology and the 
kinetics of relapse. 
The specific objectives of the work are as follows: 
1. Provide a proof-of-principle for using targeted NGS for mapping the BCR-
ABL1 genomic fusion junction, and to assess the performance of dPCR for 
quantifying residual disease compared to other available methods (chapter 2).  
2. Validate the E.A.C assay on the QS®3D RT-dPCR platform with the aim of 
assessing platform performance characteristics (chapter 3). 
3. Perform an RT-dPCR platform comparison to identify the platform of choice 
for the purpose of monitoring MRD in a routine setting (chapter 4). 
4. Optimise and assess amplicon deep sequencing for BCR-ABL1 Tyrosine 
Kinase Domaine (TKD) mutation testing (chapter 5). 
5. A review related to the new methodologies and their role in the future of CML 
clinical management in the era of effective TKI therapies, cutting-edge 
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molecular methodologies and precision medicine is presented, incorporating 
the findings from this thesis (chapter 6).     
Each chapter will review the work carried out on specific aspect of MRD monitoring 
of CML with an introduction, Material and methods pertinent to the work presented in 
each chapter followed by the results and critical discussion of the results. Figures and 
tables for each chapter are provided separately from the body of each chapter to allow 
a more fluid reading. Independent references at the end of each chapter are also 
included. 
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1.7. Figures 
 
Figure 1.1. The Translocation t(9;22)(q34;q11) in CML. The Philadelphia (Ph) chromosome is the result of 
the translocation of 3'-ABL segments on chromosome 9 to 5'-BCR segments on chromosome 22. Red 
arrows indicate common breakpoint loci on both genes. Depending on which breakpoints are involved, 
fusion transcripts of different lengths (e1a2, b2a2, b3a2, and e19a2) are produced and transcribed into 
chimeric protein products (p190, p210, and p230) with variable molecular weights. m-BCR denotes minor 
breakpoint cluster region, M-bcr major breakpoint cluster region, and µ-bcr a third rare transcript e19a2. 
Taken from Faderl, S., et al. (1999), 'The biology of chronic myeloid leukaemia', N Engl J Med, 341 (3), 164-
72. [ref 13] 
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Figure 1.2. Molecular Monitoring Milestones in CML. Molecular responses are expressed on the 
International Scale (IS) as the percentage ratio of BCR-ABL1 transcripts to those of a control gene (CG) 
where ≤10%, ≤1%, ≤0.1%, ≤0.01%, ≤0.0032%, and ≤0.001% correspond to a ≤1, ≤2, ≤3, ≤4, ≤4.5, and ≤5 log 
reductions in tumour burden compared to diagnosis. Taken from O'Hare, T., et al. (2012), 'Pushing the 
limits of targeted therapy in chronic myeloid leukaemia', Nat Rev Cancer, 12 (8), 513-26. [ref 231] 
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Figure 1.3. BCR-ABL1 TKD mutations. The most recurrent amino acid substitutions in the BCR-ABL1 TKD 
identified in clinical samples from patients reported to be resistant to TKI. Key structural motifs within the 
TKD are indicated. P-loop indicates phosphate binding loop; SH2 contact and SH3 contact indicate contact 
regions with SH2 and SH3 domain-containing proteins; A-loop indicates activation loop. Star indicates 
amino acid position reported to be directly involved in imatinib binding via hydrogen bonds or van der 
Waals interactions. Taken from Soverini, S., et al. (2011b), 'BCR-ABL kinase domain mutation analysis in 
chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: recommendations from an 
expert panel on behalf of European LeukaemiaNet', Blood, 118 (5), 1208-15. [ref 127]  
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1.8. Tables 
Table 1.1. Common points of agreement amongst reported TKI discontinuation studies. 
1 recruited patients were in MR
4
 or deeper 
2 50-60% relapse rates were common and clustered during the first 6 months (rarely up to 
2 years) 
3 they were all sensitive to imatinib re-introduction 
4 none developed TKD mutations 
5 some patients retained low-level molecular positivity without ever reaching molecular 
‘relapse’ 
6 risk factors for relapse were imatinib duration and dose, time to first MR and time in MR 
before discontinuing the therapy 
  
Sweet, K. and Oehler, V. (2013), 'Discontinuation of tyrosine kinase inhibitors in chronic myeloid 
leukaemia: when is this a safe option to consider?', Haematology Am Soc Hematol Educ 
Program, 2013, 184-8. 
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Chapter II 
 
2. NGS-assisted DNA-based Digital 
PCR for a Personalised Approach to 
the Detection and Quantification of 
Residual Disease in CML Patients. 
 
 
The content of this chapter has been published in the Journal of Molecular Diagnostic 
(JMD). 
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Whale AS, Milojkovic D, Apperley J, Huggett JF, Foroni L, Reid AG. Next-
Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized 
Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid 
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The supplementary material mentioned in this chapter refer to the online published 
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could be found at the following link: 
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2.1. Introduction 
The fusion oncogene BCR-ABL1 is the hallmark for chronic myeloid leukaemia 
(CML) [1]. The BCR-ABL1 tyrosine kinase protein is responsible for the cellular 
phenotype of CML and is, therefore, a rational target for therapy via tyrosine kinase 
inhibition, a treatment approach that has revolutionised patient outcome [2]. The 
measurement of BCR-ABL1 transcripts via reverse transcriptase quantitative 
polymerase chain reaction (RT-qPCR) is the most widely used method for monitoring 
residual disease in patients with CML, an essential aspect of modern disease 
management [3].
 
While tyrosine kinase inhibitors (TKI) are routinely administered 
indefinitely, recent studies indicate that 40% of patients who achieve undetectable 
BCR-ABL1 by RT-qPCR (molecular remission with 5 log reduction on the 
international scale, MR
5
) on imatinib that is sustained for at least two years, will 
remain disease-free after drug discontinuation [4], raising the possibility of an 
“operational cure” in this subgroup of patients. However, the safe introduction of a 
TKI withdrawal strategy would require a reliable and cost-effective method for the 
identification of those patients with the lowest likelihood of relapse. The probability of 
relapse post-withdrawal is likely to be related to persistence of residual disease, which 
may include transcriptionally quiescent TKI-resistant leukaemic stem cells [4, 5], at a 
level that is below the threshold of detection by the ‘gold-standard’ RT-qPCR (10-5) 
[6, 7]. A mean of detecting these cells that does not depend on oncogene transcription 
might be clinically valuable. 
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Here we describe a DNA-based method of detecting and quantifying low levels of 
BCR-ABL1 positive disease that improves on previous methodologies in two key 
areas. Firstly, the identification of BCR-ABL1 fusion junctions is undertaken by 
targeted next generation sequencing allowing the rapid generation of high-performing 
DNA-based hydrolysis probe assays that are specific to the unique molecular footprint 
of each patient’s CML clone. Secondly, we sought to further enhance the sensitivity of 
a DNA-based approach by optimising the technique for use on a digital PCR (dPCR) 
platform, which provides absolute molecular quantification without the need for a 
standard curve. When applied to samples with undetectable disease by RT-qPCR, 
DNA-based digital PCR (dPCR) provided a marked improvement in sensitivity, not 
only over RT-qPCR, but also compared to real-time qPCR of DNA and to digital RT-
PCR (RT-dPCR).  
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2.2. Materials and Methods 
2.2.1. Patient Cohort 
To validate the NGS part of this technique, we studied 32 CML patients treated at the 
Hammersmith Hospital. Twenty-two patients were on treatment with TKI and ten had 
received allogenic stem cell transplants (alloSCT). RNA extracted from diagnostic 
samples had been previously used to establish the fusion type using multiplex PCR as 
previously described [8]. Ethical approval was provided and informed consent was 
obtained from all patients in accordance with the declaration of Helsinki. Forty-six 
follow-up samples from six of these patients (A1–A6; median: five samples per 
patient) collected at least 28 months from diagnosis (follow-up range: 28–178 months) 
were used to compare the sensitivities of different residual disease measuring 
technologies, as described below. Thirty-six of these samples were in deep molecular 
remission (MR) as defined in Cross et al, 2015 [9], while the remaining 10 were at the 
level of MR
3
 (previously termed major molecular response MMR) or above. Of the six 
patients, A1 and A6 received TKI therapy and the remaining four were post-transplant 
(A2 to A5).  
2.2.2. Next Generation Sequencing Identification of Fusion Junctions 
2.2.2.1.DNA Extraction 
Peripheral blood cell lysates (PBCL) prepared using RLT buffer (Qiagen, Manchester, 
UK; cat number 79216) and stored at minus 80°C were collected from all 32 patients 
either from the time of diagnosis, or when the level of residual disease was ≥ 10% by 
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BCR-ABL1 RT-qPCR. DNA was extracted from 200µl of the PBCLs using the 
QIAamp DNA blood mini kit (Qiagen, cat number 51106) following the 
manufacturer's protocol on the QIAcube robotic workstation (Qiagen). DNA was 
quantified using the Qubit fluorometric method (Invitrogen, Qubit
® 
dsDNA BR Assay 
kit, cat number Q32850). DNA was further assessed for impurities using the 260/280 
and the 260/230 ratios measured using a spectrophotometer. The integrity of the DNA 
was assessed on a 2% agarose gel. 
2.2.2.2.Targeted NGS Fusion Mapping 
2.2.2.2.1. Targeted Next Generation Sequencing (NGS) 
Library preparation was performed using Illumina's TruSeq DNA sample prep and 
PCR kits, according to manufacturer’s instructions (Illumina, Cambridge, UK; ref 
numbers 15025064 and 15027084). Briefly, 1µg of DNA from each sample was 
fragmented using the Covaris DNA shearing system (Covaris S2, Massachusetts, 
U.S.A). The fragments were end-repaired and ligated with Illumina adaptors and 
barcodes for multiplexing. Individual library quality and size were assessed by 
running an aliquot of each library on a bioanalyzer using a high sensitivity DNA chip 
(2100 Bioanalyzer, Agilent Technologies) and/or capillary gel electrophoresis 
(Qiagen© Qiaxcel system). The average insert size was 400bp (ranging from 100 to 
900bps). Individual libraries were purified using AgenCourt Apure XP beads 
(A63881, Beckman Coulter), quantified using Qubit and an equimolar amount of each 
library was pooled together into a final multiplexed library. The 32 patients were 
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grouped into four batches, comprising multiplexes of six, twelve, eight and six 
patients, respectively.  
For the targeted sequencing, each pooled library was hybridised twice overnight with a 
pool of synthetic oligonucleotide probes custom-designed using Illumina's 
DesignStudio online portal to specifically capture the entire coding and non-coding 
regions of the BCR and ABL1 genes (100kb upstream and downstream from each 
gene, respectively). Probe details and coordinates are provided in (Supplementary 
Table 2.1). Sequence capture was followed by extensive washing and purification 
steps according to the manufacture's protocol (Illumina, TruSeq Custom enrichment 
kit-24 reactions-boxes one and two, ref numbers 15022030 and 15022031). Bridge 
amplification, cluster generation and 150bp paired-end sequencing were performed on 
an Illumina MiSeq following captured library quantification by qPCR using Kapa 
library quantification kit (kit code KK4835, KBiosciences). The median read coverage 
across BCR and ABL1 targets was 100x (range 50x to 150x), with minimum base call 
quality of Q20. 
2.2.2.2.2. Bioinformatics-based Prediction of Fusion Junctions  
Bioinformatics analysis of sequencing reads was performed according to the following 
steps. First, TruSeq adaptor sequences were removed using the Cutadapt [10] 
software. Trimmed reads were then aligned to the human genome reference assembly 
GRCh37 using the BWA-MEM [11] aligner software (v 0.7.2). Duplicate reads were 
marked in the BAM files and the coverage metrics for targeted regions were collected 
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using the Picard (v1.85; http://picard.sourceforge.net/) software. CREST [12] and 
BreakDancer [13] software were used to extract split reads (single reads composed of 
material from two non-contiguous genomic regions) and discordant pairs of reads (in 
which individual reads in a pair do not map at the expected distance and/or 
orientation), respectively, that were likely to mark the site of structural rearrangement 
(Figure 2.1).  
2.2.2.3.Fusion Junction Confirmation 
All predicted fusion junction sequences were validated via conventional Sanger 
sequencing. Primer sequences are listed in Table 2.1. For the validation of the ABL1-
BCR fusion junctions predicted by split reads, primers were designed at least 200bp 
upstream and downstream of the putative fusion junctions, while in cases where the 
fusion was alluded to via discordant read pairs, primers were designed 200bp upstream 
and downstream of the end of the read closest to the predicted junction on either side 
of the junction. The Primer3 [14] online software V.0.40 was used for primer design.  
Qiagen Fast Cycling PCR kit (QIAGEN, Cat. No. 203743) was used for amplification 
of junction sequences, which contains a high-fidelity HotStart Taq Plus DNA 
polymerase capable of functioning over long distances. For all PCRs, two negative 
controls, one sample of pooled DNA extracted from eight CML patients (pool1) and 
DNA extracted from a normal individual (CSC) were included in addition to a no 
template control (NTC). PCR was performed using the following temperature cycling 
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parameters: 94°C for 5 min, 30 cycles of 94°C for 30 sec, (55–65)°C for 30 sec, 72°C 
for 37 sec, followed by a final extension step at 72°C for 10 min.  
For Sanger sequencing of PCR products, two independent cycling PCR reactions, one 
forward and one reverse, was performed per patient sample using ABI's BigDye 
Terminator V3.1
TM
 Cycle Sequencing kit (Applied Biosystems, Foster City, USA) 
under the following conditions: 96°C for 1 min, 25 cycles of 96°C for 10 sec, 55°C for 
15 sec, 60°C for 4 min, prior to storage at 4°C. PCR products were purified with 
BigDye XTerminator
TM
 Purification kit following manufacturers' protocol. 
Sequencing was performed on the ABI 3500xl Genetic Analyzer (ABI, Life 
technologies Ltd, Foster City, USA). Sequence quality and traces were analysed using 
the ABI's Sequence Analysis software V5.2.  
Sequences obtained by Sanger sequencing were aligned to the reference genome for 
BCR and ABL1 using BLAST [15] (Basic Local Alignment Search Tool; NCBI) or 
BLAT [16] (Blast-Like Alignment Tool; UCSC) genome alignment tools.  
2.2.3. Residual Disease Quantification 
The sensitivity of dPCR in identifying and quantifying BCR-ABL1-positive residual 
disease in 46 post-treatment CML samples from six patients was compared to that of 
three other quantitative PCR methods, namely RT-qPCR, qPCR and RT-dPCR. Each 
was performed following the protocols described below. 
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2.2.3.1.DNA-based dPCR (dPCR) 
2.2.3.1.1. Design and Optimisation of TaqMan FAM-MGB Hydrolysis Probe 
Assays  
For six patients (A1–A6) qPCR assays were designed specific to each patient’s fusion 
junction using Primer Express 3 software v3.0.1 (ABI, Life technologies Ltd, Foster 
City, USA) and the AutoDimer tool [17]. Assays were designed specific to the BCR-
ABL1 fusion junction where available (four patients) or to ABL1-BCR, if the BCR-
ABL1 junction sequence was unavailable (two patients) (Table 2.2). Primer specificity 
was assessed using a SYBR Green melt curve assay (Sigma Ltd, Missouri, U.S.A.) 
following manufacturer protocol, in addition to capillary electrophoresis.  
DNA extracted from each patient’s diagnostic or high-level disease sample was used 
to prepare standard curves to evaluate assay efficiency, quantitative range and limit of 
detection. Primer and hydrolysis probe concentrations were optimised by real-time 
PCR using a matrix of eight different concentrations run on an Applied Biosystems 
StepOnePlus
TM
 Real-Time PCR System (Life technologies Ltd, Foster City, USA). 
The combination with the highest fluorescence and lowest quantification cycle (Cq) 
values was subsequently used.  
The standard curves produced acceptable slopes (-3.2 to -3.6) and correlation co-
efficiencies (0.98–0.99%), acceptable amplification efficiency figures (80–110%) and 
acceptable dynamic ranges, in line with the expected theoretical sensitivity range. 
Quantitative ranges (LoQ) varied from 10
-3
 to 10
-4
 and sensitivity ranges (LoD) varied 
from 10
-4
 to 5x10
-5
 (Appendix Table 2.1). SYBR Green assays showed a unique 
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melting curve per assay and capillary gel electrophoresis produced a unique band of 
the expected size.  
2.2.3.1.2. Preamplification   
Measurement of residual disease was carried out by dPCR in the follow-up samples 
either directly using unamplified DNA or including a preamplification step according 
to a previously published protocol [18] using TaqMan Preamp Master Mix 
(Invitrogen, part no. 4391128). In brief, a total reaction mixture of 20l was prepared 
using 10l of 2X preamp mix, 5l of 0.2X patient-specific assay, 2l of distilled water 
and 150ng DNA in 3l. Preamplification was performed using the following 
thermocycling conditions: 95
o
C for 10 min, then 14 cycles of 96
o
C for 15 sec and 
60
o
C for 4 min. Amplification products were diluted 1:5 in 1X TE, pH 8 and 
subsequently used for dPCR quantification. We evaluated the efficiency of 
preamplification of DNA extracted from 46 follow-up samples from six CML patients 
using a standard curve of 4 points per assay prepared from each of the corresponding 
six patients’ early disease material. The standard curves produced acceptable slopes (-
3.1 to -3.8) and correlation co-efficiencies (0.994–0.998%) and acceptable 
amplification efficiency metrics (81–114%) (Appendix Table 2.2). Of the 46 follow-
up samples, ten had previously demonstrated RT-qPCR positivity at MR
3
 or above and 
thus served as positive controls; all ten amplified within expected ranges. 
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2.2.3.1.3. dPCR Quantification 
Microfluidic digital PCR was performed using the Fluidigm Biomark HD (Fluidigm, 
California, USA) and the 48.770 dPCR array containing 770 x ~ 0.84nl reaction 
partitions in each of the 48 panels (Fluidigm, dPCR 37k IFCs, 100–6151). 
Reaction mixes of 6l were prepared containing 3l of 2X ABI Fast Advanced Master 
Mix (Invitrogen, Foster City, USA; cat no. 4444965), 0.6l of 20X GE sample loading 
reagent (Fluidigm, cat no. 85000820), 0.3l of 20X patient specific TaqMan assay, 
0.3l distilled water and 1.8l of (50ng/μl) template DNA. A partition size of nine 
panels per sample was used to allow the quantification of an equal amount of DNA as 
in qPCR (150ng). Five microliters of the prepared reaction mixes were loaded into the 
corresponding inlets on each array chip and the BioMark IFC controller MX 
(Fluidigm) was used to uniformly partition the reactions across the panels. 
Thermocycling was performed using the fast mode (5.5C/min) as follows: 95C for 
60 sec, 40 cycles of 96C for 5 sec followed by 60C for 20 sec. Data was collected 
using The Data Collection software v4. Data analysis was performed using the Digital 
PCR Analysis Software v4. The positive partitions per 9 panels for each assay were 
grouped (k), and Poisson distribution was used to estimate the average number of 
template copies () per partition in all of the 9 panels (n) where = -ln(1-k/n)(19). 
Estimated target copy number per 1l and per reaction volume were calculated in 
addition to the 95% confidence intervals to account for the counting uncertainty. The 
formulas used for these calculations are as follows and are formatted into the 
supplementary Tables 2.4 and 2.5 which could be used as a template. The probability 
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of having more than one target molecule per partition P=k/n where k is the number of 
positive partitions and n is the total number of partitions is as follows: Standard 
deviation from the mean of P is estimated as S= SQRT((P x (1-P))/n); the upper and 
lower 95% confidence interval (CI) of the P are estimated as  PL and PH = (P +/- (1.96 
x S)); the upper and lower 95% CI of the λ is estimated as λL and λH = -ln(1-PL) and -
ln(1- PH); Est target copies per reaction volume (Est targets) = λ x n; The upper and 
lower 95% CI of the Est targets (Est targets-L and Est targets-H) = λL x n and λH x n; 
Est target per 1µl= (Est Targets ÷ (DNA volume per panel x number of panels)); the 
upper and lower 95% CI of Est targets per 1µl = (Est x targets-L ÷ (DNA volume per 
panel x number of panels)) and (Est targets-H ÷ (DNA volume per panel xnumber of 
panels)). 
Positive and negative controls were run using the same partition size used per sample 
for each of the six DNA assays to assess platform function, amplification protocol and 
level of background noise. Early disease samples from each of the six patients were 
used as positive controls. DNA from a normal donor and from a pool of eight CML 
samples were used as negative controls. Three NTC panels were included in each 
array to rule out contamination. The threshold and the Cq ranges were manually set 
specific to each assay and its background noise, but consistent across all panels of the 
same assay (Table 2.3 and Appendix Figure 2.1). 
Linearity and the dynamic range of the Fluidigm platform was previously assessed 
[18]. However, we also performed a limited experiment to assess these two parameters 
in our hands. We generated a series of dilutions of two synthetic oligonucleotides each 
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containing the fusion sequence of one CML patient (A-3 and A-6; GeneArt, Life 
technologies Ltd, Foster City, USA). Two-fold dilutions of 4 to 512 molecules per 
panel were run in duplicate panels on the 48.770 chip array. Linearity was maintained 
at four molecules per panel (lambda of 0.005; approximately equal to 2 copies/1l); 
therefore we considered this a conservative limit for reliable quantification (Appendix 
Figure 2.8).  All the normal controls we tested showed complete negativity, 
additionally, none of the normal controls showed any amplification.  We, therefore, 
chose a range of 0.5 and 3 molecules per panel to be considered positive outside the 
quantitative range. These thresholds have been previously applied to other tests in the 
measurement of residual disease in acute lymphoblastic leukaemia using antigen 
receptor targets [20]. 
2.2.3.2.RT-qPCR 
After the patients’ specific fusion type was identified in the diagnostic sample by 
multiplex PCR using previously described protocols [7, 8], RT-qPCR was used to 
identify residual disease in each of the 46 follow samples as previously described 
using best practice methodology [6, 7, 21, 22]. RNA was extracted using Qiagen 
RNeasy Mini kit (Qiagen cat no 74106) and Qiagen Qiacube robot (Qiagen). Reverse 
transcription and cDNA synthesis were performed using M-MLV reverse transcriptase 
(Invitrogen, cat no 28025-013) and random hexamers (Invitrogen, cat no 48190-018) 
as described in an earlier publication [6]. RT-qPCR was performed using a duplex 
MGB TaqMan assay [22] (a modified version of the Europe Against Cancer (E.A.C.) 
assay described in Gabert et al 2003 [23] with 2x TaqMan Fast Advance Master Mix 
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(ABI, cat no 4444965) in a final 20ul reaction. The level of expression of target BCR-
ABL1 molecules was expressed as a percentage ratio between BCR-ABL1 and ABL1 to 
obtain a normalised value for the gene independent of the integrity of the RNA and  
the efficiency of the RT reaction.  
2.2.3.3.RT-dPCR 
Positive and negative controls were used to assess the amplification protocol and to 
establish the Cq range and the quantification threshold. cDNA from each patient’s 
presentation sample in addition to the in-house standardised “Wessex” plasmid, which 
contains the e14a2 BCR-ABL1 cDNA junction, were used as positive controls. cDNA 
from a healthy individual was used as negative control.  A partition size of 15 panels 
per sample was used to allow the quantification of an equal volume of cDNA as in 
RT-qPCR (3µl). All cDNA used for RT-dPCR quantification were the same used on 
the RT-qPCR platform to exclude variability introduced by the RT step.  Three NTC 
panels were included in each array to rule out contamination. Using the Digital PCR 
Analysis Software v4 (Fluidigm) the quantification threshold was determined to be 
0.03. The Cq range was manually defined as 20–32 (Table 2.3 and Appendix Figure 
2.3).  
Running a series of two-fold dilutions prepared using the ERM
®
-AD623 plasmid 
(produced by the European Commission for Reference Materials), a reference vector 
containing the BCR-ABL1 exonic fusion, we established linearity and found that 
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accurate quantification was possible down to 4 molecules per panel (2 copies/l) as 
described for DNA-dPCR (Appendix Figure 2.4).  
Total reaction mixes, volume per inlet, thermocycling conditions and data analysis 
software were as described for dPCR of DNA. Threshold and amplification range 
across the panels of the same assay were set according to the parameters defined 
during the validation stage. 
2.2.3.4.qPCR of BCR-ABL1 DNA 
Hydrolysis probe assays were as previously detailed for dPCR. Assay performance 
was assessed following MIQE guidelines [24]. In order to ensure accurate disease 
quantification, we also followed the EuroMRD recommendations for qPCR in Ph-
negative (ph
-ve
) acute lymphoblastic leukaemia [20] in which DNA extracted from 
each patient’s diagnostic sample is used to prepare standard curves (Appendix Table 
2.1). Patient-specific standard curves were prepared by performing five log dilutions 
of each patient's diagnostic sample including two half log dilutions at the end of the 
scale. The samples were diluted in tRNA buffer (Sigma-Aldrich). We used Albumin 
as a control gene to normalize the total amount of quantifiable DNA included per 
assay to 150ng/3ul/20ul reaction. The standards were run in triplicate, and in 
sextuplicate for the values below 10
-3
, in order to assess assay performance.  
The limit of quantification (LoQ) for each assay was determined based on the 
following criteria: 1) The presence of specific amplification  in six replicates;  2)  
Acceptable Cq variance between  the six replicates of the same dilution point  is ≤ 0.5 
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(for Cq < 30), ≤ 1 (for Cq between 31–33), ≤ 1.5 (for Cq >34)  Cq;  3)  Mean Cq 
variance  between  log dilution points  to  be  2.6-4 and between half log dilutions to 
be 0.5–1.5 Cq;  4) The lowest Cq with a positive signal to be at least 1 Cq lower than 
the Cq of the background.  
The limit of detection (LoD) was defined as the lowest dilution point at which the 
following could be demonstrated: 1) the presence of specific amplification in at least 
one of the six replicates in the same dilution point.  2) Mean Cq variance between the 
highest and the lowest dilution points to be <20 Cq. 3) The lowest Cq with a positive 
signal to be at least 1 Cq lower than the Cq of the background.  
DNA from healthy donors and a pool of 8 CML patients were included as negative 
controls to establish background noise in addition to an NTC. Positive signal within 
the negative controls was considered the result of unspecific amplification and was 
taken into account while defining the quantitative and sensitivity ranges where the 
mean Cq values of the replicates are required to be ≤ 3 Cq above background value. 
The assays were run on the StepOnePlus
TM
 Real-Time PCR System and data were 
analysed using the StepOnePlus
TM
Software v2.2.2. Input DNA quantities were 
normalised to Albumin and 150ng of total DNA was used per reaction. QPCR assays 
were performed in 3 independent runs; each plate containing sexduplicates per FU 
sample, triplicates for the Negative controls and NTC in addition to the optimised 
standard curve as described earlier. Repeatability and precision for qPCR runs were 
tested using ANOVA variance analysis using Microsoft Excel 2013 and SPSS on Cq 
values within LoQ and no significant difference was present among replicates (data 
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not shown). However, standard deviation increased greatly between replicates falling 
within the LoD as expected.  
As with dPCR, we also investigated whether increasing the concentration of input 
DNA improves qPCR sensitivity. Standard curves were prepared using presentation 
DNA from patients A-2 and A-4 at concentrations of 150ng/3ul, 300g/3ul and 
500ng/3ul to evaluate the effect of DNA concentration on Cq values. Higher DNA 
concentration produced no appreciable effect on the dynamic range of the qPCR 
assays. In fact, the LoQ was reduced when 500ng/3ul was used as a starting material 
(data not shown).
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2.3. Results 
2.3.1. Breakpoint Identification 
Using bioinformatics tools, we identified clusters of reads that predicted at least one 
t(9;22)-associated genomic fusion junction in all of the 32 patients tested in this study. The 
junctions were predicted either to a base pair resolution via split  reads which appeared to 
directly cover the fusion junction, or via discordant pairs of aligned reads in which each 
read in the pair mapped to different genomic loci, thus inferring indirectly the likely 
location of the junction (illustrated in Figure 2.1a). All predicted breakpoint locations were 
consistent with the exonic BCR-ABL1 fusions identified in each patient by multiplex PCR. 
In keeping with a balanced translocation in which two reciprocal fusion genes are formed, 
we found evidence of two fusion junctions in 11 of the 32 cases (34%), corresponding to 
both BCR-ABL1 (located on the derivative chromosome 22), and its reciprocate, ABL1-
BCR (situated on the derivative chromosome 9). In a further 16 cases (50%), an ABL1-
BCR fusion junction was not detected, while in the remaining 5 cases (16%) we were 
unable to detect the BCR-ABL1 junction. Nevertheless, evidence of the location of at least 
one of the two disease-specific breakpoint junctions was successfully obtained in all 32 
patients (Table 2.4). 
In the majority of split reads or discordant read pairs, both BCR and ABL1 sequences ran 
in the same genomic direction (eg 5' to 3' BCR joined to 5' to 3' ABL1). However, in a 
minority of patients (3/32) junction spanning reads were obtained in which BCR and ABL1 
sequences ran in opposite genomic directions (eg 5' to 3' ABL1 joined to 3' to 5' BCR). 
This is consistent with previous breakpoint mapping studies in CML that have reported the 
presence, in a minority of patients, of small inversions of intronic sequence at the junction 
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sites of one of the derivative chromosomes (Figure 2.1b) [25, 26)]. For each breakpoint, 
primers were designed to amplify across the fusion junctions. All BCR-ABL1 and ABL1-
BCR fusion junctions predicted by NGS for all 32 patients were successfully amplified and 
validated by Sanger sequencing of the PCR amplicons.  (Table 2.4).  
2.3.2. Comparison of Quantification Methods 
The aim of this study was to compare the specificity and sensitivity of different nucleic 
acid substrates (DNA or RNA) and different platforms, namely RT-qPCR, qPCR, dPCR 
and RT-dPCR in the detection of low levels of BCR-ABL1-positive disease. To carry out 
this comparison we tested 46 samples collected during routine clinical management from 
six patients. The patients were selected as they had been classified as good responders and 
had sustained deep molecular remission for a median of 7 years (range 2–14 years). Ten of 
the 46 samples were used as positive controls. All had a residual disease level of MR
3 
or 
above by RT-qPCR (Table 2.5 and Figure 2.2: samples A1_46; A2_1; A3_28; A4_8, 9, 
10; A5_15, 16; A6_21, 22. Also see the supplementary Tables 2.7 and 2.8 for additional 
details). The remaining 36 samples were considered negative by RT-qPCR since either 
zero or <10 molecules of BCR-ABL1 transcript had been detected (21 and 15 patients, 
respectively), which, when assessed along with control gene transcript number produced 
residual disease levels of MR
4
 (8 patients), MR
4.5 
(17 patients) or MR
5
 (11 patients; Table 
2.5 and supplementary tables 2.7 and 2.8). 
2.3.2.1.DIGITAL PCR (dPCR) Quantification 
Sixteen (44%) of the 36 negative MR samples were positive by dPCR when performed 
without a preamplification step (Table 2.5 and supplementary Tables 2.7 and 2.8). Eight of 
these samples were positive above the threshold for accurate quantification while eight 
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were positive below this threshold. Introducing a preamplification step of 14 cycles further 
increased the number of positive samples to 29 (80.5%) (Table 2.5 and supplementary 
Tables 2.7 and 2.8). Twenty-seven out of the 29 samples were positive above the threshold 
for accurate quantification with a mean number of molecules per microliter of 67 (range 2 
to 416), while the remaining two were positive below this threshold.  In the context of 
individual patients, BCR-ABL1 DNA was detected in at least one MR sample from all six 
patients (Figure 2.2). The 10 control samples that showed detectable disease by RT-qPCR 
(MR
3 
or above) were all positive by dPCR well within the quantification limit (Table 2.5 
and supplementary Tables 2.7 and 2.8).  
2.3.2.2.RT-dPCR Comparison 
Nine (25%) of the 36 MR samples showed quantifiable transcripts by RT-dPCR (mean 29 
molecules/μl, range 5 to 67) after preamplification (Table 2.5 and supplementary Tables 
2.7 and 2.8). The positive samples were detected in three of the six patients (Figure 2.2). 
Only four of the samples were positive without preamplification. Twenty-three of the 27 
samples that remained negative by RT-dPCR were found to be positive by dPCR; thus 
RT-dPCR failed to detect disease in 85% of the samples in which a positive result was 
obtained by DNA dPCR. The 10 control samples that were MR
3
 or above by RT-qPCR 
were all positive by RT-dPCR (Table 2.5 and supplementary Tables 2.7 and 2.8). 
Among MR samples, we observed no consistent proportional relationship between the 
level of transcript detected by RT-dPCR and the level of BCR-ABL1 DNA assessed by 
dPCR (Figure 2.3 and Table 2.5). For example, BCR-ABL1 transcript was frequently 
detectable in MR samples from patient A1 despite relatively low levels of DNA (mean 8 
molecules/μl), while in patient A3, a transcript was undetectable in any MR sample by RT-
dPCR even though BCR-ABL1 DNA consistently measured substantially higher (mean 57 
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molecules/μl). Finally, oncogene transcript was more frequently detected in samples 
estimated to be in MR from patients on TKI therapy (7/14; 50%) than from patients who 
had received a bone marrow transplant (1/22; 5%), implying a deeper level of remission 
post-transplant than while on TKI.  
2.3.2.3.qPCR Comparison 
Nineteen percent of the 36 MR samples (7/36; from three of the six patients) were positive 
by qPCR for the BCR-ABL1 genomic breakpoint. All seven samples had also tested 
positive by dPCR, Thus qPCR failed to detect positivity in 76% (22/29) of the dPCR 
positive samples. The 10 MR
3
 or above control samples were all positive using this 
method (Table 2.5 and supplementary Tables 2.7 and 2.8). Four samples (A4–14 and A5–
17, 18, 10) remained negative by all four quantification methods. These results might 
represent “true negative” readings particularly as they belong to patients who had received 
alloSCT.  
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2.4. Discussion 
In our study, we report a novel method of detecting and quantifying low levels of residual 
disease in peripheral blood samples from patients with CML in whom BCR-ABL1 
transcriptions are undetectable using RT-qPCR. Our DNA-based method avoids laborious 
breakpoint mapping by the use of targeted high-throughput NGS, and provides improved 
sensitivity by employing a digital PCR platform for residual disease quantification.  
The potential benefits of using genomic DNA (gDNA) for residual disease detection in 
CML are numerous [27-32]. In addition to being more stable and easier to extract than 
RNA, use of gDNA eliminates the variability introduced by the RT step, and allows target 
cell detection regardless of transcriptional activity. The latter feature ensures the detection 
of quiescent cells as well as allowing the quantification of true cellular disease burden 
rather than a mean level of oncogene expression. Furthermore, the possibility of 
amplifying benign BCR-ABL1-positive clones reported to be found in healthy individuals 
[33] is eliminated. A resulting improvement in sensitivity of at least 1 log compared to an 
RNA-based assay has been estimated for a DNA-based qPCR approach [29].  
However, a major obstacle to the routine adoption of DNA monitoring is the inherent 
difficulty of mapping the genomic breakpoints of a translocation that occurs across a wide 
area of intronic sequence, and often involves additional events such as deletions, 
insertions, duplications and inversions. The principle of using target enrichment NGS, 
which simplifies breakpoint characterization significantly, has been previously described 
[34], but earlier enrichment technology was unsuited to clinical use, being costly with 
laborious bait generation and sequencing workflows. In contrast, the technique we 
describe, with which we successfully mapped a disease-specific junction in all 32 patients 
tested, is relatively simple, cost effective and suited to a high-throughput laboratory.   
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Previous studies using qPCR have reported the detection of BCR-ABL1-positive disease in 
a substantial proportion of patients with undetectable transcripts by RT-qPCR [27-30]. 
However, one limitation of the application of DNA-based hydrolysis probe assays on a 
real-time qPCR platform is the need for positive control material with which to generate a 
standard curve. The use of patient’s presentation material for this purpose compromises 
accuracy and sensitivity because patients rarely present with 100% BCR-ABL1 positive 
cells in the peripheral blood [35-38]. The method we present circumvents this constraint 
by use of a digital PCR platform. By assigning an absolute value to the target molecules, it 
allows precise quantification without the need for a patient-specific standard curve. 
In this proof of principle analysis, we explored the impact of changing 1) the PCR 
substrate, 2) the PCR platform or 3) both these variables on the sensitivity of residual 
disease detection compared to the current gold-standard method for clinical management, 
RT-qPCR. The application of a standard BCR-ABL1 hydrolysis probe assay to cDNA 
using a digital PCR platform (RT-dPCR) showed a modest improvement in sensitivity, 
detecting disease in over 11% and 25% of post-treatment samples, without and with 
preamplification, respectively, in which BCR-ABL1 transcripts were undetectable by RT-
qPCR (Table 2.5 and supplementary Tables 2.7 and 2.8). This is in keeping with previous 
findings [18, 39]. The application of hydrolysis probe assays specific to patients’ BCR-
ABL1 DNA fusion using a real-time platform (qPCR) also provided an improved detection 
rate compared to RT-qPCR, identifying disease cells in 19% of the same samples. The 
highest sensitivity, however, was obtained by the use of the DNA assays on a digital PCR 
platform (dPCR), which detected disease in 44% of the MR samples. Introducing a 
preamplification step further increased the sensitivity allowing residual disease detection 
in 80% of the samples (Table 2.5 and  supplementary Tables 2.7 and 2.8). Digital PCR 
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preceded with 14 cycles of preamplification step for the BCR-ABL1 DNA fusion point was 
therefore by far the most sensitive available method for the detection and quantification of 
residual disease. Preamplification is increasingly becoming a required step in the 
assessment of nucleic acid quantities in samples with a limited amount of target 
molecules. However, preamplification could be associated with bias; therefore when used, 
it needs to be carefully assessed and preamplification efficiency cautiously monitored per 
assay to ensure accurate quantification [18, 40, 41]. 
DNA-based qPCR has previously been used to assess the correlation between detection of 
BCR-ABL1 at the time of stopping TKI therapy and disease recurrence [27]. Retrospective 
analysis of serial samples from 18 patients who had been in MR
5
 for at least two years has 
shown no significant correlation between the presences of BCR-ABL1 before stopping 
imatinib suggesting that perhaps factors other than the presence of residual disease cells 
must contribute to the probability of stable MR after withdrawal of imatinib [27]. One 
possible factor could be related to the level of residual disease present which could 
become a risk factor for predicting relapse once a certain threshold is crossed. A method 
of absolute quantification would be of great value to establish such a threshold if present. 
We are currently investigating the impact of residual disease level as assessed by dPCR at 
the time of treatment withdrawal on outcome within the UK based DESTINY clinical trial. 
If validated in clinical trials of stopping TKI, the technique will permit a more 
personalised approach to recommendations for dose reduction or drug cessation in 
individual patients, ensuring that therapy is withdrawn only from patients with the highest 
chance of long-term remission. In practical terms, this would require that genomic 
breakpoints be identified in a patient as soon as they are diagnosed allowing the design 
and optimisation of a patient-specific assay. Patients’ response to therapy would then be 
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monitored via standard RT-qPCR until they have reached MR; hereafter routine 
monitoring would be augmented with DNA quantification by dPCR and would benefit 
from the publication of standardised guidelines as with RT-qPCR. 
While the present study demonstrates the superiority of dPCR in a practical setting, this 
conclusion could be further supported by a precise comparison between the sensitivities of 
the templates and platforms used. Estimation of the LoD and LoQ of each platform using 
templates extracted from samples with a normalized cell count and performing serial 
dilutions of reference materials after converting their values to the international scale are 
two strategies that could be employed for such an assessment. Recently, an improvement 
in sensitivity of 1 to 3 logs was estimated for RT-dPCR compared to conventional RT-
qPCR [39, 42], and in separate studies an additional 1-log of increased sensitivity was 
observed using DNA as a template compared to cDNA on a real-time quantitative 
platform [27, 29]. The latter reports indirectly support our observation that, of currently 
available technologies, DNA-based dPCR provides the greatest sensitivity in detecting low 
levels of BCR-ABL1-positive disease. 
2.5. Conclusion 
The technologies described allow the assignment of absolute quantities to both BCR-ABL1 
DNA and RNA targets, facilitating for the first time direct comparison of mean expression 
versus cellular disease burden. In the future, it will, therefore, be important to explore not 
only whether the risk of relapse following withdrawal is a feature of the number of 
residual CML cells, but also whether it relates to the degree of transcriptional activity in 
those cells. We observed that 8% (3/36) of the samples were positive by RNA but negative 
by DNA-based methods (Table 2.5 and supplementary Tables 2.7 and 2.8). Conversely, in 
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MR samples that showed detectable BCR-ABL1 DNA, there was heterogeneity in the 
detectability of transcript by RT-dPCR that appeared to be unrelated to the amount of 
BCR-ABL1 DNA detected. It should be borne in mind that RT and cDNA synthesis steps 
remain a potential source of variation affecting cDNA concentration, and therefore these 
results should be interpreted with caution. Nevertheless, the relationship between residual 
oncogene DNA and RNA and the impact of this ratio on outcome after withdrawal 
requires further investigation.  
101 
 
2.6. Figures 
 
Figure 2.1. Pictorial representation of breakpoint mapping read types obtained by NGS of ABL1 and BCR 
sequences in a patient with CML.  a) Right hand panel: an example of split reads. These single reads are 
composed of material from two non-contiguous regions on the reference genome that map directly across the 
fusion junction and are thus capable of identifying breakpoints to base pair resolution. Based on the sequence 
information obtained from these reads, sequencing primers (grey arrows) are designed for confirmation by 
Sanger sequencing. b) Left hand panel: an example of discordant pairs of reads in which individual reads in a 
pair map to different genes. Clusters of discordant read pairs allow indirect estimation of the position of the 
fusion site to within up to 1kb. c) The effect of an inversion at the fusion site on read orientation. BCR and 
ABL1 components of the split read run in opposite genomic directions. 
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Figure 2.2. Comparison of the sensitivity of 4 methods of disease quantification in 46 samples from 6 CML 
patients. Quantification results are shown for the follow-up samples of six patients with CML according to 
substrate type and platform used. The four techniques are listed on the left hand side. Samples are 
represented by circles on a linear timeline (not to scale), with the earliest sample on the far left. The vertical 
dotted lines represent the point of achievement of MR
4
 or lower (based on RT-qPCR analysis of the proceeding 
sample). Black-filled circles represent samples in which disease was detectable and quantifiable by that 
technique. Grey-filled circles represent samples in which disease was detectable below the limit of reliable 
quantification (LoD). White-filled circles represent samples in which disease was undetectable. dPCR and RT-
dPCR values are after preamplification.   
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Figure 2.3. Comparison of the DNA-based dPCR and RT-dPCR readings in 46 samples from 6 CML patients. 
DNA dPCR results are shown on the left (blue bars) and RT-dPCR results are shown on the right (green bars). 
The vertical red dotted lines represent the point of achievement of MR
4
 or lower (based on RT-qPCR analysis of 
the proceeding sample). Precise readings are provided in Table 2.5 and supplementary tables 2.7 and 2.8. 
Plotted dPCR and RT-dPCR values are after preamplification.  The bar charts depict five scenarios: 1) DNA is 
detected while RNA is not.  2) RNA is detected while DNA is not. 3) Both DNA and RNA are detected, but DNA 
quantity is higher than RNA. 4) Both DNA and RNA are detected with higher RNA quantity compared to DNA. 5) 
Neither DNA nor RNA are detected.  
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2.7. Tables 
Table 2.1. Details of the primers used to characterise BCR-ABL1 fusion junctions in 32 CML patients. Primers were designed based 
on the results of targeted next generation sequencing. 
 
PATIENT FUSION 
GENE  
PRIMER SEQUENCE Strand AMPLICON 
SIZE (in bp) 
Tm 
(⁰C) 
A1 ABL1-BCR F 5' GTTCCTACCAGCACCCTTGA 3' + 580 61 
    R 5' CTCTCTCCCAACCCCATTC 3' -   
A2 BCR-ABL1 F 5' TTCACGCCAGACCACAATTA 3' + 233 61 
    R 5' ACTGAAACCAGCCAATGGAC 3' -   
  ABL1-BCR F 5' GCTCTAGGCTTTCCTCAGCA 3' + 299 61 
    R 5' TGTGATGACAGGGATGGGTA 3' -   
A3 BCR-ABL1 F 5' CCCATGACACTGGCTTACCT 3' + 778 61 
    R 5' GCTCTTTGCCCACTCCACTA 3' -   
  ABL1-BCR F 5' CTTAGGCACCAGCTCGTAGG 3' + 938 61 
    R 5' GGGAAACACCAGCGTTTATG 3' -   
A4 ABL1-BCR F 5' AACCCAAAAAGGAGGACTTGA 3' + 336 61 
    R 5' ACGGCGACACACAATACAAA 3' -   
A5 BCR-ABL1 F 5' GATGCTGACCAACTCGTGTG 3' + 340 61 
    R 5' CCCAGGGATGGTAAAAACCT 3' -   
  ABL1-BCR F 5' AAAATGTACGGGGGAGAAGC 3' + 235 61 
    R 5' AGATCCAAGGCACAGAGCAT 3' -   
A6 BCR-ABL1 F 5' TCTTGCGCAGATGATGAGTC 3' + 932 61 
    R 5' TGAACAACCTCCCTGTTTCC 3' -   
B1 BCR-ABL1 F 5' GCTGTTTGCGCTCACATTTAC 3' + 201 61 
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    R 5' CAGCCTCCCAAGTAGCTGAG 3' -   
B2 BCR-ABL1 F 5' TGTCATCGTCCACTCAGCCAC 3' + 246 65 
    R 5' GGCAGACAGAGTGAGACTCCATC 3' -   
B3 BCR-ABL F 5' GGAATTGTTTTTCCCGGAGT 3' + 286 61 
    R 5' CCAGGAACAGGCTTTGTTTAA 3' -   
  ABL1-BCR F 5' CCATTGGTGAACTGCTCCTT 3' + 230 61 
    R 5' CGGCCTCGAGAAACTTACAC 3' -   
B4 BCR-ABL F 5' GATGAGTCTCCGGGGCTCTA 3' + 230 61 
    R 5' CTCGTTCTGTCGCTAGGGTG 3' -   
B5 BCR-ABL F 5' GCTCTTACAGACCATGTGGGT 3' + 284 61 
    R 5' AGGACTGAGGCTGGAAGTCA 3' -   
B6 BCR-ABL F 5' TTGTGCTGGTTGATGCCTTC 3' + 200 61 
    R 5' TGCAATCTCTCTCTCCAAGGA 3' -   
B7 BCR-ABL F 5' TGGACAAGGTGGGTTAGGAG 3' + 280 61 
    R 5' AGTAAGAGCTGACGTGTATTGTGC 3' -   
  ABL1-BCR  F 5' CCAGGGTCTCATAACCAAGG 3' + 310 61 
    R 5' AAGGTTCCAAGGACAGCAGA 3' -   
B8 BCR-ABL F 5' CATGTCCACTTCTCCCCACA 3' + 211 60 
    R 5' TTCACGTGATCCCTCTGCCT 3' -   
B9 BCR-ABL F 5' ACTTCTCCAGCACTGAGCTG 3' + 258 61 
    R 5' GTCCCAATTAACGGTGGAAA 3' -   
B10 BCR-ABL F 5' ATCGTCCACTCAGCCACTG 3' + 664 61 
    R 5' TTATCAACATTCACATCTCACAGG 3' -   
  ABL1-BCR F 5' CAGCTGAAGAAGGTCTGGATTAGTA 3' + 332 61 
    R 5' CTGGTAAGCTTTCTGTCTCCACA 3' -   
B11 BCR-ABL1 F 5' GTGAAGGCTGGTAACACATGAG 3' + 384 61 
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    R 5' CCCAACCAGCTCACTTTACB 3' - 
B12 BCR-ABL1 F 5' GGAAACAGGGAGGTTGTTCA 3' + 671 60 
    R 5' GCTACAAGGAACACGCAACA 3' -   
C1 BCR-ABL1 F 5' GCCCATGACACTGGCTTACC 3' + 228 61 
    R 5' CACACCAAGCCTCCCAAGTT 3' -   
C2 ABL1-BCR F 5' GAGATGGAGTTTCACCGTGC 3' + 170 61 
    R 5' GCAAACCAGTGACTCGAAGT 3' -   
C3 BCR-ABL1 F 5' CCCATGACACTGGCTTACCT 3' + 224 60 
    R 5' TGGCCTGCTTGGTTAACTTT 3' -   
C4 ABL1-BCR F 5' TTTGGTGGTTGGGTTGCAAA 3' + 183 61 
    R 5' TATGAGGCAGCCAGAGACAG 3' -   
C5 BCR-ABL1 
(+/-) 
F 5' CTAGGCAGTGGGCACCTGTA 3' + 2722 61 
    R 5' GTAAGAAATCTTTGTGTCTACCCTAAGG 3' +   
  ABL1-BCR 
(+/-) 
F 5' GTGGTCTGTGTAAGAAATCTTTGTG 3' + 220 61 
    R 5' GGCAGTGGGCACCTGTAAT 3' +   
C6 BCR-ABL1 F 5' CTGGAGTCCGGGTGTCCTC 3' + 206 61 
    R 5' TCACGTTTGAGGCTGTGGAA 3' -   
  BCR-ABL1 
(+/-) 
F 5' ATGATGACAGTGAGTGTGGCC 3' - 282 61 
    R 5' TGTCGCATTGAAAGATGACACTTA 3' -   
  ABL1-BCR 
(+/-) 
F 5' GCTGCACGATTAGTGTTGTACATT 3' - 285   
    R 5' AACTCCCTGGCATGGTGG 3' - 61 
C7 BCR-ABL1 F 5' CCCATGACACTGGCTTACCT 3' + 300 61 
    R 5' CATACTCCGTTCCAGCGG 3' -   
  ABL1-BCR F 5' ATGATCTCATCCGCTGGAAC 3' + 350 61 
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    R 5' CCAGCTCCCAGGATCTGAG 3' -   
C8 BCR-ABL1 F 5' CCCCGTTTCCGTGTACAGG 3' + 239 60 
    R 5' CTAGGACCCTGGAGCACTGT 3' -   
D1 BCR-ABL1 F 5' TGCACCTCTTTTCCAACCTC 3' + 248 61 
    R 5' TGCAGCCAGTCCCTTAGTCT 3' -   
D2 BCR-ABL1 F 5' TCTGCTGTCCTTGGAACCTT 3' + 185 61 
    R 5' ATGAGGGAAGAGGGAGGAGA 3' -   
D3 BCR-ABL1 F 5' TGTGACCTTCTCCATGTCCA 3' + 206 61 
    R 5' TCTGCCACACAAAGAACCTG 3' -   
  ABL1-BCR F 5' CAAGGAACTGCCCTATTCCA 3' + 300 61 
    R 5' CAACATTCGTTCACTCAGTCG 3' -   
D4 ABL1-BCR F 5' TTGGGAAGAGAAGGGAACCT 3' + 200 61 
    R 5' AGGCAGTGTCACAGCACAAC 3' -   
D5 BCR-ABL1 F 5' TCACGCCAGACCACAATTAG 3' + 244 60 
    R 5' GTCCCAATTAACGGTGGAAA 3' -   
  ABL1-BCR 
(+/-) 
F 5' TGTAATCCCAGCAATTTGGGA 3' + 189 65 
    R 5' CACAGCAGGCTGCCTGG 3' +   
D6 BCR-ABL1 F 5' GAGTTGGAGACCAGCCTGAC 3' + 183 61 
    R 5' CCTCCCTCACCTCCACAAA 3' -   
  ABL1-BCR F 5' CCAACCCCTGCCCTTTTAAA 3' + 191 61 
    R 5' CGATTCTCTTCCCTCAGCCT 3' -   
 
 
 
108 
 
 
Table 2.2. Sequences of primer and probe components of 6 patient-specific hydrolysis probe assays for the BCR-ABL1 or ABL-BCR DNA junction used for 
dPCR and qPCR 
Patient Fusion Assay* Sequence Tm Length (bp) 
A1 ABL1-BCR A1_ABL1-BCR_F 5' GTTTAGTTGATGACACACCTGACTCTAA 3' 58 116 
    A1_ABL1-BCR_R 5' CCCAGGCTGGAATGCAGT 3' 58.2   
    A1_ABL1-BCR_P 6FAM- 5' CCTGGCGGAGGTTG 3' 70   
A2 BCR-ABL1 A2_BCR-ABL1_F 5' GGTGATGTGGAAAAGACCTGTGA 3' 59 127 
    A2_BCR-ABL1_R 5' CATCCACATATATAGGACTCCCAACAC 3' 59   
    A2_BCR-ABL1_P 6FAM- 5' CTTCTCCATGTCCACTTC 3' 70   
A3 BCR-ABL1 A3_BCR-ABL1_F 5' CAGATCCTGGGAGCTGGTGA 3' 59.8⁰C 145 
    A3_BCR-ABL1_R 5' GATGGTGTTTCACCACATTAGCC 3' 59.2⁰C   
    A3_BCR-ABL1_P 6FAM- 5' CGGATCACAAGGTCA 3' 69⁰C   
A4 ABL1-BCR A4_ABL1-BCR_F 5' ATCACATAACCTAAAACTTAACATTGACACC 3' 60 109 
    A4_ABL1-BCR_R 5' CGCTAACAAAGGCAGACAAAAAG 3' 59   
    A4_ABL1-BCR_P 6FAM-5' TGGAAAGAGACTTAAAAAG 3' 69   
A5 BCR-ABL1 A5_BCR-ABL1_F 5' TGATGGGACTAGTGGACTTTGGTT 3' 59.1⁰C 97 
    A5_BCR-ABL1_R 5' TCTACACCCATGTGGGAGCAG 3'    59⁰C   
    A5_BCR-ABL1_P 6FAM-5' AGAAGGAAGAGCTATGCTT 3' 70⁰C   
A6 BCR-ABL1 A6_BCR-ABL1_F 5' GGATACTACTTTTTTTTTCCTTTCCCTC 3' 58.4⁰ C 162 
    A6_BCR-ABL1_R 5' GTAACATTAACTGTTGGAAAACATGTCTTAG 3' 58.9 ⁰C   
    A6_BCR-ABL1_P 6FAM- 5' CTTAAATAGCTCTAGTTCCCT 3' 70⁰C   
 
 
Table 2.3. dPCR and RT-dPCR threshold and Cq parameta defined for each of 
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the 6 assays performed on DNA (A1-A6) and one assay performed on cDNA 
(WESSEX plasmid). 
 
Analytical method Assay Cq range threshold 
dPCR A1 20-32 0.05 
dPCR A2 20-32 0.05 
dPCR A3 20-32 0.05 
dPCR A4 18-40 0.03 
dPCR A5 16-40 0.02 
dPCR A6 20-40 0.025 
RT-dPCR WESSEX plasmid 20-32 0.03 
 
 
Table 2.4. Table showing the Sanger-validated junction sequences of BCR-ABL1 and/or ABL1-BCR fusion genes in 32 CML patients. 
Patient Fusion* Sequence** 
A1  
ABL1-
BCR 
TAACCTGCATAAGTATGAGGAAGAAAAGTGKGAACWGAATCATAACTAAAGGAAAGAAGAACATTGCTGTCTTAAGCAGATCACGCCTTTGTCGTTA
TACAGWAWGGTACAATAATCCATTACACATCTCTTTGATTCATCTTGTCTGTTAAATTTCTTTATAAAATTTGTTTAGTTGATGACACACCTGACTC
TAATATAAGAGTTGAATGTTGTATCACTTTTTTTTTTCCTGGCGGAGGTTGCAGTGAGCCGAGCTTGTGCCACTGCATTCCAGCCTGGGCGACAGAG
CAAGACTCCGCCTCAAAAAAAAAAAAAAAAAGTTCCTAGAAACAGCAAAATGTGGAGACAGAAAGCTTACCAGGGATTGTTGGGGAATGGGGTTGGG
AGAGAGGACTAACTGCAGATGAACCCAAGGGGGACTTTTTAGGTGA 
A2  
ABL1-
BCR 
GCTCTAGGCTTTCCTCAGCAGTCTGGTAATCCTGGTTGTCCATTCATGCTTAGGGTATTTTGTGAATAAAGCAAAGACGCGCGTCTACAGGGACACA
GCTGAGCCAAACTGGAACGAGGTGAGGAACTGATTCCACAAGGGCCCAGCCTGCCAGGTGGGGCACAGGATATTTTCCACTGGAGTAATCTAAACCT
TCAGGGGCTCCCTGAGGGCTTCCCCCGAAGGCAGTGCTGCTGAATTCCAGGAATCTCCTGGGGGGCCAGTAGGTGACGTGTCCAAGAGTTTTATCTC
CTTGTTCCTGAAAACCTTACCCATCCCTGTCATCACA 
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A2  
BCR-
ABL1 
GTTTAATTTTTAAAAAGAAAATTACAACCTTTTTTTTTTATTTTTATTTTTTCTGATTCTGCAAATAACACCTGCTCTTACAGACCATGTGGGTGAT
GTGGAAAAGACCTGTGACCTTCTCCATGTCCACTTCTCCCCACAGATCTGTACTGCACCCTGGAGGTGGATTCCTACATGGGAATGGAAGGGGTGTG
GAGTCCC 
A3  
BCR-
ABL1 
AAGGACTCATCGGGCAGGGTGTGGGGAAACAGGGAGGTTGTTCAGATGACCACGGGACACCTTTGACCCTGGCCGCTGTGGAGTGTTTGTGCTGGTT
GATGCCTTCTGGGTGTGGAATTGTTTTTCCCGGAGTGGCCTCTGCCCTCTCCCCTAGCCTGTCTCAGATCCTGGGAGCTGGTGAGCTGCCCCCTGCA
GGTGGATCGAGTAATTGCAGGGGTTTGGCAAGGACTTTGCGGATCACAAGGTCAGGAGATCGAGACCATCCTGGCTAATGTGGTGAAACACCATCTC
TACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATGGCGTGAACCCTGAAG
GCGGAGCTTGCAGTGAGCCGAGATGGCGCCACTGCACTCCAGCCTGGGCAACAGAGCAAGACTCCGCCTCAGAAAAAAAAAAGAAAAGAAATGCCCC
GTAGAGGCTCT 
A3  
ABL1-
BCR 
TAAACATTAACTCCCCTTTAGTATTTCATTTCTAGGGTTTCCAGCCTTGGTAACAATTACCAAGAACTTTGCTGTCATGGGGTACAGCTCTAGGCTG
CTGACAGGATCTTCATACTGGAGGAGACTATACTTTTATAGCCAATTCCAACTGCCCCAGAGATAACTTGGATAAACACTGGCTCCTCCACTACCTC
CTAATCCCTGCTGGGTTTTACACTGTGGGGAGGTTTGGGAGGCCGAGTTGGAGACCAGCCTGACCAACATGGTGAAACCCTGTGTCTACTAAAAATA
CAAAGATTAGCCAGGCTAGGCAGTGGGCACCTGTAATCACAACTGCTTGGGAGGCTGAGGGAAGAGAATCGCTTGAACCCAGGAGGCGGAGGTTGCA
GTGAGCCGAGCTTGTGCCACTGCATTCCAGCCTGGCGACAGAGCAG 
A4  
ABL1-
BCR 
AACCCAAAAAGGAGGACTTGAGATTTCTGATTTATAAACAGTTCGTCAAAAAAGACAGATCACATAACCTAAAACTTAAGATTGACACCTAAAGAAG
CCACCTATTTTGCTGGAGAAGTGTTTGGAAAGAGACTTAAAAAGGCTTTTTGTCTGCCTTTGTTAGCGCTTATGTTTACTTGGTAGGTTTCCATAGT
GTTTTTCCGCAGAAGTTGGAATGAGCTCCCGTGACCCTCTTGGCTTCCGGAAGCCTGGGGCTCTGCTGGTGGGGCTGGGACAGGGACTGTAGGGTCC
TGCTTGCTTGTCTCGGGGTGTTGGGTTTGTATTGTGTGTCGCCG 
A5  
BCR-
ABL1 
GATGCTGACCAACTCGTGTGTGAAACTCCAGACTGTCCACAGCATTCCGCTGACCATCAATAAGGAAGGTGGGCCCCCCCGTTTCCGTGTACAGGGC
ACCTGCAGGGAGGGCAGGCAGCTAGCCTGAAGGCTGATCCCCCCTTCCTGTTAGCACTTTTGATGGGACTAGTGGACTTTGGTTCAGAAGGAAGAGC
TATGCTTGTTAGGGCCTCTTGTCTCCTCCCAGGAGAGCTGCTCCCACATGGGTGTAGAAACTGGTTTTATCCTATCTGTGTGACCTCCAATAGCTGC
AAGTTGGAAATCTTGATTTAGAGTGGACCTAGGTTTTTACCATCCCTGGG 
A5 
ABL1-
BCR 
AAAATGTACGGGGGAGAAGCACATTACACAGTATCAATCAGAAAGGAATATTTCTGTCTGAGCTTTCACTTTGAGTGGAGGGCAAAGAAAAAAAATC
ACATGAGAACTTGTGGCTGCTGACCAGCAGTTTCTCCCTGAGTGGCTGCTGCTGGGTGGTTGAGGAGATGCACGGCTTCTGTTCCTAGTCACAAGGC
TGCAGCAGACGCTCCTCAGATGCTCTGTGCCTTGGATCT 
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A6  
BCR-
ABL1 
CTGGGAGCTGGTGAGCTGCCCCCTGCAGGTGGATCGAGTAATTGCAGGGGTTTGGCAAGGACTTTGACAGACATCCCCAGGGGTGCCCGGGAGTGTG
GGGTCCAAGCCAGGAGGGCTGTCAGCAGTGCACCTTCACCCCACAGCAGAGCAGATTTGGCTGCTCTGTCGAGCTGGATGGATACTACTTTTTTTTT
CCTTTCCCTCTAAAAAAAAAAAAAATCTTAAATAGCTCTAGTTCCCTGAATTATTTTCTCCTAAGACATGTTTTCCCAACAGTTAATGTTACTTATT
TCATCTTCTGATCTTACTCATATTATCCACCTTTCACTTAAATTGGAAATTTTCTGCCATTTTACAAAGTTCAAGACTTTC 
   
B1 
BCR-
ABL1 
GAGAGCAGTGTCGTGAAAAGACTGTGGTGCTGTTTGCGCTCACATTTACATTTCCTAAAATTCTTTAAACCCTACACTTGGCTGAGGCGGGTGTATC
ACCTGGGTCAGGAGTTCGAGACCAGTCTGGCCAACATGGTGAAACCCCGTCTCTACTAAAATATAAAAAAAAT 
B2 
BCR-
ABL1 
TGTCATCGTCCACTCAGCCACTGGATTTAAGCAGAGTTCAAGTAAGTACTGGTTTGGGGAGCAGGTACAGGGGTGAGCCTCCACGCCGGGCCTCTCT
TTTTAAGATAATAAAAATTACTAAACATCATAATGACATGATTTGGGATTACTCTTTCAGAGAAACAGTTCCTAAAGGTTTACTTCAGTTAGTGA 
B3 
BCR-
ABL1 
CCTGGGAGCTGGTGAGCTGCCCCCTGCAGGTGGATCGAGTAATTGCAGGGGTTTGGCAAGGACTTTGACAGACATCCCCAGGGGTGCCCGGGAGTGT
GGGGTCCAAGCCAGGAGGGCTGTCAGCAGTGCACCTTAGTGGGTGGTTTTAGAATTCCACTTCAGATGGCACTGACCTTTCCTTAATACAGCTGGTT
TCACTTAATACATTTTGTTTAAACAAAGCCTGTTCCTGG 
B3 
ABL1-
BCR 
TCCATTGGTGAACTGCTCCTTGCCTTGAGGTCCTGTAGCTAGTTTGCCACTGAGTATTTCCTTCAAAAAACAGGAAGGATGCCCTGATATTATGCAG
CAGAGCAGATTTGGCTGCTCTGTCGAGCTGGATGGATACTACTTTTTTTTTCCTTTCCCTCTAAGTGGGGGTCTCCCCCAGCTACTGGAGCTGTCAG
AACA 
B4 
BCR-
ABL1 
GATGAGTCTCCGGGGCTCTATGGGTTTCTGAATGTCATCGTTCATCCCGGCCAACATGGTGAAACCCCGTCTCTACTAACCATACAAAAATTAGCTG
GGCGTGGTGGCGCTTGCCTGTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCGCTTTAACCAGGGAGTCGGAGGTTGCAGTGAACCGAGA
TCGCGCCATTGCACTCCACCCTAGCGACAGAACGAG 
B5 
BCR-
ABL1 
TCTTACAGACCATGTGGGTGATGTGGAAAAGACCTGTGACCTTCTCCATGTCCACTTCTCCCCACAGATCTGTACTGCACCCTGGAGGTGGATTCCC
TGGTCAGGTCTGCATTTGAGAAAGATGGCCCTGATAGTAGGGAGTGGAGGTGGAATGGCCAAAGGGGGACCCAGCCAAGGGCGTGGTAGAGCATGGA
AAGGACAGAAGTGATGAGAGATTGAGGAGGAAAAGTGC 
B5 
ABL1-
BCR 
AGATTCTTCAGAGGAGGCCCCTCCAGCCACTCAGAACTTCATCATTCCAAAAAAGGAGATCCATCCTGCTCTTACAGACCATGTGGGTGATGTGGAA
AAGACCTGTGACCTTCTCCATGTCCACTTCTCCCCACAGATCTGTACTGCACCCTGGAGGTGGATTCCTTTGGGTATTTTGTGAATAAAGCAAAGAC
GCGCATCTA 
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B6 
BCR-
ABL1 
GGCCTCTGCCCTCTCCCCTAGCCTGTCTCAGATCCTGGGAGCTGGTGAGCTGCCCAAAAATAATAAATAAATAAATAAATAAATAAATAAATAAATA
AATAAATAAAGCTATGCATTTCCCACAAATACTGCTTAAAAAAAAAAGAACTATTCTTTGCTATCCTTGGAGAGAGAGATTG 
B7 
BCR-
ABL1 
TGGACAAGGTGGGTTAGGAGCAGTTTCTCCCTGAGTGGCTGCTGCTGGGTGGTTGAGGAGATGCACGGCTTCTGTTCCTAGTCACAAGGCTGCAGCA
GACGCTCCTCAGATGCTCTGTGCCTTGTCTGACTTCTCTGAGCATCTGTGGGGTTTGTTTGTTTTTAAACCTGAAGAATTGGGATAATCTGTTTCCT
CACAGAATCATTACGCAGATGCAATACAGTTAATGAA 
B7 
ABL1-
BCR 
CCAATGCTTTAATCCACTTGGAATTTATTCTTGATGTGAAGGGTCAGCATCATCCACTGGTCGGGAGCCTGATCCTTGGAGCCAGGCAGACCTGGGT
TGAGTCCATCTCCGCCTGTTTCCAGCTGTGGGCAAGGTCTGGCCCCACTCCCGTCCTCCCAGCCCTCCTCTCCTCCAGCTACCTGCCAGCCGGCACT
TTTGGTCAAGCTGTTTTGCATTCACTGTTGCACATATGCTCAGTCACACACACAGCATACGCTATGCACATGTGTCCACACACACCCCACCCACATC
CCACATCACCCCGACCCCC 
B8 
BCR-
ABL1 
CATGTCCACTTCTCCCCACAGATCTGTACTGCACCCTGGAGGTGGATTCCTTTGGGTATTTTCGGATCACTTGAGGTCAGGAGTTCGAGACCACCCT
GGCCAACATGGTGAAACCTCGTCTCTACTAAAAATACAAAAATTAGTCGGCATGGTGGCACACACCTATAGTCCCACCTACATGGGAGGCTGAGGCA
GAGGGATCACGTGAA 
B9 
BCR-
ABL1 
CTCCAGCACTGAGCTGCTTCCTGTGCCCCACAGTGGCCTGGAGTCCCCTTTGCCTTAACTCTTTGCCCCATAGTACAGCGTGGCCCCCAGCCCCGGC
ACCAGCCCCGGTAGAGCCACGCCGGATGGTGACGGCGGCGTCCGGGACCCCACAGTGCGGGCTCCCCCGAAAAAGTTTGAGAAAGCCAA 
B10 
BCR-
ABL1 
CACTGGATTTAAGCAGAGTTCAAGTAAGTACTGGTTTGGGGAGGAGGGTTGCAGCGGCCGAGCCAGGGTCTCCACCCAGGAAGGACTAATCGGGCAG
GGTGTGGGGAAACAGGGAGGTTGTTCAGATGACCACGGGACACCTTTGACCCTGGCCGCTGTGGAGTGTTTGTGCTGGTTGATGCCTTCTGGGTGTG
GAATTGTTTTTCCCGGAGTGGCCTCTGCCCTCTCCCCTAGCCTGTCTCAGATCCTGGGAGCTGGTGAGCTGCCCCCTGCAGGTGGATCGAGTAATTG
CAGGGGTTTGGCAAGGACTTTCAGGCGTGCGCCACCATGCCTGGCCAATTTTTTTGTATTTTTAGTAGAGACGGGGTTTTGCTATGTTGGTCAGGCT
GGTCTCAAACTCCTGACCTCAAGTGATCCGCCTGCCTTGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGTACCTGGCCGATATTTTCTA
TTTTATTTCATTTTGAAAAAGATAGGCTGTGACTCATTAGTAGTGGATCTCATGACTAAGAATGGATCCTGACCCAAGTTTGAAGAGACTGGTAGGG
GTAAATTTAGAGCCTGGGGCTCCAAAGTTTGTCTACCCAGTTTTAAATCCTGGCTTTCCCCTTAACTTGGGTGGGATCACAC 
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B10 
ABL1-
BCR 
TTTTCTTTTTCTTTTTTTTTTGAGACAGTCTTACTCTGTTGCCCAGGCTGGAGTGCAGTGGTGTGATCTCGGCTTACTGCAACCTCCACCTTCCAGG
TTCAAGCAGTTCTCCTGTCTCAGCCTCCCAAGTAGCTGGGACTAGGACTTTGACAGACATCCCCAGGGGTGCCCGGGAGTGTGGGGTCCAAGCCAGG
AGGGCTGTCAGCAGTGCACCTTCACCCCACAGCAGAGCAGATTTGGCTGCTCTGTCGAGCTGGATGGATACTACTTTTTTTTTCCTTTCCCTCTAAG
TGGGGGTCTCCCCCAGCTACTGGAGCTGTCAGAACAGTGAA 
B11 
BCR-
ABL1 
GTGAAGGCTGGTAACACATGAGTTGCACTGTGTAAGTTTCTCGAGGCCGGGCGCAGTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGC
AGGTGGATCGCTTGAGCTCAGGAGTTGGAGACCAGCCTGACCAACATGGTGAAACCCTACCAGTTACCATGCCGGAGTAACAGTTACCTCACTGGTA
TACCAGTTACCATGCCAGAGTGACTGATTTTGACCAAGACCTTTGGGTTGTACAGAAGGGGTGAGACCATACCTGTCCTCAAGCATTTCCAACCTAG
TGTAGAGAAAAACAGGAGCAAGATAAGAAC 
B12 
BCR-
ABL1 
TGTTTGTGCTGGTTGATGCCTTCTGGGTGTGGAATTGTTTTTCCCGGAGTGGCCTCTGCCCTCTCCCCTAGCCTGTCTCAGATCCTGGGAGCTGGTG
AGCTGCCCCCTGCAGGTGGATCGAGTAATTGCAGGGGTTTGGCAAGGACTTTGACAGACATCCCCAGGGGTGCCCGGGAGTGTGGGGTCCAAGCCAG
GAGGGCTGTCAGCAGTGCACCTTCACCCCACAGCAGAGCAGATTTGGCTGCTCTGTCGAGCTGGATGGATACTACTTTTTTTTTCCTTTCCCTCTAA
GTGGGGGTCTCCCCCAGCTACTGGGGGCATCCCTGACCTCCAAATGGTCTGTTTTGGCCTCCATTCCTATATCCTTTAAATGACTGARAATGCAGCT
GGTAAAGTTGGAARAATAAAGTTAACCAAGCAGGCCAGGCACGGTGGCTCACGCCTATAATCCCAGCACTTAGGGAGGCCAAGGCGGGCAGATCACC
TGAGGTCAATAGTTCGAGACCAGCCTGGCCAACAAGGTGAAACCCCATCTCTACTAAAAATACAAAAAATTAGCCAGGTGTGGTGGTGTGCACCTGT
AGTCCCAGCTATTTGGRAGGCTGAGGTGGGAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCTGAAATCGCGTACCACACTC 
   
C1 
BCR-
ABL1 
GCCCATGACACTGGCTTACCTTGTGCCAGGCAGATGGCAGCCACACAGTGTCCACCGGATGGTTGATTTTGAAGCAGAGTTAGCTTGTCACCTGCCT
CCCAGCCTCTGCTTTTTCTGTTTCCTTCTTGATGGGAAGACTGGCAGCAGGATTTACTTGGTTGCTACATTTGTGAATTTGTAAAATAATTCATGCT
CTGCTAGGTCTGTAACTTGGGAGGCTTGGTGTG 
C2 
ABL1-
BCR 
GAGATGGAGTTTCACCGTGCTGGCCAGGCTGGTGTCATATGCTCAGTCACACACACAGCATACGCTATGCACATGTGTCCACACACACCCCACCCAC
ATCCCAC 
C3 
BCR-
ABL1 
CCCATGACACTGGCTTACCTTGTGCCAGGCAGATGGCAGCCACACAGTGTCCACCGGATGGTTGATTTTGAAGCAGAGTTAGCTTGTCACCTGCCTC
CCTTTCCCGGGACAACAGAAGCTGACCTCTTTGATCTCTTGCGCAGATGATGAGTCTCCGGGGGGATGCCGTTTTGGCCTCCATTCCTATATCCTTT
A 
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C4 
ABL1-
BCR 
CTGCCATTTTTACTTGAAACTATGACAAACTATGGTTATTCACTTGGAATGGATGAATTACATGACATGCAGATTGCACCTTCATAACATAATCTTT
CTCCTGGGCCCCTGTCTCTGGCTGCCTCATAAACGCTGGTGTTTCCC 
C5 
BCR-
ABL1 
(+/-) 
CTAGGCAGTGGGCACCTGTAATCACAACTGCTTGGGAGGCTGAGGGAAGAGAATCGCTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCCGAGCTTGT
GCCACTGCATTCCAGCCTGGGCGACAGAGCAAGACTCCGCCTCAAAAAAAATATGAGGGAAAAAATGAACCTTCGCCCCTACACAGAAAAAACAATT
CCAGGCCAACTATAAACATGAGATGTAAGAGAGTGAAACTTCTTTGTGACCTTAGGGTAGACACAAAGATTTCTTACA 
C5 
ABL1-
BCR 
(+/-) 
TGTAAGAAATCTTTGTGTCTACCCTAAGGTCACAAAGAAGTTTCACTCTCTTACATCTCATGTTTATAGTTGGCCTGGAATTGTTTTTTCTGTGTAG
GGGCGAAGGTTCATTTTTTCCCTCATATTTTTTTTGAGGCGGAGTCTTGCTCTGTCGCCCAGGCTGGAATGCAGTGGCACAAGCTCGGCTCACTGCA
ACCTCCGCCTCCTGGGTTCAAGCGAT 
C6 
BCR-
ABL1 
TCTGGAGTCCGGGTGTCCTCGGGCAGGTCGCCAGAGAACCTGTCAAACCAAGAGTTGTATTGGCATCTGAGTAGGTTTCTGCTTGTCTCAGAGTCAG
GTGTCTGAAATGTCCTGGGATCGATGGTAAGAGCAGCTAAGAGGTCTGCTCATGGTTGGCATTTTATTTCTCCTGTCCAGAGACAATATTTCCACAG
CCTCAAACGTGA 
C6 
BCR-
ABL1 
(-/+) 
CCCTGGCATGGTGGGAGCCCTGGCCAACCTCAGCCACCCGTGCTTCTCCATGATGACAGTGAGTGTGGCCCGTCCCAGGCACAGACGCTTAGGTGTG
TTCTGAGACATGCCAAGTATGTTCTTCACAAGACTCCCACAACCAGCATAAGGCACTCATCGCTATTTATAAATTCCAGTTCTAAATCTACGCACAA
TTTTTCATGTTTTCCATTCCGTACCTTCCAAGTAACTAATTCCTCTTGAAACCAGTATCAAAAATAAGTGTCATCTTTCAATGCGACA 
C6 
ABL1-
BCR (-
/+) 
ATTTCTGTCGCATTGAAAGATGACACTTATTTTTGATACTGGTTTCAAGAGGAATTAGTTACTTGGAAGGTACGGAATGGAAAACATAAAATTGTGC
ATAGATTTAGAACTGGAATTTATAAATAGCGATGAGTGCCTTATGCTGGTTGTGGGAGTCTTGTGAAGAACATACTTGGCATGTCTCAGAACACACC
TAAGCGTCTGTGCCTGGGACGGGCCACACTCACTGTCATCATGGAGAAGCACGGGTGGCTGAGGTTGGCCAGGGCTCCCACCATGCCAGGG 
C7 
BCR-
ABL1 
CAGAGTTAGCTTGTCACCTGCCTCCCTTTCCCGGGACAACAGAAGCTGACCTCTTTGATCTCTTGCGCAGATGATGAGTCTCCGGGGCTCTATGGGT
TTCTGAATGTCATCGTCCACTCAGCCACTGGATAGATAAAATGACTTTCATCAAGCTCAAAATGTGGGAAATAATACTTTTCCTCTAAGCTCATATT
TTGAAAAGTTGTTTGAGACTGTTATAAAATAACTTGAGAATAGTCTGAGCATGATCTCATCCGCTGGAACGGAGTATG 
C7 
ABL1-
BCR 
TCCGCTGGAACGGAGTATGAAATAAAACACGAAGCCTCTTTTTAGAAGGATCTGTTTTATAGATTTTTAAATTACAGAGATTCCTTGAACTGGAGGA
TAATAGCGAAGGACCCACAAAGGAAATATGAATAAAGGCAGCGGCAGAGCCAGGGTCTCCACCCAGGAAGGACTAATCGGGCAGGGTGTGGGGAAAC
AGGGAGGTTGTTCAGATGACCACGGGACACCTTTGACCCTGGCCGCTGTGGAGTGTTTGTGCTGGTTGATGCCTTCTGGGTGTGG 
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C8 
BCR-
ABL1 
CCCCGTTTCCGTGTACAGGGCACCTGCAGGGAGGGCAGGCAGCTAGCCTGAAGGCTGACAGTCTGAAGCCTTTGAATCTGGCTTCTTTCATTCAATA
TAATGGGTGAGGAGTCAACCACGTTGTTGCATGTTATCCACATTTCCTCCTTTTGTGTCTCTGAGTAGTATTCTCTTGCATAGAT 
   
D1 
BCR-
ABL1 
CTGCAGATGCTGWCCAACTCGTGTGTGAAATCCAGACTGTCCACAGCATTCCGCTGACCATCAATAAGGAAGGTGGGCCCCCCCGTTTCCGTGTACA
GGGCTAGAAGGGTCCTGGAGGTTTGCCACTTCTCCGTGTTGAGGTACAGAGTTCCTAGACTAAGGGACTGGCTGCATTGTTATGTGTGAGTGCTAGT
CATGGTGCTGCCTGGCACCCACAAATGCCACAGCAGACCCATGGTCGAGGGAGA 
D2 
BCR-
ABL1 CTGCTGTCCTGGAACCTTATTACACTTCGAGTCACTGGTTTGCCTGTATACTGGAGTCTGGATCTGACCAGTCTCCAGATGAAAACTCTTGCAACTT
TCGTTTTTGGATAGTGCTCACCTCGTATCTGTACTCGTACCTGCTATTTCTAGGCGAATTGTCCCCTTTCTCCTCCCTCTTCCCTCAT 
D3 
BCR-
ABL1 
TGTGACCTTCTCCATGTCCACTTCTCCCCACAGATCTGTACTGCACTCTGGAGGTCTCAGGTGATCTGCCCACCTCGGCCTCCCAAAGTGCTGGGAT
TACAGGCGTGAGCCACTGTGCCCGGCCGGTTGAACGTTTTTAACATGTTTAGGGGAGATACATACTTATCTTTCTGTGAACCATCTCATCAGGTTCT
TTGTGTGGCAGA 
D3 
ABL1-
BCR 
CAAGGAACTGCCCTATTCCAAGCTCCAGAGGACCTGCTGAGTAGGTGCTTTTCAGGAGCTTGAAAAGACTGTTTCCAGGTCTACCCCCAGGGGTTAA
TTTAATTGGTCTGGGGAGAGGCCTAAGTATCAGTTTTTTTGTTTTGTTGATGGCTGCCCTCTGCTGTGGCATCACTGTGTAACAATGGCGTGTACAC
CTCTCTGTCCCCACCAGTGCAGGGCCCTTCTCATCGTAGGGGCTTTAGCTGGGGTTTGTGGATCGACTGAGTGAACGAATGTTG 
D4 
ABL1-
BCR 
CACAGACCTAGTCCTTTGTTGTGGTGCGAGGCTCAGTGGGAGGGACATGGGAGCCCTCAGGGAAGTGGTAAGTGAATCCCAGAACCCTTAGACCAGT
TCCCTTGAGGTAGTGTTGTGCTGTGACACTGC 
D5 
BCR-
ABL1 
CAACCTTTTTTTTTTATTTTTATTTTTTCTGATTCTGCAAATCCCGGCACCAGCCCCGGTAGAGCCACGCCGGATGGTGACGGCGGCGTCCGGGGCC
CCACAGTGCGGGCTCCCCCGAAAAAGTTTGAGAAAGCCAACTCGCCAGG 
D5 
ABL1-
BCR 
(+/-) 
TGGGCCCTTCCTAGGCCTCGCCGCCCGCGCGCTCCCGCCTGCGCCCTCCCCGGGTCTTGTCTTTTTTTTCTTTCTTCC…..CTCTTCTCTTCTCTTC
AGTTCTCTTATATTCTGTCTCTCTTTCTTTCTCTCTGTGTCTGTCTCTTTTCTCTTCTCTTCTCAGCTACCCCCGCGCAATTGTGAGGGTGG 
D6 
BCR-
ABL1 
GTTGGAGACCAGCCTGACCAACATGGTGAAACCCTGTGTCTACTAAAAATACAAAGATTAGCCGGGCTAAAACAGTATCTTTTGGGTAAATTCTGGA
TTTTTTCATATATCCTGCC 
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D6 
ABL1-
BCR 
TTATATACTGCTACTTAGCTGTGCAGAGAAATTACAGCATTTAAAAAAATCACCAATCTGTCTTCCTCATAAGTCATCATCTAGAAATGGGGAGAAG
CAAAGAGTGGTATTTTGGCCAGTTAATAAGGTCTTATATTCGGCAGTGGGCACCTGTAATCACAACTGCTTGGGAGGCTGAGGGAAGAGAATCG 
 
*Unless otherwise specified, fused strands run in the same genomic direction (+/+). Stands 
marked +/- or -/+ run in oposite genomic directions and are therefore evidence of micro-
inversions present at the fusion junction. 
**Key: Blue text = BCR sequence; Red text = ABL1 sequence; Yellow text = region of 
microhomology; Green text = SNP, Black text = insertion. 
 
 
Table 2.5. Target quantities assessed using four molecular quantification methodologies in 46 follow-up samples from 6 patients with CML. 
Patient demographics DNA and RNA copy numbers measured on Digital 
PCR platform 
DNA and RNA copy numbers measured on Real Time 
Quantitative PCR platform 
  
patien
t 
sampl
e 
month 
from 
therap
y  start 
dPCR 
(copy/ul
) 
dPCR  
(copy/ul)pr
eamp 
RT-dPCR 
(copy/ul) 
RT-dPCR  
(copy/ul)pr
eamp 
qPCR  RT-qPCR (IS) BCR-ABL1 
(copy/3ul
) 
ABL1 
(copy/3ul
) 
MR 
level 
A1 A1_46 54 1622 ¶ 1475 ¶ 0.140000 * 3.114583 * 8847 68300 >MR
3
 
A1 A1_37 68 11 46 7 67 0.000814 † 0.004485 † 3 20000 MR
4
 
A1 A1_38 70 1 2 0 0 0.000641 † 0.000000 ‡ 0 16000 MR
4
 
A1 A1_39 71 0 0 0 38 0.000018 ‡ 0.000831 † 2 72000 MR
5
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A1 A1_40 95 0 0 0 452 0.000284 ‡ 0.004530 † 4 26400 MR
4
 
A1 A1_41 134 1 1 0 5 0.000000 ‡ 0.000000 ‡ 0 71300 MR
4.
5
 
A1 A1_42 163 1 1 0 0 0.000000 ‡ 0.000000 ‡ 0 68200 MR
4.
5
 
A1 A1_43 169 1 9 0 0 0.000000 ‡ 0.000362 † 1 82700 MR
5
 
A1 A1_44 175 0 0 0 30 0.000000 ‡ 0.000000 ‡ 0 74900 MR
4.
5
 
A1 A1_45 178 0 11 0 0 0.000000 ‡ 0.000000 ‡ 0 91500 MR
4.
5
 
A2 A2_1 33 1833 ¶ 1167 ¶ 0.680000 * 24.916667 * 10000 12000 >MR
3
 
A2 A2_2 63 0 4 0 0 0.000000 ‡ 0.002833 † 9 95000 MR
4.
5
 
A2 A2_3 81 0 5 0 0 0.000000 ‡ 0.003504 † 10 128000 MR
4
 
A2 A2_4 104 0 2 0 0 0.000000 ‡ 0.000000 ‡ 0 11400 MR
4
 
A2 A2_5 116 0 2 0 0 0.000000 ‡ 0.000000 ‡ 0 31200 MR
4
 
A2 A2_6 122 0 3 0 0 0.000000 ‡ 0.000000 ‡ 0 93200 MR
4.
5
 
A2 A2_7 143 0 52 0 0 0.000000 ‡ 0.000000 ‡ 0 67100 MR
4.
5
 
A3 A3_28 48 75 - 68 - 0.001281 * 0.079929 * 409 153000 >MR
3
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A3 A3_29 92 3 53 3 1 0.000009 ‡ 0.000341 † 1 87800 MR
5
 
A3 A3_30 93 6 55 0 0 0.000005 ‡ 0.000000 ‡ 0 89000 MR
4.
5
 
A3 A3_31 96 4 38 0 0 0.000019 ‡ 0.000000 ‡ 0 91600 MR
4.
5
 
A3 A3_32 102 4 64 0 0 0.000068 ‡ 0.000000 ‡ 0 117000 MR
5
 
A3 A3_33 103 6 65 0 0 0.000027 ‡ 0.000549 † 2 109000 MR
5
 
A3 A3_34 106 1 72 0 0 0.000022 ‡ 0.002072 † 7 101000 MR
4.
5
 
A3 A3_35 110 2 46 0 0 0.000029 ‡ 0.000516 † 3 174000 MR
5
 
A3 A3_36 114 2 60 0 0 0.000016 ‡ 0.000000 ‡ 0 92800 MR
4.
5
 
A4 A4_8 33 808 ¶ 735 ¶ 0.163000 * 3.459297 * 4408 38100 >MR
3
 
A4 A4_9 39 127 ¶ 116 ¶ 0.004000 * 0.287023 * 695 72400 >MR
3
 
A4 A4_10 45 268 ¶ 243 ¶ 0.006000 * 0.475534 * 1460 91800 >MR
3
 
A4 A4_11 55 0 416 1 62 0.000690 * 0.003866 † 6 46400 MR
4
 
A4 A4_12 58 1 301 0 1 0.000250 † 0.000000 ‡ 0 114000 MR
5
 
A4 A4_13 59 1 177 0 0 0.000101 † 0.000000 ‡ 0 68400 MR
4.
5
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A4 A4_14 62 0 0 0 0 0.000000 ‡ 0.000000 ‡ 0 26500 MR
4
 
A5 A5_15 28 235 ¶ 214 ¶ 0.045169 * 1.194137 * 1282 32100 >MR
3
 
A5 A5_16 35 637 ¶ 579 ¶ 0.022476 * 0.586851 * 3474 177000 >MR
3
 
A5 A5_17 66 0 0 0 0 0.000000 ‡ 0.000000 ‡ 0 89500 MR
4.
5
 
A5 A5_18 67 0 0 0 0 0.000000 ‡ 0.000000 ‡ 0 67100 MR
4.
5
 
A5 A5_19 69 1 4 0 0 0.000000 ‡ 0.000000 ‡ 0 81500 MR
4.
5
 
A5 A5_20 77 0 0 0 1 0.000000 ‡ 0.000823 † 6 218000 MR
5
 
A6 A6_21 49 64 ¶ 58 ¶ 0.145103 * 0.163604 * 348 63600 >MR
3
 
A6 A6_22 77 3 ¶ 2 ¶ 0.011997 * 0.013205 * 14 31700 >MR
3
 
A6 A6_23 102 0 15 0 63 0.000443 * 0.000425 † 1 70300 MR
5
 
A6 A6_24 104 0 212 0 0 0.000128 † 0.000906 † 2 66000 MR
5
 
A6 A6_25 109 0 3 0 0 0.000000 ‡ 0.000000 ‡ 0 151000 MR
5
 
A6 A6_26 110 0 90 0 0 0.000000 ‡ 0.000000 ‡ 0 24400 MR
4
 
A6 A6_27 112 0 6 1 19 0.000000 ‡ 0.001349 † 3 66500 MR
4.
5
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dPCR: DNA-based digital PCR; RT-dPCR: RNA based digital PCR; qPCR: DNA-based quantitative PCR; RT-qPCR: RNA based quantitative PCR 
* Denotes a positive value within the LoQ of the standard curve. 
† Denotes a positive value within the LoD of the standard curve. 
‡ Denotes a negative value 
¶ Denotes no preamplification 
MR
3
 stands for Major Molecular Response 
MR
4
 stands for Deep Molecular response specified as 4 log transcript level reduction on the IS (ref Cross et al. Ann Hematol. 2015;94 Suppl 2:219-25) 
MR
4.5
 stands for Deep Molecular response specified as 4.5 log transcript level reduction on the IS (ref Cross et al. Ann Hematol. 2015;94 Suppl 2:219-25) 
MR
5
 stands for Deep Molecular response specified as 5 log transcript level reduction on the IS (ref Cross et al. Ann Hematol. 2015;94 Suppl 2:219-25) 
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Chapter III 
 
3. An Investigation of the Feasibility of 
“benchtop” Reverse Transcription 
Digital PCR (RT-dPCR) for the 
Routine Measurement of BCR-ABL1 
mRNA Transcripts. 
 
 
3.1. Introduction 
Tyrosine kinase inhibitors (TKIs) are part of the successful clinical management of 
patients with Chronic Myeloid Leukaemia (CML) [1]. BCR-ABL1 transcript levels at 
particular time points are predictive of patients’ response to TKIs and may be used to 
stratify patiens into a risk group as early as 3 months after therapy induction [2]. Reverse 
transcription quantitative PCR (RT-qPCR) is the gold-standard for monitoring patients’ 
response to therapy. Several molecular milestones have been introduced based on the log 
reduction of the transcript level from a standardized baseline at diagnosis in response to 
therapy [3]. Optimal response has been defined by the recently revised ELN guidelines as 
a BCR-ABL1 level of  ≤ 10% by 3 months, <1% by 6 months, ≤ 0.1% by 12 months then ≤ 
0.1% at any time. However, measurements can vary significantly from one centre to 
another due to limitations inherent to RT-qPCR, unless expressed on the International 
scale (IS). In addition, different labs have different strategies for reporting values falling 
  
127 
 
within the lower end (below 10 copies) of the calibration curve, which further complicates 
the process of standardization. Although in the previous chapter we demonstrated that 
dPCR using a DNA template is the most sensitive method available for monitoring 
residual disease, DNA PCR is still not a practical nor a feasible test for immediate 
implementation in routine monitoring. Mapping the genomic breakpoint and using fusion-
specific assay design for each patient is not yet cost effective for non-high-throughput 
labs. It also requires more extensive validation through inter-laboratories comparison in 
addition to the need for validating the approach through ongoing clinical trials. Therefore, 
efforts to improve the currently used quantification method remain valuable. Recently, 
digital PCR (dPCR) has been introduced as a method of quantification that promises 
simplified assay standardisation procedures and improved measurement accuracy [4]. 
Digital PCR enables absolute quantification of a target in the absence of a standard curve, 
unlike the relative quantification ascribed to RT-qPCR. When applied on reverse-
transcribed complementary DNA template, it is called Reverse Transcription-dPCR (RT-
dPCR). In this study, we sought to assess the performance of RT-dPCR for minimal 
residual disease (MRD) monitoring using the QS
®
3D RT-dPCR platform (QS
®
3D; 
ThermoFisher Scientific). We also discuss considerations for the implementing of RT-
dPCR in future clinical trial protocols or when designing experiments, reviewing and 
evaluating RT-dPCR data.  
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3.2. Materials and Methods 
The BCR-ABL1 assay used in the experiments described in this chapter was a modified 
version of the Europe Against Cancer (E.A.C.) assay described in earlier publications [5, 
6] to allow the use of an MGB quencher attached to the 3’ end of the hydrolysis probe [7] 
(Appendix Table 3.1). The assay was optimized by running a series of different 
primer/probe dilutions and PCR amplification conditions. All reverse transcription and 
dPCR experiments were implemented in accordance with the dMIQE guidelines [8].  
3.2.1. Reference Materials 
Two types of reference material were used: 1) the certified ERM
®
-AD623 reference 
plasmid produced by the European Commission for Reference Materials [9] and 2) an in-
house plasmid, labelled as the ‘Wessex plasmid’, with a similar structure to the ERM used 
to assign target copy numbers to the clinical cDNA samples. Dilutions to defined plasmid 
copy numbers were prepared using tRNA buffer as diluent. These dilutions were used as 
controls instead of cDNA, where appropriate. 
3.2.2. Clinical Samples 
Archived cDNA material from CML patients at different disease levels measured by RT-
qPCR on the IS were used. The cDNA samples were stored at minus 80°C at the 
Hammersmith Hospital for a median of 2 years (range 1–7 years) following routine 
processing of peripheral blood (PB) samples as they arrived in the laboratory [10, 11]. 
Briefly, 15–20ml of PB was washed with Red Cell Lysis Buffer (RCLB) and the total 
white blood cell pellet (WBCPs) was lysed in RLT buffer (Qiagen, Manchester, UK; cat 
number 79216) and stored at minus 80°C. RNA was extracted from 350µl of the RLT 
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lysate using the Qiagen RNeasy Mini kit (Qiagen, cat number 74106) following the 
manufacturer's protocol on the QIAcube robotic workstation (Qiagen). Reverse 
transcription and cDNA synthesis were performed using M-MLV reverse transcriptase 
(Invitrogen, cat no 28025-013) and random hexamers (Invitrogen, cat no 48190-018). All 
samples were processed within 72 hours of blood collection. Detailed procedure is 
described in a previous publication [11].  
3.2.3. Experimental Design 
The design of this study focused on the validation of a modified version of the E.A.C. 
assay used internationally for BCR-ABL1 transcript level quantification on an RT-dPCR 
platform (Figure 3.1). Three sets of experiments were conducted on the QS
®
3D RT-dPCR 
platform as this was the platform available in our laboratory. The aim was to assess certain 
platform performance characteristics including 1) linearity (the dynamic range), limit of 
detection (LoD) and quantification (LoQ), measurement accuracy (bias and precision) and 
selectability; 2) bias in relation to the in-house prepared plasmid used for reporting 
transcript levels on the IS; and 3) assay sensitivity defined based on the log reduction from 
a standardized baseline at disease diagnosis.  
The first set of experiments included a series of two-fold volumetric dilutions (2–512 
copy/chip), in addition to dilutions of 5000 increments (1,000–50,000 copy/chip) 
representing values that fall below (2–1000 copy/chip), within (2000–30,000 copy/chip) 
and above (35,000–50,000 copy/chip) the sweet spot of the chip when used as 
recommended by the manufacturer. These 20 dilutions were designated categories 1–20, 
respectively. Dilutions were prepared using the ERM
®
-AD623 reference material. The 
second set of experiments included a series of 10-fold dilutions (10, 100, 1000 copy/chip) 
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and two-fold dilutions (20,000–40,000 copy/chip) prepared using the in-house Wessex 
plasmid. These dilutions were designated categories 1–7, respectively. For the first and 
second sets of experiments, the quantification of each target concentration was performed 
in triplicate per experiment, in three independent experiments, in order to assess intra- and 
inter-run variability. Targets were BCR-ABL1 and ABL1 transcripts. Each Target 
concentration was quantified both in duplex and uniplex in order to assess the precision 
and accuracy of the assay.  
The third set of experiments included seven categories of patient cDNA samples with 
different disease levels (20%, 10%, 1%, 0.1%, 0.01%, 0.001%, 0%) assessed on the IS and 
expressed as a percentage ratio between the target and reference gene transcripts 
(categories 1 to 7, respectively). Each category contained 10 patient samples. Thirty-two 
cDNA samples prepared from individuals with no CML (negative controls) were also 
included and labelled as category 8. Samples were run in triplicate and nine replicates 
within the categories assigned to MRD level of 20%–0.1% and 0.01%–0%, respectively. 
No template controls (NTCs) were also included (category 9) to rule out contamination 
and low level background noise. BCR-ABL1 target quantities in each category after 
correction for bias were 10352–69064, 1622–15746, 263–1515, 19–362, 5–12, one and 
zero copies/3µl, respectively quantified by RT-qPCR. ABL1 copies were > 10
4
, while 
GUSB was 2.5 fold higher than ABL1 per sample (Table 3.1).  
3.2.4. QS®3D Digital PCR System (ThermoFisher Scientific) 
RT-dPCR experiments were performed using the QS
®
3D RT-dPCR System following the 
manufacturer’s instructions. For each sample, 15µl reactions were prepared containing 
QS
®
3D Digital PCR Master Mix (4482710 or 4485718), 900nM of each primer and 
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250nM of each probe (where applicable for uniplex or duplex reactions). Depending on 
the reaction set up, 1–3µL of reference material plasmid or cDNA generated from the 
clinical samples was added. Where necessary, the total reaction volume was made up to 
15µL with distilled nuclease-free water. The reaction mix was loaded into a chip (v1; 
4485507 or 4482603) according to the manufacturer’s instructions and placed into an ABI 
9700 thermocycler containing a flat plate. Thermocycling conditions were enzyme 
activation at 96°C for 10 minutes, followed by 40 cycles at 55°C for 1 min and 98°C for 
30 seconds and a final extension at 55°C for 2 minutes with a 16°C hold. Chips were read 
using the QS
®
3D chip reader. Chips were analysed using the online Analysis Suite
®  v1.0. 
3.2.5. Target copy number calculations 
Files were exported from analysis suite containing the number of positive partitions (k) 
and the total number of partitions (n) per reaction. Quantification was performed in one of 
three ways: 1) using (k) or (n) from individual reactions, 2) using the mean of (k) and (n) 
for replicate reactions per experiment, or 3) pooling (k) and (n) from replicate reactions 
per experiment. Poisson statistics was then applied to estimate the average number of 
template copies per partition () where = -ln(1-k/n) [8, 12, 13]. The associated 95% 
confidence interval of the Poisson distribution of λ was calculated using formulas 
published previously [14, 15]. Estimated target copy numbers per reaction volume were 
calculated by multiplying λ with the total number of partitions. 
3.2.6. Statistical Analysis 
Graphing and basic statistical analysis including calculation of means, variances, standard 
deviations, confidence intervals and p-values were performed using Microsoft Excel 2013, 
  
132 
 
GraphPad Prism 6.07 (GraphPad Software, Inc) and the R statistical programming 
environment (http://www.r-project.org/) for statistical analysis. P<0.05 was considered 
significant. 
The distribution of data was assessed using quantile-quantile plots (QQ plots) allowing the 
application of parametric or non-parametric tests. Between experiments variance per 
dilution point (category) was assessed applying the analysis of variance ANOVA test. 
When no significant difference was found, target mean concentration and standard 
deviation (SD) were calculated after grouping the data. When the difference was 
significant, the mean and SD per expert were used instead. Two-tail one-sample Student’s 
t-test was applied to test the significance of the measured mean target concentration 
against the reference value. Fisher’s exact test (F-test) was used to test for the status of 
equal variance between experiments. Two-tailed, paired Student’s t-test was used to test 
the significance of the difference between duplex and uniplex runs. Bland-Altman 
difference plots were used to find systematic bias associated with the test. The assessed 
concentrations were the mean target copy/chip, mean lambda (λ) or both. Paired two-tail t-
test (or Wilcoxon signed rank test) was used to test the significance of the difference in the 
measured mean concentrations when compared on two methods for both targets, per 
dilution point (category). Unpaired one-tail t-test (or Mann-Whitney U test) was used to 
test the significance of the difference between the measured means of concentrations per 
dilution point (category) against the total mean of signals detected in the negative controls 
quantified on RT-dPCR. The statistical testing strategy is illustrated in (Figure 3.2).  
  
  
133 
 
3.3. Results 
3.3.1. Accuracy (Bias and precision) 
To assess the accuracy of the measurements, a series of 20 different dilutions prepared 
using the ERM reference material were run on the QS
®
3D RT-dPCR platform in duplex 
and uniplex reactions.  
The significance of the difference between the measured mean per category for both 
targets in duplex and uniplex and the corresponding reference values were tested applying 
two-tail one-sample Student’s t-test. The produced p-values for the differences in duplex 
measurements showed no significant bias except for some borderline significance for 
categories 2, 3, 10 and 6–7 for BCR-ABL1 and ABL1, respectively compared to the 
reported uncertainty figures for the reference material (Appendix Table 3.2). Exceptions 
were categories 1 and 3 for ABL1 and 17–20 for both targets where the bias was 
significant and associated with overestimation for concentrations falling below the 
recommended sweet spot and underestimation for concentrations falling above it (Figure 
3.3a). Bland-Altman difference plots confirmed these observations. Uniplex measurements 
had a greater heterogeneity in the bias figures across the dilution range (Appendix Table 
3.2). 
The ratio between the two targets showed no significant deviation from one applying 
student’s t-test for both duplex and uniplex measurements, but the spread of data points 
around one was greater for the uniplex assay, particularly at the lower end outside the 
sweet spot (Appendix Table 3.3; Figure 3.3b).  
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Measurements were very precise with slightly increased variance at the lower end outside 
the sweet spot for duplex measurements, but more heterogeneous variance was noticed 
across the range for the uniplex measurements (Table 3.2).  The coefficient of variation 
(CV) was ≤10% for concentrations within the sweet spot and increased at the lower range 
outside the spot still remaining mostly below 40%. CV was mostly in agreement between 
duplex and uniplex measurements, but in favour of duplex assay outside the sweet spot.  
3.3.2. Linearity 
The linearity of the assay was assessed by plotting the log ratio of the lambda values for 
the ERM reference material dilution series against the measured (observed) values after 
confirming the absence of amplification bias between the two targets.  
The plots showed a good correlation with a regression line that supports linearity, 
particularly after excluding the four values above the sweet spot (which showed 
significant bias from the reference). (Figure 3.4; Appendix Figure 3.1) shows the plotted 
graphs for expected vs observed copy/chip, lambda and log lambda for the full range of 
dilutions. Linearity for both targets was maintained down to a concentration of 
approximately 8 copies/chip corresponding to a λ of 0.0008 for both the duplex and 
uniplex data with a CV of <10%. Below these levels, it was difficult to distinguish real 
signals from background noise detected in the no template controls included in the study 
(Appendix Figure 3.1). 
3.3.3. In-house Wessex plasmid associated target quantities 
Before we could quantify the cDNA samples from patients on the QS
®
3D RT-dPCR 
platform, we wanted to know the accuracy of the concentrations assigned to the in-house 
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plasmid. For this purpose, a series of 10-fold dilutions (10, 100, 1000 copy/chip) and two-
fold dilutions (20,000–40,000 copy/chip) were prepared using the in-house ‘Wessex 
plasmid’. 
An unpaired comparison for a series of dilutions (set 2 experiment) quantified on both 
platforms, in duplex, showed a highly significant systematic bias of approximately 50% 
associated with underestimation of target molecules by RT-dPCR (Figure 3.5). A 
conversion factor of 0.46 was derived applying Bland-Altman Ratio plots and applied to 
the target values in the patient cDNA samples to adjust the amounts before quantifying on 
the RT-dPCR platform (Figure 3.6; Appendix Table 3.4). The Ratio between the two 
targets quantified showed no significant difference to one indicating equal amplification of 
both targets (Figure 3.5). Linearity was maintained across the dilution range (Figure 3.5).    
3.3.4. E.A.C. assay sensitivity on the QS®3D platform 
To address the sensitivity of the RT-dPCR platform within the context of CML 
management, a series of seven categories of patient cDNA samples with different disease 
levels (20%, 10%, 1%, 0.1%, 0.01%, 0.001%, 0%) were run in a duplex reaction on the 
QS
®
3D RT-dPCR platform. 32 negative controls in addition to no template controls were 
also included.  
Plotting the percentage ratios quantified by RT-dPCR for the sample categories 1–9 
against the percentage ratio specified by RT-qPCR in the same categories, we found that 
the QS
®
3D RT-dPCR had a sensitivity of 5 logs (Figure 3.7). RT-dPCR detected a greater 
number of BCR-ABL1 targets in Categories 5 and 6 which consequently lead to an 
increase in the calculated ratio per category (from 0.001% and 0.01% to 0.1%) with a 
significant difference from the signals detected in their pair by RT-qPCR (p<0.05 by 
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Wilcoxon signed rank test) and the negative controls by RT-dPCR (p<0.05 by one-tail, 
Mann-Whitney U test) (Figure 3.8; Appendix Tables 3.5 and 3.6; Appendix Figure 3.3 and 
3.5). Category 7, which was negative by RT-qPCR, was significantly positive by RT-
dPCR, with a ratio ranging from 0.1%–0.01% (p<0.05 by Wilcoxon signed rank test); 
however the significance of the difference compared to the signals detected in the negative 
controls by RT-dPCR was in the opposite direction (p>0.05 by one-tail, Mann-Whitney U 
test) indicating false positivity (Figure 3.8; Appendix Tables 3.5 and 3.6; Appendix Figure 
3.3 and 3.5). ABL1 target transcript molecules quantified were consistent in all categories 
and did not differ significantly from the values assigned by RT-qPCR after correction for 
bias (p>0.05% by Wilcoxon signed rank test) (Figure 3.8; Appendix Tables 3.5 and 3.6; 
Appendix Figure 3.2). The results obtained followed the same pattern using either the 
mean or the sum of (k) and (n) obtained from replicate chips per sample (Appendix Table 
3.5 and 3.6). 
We observed that the performance of the ABL1 assay on cDNA template was different 
from that observed using the plasmid. On cDNA, three populations of positive partitions 
were observed instead of two distinct populations; two populations not clearly distinct 
from each other, and a third distinct population (Figure 3.9). The additional non-distinct 
population was suspected to be the result of DNA contamination and indeed was resolved 
by applying DNAase digestion to the cDNA samples (Qiagen RNeasy mini plus kit) 
(Figure 3.9). To rule out platform effect, we further confirmed the observation by applying 
different ABL1 assays (old HH and Hs0000092)(Appendix Table 3.1), in duplex and 
uniplex, on both DNAase treated and non-treated cDNA samples using both QS
®
3D and 
Fluidigm as an independent RT-dPCR platform (Figure 3.9). 
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3.4. Discussion  
The aim of the work described in this chapter was to assess the performance of a modified 
version of the E.A.C. assay used for MRD monitoring of the major BCR-ABL1 transcript 
molecules in Ph-positive (ph
+ve
) leukaemia patients on the QS
®
3D RT-dPCR platform. 
The investigation focused on comparing the accuracy of measurements, analytical 
sensitivity, and the effect of duplexing and template type by RT-dPCR analysis to 
conventional RT-qPCR.  In addition, we attempted to determine best practice for 
experimental design and highlight points to consider when implementing RT-dPCR in 
future clinical trial protocols or when reviewing and evaluating RT-dPCR data. 
Quantitative monitoring of BCR-ABL1 transcript levels in peripheral blood (PB) over the 
course of TKI therapy is an essential aspect of the clinical management of CML patients. 
RT-qPCR is the gold-standard and is routinely applied for this purpose; however it has 
inherent limitations related to reduced precision at the lower end of the calibration curve. 
This is a particularly significant issue when monitoring patients in deep molecular 
response. RT-qPCR is also challenging to standardize due to significant variation in assay 
performance between different labs which could give rise to discordant quantitative 
results. The use of conversion factors (CFs) and the introduction of international reference 
materials to act as calibration standards has helped mitigate this problem, but the former 
requires a burdensome system of sample exchange, while the latter are difficult to 
produce, thus limiting their availability. RT-dPCR offers an elegant potential solution to 
these complications. 
Digital PCR is an accurate and precise analytical technique for absolute quantification of 
nucleic acids based on PCR amplification of single template molecule without the need for 
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a calibration curve [16-20]. Partitioning targets within a sample after performing limiting 
dilution allows individual molecule PCR [21-24]. This, in turn, increases the signal-to-
noise ratio improving the chance of a rare target being detected. The ability to convert the 
analog Cq data to an absolute linear copy number count confers greater precision because 
the method is not negatively influenced by the inherent factors affecting Cq values [8, 24].  
Analytical sensitivity can also be improved by increasing the number of individual 
reaction replicates. This has become more practical via the introduction of nanofluidics 
technology, which allows a greater number of replicates to be performed while 
maintaining the same volume of sample used in conventional RT-qPCR.  
3.4.1. Assay performance on the QS®3D RT-dPCR platform 
Although RT-dPCR has the potential to minimize efforts for standardization, platform 
calibration and performance assessments remain a requirement [8, 25]. Previous 
investigators and opinion leaders have recommended that measurement accuracy (bias and 
precision) and reproducibility should be evaluated before routine implementation of RT-
dPCR [8, 16, 20, 24, 26-28]. The use of templates with well-defined amounts and 
uncertainty is, therefore, critical for such an evaluation. The advantage of using the ERM 
plasmid for this purpose lies in the fact that its quantities are assigned using an RT-dPCR 
platform (Fluidigm) [9]. For the most accurate measurements using the QS
®
3D platform it 
is recommended that RT-dPCR is performed with a concentration of 200–2000 copies/µl 
(corresponding to a λ of 0.6–1.6 and Poisson-corrected 1,500–30,000 copy/chip) [29]. 
Appendix Figure 3.2 shows the relationship between positive counts per chip and 
estimated copy number. Running dilutions within as well as outside the recommended 
sweet spot, our data showed that the QS
®
3D performed with high accuracy within the 
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sweet spot and down to very low concentrations outside this spot when performed both in 
duplex and uniplex, albeit less uniformly in uniplex. The systematic bias observed at the 
higher end outside the sweet spot was explained by the manufacturing company by the 
non-uniformity in the effective load volume in the chips. The non-uniformity in the 
loading volume leads to a variation in the total reaction volume within individual 
partitions which in turn affects the Poisson modelling at the higher end of the 
concentration spectrum with minimal impact on the lower end of the spectrum.  Working 
together with the vendor, they introduced the ‘Poisson plus’ option in the analysis suite 
that corrects the estimation of target concentrations in the reaction by taking the non-
uniformity in load volume into account. Non-uniformity in loading is assessed by 
estimating the variation in the ROX reference dye levels compared the central region of 
each chip (personal communication with the company).  
It is established now that dPCR has improved measurement precision over qPCR [16, 24, 
26, 30], and this precision could further be improved by using duplex reactions within the 
recommended sweet spot of a particular platform, despite the widening of the variance 
outside this spot [30]. Our findings were in agreement with this notion showing more 
precise duplex measurements compared to uniplex across the range of dilutions. In a 
plasmid where the two targets are present at equal quantity, duplex and uniplex assays 
differ in that the former measures the two targets in the same panel while the later 
measures them in two different panels. As a consequence, the targets can be considered 
“linked” in the former, but not in the latter. The “linked” status of duplex targets could, 
therefore, be utilized to investigate the presence of molecular dropout where equally 
amplified targets would produce a ratio of one. Our findings showed that increased 
variance in the uniplex measurements leads to more heterogeneous bias figures across the 
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range of dilutions compared to the duplex measurements. This could be explained by the 
occurrence of molecular dropout more frequently in uniplex reactions. Molecular dropout 
is defined as failure to quantify the target molecule despite it being present in the reaction 
[30], and has been shown to be common in biological samples compared to linearized 
plasmids increasing the technical variability in this type of samples [30]. Better precision 
in duplex reactions could also be explained by the absence of the Poisson-distributed 
sampling variance in duplex reactions in contrast to uniplex reactions where targets are 
quantified independently [30]. In addition to improved precision, duplexing can have other 
advantages in a diagnostic setting such as allowing higher throughput and reducing the 
amount of sample material required for investigation [30-34]. 
Sensitivity is expressed as the limit of detection (LoD) denoting the lowest concentration 
that can be accurately detected with a reasonable 95% certainty [35]. Based on Poisson 
statistics, the theoretical LoD is 3 copies per reaction volume with a 95% CI of 
quantifying at least 1 copy per reaction [35]. However, the detection of positive signals 
within the NTC lead to an LoD of 8 copies/chip (± 1.786 95% CI)( λ of 0.000471555 with 
± 0.0000611 95% CI) highlighting the importance of including negative reactions in the 
experimental design. The low level signal detected in the NTC reactions could be 
explained by assay design and selectability, cDNA secondary structure [36, 37], assay 
cross/auto dimerization [8] or low level contamination. The latter is unlikely as NTCs 
prepared using the same reagents with different assays (GUSB) within the same run did 
not produce similar background noise.  Nonetheless, an LoD of eight copies/chip confirms 
that RT-dPCR is capable of measuring template molecules at low concentrations with 
good precision, consistent with previous reports [24, 26]. 
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3.4.2. In-house plasmid bias 
The observation of bias between dPCR quantities and UV based quantities has been 
reported and explained previously [8, 24]. The systematic bias of almost 50% observed 
quantifying the Wessex plasmid on an RT-dPCR platform could be explained by the fact 
that the plasmid dilutions are prepared for duplex plasmid template and are quantified 
using non-accurate methodologies [9, 38]. Correcting target copy number in the cDNA 
samples for the bias before quantifying them on RT-dPCR is, therefore, an essential step 
in order to obtain meaningful target copy number comparison that will reflect assay 
sensitivity.  
3.4.3. Platform sensitivity in the context of CML monitoring 
The dynamic range of dPCR is defined by the number of partitions it allows and the 
volume of sample interrogated [39]. However, the dynamic range of a dPCR assay can be 
extended beyond the number of partitions analysed via the application of Poisson 
corrections, albeit at the cost of reduced precision at each end [13, 14, 26], with the most 
accurate quantification reached when λ= 0.6–1.6 [8]. 
In RT-qPCR, the disease level is defined as a percentage ratio between the transcript levels 
of the target and reference gene. The copy numbers are produced in a 3µl of input cDNA 
containing a range of BCR-ABL1 targets (0–10.000 copies), but almost a fixed median of 
ABL1 (10
4
 – 105 copies) indicating a good quality sample. This has to be taken into 
consideration when loading a dPCR chip to find the balance for accurately quantifying 
both the highly abundant reference gene without compromising the sensitivity for the low-
abundance target gene; the high level of the reference transcripts would saturate the wells 
and diluting the sample will affect the sensitivity of detecting the BCR-ABL1 transcripts. 
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Therefore, when aiming to quantify 1 copy in 100,000 molecules, at least 3 chips per 
sample of 20,000 partitions per reaction [100,000/1.6 = 62,500 partitions (~3chips)] will 
be required to reach the desired sensitivity.  
To ensure equal target amount interrogation on RT-dPCR as on RT-qPCR, duplex 
reactions interrogated 1µl of total cDNA per chip using 3 chips per sample, whereas 
uniplex reactions interrogated 3µl of cDNA per chip for BCR-ABL1 quantification, but 1µl 
cDNA per chip for ABL1 quantification.  Our results showed that down to major molecular 
response (MMR or MR
3
) level (0.1%), there was no significant difference in the amount 
of targets quantified by both methods. However below this milestone, sensitivity was 
improved by RT-dPCR shifting patient response level by 1 log higher, respectively.  In 
these samples, the number of ABL1 copies detected by the QS
®
3D did not significantly 
differ from those detected by RT-qPCR indicating that any improvement in sensitivity was 
related to the platform’s ability to detect more BCR-ABL1 molecules. One hurdle while 
interpreting positive results in the MR level was the presence of some overlap between the 
signals in these samples and the false positive signals detected in the negative controls 
where no signal is expected. The detection of false positive signals in the negative controls 
requires further effort to resolve as these signals could be eliminated by changing the 
assay design or sample processing protocols. Achieving clearer negative signal detection 
will reflect on assay sensitivity and consequently on a more accurate classification of 
patients into molecular response groups. Nonetheless, the platform reached a sensitivity of 
5 logs agreeing with a pervious report by Jennings et al despite the difference in 
experimental design, platform and investigation approach [40]. What is worth noting here 
is that by quantifying more BCR-ABL1 molecules, the RT-dPCR platform could change 
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the response category within which the patients were originally classified simply by 
increasing the BCR-ABL1:ABL1 ratio.  
It should be borne in mind here that while RT-dPCR is less susceptible to the inherent 
factors responsible for increased variation in qPCR quantifications (mainly the Cq 
readouts), it is still influenced by the variability related to pre-PCR sample preparation 
[37, 41-43] including the RT step [44, 45], choice of reagents [46] and cDNA synthesis [8] 
in addition to the amount analysed per reaction [30]. The importance of careful 
consideration of the latter variables is illustrated by the findings of an early investigation 
into the performance of RT-dPCR in which extra replication or pre-amplification template 
modifications were not applied. The study reported a sensitivity of only 4 logs, with no 
significant difference to that of RT-qPCR [47]. The same principle also applies to findings 
related to RT-dPCR applications in other disciplines [28, 48]. 
3.5. Conclusion 
“The ability to measure extremely low concentrations of a specific target molecule, 
independent of a standard curve with high precision in a complex background is unique to 
dPCR” [8]. For CML MRD monitoring, RT-dPCR has the potential to simplify assay 
standardization and improve the sensitivity and precision of the measurements, 
particularly for patients in deep molecular remission (MR). We have shown that there was 
no significant difference between RT-qPCR and RT-dPCR when quantifying disease 
down to MMR level. Although the sensitivity of RT-dPCR was similar to that of RT-
qPCR below this level, it was difficult to interpret results due to the false positive noise 
picked-up in the negative controls. Quantifying true positive BCR-ABL1 targets below 
MMR could result in a change in patients’ response level with embedded clinical 
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implications. Therefore, further work is required to eliminate the false positivity in 
negative controls in order to increase the depth of accurate BCR-ABL1 quantification using 
RT-dPCR.   
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3.6. Figures 
 
Figure 3.1. E.A.C. assay validation on the QD3D RT-dPCR platform - Experimental Design. The design includes 3 sets of experiments: set one includes a serial 
dilution points prepared using the ERM secondary reference material in order to assess assay performance characteristics on the QS
®
3D RT-dPCR platform; 
set 2 includes a serial dilution points prepared using the in-house plasmid that is used as a calibration curve to assign copy number quantities to the target 
molecules in clinical samples to assess the accuracy of the calibration curve; and set 3 where a range of clinical samples at different response levels are run 
on the QS
®
3D platform to assess assay sensitivity defined based on the log reduction of the ration between the two target transcript levels from a 
standardized baseline at disease diagnosis . "Expt" stands for experiment; ERM ref material consists of 6 dilutions: ERM (a) = 1.08E+06 copy/µl, ERM (b) = 
1.08E+05 copy/µl, ERM (c) = 1.03E+04; "Cat." stands for category; "Rxn" stands for reaction. 
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Figure 3.2. E.A.C. assay validation on the QD3D RT-dPCR platform - statistical testing strategy. Quantile-
Quantile plots (QQ plots) were used to assess the distribution of data. Parametric tests were used when 
the data was normally distributed and non-parametric tests were used when the spread of data was 
skewed.   
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Figure 3.3. Assay performance on the QS
®
3D RT-dPCR platform - Accuracy. (a) The graphs show the 
difference between the expected and the measured lambda values for both BCR-ABL1 and ABL1 using the 
dilutions prepared with the ERM reference material. Duplex reactions are represented on the left panel 
and uniplex reaction on the right panel. Blue and red dotted lines specify the sweet of the QS3D chips as 
recommended by the manufacturer. (b) The graphs show the plotted log ratio between the two targets: 
BCR-ABL1 and ABL1 which are present on the same plasmid. An expected log ratio of zero indicates equal 
quantity for both targets; therebye the absence of molecular drop-out. Duplex reactions are represented 
on the left panel and uniplex reaction on the right panel. Data points quantified in the uniplex reaction 
have greater spread compared to duplex reactions.  
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Figure 3.4. Assay performance on the QS
®
3D RT-dPCR platform – Linearity. Shows the plotted graphs for 
expected vs observed log lambda values for the full range of the ERM secondary reference material 
dilutions. Duplex reactions are represented on the left panel and uniplex reaction on the right panel. 
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Figure 3.5. In-house plasmid accuracy. Expected versus measured quantities of each target are plotted 
using a series of dilutions from the in-house plasmid. Target quantities represented as (a) lambda and (b) 
copy/chip, are shown for both targets (BCR-ABL1 and ABL1). 
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Figure 3.6. In-house plasmid bias. Bland-Altman plot showing a systematic measurement bias of 0.46. 
This value was considered as a conversion factor, and target values quantified on RT-qPCR were multiplied 
by this factor before quantifying them on RT-dPCR to ensure accurate comparison.  
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(a) 
(b) 
 
Figure 3.7. E.A.C. 
assay sensitivity on 
the QS
®
3D RT-dPCR 
platform. The 
percentage ratio 
between both 
targets, BCR-ABL1 
and ABL1 for the 
clinical samples is 
plotted against the 
sample category. 
Each category 
contains 10 
individual samples 
represented as 
diamonds. (a) shows 
the full range of 
clinical samples: 
20%, 10%, 1%, 0.1%, 
0.01%, 0,001%, 0%, 
eve controls and 
NTC. (b) Restricts 
the view to the 
samples falling in 
the deep molecular 
response level. 
‘SNH’ and ‘SNB’ 
represent the 
negative controls 
and they stand for 
‘sample negative 
Hammersmith’ and 
‘sample negative 
Birmingham’, 
respectively. 
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Figure 3.8. E.A.C assay sensitivity on the QS
®
3D. (a) BCR-ABL1 transcript copies per chip (copy per 1ul of 
cDNA) quantified on the QS
®
3D (blue) and RT-qPCR (black). (b) ABL1 transcript copies per chip (copy per 
1ul of cDNA) quantified on the QS
®
3D (blue) and RT-qPCR (black). (c) Whisker and box plots representing 
BCR-ABL1 transcript copies per chip (copy per 1ul of cDNA) quantified on the QS
®
3D (blue) and RT-qPCR 
(black) for the full range of clinical sample categories investigated. (d) The same as (c) restricting the view 
to the patient groups within the MR response level and the negative controls. 
 
(a) 
(c) 
(b) 
(d) 
RT-qPCR 
RT-dPCR 
RT-qPCR 
RT-dPCR 
RT-qPCR 
RT-dPCR 
RT-qPCR 
RT-dPCR 
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Figure 3.9. Assay specificity. (a), (b) and (c) show QS
®
3D histograms from the modified duplex E.A.C assay 
quantifying BCR-ABL1 and ABL1 on a cDNA template and ABL1 on a DNase treated cDNA template, 
respectively. (d), (e) and (f) compare different ABL1 assays. (d) Shows the result of amplifying ABL1 using 
the modified E.A.C assay on a cDNA template. The extra unspecific peak is confirmed using QS
®
3D (top 
panel) and Fluidigm (bottom panel). (e) Shows the result of amplifying ABL1 using a different assay design. 
The extra unspecific peak is not present as the design of this assay doesn't amplify intron 2-3 of ABL1 
which is picked up via the E.A.C. assay.  (f) The Hs0000092 assay also amplifies intron 2-3 of ABL1 and 
shows the unspecific third peak.  
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3.7. Tables 
Table 3.1. BCR-ABL1 and ABL1 transcript levels quantified by RT-qPCR in the clinical samples. 
sample category BCR-ABL1 
copy/3μl 
ABL1 copy/3μl GUSB copy/3μl BCR-ABL1/ABL1 Ratio  
mrd134011 p1 20% 1 37957 157000 180550 24% 
mrd134966 p2 20% 1 11396 56400 64860 20% 
mrd134790 p3 20% 1 10352 43800 50370 24% 
mrd135172 p4 20% 1 22343 95900 110285 23% 
mrd134697 p5 20% 1 32807 142000 163300 23% 
mrd134081 p6 20% 1 65173 283000 325450 23% 
mrd133195 p7 20% 1 25786 113000 129950 23% 
mrd134125 p8 20% 1 69064 304000 349600 23% 
mrd134068 p9 20% 1 24788 111000 127650 22% 
mrd134249 p10 20% 1 18977 85000 97750 22% 
mrd134820 p1 10% 2 5181 50400 57960 10% 
mrd133090 p2 10% 2 6096 62300 71645 10% 
mrd133956 p3 10% 2 8089 83400 95910 10% 
mrd133571 p4 10% 2 3640 37800 43470 10% 
mrd133494 p5 10% 2 15746 168000 193200 9% 
mrd134898 p6 10% 2 2506 27000 31050 9% 
mrd133037 p7 10% 2 1622 18100 20815 9% 
mrd132773 p8 10% 2 2179 24900 28635 9% 
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mrd134131 p9 10% 2 5856 70300 80845 8% 
mrd132703 p10 10% 2 2023 20100 23115 10% 
mrd134446 p1 1% 3 986 33200 38180 3% 
mrd132819 p2 1% 3 755 25600 29440 3% 
mrd133238 p3 1% 3 1451 54000 62100 3% 
mrd132964 p4 1% 3 365 13600 15640 3% 
mrd132614 p5 1% 3 1515 56500 64975 3% 
mrd134994 p6 1% 3 1013 96000 110400 1% 
mrd135732 p7 1% 3 391 37400 43010 1% 
mrd133758 p8 1% 3 894 87600 100740 1% 
mrd133908 p9 1% 3 980 56300 64745 2% 
mrd132845 p10 1% 3 263 26300 30245 1% 
mrd135738 p1 0.10% 4 38 12700 14605 0% 
mrd133604 p2 0.10% 4 137 45900 52785 0% 
mrd135742 p3 0.10% 4 31 10400 11960 0% 
mrd135561 p4 0.10% 4 143 48000 55200 0% 
mrd135731 p5 0.10% 4 362 123000 141450 0% 
mrd135230 p6 0.10% 4 56 48800 56120 0% 
mrd133444 p7 0.10% 4 33 32800 37720 0% 
mrd132735 p8 0.10% 4 19 18900 21735 0% 
mrd134097 p9 0.10% 4 68 67700 77855 0% 
mrd132792 p10 0.10% 4 59 58900 67735 0% 
mrd134305 p1 0.01% 5 5 33400 38410 0% 
mrd133393 p2 0.01% 5 12 80300 92345 0% 
mrd135567 p3 0.01% 5 3 20100 23115 0% 
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mrd132908 p4 0.01% 5 10 67200 77280 0% 
mrd133845 p5 0.01% 5 12 81200 93380 0% 
mrd135390 p6 0.01% 5 9 60900 70035 0% 
mrd133567 p7 0.01% 5 9 60900 70035 0% 
mrd132675 p8 0.01% 5 4 27100 31165 0% 
mrd134457 p9 0.01% 5 9 61000 70150 0% 
mrd134926 p10 0.01% 5 12 86900 99935 0% 
mrd136122 p1 0.001% 6 1 92100 105915 0% 
mrd135790 p2 0.001% 6 1 45200 51980 0% 
mrd135574 p3 0.001% 6 1 105000 120750 0% 
mrd135576 p4 0.001% 6 1 91800 105570 0% 
mrd134988 p5 0.001% 6 1 68800 79120 0% 
mrd134682 p6 0.001% 6 1 29300 33695 0% 
mrd134629 p7 0.001% 6 1 58700 67505 0% 
mrd134282 p8 0.001% 6 1 52000 59800 0% 
mrd134051 p9 0.001% 6 1 68700 79005 0% 
mrd133965 p10 0.001% 6 1 75700 87055 0% 
mrd132714 p1 0% 7 0 19400     
mrd132683 p2 0% 7 0 21500     
mrd132679 p3 0% 7 0 56000     
mrd132677 p4 0% 7 0 40100     
mrd132665 p5 0% 7 0 36600     
mrd132663 p6 0% 7 0 21100     
mrd132656 p7 0% 7 0 39600     
mrd132611 p8 0% 7 0 18900     
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mrd132608 p9 0% 7 0 13200     
mrd132607 p10 0% 7 0 15900     
mrd131371 SNH1 -ve 8 0 56100     
mrd132049 SNH2 -ve 8  96300     
mrd132183 SNH3 -ve 8  12800     
mrd135908 SNH4 -ve 8  73400     
mrd133611 SNH5 -ve 8  135000     
mrd134299 SNH6 -ve 8  610000     
mrd134503 SNH7 -ve 8  82000     
mrd134897 SNH8 -ve 8  136000     
mrd135377 SNH9 -ve 8  220000     
mrd135476 SNH10 -ve 8  67100     
mrd135548 SNH11 -ve 8  24600     
mrd135607 SNH12 -ve 8  423000     
mrd135895 SNH13 -ve 8  517000     
mrd135373 SNH14 -ve 8        
mrd138068 SNH15 -ve 8  84000     
mrd131608 SNH16 -ve 8  11000     
mrd137154 SNH17 -ve 8  210000     
mrd137373 SNH18 -ve 8  88300     
mrd137621 SNH19 -ve 8  142000     
014-14564 SNB1 -ve 8        
011-03583 SNB2 -ve 8        
013-46747 SNB3 -ve 8        
015-07304 SNB4 -ve 8        
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009-20821 SNB5 -ve 8        
014-36175 SNB6 -ve 8        
014-36036 SNB7 -ve 8        
014-25583 SNB8 -ve 8        
013-46342 SNB9 -ve 8        
014-11750 SNB10 -ve 8        
012-12037 SNB11 -ve 8        
013-43921 SNB12 -ve 8        
011-39810 SNB13 -ve 8        
“-ve” stands for negative control; “SNH” stands for sample negative Hammersmith; “SNB” stands for sample negative Birmingham 
 
 
Table 3.2.  The precision of the E.A.C. assay quantifying BCR-ABL1 and ABL1 targets on the QS
®
3D platform expressed as coefficient of variation (CV). 
Rxn Catego
ry 
Ref. 
Valu
e 
mean  
BCR-ABL1 
copy/chip 
SD  V  CV  CV 
% 
95% CI mean  
ABL1 
copy/chip 
SD  V  CV  CV 
% 
95% CI 
Duplex 1 2 2.00 0.87 0.75 0.43 43 0.67 1.67 0.50 0.25 0.30 30 0.38 
Duplex 2 4 3.22 0.83 0.69 0.26 26 0.64 3.56 0.73 0.53 0.20 20 0.56 
Duplex 3 8 9.00 2.18 4.76 0.24 24 1.68 8.56 1.33 1.78 0.16 16 1.03 
Duplex 4 16 16.26 3.54 12.52 0.22 22 2.96 16.76 2.12 4.51 0.13 13 1.78 
Duplex 5 32 32.15 4.06 16.46 0.13 13 3.39 31.53 4.38 19.20 0.14 14 3.66 
Duplex 6 64 69.25 4.20 17.66 0.06 6 3.51 70.38 3.46 12.00 0.05 5 2.90 
Duplex 7 128 130.57 17.68 312.71 0.14 14 14.78 131.58 14.98 224.31 0.11 11 12.52 
Duplex 8 256 261.11 36.74 1349.66 0.14 14 28.24 262.34 30.27 916.58 0.12 12 23.27 
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Duplex 9 512 514.12 15.30 234.06 0.03 3 11.76 513.33 16.41 269.39 0.03 3 12.62 
Duplex 10 1000 1046.07 71.51 5113.75 0.07 7 54.97 1065.67 73.15 5350.29 0.07 7 56.22 
Duplex 11 5000 5174.30 246.10 60565.07 0.05 5 189.17 5173.96 242.25 58685.17 0.05 5 186.21 
Duplex 12 1000
0 
10397.76 403.78 163040.35 0.04 4 310.37 10432.51 395.61 156509.34 0.04 4 304.09 
Duplex 13 1500
0 
15612.28 934.75 873751.96 0.06 6 718.51 15671.21 924.80 855253.76 0.06 6 710.86 
Duplex 14 2000
0 
21336.99 1008.1
7 
1016408.09 0.05 5 774.95 21533.44 794.59 631377.32 0.04 4 610.78 
Duplex 15 2500
0 
23415.04 1525.0
2 
2325697.43 0.07 7 1172.2
4 
23548.90 1545.1
1 
2387378.59 0.07 7 1187.68 
Duplex 16 3000
0 
27365.57 2666.1
4 
7108287.74 0.10 10 2049.3
7 
27301.28 2595.1
3 
6734720.53 0.10 10 1994.80 
Duplex 17 3500
0 
25313.25 1017.9
6 
1036252.63 0.04 4 941.46 25404.55 946.47 895799.35 0.04 4 875.34 
Duplex 18 4000
0 
30766.42 3417.6
1 
11680060.26 0.11 11 2627.0
1 
30832.29 3213.7
0 
10327889.8
8 
0.10 10 2470.27 
Duplex 19 4500
0 
38749.00 2191.3
7 
4802120.83 0.06 6 1684.4
4 
39100.38 2445.9
3 
5982582.29 0.06 6 1880.11 
Duplex 20 5000
0 
43171.44 5511.5
1 
30376711.79 0.13 13 4236.5
2 
43343.74 5543.3
8 
30729025.0
5 
0.13 13 4261.02 
Duplex NTC 0 1.96 3.17 10.03 1.62 0 0.00 2.12 2.15 4.61 1.01 0 0.00 
Uniplex 1 2 2.38 1.19 1.41 0.50 50 0.99 1.67 0.71 0.50 0.42 42 0.54 
Uniplex 2 4 5.56 2.13 4.53 0.38 38 1.64 4.22 1.20 1.45 0.28 28 0.92 
Uniplex 3 8 9.11 1.97 3.86 0.22 22 1.51 10.23 2.64 6.95 0.26 26 2.03 
Uniplex 4 16 17.23 3.64 13.22 0.21 21 2.79 17.01 3.08 9.52 0.18 18 2.37 
Uniplex 5 32 32.92 2.85 8.14 0.09 9 2.19 38.54 6.58 43.32 0.17 17 5.50 
Uniplex 6 64 55.33 7.58 57.39 0.14 14 6.33 58.72 8.27 68.35 0.14 14 6.91 
Uniplex 7 128 122.63 24.21 586.27 0.20 20 18.61 113.57 18.18 330.40 0.16 16 13.97 
Uniplex 8 256 209.95 36.70 1346.85 0.17 17 28.21 248.29 39.33 1546.62 0.16 16 30.23 
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Uniplex 9 512 403.73 61.12 3735.49 0.15 15 46.98 414.22 46.25 2138.60 0.11 11 38.66 
Uniplex 10 1000 892.63 158.20 25027.44 0.18 18 121.60 979.20 55.35 3063.75 0.06 6 42.55 
Uniplex 11 5000 4663.20 314.30 98781.61 0.07 7 262.76 4465.19 326.98 106912.92 0.07 7 251.34 
Uniplex 12 1000
0 
8948.18 507.83 257895.27 0.06 6 424.56 8099.26 627.96 394331.35 0.08 8 482.69 
Uniplex 13 1500
0 
19867.12 2149.0
7 
4618489.62 0.11 11 1651.9
2 
18967.38 1001.2
9 
1002590.59 0.05 5 1050.79 
Uniplex 14 2000
0 
21633.11 1698.3
0 
2884213.86 0.08 8 1305.4
3 
22093.79 1670.5
6 
2790780.43 0.08 8 1284.11 
Uniplex 15 2500
0 
24447.05 1900.7
5 
3612833.85 0.08 8 1757.9
0 
25168.80 1345.3
5 
1809963.44 0.05 5 1124.74 
Uniplex 16 3000
0 
30642.38 2230.5
0 
4975118.88 0.07 7 1714.5
1 
27322.35 1263.4
9 
1596412.43 0.05 5 971.21 
Uniplex 17 3500
0 
25346.27 6690.9
5 
44768857.85 0.26 26 7021.7
2 
25298.74 1283.1
1 
1646369.50 0.05 5 986.29 
Uniplex 18 4000
0 
32784.60 3109.4
6 
9668743.47 0.09 9 2390.1
4 
33854.59 2696.4
5 
7270859.63 0.08 8 2072.68 
Uniplex 19 4500
0 
36891.97 11314.
57 
128019450.8
8 
0.31 31 9459.2
2 
40864.16 5591.3
3 
31262978.0
6 
0.14 14 4297.88 
Uniplex 20 5000
0 
45124.81 6249.5
8 
39057255.06 0.14 14 5224.7
8 
48788.90 2474.9
5 
6125399.73 0.05 5 2288.95 
Uniplex NTC 0 3.32 51.42 2644.07 15.49 0 0.00 2.55 3.68 13.54 1.44 0 0.00 
Duplex 1 0.00
011 
0.0001092
66 
4.41E-
05 
1.94284E-09 0.403
398 
40 3.39E-
05 
9.19377E-
05 
2.83E-
05 
7.98372E-10 0.307
333 
31 2.17E-05 
Duplex 2 0.00
022 
0.0001813
6 
4.45E-
05 
1.97609E-09 0.245
111 
25 3.42E-
05 
0.0002010
29 
4.43E-
05 
1.95984E-09 0.220
217 
22 3.4E-05 
Duplex 3 0.00
043 
0.0004960
32 
0.0001
24 
1.54024E-08 0.250
198 
25 9.54E-
05 
0.0004715
55 
7.95E-
05 
6.32589E-09 0.168
666 
17 6.11E-05 
Duplex 4 0.00
086 
0.0008739
16 
0.0001
73 
2.99055E-08 0.197
882 
20 0.0001
45 
0.0009030
02 
0.0001
02 
1.04526E-08 0.113
22 
11 8.55E-05 
Duplex 5 0.00
173 
0.0016907
77 
0.0002
14 
4.56671E-08 0.126
391 
13 0.0001
79 
0.0016581
75 
0.0002
32 
5.3672E-08 0.139
715 
14 0.000194 
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Duplex 6 0.00
345 
0.0036167
5 
0.0001
9 
3.59625E-08 0.052
433 
5 0.0001
59 
0.0036754
97 
0.0001
37 
1.86525E-08 0.037
158 
4 0.000114 
Duplex 7 0.00
690 
0.0067646
78 
0.0008
86 
7.85593E-07 0.131
024 
13 0.0007
41 
0.0068191
39 
0.0007
63 
5.82068E-07 0.111
881 
11 0.000638 
Duplex 8 0.01
381 
0.0134563
22 
0.0018
73 
3.50837E-06 0.139
196 
14 0.0014
4 
0.0135212
9 
0.0015
59 
2.42936E-06 0.115
273 
12 0.001198 
Duplex 9 0.02
761 
0.0266347
19 
0.0008 6.40032E-07 0.030
037 
3 0.0006
15 
0.0265914
84 
0.0007
92 
6.27247E-07 0.029
784 
3 0.000609 
Duplex 10 0.05
393 
0.0552022
57 
0.0066
23 
4.38673E-05 0.119
981 
12 0.0050
91 
0.0562179
05 
0.0065
31 
4.26488E-05 0.116
166 
12 0.00502 
Duplex 11 0.26
967 
0.2735041
21 
0.0193
72 
0.000375261 0.070
828 
7 0.0148
9 
0.2734859
4 
0.0192
25 
0.00036961
6 
0.070
298 
7 0.014778 
Duplex 12 0.53
933 
0.5447907
12 
0.0331
84 
0.001101156 0.060
911 
6 0.0255
07 
0.5465748
84 
0.0322
01 
0.00103690
1 
0.058
914 
6 0.024752 
Duplex 13 0.80
900 
0.8159100
15 
0.0602
48 
0.003629792 0.073
841 
7 0.0463
11 
0.8190730
36 
0.0612
79 
0.00375516
4 
0.074
816 
7 0.047104 
Duplex 14 1.07
867 
1.0950046
8 
0.0503
01 
0.002530194 0.045
937 
5 0.0386
65 
1.1050554
57 
0.0382
81 
0.00146542
3 
0.034
642 
3 0.029425 
Duplex 15 1.34
833 
1.1979655
08 
0.0753
01 
0.005670316 0.062
858 
6 0.0578
82 
1.2048821
2 
0.0773
32 
0.00598028 0.064
182 
6 0.059443 
Duplex 16 1.61
800 
1.4459627
86 
0.1050
31 
0.011031591 0.072
638 
7 0.0807
34 
1.4428684
7 
0.1050
13 
0.01102776
6 
0.072
781 
7 0.08072 
Duplex 17 1.88
767 
1.3071247
01 
0.0638
91 
0.004082039 0.048
879 
5 0.0590
89 
1.3119211
75 
0.0628
86 
0.00395468
8 
0.047
935 
5 0.05816 
Duplex 18 2.15
733 
1.6253525
8 
0.1497
29 
0.022418822 0.092
121 
9 0.1150
92 
1.6292084
61 
0.1411
73 
0.01992973 0.086
651 
9 0.108515 
Duplex 19 2.42
700 
2.0096085
69 
0.1197
32 
0.014335849 0.059
58 
6 0.0920
34 
2.0280594
72 
0.1368
3 
0.01872231
6 
0.067
468 
7 0.105176 
Duplex 20 2.69
667 
2.2185354
16 
0.2706
75 
0.073264686 0.122
006 
12 0.2080
59 
2.2275394
73 
0.2741
08 
0.07513546
5 
0.123
054 
12 0.210698 
Uniplex 1 0.00
011 
0.0001246
42 
6.31E-
05 
3.9782E-09 0.506
034 
51 5.27E-
05 
8.79814E-
05 
3.82E-
05 
1.46106E-09 0.434
454 
43 2.94E-05 
Uniplex 2 0.00 0.0002843 0.0001 1.16717E-08 0.379 38 8.3E-05 0.0002187 5.96E- 3.54666E-09 0.272 27 4.58E-05 
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022 77 08 904 16 05 288 
Uniplex 3 0.00
043 
0.0004695
46 
9.96E-
05 
9.91128E-09 0.212
025 
21 7.65E-
05 
0.0005348
04 
0.0001
39 
1.94191E-08 0.260
567 
26 0.000107 
Uniplex 4 0.00
086 
0.0008918
03 
0.0001
89 
3.57437E-08 0.211
998 
21 0.0001
45 
0.0008957
89 
0.0001
66 
2.74641E-08 0.185
002 
19 0.000127 
Uniplex 5 0.00
173 
0.0017007
75 
0.0001
61 
2.58704E-08 0.094
57 
9 0.0001
24 
0.0020020
83 
0.0003
75 
1.4038E-07 0.187
142 
19 0.000313 
Uniplex 6 0.00
345 
0.0028683
95 
0.0003
54 
1.25349E-07 0.123
43 
12 0.0002
96 
0.0031954
32 
0.0004
49 
2.01764E-07 0.140
57 
14 0.000376 
Uniplex 7 0.00
690 
0.0065110
07 
0.0011
93 
1.42324E-06 0.183
228 
18 0.0009
17 
0.0059412
77 
0.0010
3 
1.06043E-06 0.173
325 
17 0.000792 
Uniplex 8 0.01
381 
0.0109049
43 
0.0017
42 
3.0362E-06 0.159
787 
16 0.0013
39 
0.0128848
28 
0.002 3.99916E-06 0.155
205 
16 0.001537 
Uniplex 9 0.02
761 
0.0210321
85 
0.0025
68 
6.59612E-06 0.122
112 
12 0.0019
74 
0.0215062
65 
0.0024
9 
6.20124E-06 0.115
791 
12 0.002082 
Uniplex 10 0.05
393 
0.0491914
78 
0.0046
12 
2.12715E-05 0.093
758 
9 0.0035
45 
0.0510964
96 
0.0021
15 
4.47444E-06 0.041
398 
4 0.001626 
Uniplex 11 0.26
967 
0.2416548
69 
0.0141
17 
0.000199282 0.058
417 
6 0.0118
02 
0.2341444
35 
0.0175
54 
0.00030814
3 
0.074
971 
7 0.013493 
Uniplex 12 0.53
933 
0.4700473
32 
0.0278
47 
0.000775431 0.059
242 
6 0.0232
8 
0.4287910
3 
0.0287
79 
0.00082821
5 
0.067
116 
7 0.022121 
Uniplex 13 0.80
900 
1.0220901
04 
0.1080
95 
0.011684628 0.105
759 
11 0.0830
9 
0.9780701
87 
0.0489
65 
0.00239757
5 
0.050
063 
5 0.051386 
Uniplex 14 1.07
867 
1.1158549
42 
0.0940
53 
0.008846013 0.084
288 
8 0.0722
96 
1.1393037
8 
0.0939
02 
0.00881758
8 
0.082
421 
8 0.072179 
Uniplex 15 1.34
833 
1.2604709
67 
0.0900
95 
0.008117126 0.071
477 
7 0.0833
24 
1.3114905
05 
0.0788
54 
0.00621790
5 
0.060
125 
6 0.065923 
Uniplex 16 1.61
800 
1.5844389
72 
0.1206
46 
0.014555515 0.076
144 
8 0.0927
37 
1.4564579
5 
0.0834
49 
0.00696379
6 
0.057
296 
6 0.064145 
Uniplex 17 1.88
767 
1.4335974
49 
0.2140
08 
0.045799385 0.149
28 
15 0.2245
88 
1.3029611
44 
0.0796
05 
0.00633697
1 
0.061
096 
6 0.06119 
Uniplex 18 2.15
733 
1.7151850
84 
0.1178
92 
0.013898509 0.068
734 
7 0.0906
2 
1.7587007
08 
0.1200
99 
0.01442383
7 
0.068
289 
7 0.092316 
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Uniplex 19 2.42
700 
2.1187061
64 
0.1988
83 
0.039554573 0.093
87 
9 0.1662
71 
2.0965881
94 
0.2982
29 
0.08894046 0.142
245 
14 0.229239 
Uniplex 20 2.69
667 
2.3300500
22 
0.3039
01 
0.092355633 0.130
427 
13 0.2540
67 
2.5199900
02 
0.1475
62 
0.02177440
4 
0.058
556 
6 0.136472 
Rxn = Reaction; SD = standard deviation; V = variance; CV = coefficient of variation; CI = confidence interval 
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Chapter IV 
 
4. Toward Personalised Clinical 
Management of CML: Cross RT-
dPCR platform comparison using the 
E.A.C. assay. 
 
 
4.1. Introduction 
Digital PCR (dPCR) is a highly precise analytical technique for absolute quantification of 
nucleic acids based on PCR amplification of a single template molecule without the need 
for a calibration curve [1-5]. Individual molecule PCR takes place via partitioning targets 
within a sample after performing limiting dilution where each partition contains ≥1 or no 
target molecule [6-9] diluting the background noise and thereby improving the chances for 
rare target detection. Digital PCR has improved measurement precision over qPCR [1, 9-
11], particularly when performed in a duplex reaction [11, 12]. This superiority has been 
ascribed to the ability of dPCR to perform absolute linear copy number quantification [9, 
13]. Advances in nanofluidics technologies and the introduction of emulsion-based 
technologies have improved the analytical sensitivity of dPCR by increasing the number 
of individual reaction replicates. There is a range of dPCR platforms that differ in their 
methods for generating reaction partitions (prefabricated reaction wells or water-in-oil 
droplets), the number of partitions, volume of input sample, real-time or end-point results, 
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hands-on time and cost. Interrogation of a sample with a platform that enables a greater 
partitioning of the reaction (large n) is theoretically more sensitive, which has been 
demonstrated experimentally [12, 14, 15].  
In their current format, however, most dPCR platforms are limited by the amount of 
sample that can be analysed [16] and therefore cannot compete with the absolute 
sensitivity of qPCR. Furthermore, a large reaction volume is required to reach absolute 
sensitivity using limiting dilutions [17]. Nevertheless, in Chronic Myeloid Leukaemia 
(CML), Reverse Transcription Digital PCR (RT-dPCR) holds a distinct potential not only 
for the monitoring of residual disease in patients on Tyrosine kinase Inhibitor (TKI) 
therapy, but also in patients with sustained molecular remission who are considering 
therapy discontinuation where improved sensitivity and precision of measurement are key 
in  patient clinical management.  
In the previous chapter, we evaluated the performance of the E.A.C. assay on the QS
®
3D 
RT-dPCR platform and found that false-positive signals detected in the negative controls 
were a major limitation for the accurate interpretation of positive results in samples 
classified within the MR range based on RT-qPCR. We wanted to understand the kinetics 
of this false-positivity on the other dPCR platforms as a mean for addressing the issue and 
finding the best approach for false-positive elimination.Therefore, the aim of this chapter 
was to extend our work in the previous chapter with a particular emphasis on assay 
sensitivity relevant to the log reduction of BCR-ABL1 transcript levels on the International 
Scale (IS). Hence, we performed a cross RT-dPCR platform comparison including the 
most widely used RT-dPCR platforms: QuantSudio
®
3D (QS
®
3D; ThermoFisher 
Scientific), BioRad
®
QX200 (Bio-Rad LifeSciences) and RainDrop
®
 (RainDance
®
 
Technologies).  
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4.2. Materials and Methods 
The three platforms were made available in collaboration with three different centres: the 
BioRad
®
 at the LGC, the RainDrop
®
 at the Birmingham Women’s Hospital and the 
QS
®
3D at the Hammersmith Hospital in London. The assay used was a modified version 
of the Europe Against Cancer (E.A.C.) assay described in [18, 19] to allow the use of an 
MGB quencher attached to the 3’ end of the hydrolysis probe (Appendix Table 
3.1_chapter III). One exception to this was that the hydrolysis probe of the assay used on 
the RainDrop
®
 platform was modified to include TET as a quencher instead of MGB at the 
3’ end (Appendix Table 3.1_chapter III). The assay was optimized by running a series of 
different primer/probe dilutions and PCR amplification conditions per platform. All 
reverse transcription and dPCR experiments were implemented in accordance with the 
dMIQE guidelines [13].  
4.2.1. Clinical Samples 
Clinical samples were as described in chapter III. Archived cDNA material from CML 
patients at different disease levels measured by RT-qPCR on the IS were used. The cDNA 
samples were stored at minus 80°C at the Hammersmith hospital (for a median of 2 years, 
range 1–7 years) following routine processing of peripheral blood (PB) samples as they 
arrived at the laboratory [20, 21].  
4.2.2. Experimental Design 
A cross-platform comparison was conducted on the three RT-dPCR platforms most widely 
available for clinical use: the BioRad
®
 QX200 (BioRad
®
 Laboratories), the RainDrop
®
 
(RainDance
®
 Technologies) and the QuantStudio
®
3D (ThermoFisher Scientific) 
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platforms. The 70 clinical cDNA samples (categories 1–7) described in the set 3 
experiments in chapter III were run on each of these platforms. The samples included 
seven categories of patient cDNA samples with different disease levels (20%, 10%, 1%, 
0.1%, 0.01%, 0.001%, 0%) assessed on the IS and expressed as a percentage ratio between 
the target and reference gene transcripts (categories 1 to 7, respectively). Each category 
contained 10 patient samples. 32 negative cDNA samples prepared from individuals with 
no CML diagnosis were also included as negative controls and labelled as category 8. 
Samples were run in triplicate and 9 replicates within the categories 20%–0.1% and 
0.01%–0%, respectively. No template controls (NTCs) were also included and labelled as 
category 9 to control for contamination and low-level background noise (Figure 4.1; Table 
3.1_ chapter III).  
4.2.3. QS®3D Digital PCR System (ThermoFisher Scientific) 
RT-dPCR experiments were performed using the QS
®
3D RT-dPCR System following 
manufacturer instructions as described in Chapter III. 
4.2.4. QX200® Droplet Digital PCR System (BioRad® Laboratories) 
RT-dPCR experiments were performed using the BioRad
®
 QX200
®
 RT-dPCR System 
following manufacturer’s instructions. For each sample, 20µl reactions were prepared 
containing BioRad
®
 dPCR Super Mix (186–3010), 900nM of each primer and 250nM of 
each probe in a duplex reaction. 1µl of cDNA generated from the clinical samples was 
added. Samples were run in triplicate and nine replicates within the categories 20%–0.1% 
and 0.01%–0%, respectively. The total reaction volume was made up to 20 µl with 
distilled nuclease-free water. Droplets were generated using the QX200 according to the 
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manufacturer’s instructions and transferred to a 96 well plate. Thermocycling was 
performed on the BioRad
®
 C1000 Touch thermocycler. Thermocycling conditions were 
enzyme activation at 96°C for 10 minutes at ramp rate of 2°C/sec, followed by 40 cycles 
at 94°C for 30 sec and 60°C for 1 minute, and an enzyme heat kill step at 98°C for 10 
mins with a 12°C hold. Droplets were quantified using the droplet reader. Data were 
analysed using the QuantaSoft v3.0 software. 
4.2.5. RainDrop® Droplet Digital PCR System (RainDance®) 
RT-dPCR experiments were performed using the RainDance
®
 Technologies RainDrop® 
RT-dPCR System following manufacturer’s instructions. For each sample, 40µl reactions 
were prepared containing 1X Applied Biosystems® TaqMan® Universal PCR Master Mix 
(2X stock) (PN 4305719), 900nM of each primer and 200nM of each probe in a duplex 
reaction and 1X Droplet Stabiliser (10X stock). 10µl of cDNA generated from the clinical 
samples was added. Samples were run once with no replicates. The total reaction volume 
was made up to 40µl with distilled nuclease-free water. Droplets were generated using the 
RainDrop
®
 Source according to the manufacturer’s instructions and collected 
automatically in an Axygen 8 well tube strip (PN PCR-0208-C). Thermocycling was 
performed on the Bio-Rad Thermal Cycler (CT004506), C1000 Touch. Thermocycling 
conditions were enzyme activation at 95°C for 10 minutes, followed by 49 cycles at 95°C 
for 15 sec and 60°C for 1 minute, an enzyme heat kill step at 98°C for 10 mins followed 
by a 10°C hold. Droplets were counted and populations of BCR-ABL1 and ABL1 
quantified using the RainDrop
®
 Sense. Data were analysed using the RainDrop
®
 Analyst 
software. 
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4.2.6. Target copy number calculations 
Files were exported from each RT-dPCR platform containing the number of positive 
partitions (k) and the total number of partitions (n) per reaction. Quantification was 
performed either using (k) or (n) from individual reactions, or using the mean of (k) and 
(n) for replicate reactions per experiment, or pooling the (k) and (n) from replicate 
reactions per experiment. Poisson statistics was then applied to estimate the average 
number of template copies per partition () where = -ln(1-k/n) [13, 22, 23]. The 
associated 95% confidence interval of the Poisson distribution of λ was calculated using 
formulas published previously [24]. Estimated target copy numbers per reaction volume 
were calculated by multiplying λ with the total number of partitions. 
4.2.7. Statistical Analysis 
The statistical analysis was performed as described in chapter III. The statistical testing 
strategy is illustrated in Figure 4.2_chapter III.  
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4.3. Results 
4.3.1. In-house Wessex plasmid quantity bias 
Before cDNA samples from patients were quantified on the RT-dPCR platforms, the 
values were corrected for the bias introduced by the Wessex plasmid used to assign the 
values to these samples. The process is described in chapter III. A non-paired comparison 
for a series of dilutions (set 2 experiments in chapter III) quantified in duplex on both 
platforms, showed a highly significant systematic bias of approximately 50% associated 
with underestimation of target molecules by RT-dPCR. A conversion factor of 0.46 was 
derived by applying Bland-Altman Ratio plots and applied to the target values in the 
patient cDNA samples to adjust the amounts before quantifying on the RT-dPCR platform 
(Figure 3.6_chapter III).    
4.3.2. Cross RT-dPCR platform comparison 
In chapter III, We showed that QS
®
3D RT-dPCR had a sensitivity of 5 logs by plotting the 
percentage ratios quantified by RT-dPCR for the sample categories 1–9 against the 
percentage ratio specified by RT-qPCR per category. A greater number of BCR-ABL1 
targets were detected in categories 5 and 6 by RT-dPCR, which consequently lead to an 
increase in the calculated ratio in these samples (from 0.001% and 0.01% to 0.1%) with a 
significant difference from the signals detected in the same samples by RT-qPCR (p<0.05 
by Wilcoxon signed-rank test) and the negative controls by RT-dPCR (p<0.05 by Mann-
Whitney U test)(Appendix Figures 4.1–4.5). Application of RT-dPCR to Category 7 
samples, which tested negative by RT-qPCR, produced positive results, with ratios 
ranging from 0.1%–0.01% (p<0.05 by paired Student’s t-test), however the significance of 
the difference compared to the signals detected in the negative controls by RT-dPCR was 
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in the opposite direction (p>0.05 by Mann-Whitney U test) indicating that the positive RT-
dPCR results in the category 7 samples represented false positivity (Tables 4.1 and 4.2; 
Appendix Figures 4.1, 4.2 and 4.3). ABL1 target transcript molecules quantified were 
consistent in all categories and didn’t differ significantly from the values assigned by RT-
qPCR after correction for bias (p>0.05% by Wilcoxon signed-rank test). The results 
obtained followed the same pattern using either the mean or the sum of the (k) and (n) 
obtained from replicate chips per sample. See also Figures 3.7 and 3.8_Chapter III; 
Appendix Tables 3.5 and 3.6_Chapter III; Appendix Figure 3.3–3.5_Chapter III. 
As with the QS
®
3D, plotting the observed percentage ratios for sample categories 1–9 
against the percentage ratio specified by RT-qPCR, we found that the RainDrop
®
 RT-
dPCR platform had a sensitivity of at least 5 logs (Figure 4.2) having detected 
significantly true positive BCR-ABL1 molecules in category 7 (p<0.05 by Wilcoxon 
signed rank test) compared to no molecules detected by RT-qPCR, and compared to the 
signals obtained in the negative controls by RT-dPCR (p<0.05 by Mann-Whitney U test) 
(Appendix Table 4.1; Appendix Figures 4.1–4.5). As a result, ratios changed from 0% to 
0.001%, 0.001% to 0.01% and 0.01% to 0.1% for categories 7, 6, and 5, respectively. Both 
BCR-ABL1 and ABL1 quantities were significantly higher compared to the RT-qPCR 
despite the fact that we observed no significant difference in the ratio between the two 
targets for categories 1–4 (p>0.05 by Wilcoxon signed rank test), and significantly higher 
ratio for categories 5–7 (P<0.05) (Figure 4.3; Tables 4.1 and 4.2; Appendix Table 4.1).  
 BioRad
®
 showed heterogeneity in quantifying both targets compared to the gold-standard 
RT-qPCR as there was significant underestimation of both targets in categories 1 and 2 
which lead to a significant difference in the ratio in category 1 comparing the two 
platforms (p<0.05 by Wilcoxon signed rank test) (Appendix Table 4.1; Appendix Figures 
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4.1, 4.2 and 4.3). ABL1 was also underestimated in category 5 which lead to no significant 
ratio increase by RT-dPCR as was the case with the other two RT-dPCR platforms. The 
ratios in categories 6 and 7 were significantly higher as a result of higher BCR-ABL1 
quantities detected by the RT-dPCR (p<0.05 by Wilcoxon signed rank test), however, as 
with the QS
®
3D, these quantities were not significantly different from the noise detected 
in the negative controls (Mann-Whitney test) (Figure 4.3; Table 4.1; Appendix Table 4.1; 
Appendix Figures 4.1–4.4). The consequence was a sensitivity of only 4 logs for the 
BioRad
®
 platform with an increased ratio for category 6 from 0.001% by RT-qPCR to 
0.01% by RT-dPCR (Figure 4.2). Importantly, however, values obtained for category 7 
became significantly different from the noise in the negative controls (Mann-Whitney U 
test) and categories 5 and 6 became significantly different (Mann-Whitney U test) when 
BCR-ABL1 and ABL1 target concentration on both methods were compared using the sum 
of (k) and (n) in all replicates instead of the mean per sample. This resulted in an improved 
sensitivity of 5 logs with increased ratios for categories 7, 6, and 5 from 0% on RT-qPCR 
to 0.1% on RT-dPCR (Table 4.2; Appendix Tables 4.1 and 4.2; Appendix Figure 4.5).  
Comparing the regression line for the mean BCR-ABL1 target values quantified on the 
three RT-dPCR platforms, we found that all three platforms had a concordant linearity 
down to the major molecular response (MMR or MR
3
) level, but their linearity differed at 
the deep molecular response (MR) level (Figures 4.4 and 4.5).  Both The RainDrop
®
 and 
BioRad
®
 platforms had closer concordant linearity down to the smallest sample category 
(0.001%) with a mean slope and R
2 
values closer to one (slope and R
2
 of 0.85, 0.78 and 
0.94, 0.92, respectively) compared to the QS
®
3D that had a mean slope and R
2
 values 
significantly different from those on the other two platforms away from one (slope and R
2
 
of 0.60 and 0.84) (Figures 4.4 and 4.5). A similar pattern was observed using the sum of 
  
178 
 
the replicate values for the quantified BCR-ABL1 target molecules on the three platforms 
(Figure 4.5).   
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4.4. Discussion  
The primary aim of this work was to compare the performance of the E.A.C. BCR-ABL1 
hydrolysis probe assay on different RT-dPCR platforms available for diagnostic testing by 
determining performance characteristics relevant to each platform with particular 
emphasis on sensitivity. A further goal was to assess the practical considerations of 
different platforms to allow conclusions to be drawn on appropriate experimental design 
and to highlight important points for consideration when implementing RT-dPCR in future 
clinical trials or when reviewing and evaluating RT-dPCR data. 
Quantitative monitoring of BCR-ABL1 transcript levels in PB over the course of TKI 
therapy is an essential aspect of the clinical management of CML patients. RT-qPCR is the 
gold-standard and is routinely applied for this purpose; however it has inherent limitations 
related to reduced precision at the lower end of the calibration curve in addition to 
significant variation in assay performance between different labs emphasising the need for 
extensive standardisation. RT-dPCR offers an elegant potential solution to simplify the 
standardization procedure and improve on both the sensitivity and precision of 
measurement.  
Although all based on the same principle, dPCR platforms vary in the number of 
partitions, type (chip or droplet), dynamic rage, throughput, hands-on-time and cost. The 
QS
®
3D and BioRad
®
 platforms allow 20,000 partitions of prefabricated reaction wells (in 
a chip or well) or droplets (water-in-oil emulsion), respectively. In theory, droplet 
partitions are more heterogeneous in size compared to solid reaction wells due to inherent 
technicalities of droplet generation. Variable partition size has implications on the 
accuracy of measurements as Poisson statistics mandates a fixed partition size for optimal 
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estimation of target copy numbers; otherwise underestimation occurs due to multiple 
occupancy of partitions. This becomes particularly apparent when quantifying high 
abundance target molecules. Therefore, it is important that this information is provided by 
the manufacturer, so that, if necessary, the variability can be factored into the Poisson 
calculations [16]. However, our experimental evidence has shown that the variability in 
the number of the partitions also affects the final results as the number of partitions 
directly influences the dynamic range. The RainDrop
®
 platform allows interrogation of a 
larger volume of sample per individual reaction than QS
®
3D and BioRad
®
 (50µl versus 15 
and 20µl, respectively). The larger capacity and greater number of partitions per reaction 
make this platform theoretically more sensitive. This was reflected in our results as 
RainDrop
®
 provided sensitivity of at least 5 logs, whereas QS
®
3D and BioRad
®
 had 
sensitivities of 5 and 4 log, respectively when the mean of (k) and (n) from replicate 
reactions per sample was taken (Appendix Table 4.2). The sensitivity of BioRad
®
 was 
compromised by the reduced and heterogeneous amount of droplets produced per reaction. 
While the latter limitation was controlled for, in part, by taking the sum of (k) and (n) to 
calculate the copy number, this strategy also increased the cost per sample as it implies the 
need for more than one reaction per sample.  
By RT-qPCR, disease level is defined as a percentage ratio between the transcript levels of 
the target and reference genes. The copy numbers are obtained from 3µl of cDNA 
containing an unknown number of BCR-ABL1 targets (0–10,000 copies), but an almost 
fixed median of ABL1 copies (10
4–105) indicating a good quality sample. As duplex 
reactions have been shown to be more precise, a balance must be achieved between 
accurate quantification of both the highly abundant reference gene and the low abundance 
target gene, without unduly compromising the sensitivity of the assay. This juxtaposition 
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results in a limitation of sensitivity when aiming to quantify a rare target in a background 
of highly abundant reference gene. In the latter scenario, therefore, a platform with a larger 
number of partitions would be of particular advantage. RT-qPCR interrogates 3µl of 
cDNA per reaction, in triplicate. When aiming to accurately quantify 1 copy in 100,000 
molecules on a RT-dPCR platform with a 20,000 partition, at least 3 or 9 reactions per 
sample would be required to reach a comparable sensitivity per reaction or triplicate 
reactions by RT-qPCR, respectively. On the other hand, a partition size of 10 million 
allows one reaction per sample to reach the sensitivity of the triplicate RT-qPCR reactions 
combined. To ensure equal target amount interrogation by RT-dPCR and RT-qPCR, we 
designed our experiments such that both reference and target genes were quantified in 
duplex interrogating 1µl of total cDNA per reaction per sample, using triplicates and nine 
replicates for samples between 20%–0.1% and 0.01–0.00%, respectively on the QS®3D 
and BioRad
®
 platforms, while RainDrop
®
 interrogated 10µl cDNA per reaction per 
sample, once.  Our results showed that down to MMR level (0.1%), there was no 
significant difference in the number of targets quantified by any of the platforms compared 
to RT-qPCR. However, below 0.1%, significant differences were observed between the 
RT-dPCR platforms and RT-qPCR that, in a clinical setting, would result in re-
categorisation of a patient’s molecular response level.  In these samples, the number of 
ABL1 copies detected by the RT-dPCR platforms did not significantly differ from those 
detected by RT-qPCR, indicating that any improvement in sensitivity was related to the 
platform’s ability to detect more BCR-ABL1 molecules.  
Another important aspect of performance to consider is the level of noise detected in the 
negative controls on each platform. This level varied from one platform to another for the 
same sample indicating that noise level is most likely platform chemistry-dependent. 
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Although the RainDrop
®
 platform appeared to be the noisiest platform in terms of the 
absolute number of copies detected in negative samples, the normalisation of this signal to 
the total number of partitions generated by this platform, in fact, rendered the platform the 
least noisy compared to the other two. Therefore, negative controls, including samples 
from healthy individuals and NTC, are very informative and their inclusion is an essential 
component of the platform validation process as they help to discriminate between real 
and false-positive results and guide the establishment of the threshold for the method’s 
limit of true positive quantification. Nontheless, as the false positivy was detected on the 
three RT-dPCR platforms investigated using a single assay design, suggests that the issue 
could be assay dependent; therefore  investigating different assays, designed specificly for 
RT-dPCR, could help mitigate the problem. 
Up-front machine cost, cost per experiment, hands-on time, experimental set-up and 
throughput are also important factors when considering RT-dPCR. Some platforms are 
more affordable than others. The QS
®
3D has the lowest upfront machine cost; however it 
has a lower throughput and is more labour intensive compared to BioRad
®
. QS
®
3D allows 
24 reactions per run, with a maximum of three runs per day whereas BioRad
®
 can perform 
96 reactions per run, and three runs a day (288 reactions in total, daily). RainDrop
®
 allows 
eight reactions per run, and 24 reactions per day making this platform the least high-
throughput. However, since QS
®
3D and BioRad
®
 platforms require multiple reactions per 
sample to reach optimal sensitivity, throughput is counter-balanced by sensitivity and cost 
of consumables. In summary, therefore, the choice of instrument is application-dependent 
and should take into account several factors including desired sensitivity, precision, 
throughput and budget.  
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4.4.1. RT-dPCR in therapy discontinuation trials 
Recent data indicate that withdrawal of imatinib therapy in patients in deep remission is 
associated with a 60% relapse rate that has been ascribed to the persistence of residual 
disease [25]. The potential benefits of studying the kinetics of residual disease via 
monitoring patients’ BCR-ABL1 transcript levels prior to, and during therapy 
discontinuation are twofold: 1) measurement at the point of withdrawal may provide a 
means of prognostic stratification of patients eligible to safely come off the drug and 2) to 
identify imminent relapse post-withdrawal and therefore direct the timely therapeutic re-
intervention. Application of RT-dPCR in these areas could be of significant clinical value, 
and this potential is being investigated in several TKI withdrawal trials involving large 
cohort of patients with longer follow-up and longer periods of pre-withdrawal sustained 
molecular remission. Therefore, it is likely that RT-dPCR monitoring will constitute an 
important component of future clinical practice. Points discussed here are likely to be of 
considerable value for future design and implementation of RT-dPCR-based monitoring, 
and results of early trials would benefit from the use of the digital MIQE guidelines [13, 
26] for accurate and transparent interpretation of findings.   
The introduction of RT-dPCR to routine clinical practice would require a clear definition 
of terminology associated with it to harmonize its use among early adopters [16]. The 
digital MIQE guidelines (dMIQE)(13) were published for this purpose and it would be less 
confusing if all publications adhere to the recommendations and terminology adopted in it.  
The most common terminologies that accompany dPCR applications are: partitions, 
lambda (λ), Poisson distribution and the dynamic range of quantification commonly 
referred to as the “sweet spot” [13], discussed in greater detail in chapter VI. Similar to 
RT-qPCR, the term RT-dPCR is recommended for applications using reverse transcribed 
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cDNA material as template compared to dPCR when using genomic material or referring 
to the method in general. 
Despite its indispensability in applications such as monitoring residual disease within 
clinical trials, in its current format, RT-dPCR is limited by the amount of sample that can 
be analysed [16] and thus cannot compete with the absolute sensitivity of RT-qPCR. In 
RT-dPCR, a large reaction volume is required to reach absolute sensitivity using limiting 
dilutions [17]; hence if simplified quantification by RT-dPCR is to have an impact on 
patient care, then versatile higher throughput instruments that facilitate large reaction 
volume (>50µl) would be required to facilitate the move towards a new paradigm of 
personalized therapeutic management in CML. External quality control programs (EQA) 
would be also required to monitor for accuracy and precision within and between labs.  
Reproducibility should also be defined in a controlled multi-centre study.  
One aspect of RT-dPCR that already has shown an impact on patient care is its use in 
value assignment for reference materials [5, 27] to support existing molecular diagnostics 
in CML such as the generation of the ERM secondary reference material [28]. 
Furthermore, RT-dPCR is a valid method for the routine calibration of the standard curves 
used in RT-qPCR whether these are in-house plasmids or tied to other reference materials, 
as RT-dPCR improves the accuracy of assigning numeric values to the calibrators and thus 
the reproducibility of RT-qPCR. 
4.5. Conclusion 
Digital PCR is unique in its ability to assign absolute copy numbers to very low 
concentrations of specific target molecules without the need for calibration. Several RT-
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dPCR platforms are already available for clinical implementation and others are on their 
way to market. The limiting factors for the currently available platforms are the number of 
partitions per reaction and the volume of sample interrogated per reaction for each 
individual sample. The exception to this is the RainDrop
®
 platform that allows a large 
number of partitions and the interrogation of a sufficient sample volume to investigate the 
presence of one target molecule in the background of a million within one reaction. This is 
of particular interest when quantifying low levels of persisting disease transcripts in 
patients classified as being in deep molecular remission. We have shown in this work that 
the RainDrop
®
 platform had a sensitivity of at least 5-logs compared to four or five logs 
for the other two RT-dPCR platforms investigated. The clinical relevance of the ability to 
detect positive disease burden in samples classified as negative by RT-qPCR is, howerver, 
to be addressed in clinical trials. In addition to platform related limitations, the false 
positivity detected in negative and no template controls indicated assay-chemistry related 
hitches.  To improve the accuracy of quantification at the deep molecular response level, 
further work is required to eliminate the false-positive signlas for RT-dPCR to function at 
its full potential.   
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4.6. Figure  
 
Figure 4.1. Cross RT-dPCR platform comparison using the E.A.C assay - Experimental Design. A range of clinical samples at different response levels 
are run on three RT-dPCR platforms: QS
®
3D, BioRad
®
, RainDrop
®
. The aim is to assess assay sensitivity defined based on the log reduction of target transcript 
levels from a standardized baseline at disease diagnosis, in addition to interrogating the kinetics of false-postive results. "Expt" stands for experiment; "Cat." 
stands for category; "Rxn" stands for reaction. 
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Figure 4.2. E.A.C. assay sensitivity on the three RT-dPCR platforms. The percentage ratio between both 
targets, BCR-ABL1 and ABL1 for the clinical samples is plotted against the sample category. Each category 
contains 10 individual samples shown as diamonds. (a) Shows the full range of clinical samples: 20%, 10%, 
1%, 0.1%, 0.01%, 0,001%, 0%, negative controls and NTC. (b) Restricts the view to the samples falling in 
the deep molecular response level. ‘SNH’ and ‘SNB’ represent the negative controls and they stand for 
‘sample negative Hammersmith’ and ‘sample negative Birmingham’, respectively. 
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Figure 4.3. E.A.C assay sensitivity on the three RT-dPCR platforms. (a) BCR-ABL1 transcript copies per 
chip (copy per 1ul of cDNA) quantified on the three RT-dPCR platforms (blue for QS
®
3D, green for BioRad
®
 
and red for RainDrop
®
) and RT-qPCR (black). (b) ABL1 transcript copies per chip (copy per 1ul of cDNA) 
quantified on the three RT-dPCR platforms (blue for QS
®
3D, green for BioRad
®
 and red for RainDrop
®
) and 
RT-qPCR (black). (c) Whisker and box plots representing BCR-ABL1 transcript copies per chip (copy per 1ul 
of cDNA) quantified on the three RT-dPCR platforms and RT-qPCR (black) for the full range of clinical 
sample categories investigated. (d) The same as (c) restricting the view to the patient groups within the 
MR response level and the negative controls. The coloured dotted lines represent the threshold for true 
positivity per platform.  
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Figure 4.4. Linear Regression. (a) Linear regression is applied on the mean log transformed BCR-ABL1 
copy values for the entire patient category range (20% - 0%). (b) The range is restricted down to the MMR 
level (≤0.1%) showing a good concordance between the three RT-dPCR platforms. on both axises, the log 
transformed value of 1 represents the MMR cut-off. 
≥MMR (0.1%) 
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Figure 4.5. Linear 
Regression on individual 
RT-dPCR platforms. 
Linear regression is 
applied on the (a) mean 
log transformed BCR-
ABL1 copy values for the 
entire patient category 
range (20% - 0%), and the 
(b) sum log transformed 
BCR-ABL1 copy values for 
the entire patient 
category range (20% - 
0%). on both axises, the 
log transformed value of 
1 represents the MMR 
cut-off. 
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4.7. Tables 
Table 4.1. The mean of target copy numbers quantified using the three RT-dPCR platforms. 
category BCR-ABL1       ABL1       % Ratio       
 RT-qPCR     
(1ul) 
QS3D 
(1ul) 
BioRad 
(1ul) 
RainDrop 
(1ul) 
RT-qPCR     
(1ul) 
QS3D 
(1ul) 
BioRad 
(1ul) 
RainDrop 
(1ul) 
RT-qPCR     
(1ul) 
QS3D 
(1ul) 
BioRad 
(1ul) 
RainDrop 
(1ul) 
P1_20% 5820 7237.036 3423.206 4962.616 24073 29587.36 11034.71 17341.18 24.1765% 24.4599% 31.0222% 28.6175% 
P2_20% 1747 1488.19 687.0728 794.6811 8648 9740.229 4072.57 5329.59 20.2012% 15.2788% 16.8707% 14.9107% 
P3_20% 1587 1669.293 974.1726 1090.011 6716 6060.726 3559.594 4539.876 23.6301% 27.5428% 27.3675% 24.0097% 
P4_20% 3426 4185.485 2099.804 2517.57 14705 14249.5 7043.03 9984.547 23.2982% 29.3729% 29.8139% 25.2147% 
P5_20% 5030 6019.341 2654.297 2980.658 21773 22702.84 8390.502 12269.9 23.1020% 26.5136% 31.6345% 24.2924% 
P6_20% 9993 10762.46 5782.995 2737.51 43393 29072.63 13719.32 7724.388 23.0291% 37.0192% 42.1522% 35.4398% 
P7_20% 3954 4953.294 2620.621 1683.58 17327 16009.4 7582.27 6654.375 22.8199% 30.9399% 34.5625% 25.3003% 
P8_20% 10590 17042.69 6447.455 8792.597 46613 44870.59 17372.46 29024.52 22.7190% 37.9819% 37.1131% 30.2937% 
P9_20% 3801 5063.506 2525.41 2873.458 17020 12734.78 6413.216 7946.092 22.3325% 39.7612% 39.3782% 36.1619% 
P10_20% 2910 3339.163 1588.466 1614.733 13033 17265.1 7804.276 9086.169 22.3279% 19.3405% 20.3538% 17.7713% 
P1_10% 794 921.7256 304.7352 155.4228 7728 7443.152 3793.957 3974.983 10.2743% 12.3835% 8.0321% 3.9100% 
P2_10% 935 998.537 333.4377 362.7057 9553 12231.8 3975.67 4677.24 9.7875% 8.1635% 8.3870% 7.7547% 
P3_10% 1240 1076.159 677.8364 630.0095 12788 13081.68 8629.072 9729.268 9.6966% 8.2265% 7.8553% 6.4754% 
P4_10% 558 458.516 278.0813 246.4547 5796 5340.816 3230.225 3508.567 9.6273% 8.5851% 8.6087% 7.0244% 
P5_10% 2414 2815.971 1617.755 1695.775 25760 17260.65 9350.629 11840.96 9.3711% 16.3144% 17.3010% 14.3213% 
P6_10% 384 429.0683 172.7924 102.3085 4140 3190.848 1360.035 796.3159 9.2754% 13.4468% 12.7050% 12.8477% 
P7_10% 249 274.9535 146.7169   2775 2328.989 1359.966   8.9730% 11.8057% 10.7883% #DIV/0! 
P8_10% 334 361.7103 300.26 250.7519 3818 3304.378 3058.952 3411.085 8.7480% 10.9464% 9.8158% 7.3511% 
P9_10% 898 873.4982 371.8334 321.7001 10779 12796.78 6409.052 6403.503 8.3310% 6.8259% 5.8017% 5.0238% 
P10_10% 310 257.7067 140.3534   3082 2457.881 1544.501   10.0584% 10.4849% 9.0873% #DIV/0! 
P1_1% 151 164.7089 72.85427   5091 5848.773 3089.626   2.9660% 2.8161% 2.3580% #DIV/0! 
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P2_1% 116 144.5442 83.92276 69.00333 3925 6585.367 4019.939 5418.785 2.9554% 2.1949% 2.0877% 1.2734% 
P3_1% 222 9.33565 180.1431 133.8149 8280 6531.844 7749.871 7504.49 2.6812% 0.1429% 2.3245% 1.7831% 
P4_1% 56 82.51421 68.84312 76.20453 2085 1991.931 2044.221 2366.265 2.6859% 4.1424% 3.3677% 3.2205% 
P5_1% 232 281.0552 181.5539 138.5154 8663 11253.78 8319.966 8738.809 2.6781% 2.4974% 2.1821% 1.5851% 
P6_1% 155 181.204 43.40517 55.9022 14720 20469.78 5051.34 7118.4 1.0530% 0.8852% 0.8593% 0.7853% 
P7_1% 60 70.12946 17.67901 21.10033 5735 7567.519 2662.06 3105.25 1.0462% 0.9267% 0.6641% 0.6795% 
P8_1% 137 177.8328 129.2847 132.9132 13432 13687.77 11890.41 12968.07 1.0200% 1.2992% 1.0873% 1.0249% 
P9_1% 150 188.9204 3.333715 5.200019 8633 7077.141 187.1995 213.0325 1.7375% 2.6694% 1.7808% 2.4410% 
P10_1% 40 59.75987 180.8428 140.1158 4033 3622.111 13481.4 11494.36 0.9918% 1.6499% 1.3414% 1.2190% 
P1_0.1% 6 9.002121 12.34022 17.30028 1947 1081.729 2361.257 2941.218 0.3082% 0.8322% 0.5226% 0.5882% 
P2_0.1% 21 38.37103 10.67204 16.70023 7038 15235.99 8324.878 11803.54 0.2984% 0.2518% 0.1282% 0.1415% 
P3_0.1% 5 258.8215 42.74765 42.40165 1595 13702.23 2764.704 3647.775 0.3135% 1.8889% 1.5462% 1.1624% 
P4_0.1% 22 43.04881 12.67268 20.70033 7360 7424.475 22623.02 4939.662 0.2989% 0.5798% 0.0560% 0.4191% 
P5_0.1% 56 56.41792 27.69569 19.90032 18860 15935.53 8459.02 8900.822 0.2969% 0.3540% 0.3274% 0.2236% 
P6_0.1% 9 13.67158 4.000668 5.20002 7483 6870.551 4470.095 4283.738 0.1203% 0.1990% 0.0895% 0.1214% 
P7_0.1% 5 13.33809 5.334358 4.000013 5029 4914.575 4633.184 3482.484 0.0994% 0.2714% 0.1151% 0.1149% 
P8_0.1% 3 10.0026 2.666952 3.400009 2898 2085.939 891.0645 1184.838 0.1035% 0.4795% 0.2993% 0.2870% 
P9_0.1% 10 20.67783 5.001098 3.200009 10381 11861.91 5034.228 3826.798 0.0963% 0.1743% 0.0993% 0.0836% 
P10_0.1% 9 29.35609 5.668058 9.600075 9031 7054.117 4487.203 6689.368 0.0997% 0.4162% 0.1263% 0.1435% 
P1_0.01% 0.8 20.636 0.6666824 1.000001 5121 10219.28 5144.187 5532.575 0.0156% 0.2019% 0.0130% 0.0181% 
P2_0.01% 1.8 14.3803 2.125167 2.000003 12313 15765.78 11716.52 12990.24 0.0146% 0.0912% 0.0181% 0.0154% 
P3_0.01% 0.5 14.72007 0.6000135 0.900001 3082 1947.84 1353.454 1357.582 0.0162% 0.7557% 0.0443% 0.0663% 
P4_0.01% 1.5 8.877093 1.222274 2.000003 10304 8034.426 9112.275 7080.554 0.0146% 0.1105% 0.0134% 0.0282% 
P5_0.01% 1.8 13.71912 1.555643 1.800003 12451 16931.2 10166.18 9782.109 0.0145% 0.0810% 0.0153% 0.0184% 
P6_0.01% 1.4 9.752493 3.333703 2.200004 9338 11016.88 8276.001 3047.915 0.0150% 0.0885% 0.0403% 0.0722% 
P7_0.01% 1.4 23.41394 1.777893 1.400002 9338 16285.65 8541.151 6670.419 0.0150% 0.1438% 0.0208% 0.0210% 
P8_0.01% 0.6 8.501929 1.333395 1.700002 4155 4272.549 5484.735 6350.062 0.0144% 0.1990% 0.0243% 0.0268% 
P9_0.01% 1.4 14.88072 1.777885 1.800003 9353 12450.3 8019.204 5199.111 0.0150% 0.1195% 0.0222% 0.0346% 
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P10_0.01% 1.8 21.38695 0.5555658 1.700002 13325 17249.48 7405.058 7913.048 0.0135% 0.1240% 0.0075% 0.0215% 
P1_0.001% 0.2 14.33868 0.7777979 1.200001 14122 15933.47 11807.1 13279.95 0.0014% 0.0900% 0.0066% 0.0090% 
P2_0.001% 0.2 8.501929 0.1111115 2.000003 6931 8040.652 11203.99 11479.38 0.0029% 0.1057% 0.0010% 0.0174% 
P3_0.001% 0.2 8.501932 0.7777963 2.600005 16100 11450.33 14789.25 13207.43 0.0012% 0.0743% 0.0053% 0.0197% 
P4_0.001% 0.2 15.45058 0.2222239 1.200001 14076 15520.4 12418.52 9500.898 0.0014% 0.0996% 0.0018% 0.0126% 
P5_0.001% 0.2 10.57432 0.666682 0.3 10549 14145.74 4060.04 3339.626 0.0019% 0.0748% 0.0164% 0.0090% 
P6_0.001% 0.2 10.22499 0.44445 1.300001 4493 5278.365 3403.655 1906.365 0.0045% 0.1937% 0.0131% 0.0682% 
P7_0.001% 0.2 15.0061 0.7778035 0.5 9001 10721.15 10021.8 4105.128 0.0022% 0.1400% 0.0078% 0.0122% 
P8_0.001% 0.2 12.11498 1.111158 0.900001 7973 6811.773 7154.064 5758.124 0.0025% 0.1779% 0.0155% 0.0156% 
P9_0.001% 0.2 12.75418 0.3333377 1.300001 10534 15401.59 12660.7 6938.646 0.0019% 0.0828% 0.0026% 0.0187% 
P10_0.001% 0.2 12.25383 0.555567 2.000003 11607 17498.97 18221.65 11848.33 0.0017% 0.0700% 0.0030% 0.0169% 
p1_0% 0 1.666741 0.1111116 1.100001 2975 2643.509 2781.654 2193.112 0.0000% 0.0631% 0.0040% 0.0502% 
p2_0% 0 0.6666789 0.2222239 1.200001 3297 1990.999 2540.967 1890.331 0.0000% 0.0335% 0.0087% 0.0635% 
p3_0% 0 5.667542 1.333401 1.700002 8587 13496.93 16172.91 13012.91 0.0000% 0.0420% 0.0082% 0.0131% 
p4_0% 0 6.000997 1.666771 1.800002 6149 11952.9 15441.65 11066.28 0.0000% 0.0502% 0.0108% 0.0163% 
p5_0% 0 4.333849 1.000034 1.500002 5612 7384.323 8714.045 6132.933 0.0000% 0.0587% 0.0115% 0.0245% 
p6_0% 0 2.666859 0.444451 0.900001 3235 2400.773 3341.915 1736.713 0.0000% 0.1111% 0.0133% 0.0518% 
p7_0% 0 4.667366 1.555634 1.800002 6072 7200.108 10674.9 5853.977 0.0000% 0.0648% 0.0146% 0.0307% 
p8_0% 0 4.500543 0.4444509 0.8 2898 2018.989 3404.277 1731.097 0.0000% 0.2229% 0.0131% 0.0462% 
p9_0% 0 4.500555 1.777877 0.6 2024 2543.257 3459.046 2301.065 0.0000% 0.1770% 0.0514% 0.0261% 
p10_0% 0 4.667256 0.8889153 1.700002 2438 2819.009 3532.088 2252.423 0.0000% 0.1656% 0.0252% 0.0755% 
SNH1 0 7.001333 1.000042 0.4  11679.63 9140.719 6456.53  0.0599% 0.0109% 0.0062% 
SNH2 0 16.00676 0.6666827 0.4  28775.35 8963.141 6729.17  0.0556% 0.0074% 0.0059% 
SNH3 0 4.000434 0.3333379 0.3  2261.229 1299.443 1266.158  0.1769% 0.0257% 0.0237% 
SNH4 0 5.000704 3.667142 0.7  6169.737 15341.29 13939.78  0.0811% 0.0239% 0.0050% 
SNH5 0 11.00308     32322.46     0.0340% #DIV/0! #DIV/0! 
SNH6 0 14.00544 0.3333376 0.900001  100652 95339.55 55224.03  0.0139% 0.0003% 0.0016% 
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SNH7 0 6.000931 1.000033 0.7  2775.98 14779.46 8124.77  0.2162% 0.0068% 0.0086% 
SNH8 0 3.000254  0.3  28582.1  18160.9  0.0105% #DIV/0! 0.0017% 
SNH9 0 10.00264 0.3333376 0.5  51505.87 41507.95 24747.37  0.0194% 0.0008% 0.0020% 
SNH10 0 2.000111 0 0.3  7174.882 6078.957 6701.994  0.0279% 0.0000% 0.0045% 
SNH11 0 5.000704     6169.737     0.0811% #DIV/0! #DIV/0! 
SNH12 0 0 1.333397 0.8  83080.02 79599.57 86154.12  0.0000% 0.0017% 0.0009% 
SNH13 0 0 1.333407 0.5  10468.98 97043.57 58785.45  0.0000% 0.0014% 0.0009% 
SNH14 0 3.000266  1.300001  16419.43  11531.29  0.0183% #DIV/0! 0.0113% 
SNH15 0 0 1.000036    10468.98 12412.81    0.0000% 0.0081% #DIV/0! 
SNH16 0  0     1038.696    #DIV/0! 0.0000% #DIV/0! 
SNH17 0  2.666937 0.900001   11056.5 7765.548  #DIV/0! 0.0241% 0.0116% 
SNH18 0  0.666683     17096.67    #DIV/0! 0.0039% #DIV/0! 
SNH19 0  2.000146     22912.4    #DIV/0! 0.0087% #DIV/0! 
SNB1 0 1.500062 0 0  1380.275 999.2255 1214.789  0.1087% 0.0000% 0.0000% 
SNB2 0 1.000027 0 0.1  1217.454 702.8805 141.9553  0.0821% 0.0000% 0.0704% 
SNB3 0 2.000112 0.3333381 0.2  4969.957 3039.134 5099.165  0.0402% 0.0110% 0.0039% 
SNB4 0 1.500062 0.3333377 0.1  2703.292 1943.334 1800.004  0.0555% 0.0172% 0.0056% 
SNB5 0 2.333482 0 0.1  1419.089 517.3695 658.0847  0.1644% 0.0000% 0.0152% 
SNB6 0 1.000028 0 0  1630.059 1214.274 609.9571  0.0613% 0.0000% 0.0000% 
SNB7 0 1.333384 0.3333379    2615.692 2006.094    0.0510% 0.0166% #DIV/0! 
SNB8 0 4.000419 0 0.1  4423.512 2473.679 2629.93  0.0904% 0.0000% 0.0038% 
SNB9 0 3.000247 0.3333385 0.4  6035.554 3285.988 2446.035  0.0497% 0.0101% 0.0164% 
SNB10 0 4.000458 0 0.4  1182.086 724.5149 999.3168  0.3384% 0.0000% 0.0400% 
SNB11 0 2.000108 0 0.1  1485.379 1174.449 971.3993  0.1347% 0.0000% 0.0103% 
SNB12 0 0 0 0.700001  3162.881 1582.534 2227.087  0.0000% 0.0000% 0.0314% 
SNB13 0 1.333387 0 0.4  907.8358 499.8372 351.1703  0.1469% 0.0000% 0.1139% 
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NTC 0 0 0 1.100001  2.000113 1.000034 0.2     
NTC 0 7.002202 0 1.000001  7.002202 0 0.1     
NTC 0 1.000026 0 0.7  1.000026 0 0     
NTC 0 5.000692 1.000044 1.100001  7.001357 1.000044 0.2     
NTC 0 9.002373 0 0.7  9.002373 1.000048 0.1     
NTC 0 2.000104 0 0.6  1.000026 0 0     
NTC 0 6.000979 0 0.8  1.000027 6.001203 0.4     
NTC 0 0 0 0.900001  1.000029 5.00089 0.2     
NTC 0 7.001288 0 0.8  3.000236 3.000283 0.1     
NTC 0 1.000026 0 0.5  2.000103 4.000484 0.5     
NTC 0 1.000028 0 0  1.000028 3.000356 0     
NTC 0 4.000395 0 0.2  3.000222 1.000038 0     
NTC 0 5.000627 0 0.4  8.001606 0 0.1     
NTC 0 0 0 0.7  0 0 0.4     
NTC 0 1.000026     0 2.000163       
NTC 0 5.000704     5.000704 1.000038       
NTC        0       
NTC        1.000048       
NTC        1.00004       
NTC        0       
NTC        2.000301       
NTC        0       
NTC        0       
NTC        0       
NTC        0       
NTC        0       
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NTC        0       
NTC        0       
NTC        0       
NTC        0       
 
 
Table 2. The sum of target copy numbers quantified using the three RT-dPCR platforms. 
catego
ry 
BCR-
ABL1 
      ABL1       % Ratio       
 RT-qPCR     
(3ul) 
QS3D 
(Rxn)(3or9
ul) 
BioRad 
(Rxn)(3or9
ul) 
RainDrop 
(Rxn)(10
ul) 
RT-
qPCR     
(3ul) 
QS3D 
(Rxn)(3or9
ul) 
BioRad 
(Rxn)(3or9
ul) 
RainDrop 
(Rxn)(10
ul) 
RT-
qPCR     
(3ul) 
QS3D 
(Rxn)(3or9
ul) 
BioRad 
(Rxn)(3or9
ul) 
RainDrop 
(Rxn)(10
ul) 
20% 17460.2
2 
21711.11 10269.62 49626.16 72220 88762.07 33104.13 173411.8 24.1764
% 
24.4599% 31.0222% 28.6175
% 
20% 5242.16 4464.569 2061.218 7946.811 25944 29220.69 12217.71 53295.9 20.2057
% 
15.2788% 16.8707% 14.9107
% 
20% 4761.92 5007.878 2922.518 10900.11 20148 18182.18 10678.78 45398.76 23.6347
% 
27.5428% 27.3675% 24.0097
% 
20% 10277.7
8 
12556.46 6299.413 25175.7 44114 42748.49 21129.09 99845.47 23.2982
% 
29.3729% 29.8139% 25.2147
% 
20% 15091.2
2 
18058.03 7962.89 29806.58 65320 68108.53 25171.51 122699 23.1035
% 
26.5136% 31.6345% 24.2924
% 
20% 29979.5
8 
21524.91 17348.98 27375.1 13018
0 
58145.26 41157.96 77243.88 23.0293
% 
37.0192% 42.1522% 35.4398
% 
20% 11861.5
6 
14859.88 7861.862 16835.8 51980 48028.21 22746.81 66543.75 22.8195
% 
30.9399% 34.5625% 25.3003
% 
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20% 31769.4
4 
51128.07 19342.37 87925.97 13984
0 
134611.8 52117.38 290245.2 22.7184
% 
37.9819% 37.1131% 30.2937
% 
20% 11402.4
8 
15190.52 7576.23 28734.58 51060 38204.35 19239.65 79460.92 22.3315
% 
39.7612% 39.3782% 36.1619
% 
20% 8729.42 6678.326 4765.398 16147.33 39100 34530.2 23412.83 90861.69 22.3259
% 
19.3405% 20.3538% 17.7713
% 
10% 2383.26 2765.177 914.2057 1554.228 23184 22329.46 11381.87 39749.83 10.2798
% 
12.3835% 8.0321% 3.9100% 
10% 2804.16 1997.074 1000.313 3627.057 28658 24463.59 11927.01 46772.4 9.7849
% 
8.1635% 8.3870% 7.7547% 
10% 3720.94 3228.478 2033.509 6300.095 38364 39245.03 25887.22 97292.68 9.6990
% 
8.2265% 7.8553% 6.4754% 
10% 1674.4 1375.548 834.2438 2464.547 17388 16022.45 9690.674 35085.67 9.6296
% 
8.5851% 8.6087% 7.0244% 
10% 7243.16 8447.913 4853.266 16957.75 77280 51781.96 28051.89 118409.6 9.3726
% 
16.3144% 17.3010% 14.3213
% 
10% 1152.76 1287.205 518.3773 1023.085 12420 9572.543 4080.106 7963.159 9.2815
% 
13.4468% 12.7050% 12.8477
% 
10% 746.12 824.8606 440.1506  8326 6986.967 4079.897  8.9613
% 
11.8057% 10.7883% #DIV/0! 
10% 1002.34 1085.131 900.78 2507.519 11454 9913.135 9176.856 34110.85 8.7510
% 
10.9464% 9.8158% 7.3511% 
10% 2693.76 2620.494 1115.5 3217.001 32338 38390.35 19227.16 64035.03 8.3300
% 
6.8259% 5.8017% 5.0238% 
10% 930.58 773.1201 421.06  9246 7373.642 4633.504  10.0647
% 
10.4849% 9.0873% #DIV/0! 
1% 453.56 494.1266 218.5628  15272 17546.32 9268.879  2.9699
% 
2.8161% 2.3580% #DIV/0! 
1% 347.3 433.6326 251.7683 690.0333 11776 19756.1 12059.82 54187.85 2.9492
% 
2.1949% 2.0877% 1.2734% 
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1% 667.46 28.00695 540.4293 1338.149 24840 19595.53 23249.61 75044.9 2.6870
% 
0.1429% 2.3245% 1.7831% 
1% 167.9 247.5426 206.5294 762.0453 6256 5975.793 6132.663 23662.65 2.6838
% 
4.1424% 3.3677% 3.2205% 
1% 696.9 843.1658 544.6618 1385.154 25990 33761.34 24959.9 87388.09 2.6814
% 
2.4974% 2.1821% 1.5851% 
1% 465.98 543.6119 130.2155 559.022 44160 61409.36 15154.02 71184 1.0552
% 
0.8852% 0.8593% 0.7853% 
1% 179.86 210.3884 53.03704 211.0033 17204 22702.56 7986.181 31052.5 1.0455
% 
0.9267% 0.6641% 0.6795% 
1% 411.24 533.4984 387.854 1329.132 40296 41063.3 35671.24 129680.7 1.0205
% 
1.2992% 1.0873% 1.0249% 
1% 450.8 566.7612 10.00115 52.00019 25898 21231.42 561.5984 2130.325 1.7407
% 
2.6694% 1.7808% 2.4410% 
1% 120.98 179.2796 542.5284 1401.158 12098 10866.33 40444.2 114943.6 1.0000
% 
1.6499% 1.3414% 1.2190% 
0.10% 17.48 27.00636 37.02066 173.0028 5842 3245.188 7083.77 29412.18 0.2992
% 
0.8322% 0.5226% 0.5882% 
0.10% 63.02 115.1131 32.01611 167.0023 21114 45707.97 24974.63 118035.4 0.2985
% 
0.2518% 0.1282% 0.1415% 
0.10% 14.26 776.4644 128.2429 424.0165 4784 41106.69 8294.11 36477.75 0.2981
% 
1.8889% 1.5462% 1.1624% 
0.10% 65.78 129.1464 38.01804 207.0033 22080 22273.42 67869.06 49396.62 0.2979
% 
0.5798% 0.0560% 0.4191% 
0.10% 166.52 169.2538 83.08708 199.0032 56580 47806.59 25377.06 89008.22 0.2943
% 
0.3540% 0.3274% 0.2236% 
0.10% 25.76 41.01474 12.002 52.0002 22448 20611.65 13410.29 42837.38 0.1148
% 
0.1990% 0.0895% 0.1214% 
0.10% 15.18 40.01426 16.00308 40.00013 15088 14743.72 13899.55 34824.84 0.1006
% 
0.2714% 0.1151% 0.1149% 
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0.10% 8.74 30.00779 8.000855 34.00009 8694 6257.817 2673.194 11848.38 0.1005
% 
0.4795% 0.2993% 0.2870% 
0.10% 31.28 62.03349 15.0033 32.00009 31142 35585.72 15102.68 38267.98 0.1004
% 
0.1743% 0.0993% 0.0836% 
0.10% 27.14 88.06827 17.00417 96.00075 27094 21162.35 13461.61 66893.68 0.1002
% 
0.4162% 0.1263% 0.1435% 
0.01% 2.3 165.088 6.000142 10.00001 15364 81754.27 46297.68 55325.75 0.0150
% 
0.2019% 0.0130% 0.0181% 
0.01% 5.52 115.0424 17.00134 20.00003 36938 126126.3 93732.16 129902.4 0.0149
% 
0.0912% 0.0181% 0.0154% 
0.01% 1.38 103.0405 3.000068 9.000007 9246 13634.88 6767.27 13575.82 0.0149
% 
0.7557% 0.0443% 0.0663% 
0.01% 4.6 71.01675 11.00046 20.00003 30912 64275.41 82010.47 70805.54 0.0149
% 
0.1105% 0.0134% 0.0282% 
0.01% 5.52 96.03385 14.00079 18.00003 37352 118518.4 91495.59 97821.09 0.0148
% 
0.0810% 0.0153% 0.0184% 
0.01% 4.14 78.01994 30.00333 22.00004 28014 88135.03 74484.01 30479.15 0.0148
% 
0.0885% 0.0403% 0.0722% 
0.01% 4.14 117.0697 16.00103 14.00002 28014 81428.25 76870.36 66704.19 0.0148
% 
0.1438% 0.0208% 0.0210% 
0.01% 1.84 68.01543 12.00056 17.00002 12466 34180.39 49362.61 63500.62 0.0148
% 
0.1990% 0.0243% 0.0268% 
0.01% 4.14 119.0458 16.00097 18.00003 28060 99602.39 72172.84 51991.11 0.0148
% 
0.1195% 0.0222% 0.0346% 
0.01% 5.52 171.0956 5.000093 17.00002 39974 137995.8 66645.52 79130.48 0.0138
% 
0.1240% 0.0075% 0.0215% 
0.001% 0.46 129.0481 7.000181 12.00001 42366 143401.3 106263.9 132799.5 0.0011
% 
0.0900% 0.0066% 0.0090% 
0.001% 0.46 68.01543 1.000004 20.00003 20792 64325.22 100836 114793.8 0.0022
% 
0.1057% 0.0010% 0.0174% 
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0.001% 0.46 68.01545 7.000166 26.00005 48300 91602.61 133103.3 132074.3 0.0010
% 
0.0743% 0.0053% 0.0197% 
0.001% 0.46 139.0553 2.000015 12.00001 42228 139683.6 111766.7 95008.98 0.0011
% 
0.0996% 0.0018% 0.0126% 
0.001% 0.46 74.02023 6.000137 3.000001 31648 99020.2 36540.36 33396.26 0.0015
% 
0.0748% 0.0164% 0.0090% 
0.001% 0.46 92.02488 4.00005 13.00001 13478 47505.29 30632.89 19063.65 0.0034
% 
0.1937% 0.0131% 0.0682% 
0.001% 0.46 60.02439 7.000232 5.000002 27002 42884.6 90196.23 41051.28 0.0017
% 
0.1400% 0.0078% 0.0122% 
0.001% 0.46 109.0348 10.00042 9.000005 23920 61305.96 64386.57 57581.24 0.0019
% 
0.1779% 0.0155% 0.0156% 
0.001% 0.46 102.0335 3.000039 13.00001 31602 123212.7 113946.3 69386.46 0.0015
% 
0.0828% 0.0026% 0.0187% 
0.001% 0.46 98.03067 5.000103 20.00003 34822 139991.8 163994.9 118483.3 0.0013
% 
0.0700% 0.0030% 0.0169% 
0% 0 5.000224 1.000004 11.00001 8924 7930.527 25034.88 21931.12 0.0000
% 
0.0631% 0.0040% 0.0502% 
0% 0 2.000037 2.000016 12.00001 9890 5972.998 22868.7 18903.31 0.0000
% 
0.0335% 0.0087% 0.0635% 
0% 0 17.00263 12.00061 17.00002 25760 40490.8 145556.2 130129.1 0.0000
% 
0.0420% 0.0082% 0.0131% 
0% 0 18.00299 15.00094 18.00002 18446 35858.69 138974.8 110662.8 0.0000
% 
0.0502% 0.0108% 0.0163% 
0% 0 13.00155 9.000305 15.00002 16836 22152.97 78426.41 61329.33 0.0000
% 
0.0587% 0.0115% 0.0245% 
0% 0 8.000576 4.000059 9.000006 9706 7202.32 30077.23 17367.13 0.0000
% 
0.1111% 0.0133% 0.0518% 
0% 0 14.0021 14.00071 18.00002 18216 21600.32 96074.12 58539.77 0.0000
% 
0.0648% 0.0146% 0.0307% 
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0% 0 9.001086 4.000059 8.000005 8694 4037.978 30638.49 17310.97 0.0000
% 
0.2229% 0.0131% 0.0462% 
0% 0 9.00111 16.0009 6.000003 6072 5086.514 31131.41 23010.65 0.0000
% 
0.1770% 0.0514% 0.0261% 
0% 0 14.00177 8.000238 17.00002 7314 8457.027 31788.79 22524.23 0.0000
% 
0.1656% 0.0252% 0.0755% 
SNH1  10.503 3.000126 4.000002  11679.63 27422.16 64565.3  0.0899% 0.0109% 0.0062% 
SNH2  24.01522 2.000048 4.000001  28775.35 26889.42 67291.7  0.0835% 0.0074% 0.0059% 
SNH3  6.000977 1.000014 3.000001  2261.229 3898.33 12661.58  0.2654% 0.0257% 0.0237% 
SNH4  7.501584 11.00143 7.000005  6169.737 46023.88 139397.8  0.1216% 0.0239% 0.0050% 
SNH5  16.50693    32322.46    0.0511% #DIV/0! #DIV/0! 
SNH6  21.01224 1.000013 9.000009  100652 286018.6 552240.3  0.0209% 0.0003% 0.0016% 
SNH7  9.002094 3.000098 7.000005  2775.98 44338.4 81247.7  0.3243% 0.0068% 0.0086% 
SNH8  4.500572  3.000001  28582.1  181609  0.0157% #DIV/0! 0.0017% 
SNH9  15.00593 1.000013 5.000003  51505.87 124523.8 247473.7  0.0291% 0.0008% 0.0020% 
SNH10  3.000251 0 3.000001  7174.882 18236.87 67019.94  0.0418% 0.0000% 0.0045% 
SNH11  7.501584    6169.737    0.1216% #DIV/0! #DIV/0! 
SNH12  0 4.00019 8.000005  83080.02 238798.7 861541.2  0.0000% 0.0017% 0.0009% 
SNH13  0 4.00022 5.000003  10468.98 291130.7 587854.5  0.0000% 0.0014% 0.0009% 
SNH14  4.500599  13.00001  16419.43  115312.9  0.0274% #DIV/0! 0.0113% 
SNH15  0 3.000107   10468.98 37238.42   0.0000% 0.0081% #DIV/0! 
SNH16   0    3116.087   #DIV/0! 0.0000% #DIV/0! 
SNH17   0 9.000008   33169.51 77655.48  #DIV/0! 0.0000% 0.0116% 
SNH18   0    51290.02   #DIV/0! 0.0000% #DIV/0! 
SNH19   8.00078    68737.2   #DIV/0! 0.0116% #DIV/0! 
SNB1  3.000124 0 0  2760.549 2997.676 12147.89  0.1087% 0.0000% 0.0000% 
SNB2  2.000054 0 1  2434.907 2108.642 1419.553  0.0821% 0.0000% 0.0704% 
SNB3  4.000224 2.000057 2  9939.914 9117.403 50991.65  0.0402% 0.0219% 0.0039% 
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SNB4  3.000124 0 1  5406.584 5830.002 18000.04  0.0555% 0.0000% 0.0056% 
SNB5  7.000445 0 1  4257.267 1552.109 6580.847  0.1644% 0.0000% 0.0152% 
SNB6  3.000083 6.000479 0  4890.177 3642.822 6099.571  0.0613% 0.1647% 0.0000% 
SNB7  4.000153 0   7847.076 6018.281   0.0510% 0.0000% #DIV/0! 
SNB8  8.000837 0 1  8847.025 7421.037 26299.3  0.0904% 0.0000% 0.0038% 
SNB9  9.00074 0 4.000002  18106.66 9857.965 24460.35  0.0497% 0.0000% 0.0164% 
SNB10  4.000458 0 4.000001  1182.086 2173.545 9993.168  0.3384% 0.0000% 0.0400% 
SNB11  4.000216 0 1  2970.759 3523.347 9713.993  0.1347% 0.0000% 0.0103% 
SNB12  0 0 7.000005  6325.762 4747.601 22270.87  0.0000% 0.0000% 0.0314% 
SNB13  4.000161 0 4.000002  2723.508 1499.512 3511.703  0.1469% 0.0000% 0.1139% 
NTC  0 0 11.00001  2.000113 1.000034 2     
NTC  7.002202 0 10.00001  7.002202 0 1     
NTC  1.000026 0 7.000003  1.000026 0 0     
NTC  5.000692 1.000044 11.00001  7.001357 1.000044 2     
NTC  9.002373 0 7.000004  9.002373 1.000048 1     
NTC  2.000104 0 6.000003  1.000026 0 0     
NTC  6.000979 0 8.000004  1.000027 6.001203 4.000001     
NTC  0 0 9.000005  1.000029 5.00089 2     
NTC  7.001288 0 8.000004  3.000236 3.000284 1     
NTC  1.000026 0 5.000002  2.000103 4.000484 5.000002     
NTC  1.000028 0 0  1.000028 3.000356 0     
NTC  4.000395 0 2  3.000222 1.000038 0     
NTC  5.000627 0 4.000001  8.001606 0 1     
NTC  0 0 7.000004  0 0 4.000001     
NTC  1.000026 0   0 2.000163      
NTC  5.000704 0   5.000704 1.000038      
NTC   0    0      
NTC   0    1.000048      
  
203 
 
NTC   0    1.00004      
NTC   0    0      
NTC   0    2.000301      
NTC   0    0      
NTC   0    0      
NTC   0    0      
NTC   0    0      
NTC   0    0      
NTC   0    0      
NTC   0    0      
NTC   0    0      
NTC   0    0      
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Chapter V 
5. Next Generation Sequencing (NGS) 
Guided Management of Resistance to 
Tyrosine Kinase Inhibitors (TKIs) in 
Chronic Myeloid Leukaemia (CML). 
 
 
5.1. Introduction 
Resistance to Tyrosine Kinase Inhibitor (TKI) therapy occurs in 25-30% of patients with 
Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) [1]. Mutations in the Tyrosine 
Kinase Domain (TKD) remain the most widely studied cause of resistance and have a 
pivotal role in guiding decisions for the clinical management of resistant disease.  
Before the introduction of the second and third generation TKIs, 70–80% of the mutations 
associated with imatinib resistance were confined to 7–15 amino acids, including M244V, 
G250E, Y253F/H, E255K/V, V299L, T315I/A, F317L/I, M351T, E355G, F359V/I/C, 
H396R/P, E450G/V and E459K [2-5]. These lesions were shown to affect drug efficacy 
either via directly affecting imatinib binding to the TKD, or via inducing conformational 
changes as a result of changes in the van-der-Waals bonds formed between imatinib and 
the TKD, or via inducing changes to intra-TKD regulatory interactions [3, 5-8]. Second 
and third generation TKIs were developed to overcome resistance caused by TKD 
mutations. However, approximately 14–33% of CML patients treated with second 
generation TKI
 
as second-line develop new BCR-ABL1 mutations (9-12), and each TKI 
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has its own resistance profile. For instance, dasatinib-treated patients frequently develop 
the V299L, T315I, T315A, T317L/V/I/C and M351T mutations [13-16] whereas nilotinib 
exerts selection for p-loop mutations such as Y253H, E255K/V, F359V/I/C [15-18]. The 
study of mutations in bosutinib-treated patients is less extensive but they appear to overlap 
with other second generation TKI (M244V, L248V, G250E, V299L, F317L, M351T, 
F359V/C) [19-20]. The T315I mutation remains resistant to all TKIs except for the third 
generation TKI ponatinib [2, 21-23]. Recent in-vitro studies have shown that although 
ponatinib overcomes resistance to the T315I mutation, it fails to overcome compound 
mutations, i.e. when more than one mutation occurs in the same clone. The most resistant 
of these are the ones including the T315I mutation (T315I/F359V and E255V/T315I) [24-
26].  
Recommendations from the most recent ELN guideline regarding TKD mutation testing 
aim to guide the choice for appropriate therapeutic intervention when necessary [27]. 
There are currently no recommendations for TKD mutation screening as a prognostic test. 
The gold-standard method for testing is Sanger sequencing with an estimated limit of 
detection of ~20%. The deployment of ultra-sensitive methods for investigation has 
revealed the presence of low-level mutations with no clear prognostic associations. Some 
studies have correlated the presence of TKI-resistant low-level mutations while in CCyR 
and at the time of relapse with shorter PFS, OS and loss of response [26], while others 
were unable to confirm the correlation [28-31].  
The unique advantage of Next Generation Sequencing (NGS) over the currently used 
methodologies for mutation screening is that it combines the best characteristics of all 
other methods in one platform, including high sensitivity, quantitation capacity, ability to 
  
209 
 
detect known and novel mutations in addition to InDels or any variation that occurs within 
the TKD, and the aptitude for distinguishing compound from polyclonal mutations [28]. 
Given these advantages, we sought to evaluate the Ion Torrent PGM Next Generation 
Sequencing platform for the routine testing of referral cases for TKD mutation analysis. 
For this purpose, we first used a set of positive and negative samples to validate the Ion 
Torrent PGM NGS platform. The validation was followed with a prospective analysis of 
referral samples over a period of one year (Jan-December 2015) to evaluate the 
performance of the platform and assess the practical need for replacing the current 
methodologies with NGS, notwithstanding its potential technical superiority. 
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5.2. Materials and Methods 
5.2.1. Patient Cohorts and cell line dilutions 
Thirty samples from 30 different patients were selected for the initial platform validation. 
The selection was based on the presence of TKD mutations recorded in our database 
following Sanger sequencing and/or pyrosequencing analysis (the latter was restricted to 
testing only the Y253H, E255K/V, T315I, F317L and V299L mutations) between 2010 
and 2015. In 11/30 (37%) of the cases, we identified 45 longitude samples for further 
retrospective TKD mutation testing (median of 5 samples per patient, range 2–14 
samples)(Figure 5.1a). An additional eight archived NEQAS samples (Lyophilized cells), 
14 samples with no CML diagnosis and 6 CML samples with no mutations identified by 
Sanger or pyrosequencing were included as positive and negative controls, respectively. 
No Template Controls (NTCs) were also included with each library as a negative control. 
A serial dilution of the BAF3 cell line containing the T315I mutation diluted in HL60 cell 
line at 100%, 50%, 20%, 10%, 5% and 1% was also investigated in three independent 
runs.  
Following validation, 196 samples from 175 patients were prospectively screened for 
TKD mutations. Referrals were from within the Imperial NHS Trust, and clinical 
haematology departments elsewhere in the UK. All samples analysed in the prospective 
cohort had been received between Jan and Dec 2015.  Referral reasons included: the loss 
of major molecular response (MMR or MR
3
), an increase in BCR-ABL1 transcript levels 
without losing MMR, monitoring after SCT and the need to switch TKI for various 
reasons. In some cases, the reason for referral was neither provided nor was it clear on the 
accompanying form. Eighteen (10%) of the patients had sequential samples (12 patients 
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with two samples tested and six patients with three samples tested) (Figure 5.1b). One 
sample with a compound mutation (Y253H 20% and F317L 65%) was included as a 
positive control in each run.   
5.2.2. Material 
RNA was extracted as previously described in Chapter 3 of this thesis and previously 
reported [32]. 
DNA was extracted from 200µl of the same stored RLT lysates as RNA.  The QIAamp 
DNA blood mini kit (Qiagen, cat number 51106) and the QIAcube robotic workstation 
(Qiagen) were used following the manufacturer's instructions. DNA was quantified using 
the Qubit fluorometric method (Invitrogen, Qubit
® 
dsDNA BR Assay kit, cat number 
Q32850), and impurities were further assessed using the 260/280 and the 260/230 ratios 
measured using a spectrophotometer. 
5.2.3. Experimental Design 
This work was carried out in three stages: 1) Validation of the Ion Torrent PGM platform 
for TKD mutation testing in which sample input, library prep strategy, sequencing 
chemistry, run quality metrics, analytical limit of detection (LoD or sensitivity) and 
turnaround time were established. Different template types (cDNA vs DNA) were also 
investigated. 2) Once validated, the workflow was implemented for prospective testing, 
with 196 samples screened since implementation. 3) Correlation of different levels of 
mutations with clinical outcome was performed, although this was limited by the lack of 
clinical information provided. A summary of the experimental design is shown in (Figure 
5.2). 
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5.2.4. Ion Torrent PGM Amplicon Deep Sequencing Workflow 
The Amplicon deep sequencing workflow on the Ion Torrent PGM platform was 
performed following different protocols. Briefly, the workflow consists of four major 
steps: 1) Nested PCR for amplicon generation (3h), 2) library preparation (5h), 3) 
emulsion PCR (emPCR) for template preparation (templating) (6–8h) and 4) 
semiconductor sequencing (6–8h). (Figure 5.3).  
5.2.4.1.Amplicon Generation 
Nested PCR was used to ensure the specific amplification of the TKD within the fusion 
transcript, thus excluding the transcript from the wild-type ABL1 allele. The 1
st
 round 
primers are published in [33] (Appendix table 5.1). The PCR amplification reaction 
included 10µl of 2x Qiagen Fast Cycling Master Mix (PN 203745, Qiagen), 7.6µl distilled 
water, 0.2µl of 10uM of each primer, 2µl of cDNA in a total of 20µl reaction volume. 
Amplification conditions were as follows: 95°C for 5 min followed by 25 cycles of 96°C 
for 5 sec, 61°C for 5 sec, 68°C for 37 sec and a final extension of 10min at 72°C followed 
by indefinite storage at 10°C.  
The second round PCR amplification was carried out on the first round PCR products 
using the kit method. The second round primers are published in [24] (Appendix table 
5.1). Briefly, two pools of six overlapping sets of primers spanning the ABL1 TKD exons 
4–10, were amplified in two multiplexed PCR reactions generating mean amplicon sizes 
of about 350bp (Figure 5.3). PCR reactions contained 18µl distilled water, 25µl of 2x 
Qiagen Multiplex PCR Plus Master Mix (PN 206152, Qiagen), 5µl of 10x primer mix 
(2uM each primer), and 2µl of 1st round PCR product. The PCR amplification conditions 
were as follows: 95°C for 5 min followed by 20 cycles of 95°C for 30 sec, 60°C for 90 
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sec, 72°C for 30 sec and a final extension time of 10 min at 68°C followed by infinite 
storage at 10°C. Second round PCR products were subjected to capillary electrophoresis 
(Qiagen, QIAxcel) (Figure 5.3), purified using magnetic beads (Agencourt® AMPure® 
XP, Beckman Coulter) and quantified using the Qubit
®
 Fluorometric method (Invitrogen), 
following manufacturer’s instructions. Equimolar amounts of the two amplicon pools per 
sample were combined into a final pool of 10–100ng in 79µl of TE buffer required in the 
barcoding reaction. At the end of this process, individual libraries were ready for 
barcoding. 
5.2.4.2.Library preparation 
Following amplicon generation using the kit method, pooled PCR products were end-
repaired and ligated with adapters and barcodes using the Ion Plus Fragment Library Kit 
and the Ion Express barcode Adapter Kit (PN 4471252 and 4471250, ThermoFisher 
scientific) following manufacturer instructions (Publication PN 4471989 Revision. B). 
Barcoded libraries were quantified using the KAPA library quantification kit for the Ion 
Torrent platform (kk4827, Kapa Biosystems). The Template Dilution Factor (TDF) was 
calculated using the following formula: TDF= [mean concentration taken from the qPCR 
reaction x (153/average fragment length)] x qPCR dilution factor. Based on the TDF, 
amplicon libraries were diluted and equal volumes of each were pooled together to form a 
final pooled library of 25µl required in the templating reaction. At the end of this process, 
libraries are ready for templating. 
Library preparation using DNA as template was performed using the Ampliseq library 
preparation v2 kit and the Ion Express barcode Adapter kit (PN 4475345 and 4471250, 
ThermoFisher scientific) following the manufacturer’s protocol (Publication PN 4472261 
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Rev. E).  The panel was custom designed using the Ion Ampliseq Designer online portal. 
Briefly, amplicons were generated using the custom Ampliseq panel then barcoded, 
adaptor ligated (8–16 samples/run) and equimolar amounts of amplicons were pooled in a 
final library ready for templating.  
5.2.4.3.Templating and Emulsion PCR 
Following library preparation, the final pooled library was subjected to emulsion PCR 
(emPCR).  Based on the subsequent sequencing chemistry, emPCR was performed using 
the Ion PGM™ Template OT2 400 kit or the Ion PGM™ Hi-Q™ OT2 Kit (part numbers 
4479878 and A27739, ThermoFisher scientific) following manufacturer’ instructions 
(Publication PN MAN0007218, Rev 2 and MAN0010902, Rev A). For Ampliseq library 
templating, the Ion PGM™ Hi-Q™ OT2 Kit was used. The reaction was run on the Ion 
One Touch instrument using the Hi-Q 400 chemistry option (8–6 hours). Following 
emPCR and the clonal amplification of library fragments on the Ion Sphere Particles 
(ISPs), the ISPs were enriched using the Ion One Touch ES instrument following the 
manufacturer’ instructions. The enriched ISPs were then collected, washed and quality 
controlled to assess the percentage of templates to beads (typical values is between 10–
30%) using the Qubit Ion Sphere™ Quality Control Kit (PN 4468656, ThermoFisher 
scientific) following the manufacturer’ instructions. 
5.2.4.4.Ion Torrent Semiconductor Sequencing 
Enriched ISPs were prepared for sequencing and the chip was loaded following the 
manufacturer’ instructions (Publication PN MAN0007242, Rev 2 for the 400 chemistry 
and MAN0009816, Rev C for the Hi-Q chemistry). Sequencing was performed using 
either the 400 sequencing kit or the Ion PGM™ Hi-Q™ Sequencing Kit (PN 4482002 and 
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A25592, ThermoFisher scientific) and the 316 v2 (part number 4483324, ThermoFisher 
scientific) chip type.  
5.2.5. Data Analysis 
For platform validation, data were analysed using three bioinformatics packages: SeqNext 
Sequence Pilot software (JSI Medical Systems GmbH, Germany), Ion Torrent variant 
caller (IVC; ThermoFisher Scientific, USA) and the NextGen software (Soft Genetics, 
USA). The settings for alignment and variant calling on the NextSeq software were 
extensively validated through the IRON II (Inter-laboratory Robustness of Next 
Generation Sequencing) study (34) and therefore served as a reference to calibrate the 
settings on the other two software. Only IVC was used for the prospective analysis. The 
reference sequences used were the NM_005157.4 ABL1 transcript for mutation analysis on 
cDNA or the Hg19 human reference genome for DNA. With the NM_005157.4 reference, 
a custom prepared “target region” file and a “HotSpot” bed file were used for variant 
annotation. The Hg19 reference had its own “target region” file and mutation “HotSpot” 
bed file. All files are available in (Appendix Tables 5.2, 5.3 and 5.4). Alignment was 
performed on reads with a quality score of Q20 or above. (Settings are provided in 
Appendix Tables 5.5, 5.6, 5.7 and 5.8). A minimum coverage of 1000 reads per HotSpot 
was required for an LoQ of 5%. LoQ of 1% was accepted provided a coverage of 2000 
reads was achieved with at least 20 reads containing the mutation (10 in each direction) in 
agreement with the recommendations from the IRON II study. Appendix Figure 5.1 
provides a snap shot comparison between the three platforms with a brief summary of the 
advantages and disadvantages of each. 
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5.2.6. Statistical Analysis 
Comparison of the results with the gold-standard method (Sanger sequencing) was 
performed using the non-parametric paired t-test statistical analysis to assess the 
significance of differences in called variants. ANOVA Analysis of Variance test and 
Student’s t-test were used to assess inter and intra-run variabilities using the high and low 
mutation control and the different run metrics as parameter. The Chi-Squared frequency 
test (χ2) was used to compare the response of patients to TKI therapy in different 
subgroups. In all tests, a p-value of ≤ 0.05 was considered significant. Low-level 
mutations were defines as <20% in the validation cohort and <5% in the porspective 
cohort. 
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5.4. Results 
We applied amplicon deep NGS to validate the ion torrent platform for BCR-ABL1 TKD 
mutation testing for the clinical management of CML. As the mutations in the validation 
cohort were originally determined using Sanger sequencing (LoD of ~20%) and 
pyrosequencing for the 5 clinically relevant mutations (LoQ of ~5%), we used  20% as the 
cut-off below which, detected mutations by NGS were defined as low-level. Exceptions 
were the five mutations originally quantified by pyrosequencing, in which the cut-off was 
defined as 5%. For this reason, we refer to both Sanger and pyrosequencing together as the 
gold-standard. The validation was followed by a period of 12 months of prospective 
testing of samples referred to Imperial Molecular Pathology using NGS only. In this 
cohort, a ≥5% cut-off was used to distinguish low-level mutations as defined through the 
validation study.  
5.4.1. Ion Torrent PGM Platform Validation 
5.4.1.1.Platform concordance 
In the validation cohort, all negative samples on the gold-standard were also negative by 
NGS. Similarly, there was a 100% concordance in detecting mutations, both single and 
double, in the NEQAS positive controls (Table 5.1). Two samples made an exception. An 
additional third mutation >20% (E282K; 23%) was observed in one NEQAS sample 
supposed to contain double mutations (M244V, G250E; 43%, 42%) according to the gold-
standard. Another NEQAS sample contained an additional second mutation <20% 
(M351T; 4%) alongside another mutation (Y253H; 10%).  
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Overall, there was 83% (25/30) concordance in detecting mutations between the gold-
standard and NGS among the 30 samples used for the validation in favour to NGS, as 17% 
of the mutations detected by NGS were not reported by the gold-standard. There was 
100% concordance between the two platforms in 53% (16/30) and 10% (3/30) of the 
cases, where single and multiple mutations were detected by both platforms, respectively 
(Table 5.2).  In 17% of the cases (5/30), multiple mutations were detected by NGS where 
the gold-standard referred to a single mutation, whereas in one case (3%), NGS detected 
additional multiple mutations when the gold-standard was reefing to a double mutation. 
An interesting observation was that 30% (9/30) of the samples had additional mutations at 
level <5% detected only by NGS alongside the expected mutation(s) (Table 5.2).  
The most frequently observed artefacts included exon 8-9 insertion, c.1220C>T 
(p.A407V) and random single base pair insertions/deletions at low-level (1–4%). These 
were determined by observing similar events in the sequence of the negative controls and 
also by sequencing the same samples omitting the nested PCR step, i.e. amplifying the 
TKD from cDNA using the second-round primers. Low-level contamination was 
observed, particularly at loci where a high-level mutation was present in the same run. The 
occurrence of this type of contamination was confirmed by the detection of low-level (1–
4%) SNPs in almost all samples of a run in which a sample with a heterozygous (50%) or 
homozygous (100%) SNP was included. 
Retrospective analysis of TKD mutations in the longitude samples revealed the possibility 
for 3 scenarios: 1) high-level mutations (>20) detected were present at a lower percentage 
in earlier samples (in 6/11; 55%) (Figure 5.4a; Table 5.3). 2) The mutations in samples 
with multiple mutational profile were very dynamic where a dominant mutation 
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disappeared and another one, previously low-level, appeared throughout the course of 
therapy (in 3/11; 27%) (Figure 5.4b; Table 5.3). 3) In some samples, the dominant 
mutation detected at the time of relapse was preceded by different lower level mutations 
with no evidence for the dominant mutation at low-level (in 2/11; 18%)(Figure 5.4c; Table 
5.3). 
5.4.1.2.Run metrics 
Using the IVC software, mean data output per run was 477 Mb (range 366–641 Mb; CI 
±98 Mb). Mean total number of reads per run was 1647242.54 reads (range 77,405.8–
2,411,792; CI ±723148.93 reads). Mean and median total read length of Q20 quality score 
was 244 bp (range 235–254 bp; CI ±6.33 bp) and 222 bp (range 206–241; CI ±16 bp), 
respectively. Mean longest read length was 489 (range 483–496 bp; CI ±5 bp). Mean 
coverage depth at Q20 quality score was 74381 (range 56972–103134; CI ± 15370.69). 
98% alignment to the NM_005157 reference transcript was achieved (range 98–99%) with 
97% uniformity (range 95–99%) and 68% (range 62–75%) clonality of aligned reads 
(Figure 5.5). 
Mean coverage for amplicons one to six was 15477, 11436, 29681, 18175, 27888 and 
36763 reads, respectively. Mean coverage per barcodes one to 15 was 31592, 27746, 
26376, 35337, 37213, 30592, 36927, 27160, 36387, 29665, 29651, 37669, 32105 and 
31997, respectively. Barcode 16 was usually used to label the NTC; therefore no coverage 
information was available. Mean total coverage per hotspot was 4954 reads (range 3498–
5114; CI ±121). Strand bias was minimal. Mean forward and reverse coverage per hotspot 
was 2872 reads (range 1620–4072 reads; CI ±256 reads) and 2082 reads (range 957–3368; 
CI ±253 reads), respectively (Figure 5.5). The difference between a good and a bad run, as 
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assessed by chip loading, alignment of reads to the reference sequence and the mean 
length of the mapped reads, is shown in Appendix Figure 5.2. 
5.4.1.3.Further investigations 
Forty-five cDNA samples previously sequenced with the 400 chemistry were re-
sequenced with the Hi-Q chemistry to assess its performance as the Hi-Q chemistry is 
known to have reduced sequencing error rates and shorter time for templating and 
sequencing. The results did not differ significantly from the 400 chemistry for mutations 
that were ≥5%. However, only 6% (2/30) of the samples that had low-level (<5%) 
mutations using the 400 chemistry showed no evidence of these with the Hi-Q chemistry, 
while the frequency of common errors such as the exon 8-9 insertion and c.1220C>T 
(p.A407V) were 9% (3/30) lower with this chemistry. The aforementioned finding of low-
level mutations occurring as the result of the presence of a sample with high-level 
mutations in the same run was persistent. 
Thirty-eight samples with high-level mutations were sequenced using DNA as a template. 
The mutations were detected in 19 (50%) of the samples, but were not detected in the 
remainder. Six of the 19 (32%) mutation negative samples had low coverage at the 
mutation loci whereas the remaining 13 samples (68%) had optimal coverage of >1000 
reads. In 16 (84%) samples in which mutations were detected, the level of the mutations 
was assessed to be two fold-lower than the level detected using the nested approach. In the 
remaining three (16%), the percentage was further reduced at eight, nine and 15-fold lower 
than was calculated using the nested method.  
Using nested PCR and the Hi-Q chemistry for sequencing, mutations in the serially diluted 
T315I-mutated cell line were detected down to 5%; however the mutation in the 1% 
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dilution was not consistently detected, and when detected it was difficult to distinguish 
from background noise due to the presence of low-level contamination coming from the 
control sample with a high-level T315I mutation.  
5.4.2. Prospective Analysis 
5.4.2.1.Mutational frequencies 
In the prospective cohort, 5% was the cut-off for defining low-level mutations as 
established through the validation study. Accordingly, the majority of the samples in this 
cohort had no mutations detected (ND) by NGS (115/196; 59%).  2% of the samples 
(3/196) failed due to low amount of fusion gene available to test (BCR-ABL1 transcript 
number <50 molecules identified by RT-qPCR), 20% (40/196) had only low-level 
mutations detected, 13% (25/196) had high-level mutations with no evidence for low-level 
mutations and 6% (12/196) had both high and low-level mutations present together.  
Considering all the samples with ≥5% mutations (37/196; 19%), we found that 16% (6/37) 
had multiple mutations whereas 84% (31/37) had only one mutation. Samples with 
mutations in the rage 5–20% represented 19% (7/37) of these cases regardless if the 
sample contained single or multiple high-level mutations. Interestingly, all samples with 
evidence of multiple mutations showed both compound and polyclonal scenarios except in 
one sample where E255K and T315I mutations were polyclonal only. The two scenarios 
were distinguished by the presence of the mutations on a single read (compound) or on 
two independent reads (polyclonal). The most frequently detected high-level mutations 
were T315I (4%), E255K (3.6%) and F317L (2%). The most frequently detected low-level 
mutations were F317L (3.4%), Y253H (2.6%), M351T (2.6%), F359V (2.6%), D276G 
(1.8%), T315A (1.8%), E450V (1.4%), E459K (1.4%), Y253F (1%) and E255V (1%) 
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(Figure 5.6). The most common mutations that occurred together in the same sample were 
1) p-loop mutations with T315I, 2) E255K with V299L and 3) E255K with F317L. P-loop 
mutations appeared to be mutually exclusive similar to the ATP-binding domain mutations 
in exon 6. Genuine SNPs were observed in 3% of the patients including E499E, K247R 
and E197K. 
5.4.2.2.Performance of the controls 
Monitoring the performance of the positive control with a double mutation over time 
showed that the platform performance was reproducible and precise. The reported mean 
percentage for both mutations (Y253H 20% and F317L 65%) was 20% and 68% with a 
coefficient of variation of 29% and 36%, respectively (Figure 5.7a,b). The difference 
between the mean measured mutation percentages for both mutations did not significantly 
differ from those obtained by pyrosequencing (p values of 0.9 and 0.3, respectively using 
Student's t-test; Figure 5.7c). 
5.4.2.3.Clinical correlation with mutation aetiology 
In our prospective cohort, we classified samples into three sub-groups based on mutation 
aetiology: 1) samples with low-level mutations only (<5%)(Appendix Table 5.9), 2) 
samples with high-level mutations only (≥5%) and 3) samples with both high and low-
level mutations (≥ & < 5%)(Appendix Table 5.10). We further classified samples in both 
sub-categories two and three together into: a) samples with one mutation, b) samples with 
multiple mutations and (Appendix Table 5.11) c) samples with mutations ranging from 5–
20% regardless if already classified within the sub-groups a or b (Appendix Table 5.12). 
In each sub-category, the patients were considered as responders or non-responders to TKI 
based on their ability to achieve MMR, at any point. Chi-Squared t-test comparing the 
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frequency of responders and non-responders in each sub-category did not show any 
significant difference in the outcome of the sub-groups (p = 0.4895).  
The patients within the sub-category number one (with mutations at <5% only) were 
further classified into four groups on the ground of their TKI resistance (Table 5.4): 1) 
patients with multiple TKI resistance (9/15; 60%; patients 26, 29, 31, 47, 60, 61, 75, 
133,156), 2) patients with transient resistance to one TKI followed by regaining MMR 
(2/15; 13%; patients 25, 82), 3) patients with stable MMR but no evidence of deep 
molecular response (5/15; 33%; patients 9, 26, 144, 152, 167), and 4) patients who lost 
deep molecular response while on a TKI (2/15; 13%; patients 72, 171). An interesting 
observation within the sub-category three (with both ≥&< 5%) was the presence of 
patients with unexplained resistance to TKI despite receiving a TKI sensitive to the 
dominant mutation detected (Table 5.5). 
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5.5. Discussion 
This part of the work aimed to validate the Ion Torrent PGM NGS platform for BCR-ABL1 
TKD mutation analysis. In particular, we focused on identifying ideal library prep 
strategy, sequencing chemistry, run quality metrics and analytical limit of quantification 
(LoQ or sensitivity), in addition to mutation calling settings and common errors. The 
validation was followed by 12 months of prospective testing of referral samples with the 
aim of monitoring platform repeatability, as well as the aetiology of low-level mutations 
and their association with clinical outcome. 
5.5.1. NGS Pros and Cons 
In CML, mutations in the BCR-ABL1 TKD are the most studied cause of resistance to 
different TKI therapies and play a crucial role in planning patients’ management. The 
gold-standard method used for testing is Sanger sequencing which has a number of 
established limitations including an LoD of around 20% and semi-quantitative 
performance. In addition, Sanger sequencing is unable to distinguish between a compound 
and polyclonal mutation scenarios, the former having recently been shown to affect 
response to TKI therapy particularly after developing resistance to one of the TKIs. 
Pyrosequencing is also used as a complementary method to Sanger sequencing in some 
labs mainly due to its quantitative advantage. However, pyrosequencing has its own 
limitations including low-throughput, short amplicon size (~25bp), specificity for 
individual mutations, and the requirement for prior knowledge of the mutation. Similar to 
Sanger, pyrosequencing is unable to distinguish between compound and polyclonal 
mutations. In contrast, deep NGS sequencing improves on the previous two methodologies 
by being quantitative and sensitive, high-throughput, allowing multiple sample analysis 
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(via multiplexing), relatively cost-effectiveness (for high-throughput labs), and is uniquely 
capable of distinguishing polyclonal from compound mutations.  
Comparing the two platforms, our validation study showed 100% concordance in 
detecting mutations >20%.  NGS excelled in 17% of the cases as it identified mutation not 
reported by the gold-standard. The failure of the gold-standard was explained as follows: 
1) mutations were <20% and not part of those quantified by pyrosequencing. 2) Mutations 
were >20% and detected by the gold-standard, but not reported because they were not 
clinically actionable mutations (L298V, L387M). The first scenario also explained the 
observation of an additional <20% mutation in one of the positive NEQAS controls. In 
20% of the samples where Sanger sequencing showed the presence of a single mutation, 
NGS showed multiple mutations but these were all between 5 to 20%. Thus, 30% of the 
samples in the validation cohort were shown to have multiple mutations by NGS 
compared to 10% by Sanger sequencing in addition to delineating whether the mutations 
were present within the same clone, or were mutually exclusive, i.e. occurring in different 
clones.  Furthermore, NGS identified additional mutations that were <5% in 30% and 26% 
of the samples in the validation and prospective cohorts, respectively. This level of 
mutations was not expected to be detected by the gold-standard emphasising the unique 
advantage of the NGS application. 
One of the main hurdles during deep sequencing is the ability to distinguish true low-level 
mutations from background noise or PCR and sequencing errors. It is known that PCR 
fidelity affects error rate [35], and that different NGS sequencing chemistries are 
associated with different error types [26, 36]. The reported sequencing error type for the 
Ion Torrent platform is small insertions/deletions (InDels) of one or two nucleotides, 
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partially occurring at homopolymeric sights (five or more identical nucleotides) with an 
error rate of up to 3% [36]. This error is the result of inaccurate flow calls. In our hands, 
random small insertions and deletions were very frequent at low levels (<5%) in addition 
to some recurrent artefacts including the 35bp insertion between exons 8 and 9 and the 
A407V loci. The error rate for single nucleotide transition (G>A or A>G or C>T or T>C) 
were higher compared to transversions (G>C,T or A>C,T or T>G,A or C>G,A) suggesting 
PCR errors. These observations are in agreement with previous reports (26, 37-38). The 
fact that the TKD amplification is based on nested PCR means that such errors could be 
further exposed. Another layer of complexity was added by contamination problems. It is 
very difficult to explain the source of this contamination, but its occurrence was 
corroborated by two observations: 1) the presence of low-level SNPs in almost all the 
samples in a run where a positive control for that SNP had been included. 2) The 
occurrence at low-level (<5%) mutations present in all samples in runs where a positive 
control carrying those same mutations had been included in the run. To rule out false 
positive low-level mutations due to possible contamination, our LoQ threshold for true 
positive was set up at ≥5%. An LoD of 1–4% was applied only with caution and when the 
above source of contaminations had been excluded in each run. Such criteria also applied 
to the detection of the T315I mutation. 
To investigate further such possible source of contamination, we applied several different 
approaches. We sequenced negative samples, re-sequenced some samples with a different 
chemistry (the Hi-Q), amplified the TKD eliminating nested PCR step, and even used 
DNA as a template instead of RNA. These different approaches showed that the 
commonly observed mutations were still present, albeit at a lower frequency, in all tests 
except when using DNA as a template. However, using DNA as a template introduced two 
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other variables: 1) the need for increasing the sequencing depth to compensate for the 
diluting effects exerted by the presence of the normal ABL1 allele and the variable level of 
this expression; and 2) the coverage uniformity of the primers in the Ampliseq design 
covering the exons of the ABL1 gene.  The design we used had 60% uniformity and failed 
to cover all exons with sufficient depth, resulting in a failure to detect mutations in 50% of 
the samples analysed. In exons covered with >1000 reads, high ABL1 expression reduced 
the mutational burden by 2–5 folds compared to its percentage applying nested PCR on 
the cDNA. Similar to using DNA, eliminating the nested step before sequencing the TKD 
from a cDNA template reduced the detection rate by 50%, or failed to detect the mutation 
altogether. 
5.5.2. The significance of multiple mutations 
Several preclinical studies have recently shown that when multiple mutations are present 
in compound status, they have a severe effect on the response to sequential TKI treatment 
[25, 29, 39-41]. Certain combinations have worse effects particularly those combining the 
T315I mutation with a p-loop mutation [25]. Interrogating the data from our prospective 
study, three groups of samples with multiple mutations were observed:  1) samples where 
two mutations were at ≥5% and of relatively equal percentages, 2) samples where one of 
the two mutations was ≥5% and the other was <5%, or 3) samples where at least one of 
several multiple mutations was ≥5% and the rest were <5%. The possibility of low-level 
contamination or PCR cross-talk cannot be excluded especially with multiple mutations 
<5%. The possibility for material exchange among amplicons during PCR, as suggested 
earlier, is difficult to justify [42] for two reasons: 1) the samples are multiplexed after the 
nested PCR step, i.e. the amplicons representing the TKD in each patient are amplified 
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independently, then pooled together before templating. 2) The templating emulsion PCR is 
based on the principle of partitioning the amplicons to individual oil-in-water micro-
reactors so that each micro-reactor clonally amplifies an individual amplicon. In theory, 
therefore, cross-talk between amplicons would not be possible. Nonetheless, the 
possibility of low-level contamination occurring at different stages during the process of 
library preparation cannot be excluded completely.  
Another consideration when investigating multiple mutations in the same sample is 
amplicon length. With the current chemistry allowing the sequencing of a maximum read 
length of 400bp, compound TKD mutations present at a distance greater than this length 
are frequently not covered with a single amplicon. Therefore, in a sample with two 
mutations, three types of reads will be produced: reads spanning the proximal mutation, 
reads spanning the distal mutation and reads spanning both mutations. In the presence of 
the three types of reads in one sample, it is, therefore, difficult to discern whether the cells 
carrying the mutations are clonal, polyclonal, or both. In the latter scenario, reads spanning 
both mutations are the only truly informative reads. This is compounded by the established 
occurrence of in-vitro recombination between mutations in trans [42]. Deininger M and 
colleagues have identified a statistical method to overcome this issue by calculating the 
expected false compound frequency between two possible mutations. This calculation was 
based on estimating the recombination rate between the two mutations taking into account 
the distance between them. The frequency of an observed compound mutation was thus 
compared to the expected frequency of false compound reads. If the observed was equal or 
less than the expected, the compound mutation was considered as a false positive [31]. 
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Nevertheless, with a frequency of 6% (6/196) in the entire cohort, multiple mutations 
which occur at a percentage ≥5% seem to be non-frequent. With such a small number, it 
would be difficult to investigate any meaningful effect they could have on patient 
outcome.  
5.5.3. The clinical significance of the low-level mutations 
As samples in the validation cohort were selected based on prior knowledge of the 
mutations (to validate the NGS method) and in the prospective cohort, the reason for 
requesting TKD mutation testing varied including ‘unknown’ or ‘unspecified’ reasons, it 
was very difficult to interpret the values of the mutation in a meaningful way. In addition, 
the full set of clinical data was not available in many, if not all cases, even for internal 
patients as these were often referred from external hospitals to our out patients clinic with 
a minimum data set. For samples received from referral hospital as a ‘one-off mutation 
analysis’ very little clinical information was generally provided.   
However, we were at least able to use the level of minimal residual disease (MRD), 
measured on IS, to classify the patients as having achieved MMR (i.e. being a responder) 
or not (i.e. being a non-responder) as a criterion for defining response. The achievement of 
MMR was determined as the earliest point during treatment when the patients achieved 
<0.1% 
IS
 (best if 3 months from starting treatment) and if the patient was then able to 
remain in MMR. In patients who achieved MMR and then lost their MMR, the patient was 
classified as non-responder whether they lost or never achieved MMR. We recognise that 
this is still a very empirical classification and will require further analysis as soon as all 
clinical data are collected (work in progress) and which were not available at the time the 
work was summarised in this thesis.  
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Based on this criteria and applying Chi-squared frequency test on the number of responder 
and non-responder patients in each sub-category, we found no significant differences in 
the responses within the sub-categories. In details, the response in patients with either 
high-level mutations, low-level mutations or both, did not differ significantly from each 
other nor from the response of patients with no mutations detected at all. Perhaps this 
result is not completely unexpected as taking the achievement of MMR at any point does 
not take into consideration the full clinical history nor it reflects the path through which 
the final outcome was achieved, i.e. through single TKI, multiple TKIs, or all-SCT, etc.  
The cause for TKI resistance in CML is explained when a mutation is detected in the 
BCR-ABL1 TKD. However, mutations are not always detected in resistant patients. Based 
on limited clinical data available from 15 internal cases that belong to the sub-category of 
low-level (<5%) mutations (table 5.4), we observed that the majority of the patients in this 
sub-category either did not achieve MMR or lost their MMR triggering the request for 
TKD mutation testing. These patients did not have a high-level mutation; therefore their 
resistance was left unexplained (Figure 5.8). Furthermore, in the sub-category of patients 
where low-level mutations were identified by NGS in addition to a dominant mutation, we 
observed that some of these patients were resistant to the TKI administered despite the 
TKI being sensitive to the dominant mutation (Table 5.5). These observations lead to the 
conclusion that mutation cannot always explain the cause for poor response or loss of 
response, but their presence at low-level can be a surrogate for additional events within the 
cells that can be responsible for the resistance. Therefore, the increased sensitivity 
advantage provided by NGS remains of uncertain clinical value. 
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Ponatinib is a pan-TKD mutation inhibitor that is active against the pan-resistant T315I 
mutation.  Although the pre-clinical data showed that compound mutations may cause 
resistance to ponatinib, the latest update from the PACE clinical trial using amplicon deep 
NGS showed that neither single nor compound mutations, including those with T315I, 
have any impact on the cytogenetic or molecular responses of CP-CML patients treated 
with ponatinib [31]. Conversely, a very recent study performed on CP-CML patients from 
the same clinical trial showed that although CP-CML patients with sole T315I mutations 
have better responses to ponatinib treatment, those with T315I in addition to low-level 
mutations have significantly inferior responses and outcome [43]. Furthermore, those with 
multiple low-level mutations without T315I also have good responses to ponatinib, unlike 
the inferior responses previously noticed with dasatinib or nilotinib. These reports suggest 
that identifying the status of the T315I mutation in addition to detecting low-level 
mutations have a unique clinical application in determining when ponatinib should be 
administered or refrained to be replaced by experimental approaches or all-SCT.  This is 
of particular interest given the toxicity profile associated with ponatinib.  
  
  
232 
 
5.7. Conclusion 
When the clinical situation dictates the necessity for a change in management strategy and 
in the absence of other informative tools to explain resistance, TKD mutation testing 
remains the most informative guide to decision making for therapeutic intervention. As 
imatinib goes off-patent in December 2016 implying its wider use as 1
st
 line agent, 
mutation testing after imatinib failure would be increasingly valuable to guide 
personalized management. Despite its efficacy as a pan mutation inhibitor, ponatinib is 
associated with high-risk safety profile and intolerance confining its use in cases where no 
other alternative is possible. Therefore, establishing the status of multiple low-level 
mutations, with or without T315I, would be of practical value. However, whether or not 
applying NGS would add any clinical value in this contest remain to be answered. 
Although NGS has a superior sensitivity, our investigation didn’t provide enough evidence 
to support the immediate need for replacing the gold-standard in routine clinical testing, 
particularly when taking into account the increase in the cost of testing associated with 
NGS. 
Although effective in guiding therapeutic intervention, the prognostic value of detecting 
mutations while in CP remains an unresolved issue. To answer this question, a large, 
multicentre study will be required that includes a large number of sample at different 
disease stages, with unified protocol and one method, preferably NGS, for retrospectively 
investigating the prognostic value of these mutations. Another approach would be the 
prospective monitoring of patients within a clinical trial with a well-defined end-points 
and clinical questions.  
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If NGS is to be used in such studies as the testing method, we have demonstrated that the 
Ion Torrent PGM NGS is a suitable platform for this purpose with an LoD and LoQ of 1% 
and 5%, respectively. Nested PCR is required to ensure the accurate estimation of the 
mutational burden despite increasing the risk for low-level contamination. Therefore, low-
level results (1-5%) should be interpreted with caution. It is preferred not to include a 
positive control in the runs to minimize the contamination. 
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5.8. Figures 
 
Figure 5.1. Study cohorts. (a) Validation cohort (retrospective). 19/30 (63%) patients have one sample; 11/30 
(37%) patients have more than one sample of which 1, 3, 1, 4, 1, 1 patients have 2, 3, 4, 5, 7, 14 samples, 
respectively. (b) Prospective analysis cohort. 154/175 (88%) patients have one sample; 18/175 (10%) patients 
have more than one sample of which 12 and 6 patients have 2 and 3 samples, respectively. 
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Figure 5.2. Experimental Design. The workflow for sequencing the samples in the validation cohort varied 
including: Nested PCR or one-step PCR on cDNA or DNA templates, the kit method for library preparation and 
the 400 chemistry or the Hi-Q chemistry for sequencing. The workflow for sequencing the samples in the 
prospective cohort included: nested PCR for amplicon generation on cDNA templates, kit library preparation 
method and the 400 sequencing chemistry.  
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Figure 5.3. Ion Torrent PGM Amplicon Deep Sequencing Workflow. The workflow contains four major steps: 
Amplicon generation, Library preparation, templating and sequencing. In day (1), nested PCR is performed to 
generate the amplicons covering the TKD within the fusion BCR-ABL1 gene, quality-controlled on capillary gel 
electrophoresis followed by barcoding and individual sample library preparation. In day (2), Individual sample 
libraries are quantified and equimolar amount from each library is pooled together into a final pooled library 
ready for emulsion PCR. Templating is performed overnight on the OT2 templating machine. In day (3), the 
beads carrying the templated library are enriched and proceeded for sequencing on the PGM. Data analysis 
could be performed on the same day or the following day. “S” refers to sample; “QC” refers to quality control. 
  
237 
 
 Figure 5.4. 
Longitude 
cases in the 
validation 
cohort. (a) This 
panel presents 
cases where 
the high level 
mutation 
detected at the 
time of 
resistance, was 
identified at 
lower levels in 
earlier samples. 
Red arrow = 
mutation 
testing by NGS 
for platform 
validation 
purpose; filled 
blue arrow = 
mutation 
testing by NGS 
of longitude 
samples from 
the same 
individual; open 
blue arrow = 
mutation 
testing result is 
available from 
routine testing; 
mut = 
mutation; ND = 
not detected; 
im = imatinib; 
das = dasatinib; 
nil = nilotinib; 
pon = 
ponatinib. The 
dotted 
horizontal red 
line = MMR 
(0.1%). Y-axis 
ratio = %BCR-
ABL1/ABL1 on 
IS. 
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 Figure 5.4. 
Longitude cases 
in the 
validation 
cohort. (b) This 
panel presents 
cases with 
dynamic 
multiple 
mutations at 
different levels. 
(c) This panel 
presents cases 
where different 
types of 
mutations were 
identified in the 
same patient, at 
different time 
points. Red 
arrow = 
mutation 
testing by NGS 
for platform 
validation 
purpose; filled 
blue arrow = 
mutation 
testing by NGS 
of longitude 
samples from 
the same 
individual; open 
blue arrow = 
mutation 
testing result is 
available from 
routine testing; 
mut = mutation; 
ND = not 
detected; im = 
imatinib; das = 
dasatinib; nil = 
nilotinib; pon = 
ponatinib. The 
dotted 
horizontal red 
line = MMR 
(0.1%). Y-axis 
ratio = %BCR-
ABL1/ABL1 on 
IS. 
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Figure 5.5. Ion Torrent PGM run metrics. (a) Mean total coverage per hotspot. (b) Mean total, Forward and 
Reverse reads coverage per hotspot. (c) Mean coverage per amplicon and barcode. (d) Mean mapped reads 
per barcode. (e) Mean coverage per barcode. (f) Coverage uniformity per barcode. (g) Mean coverage per 
amplicon.
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Figure 5.6. Mutations’ frequency in the prospective cohort. 
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Figure 5.7. The performance of the mutations in the control sample. A sample with two mutations; Y253H 
and F317L at two different percentages is used in every run as positive control. (a) The performance of the 
(Y253H; 20%) mutation over time. (b) The performance of the (F317L; 65%) mutation over time. (c) The 
difference between the mean measured mutation percentages for both mutations did not significantly vary 
from that quantified by pyrosequencing (p-values of 0.9 and 0.3, respectively using Student's t-test).  
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Figure 5.8. Clinical case scenarios in the prospective cohort. All three cases presented are resistant cases who 
never reached MMR or have lost their MMR after primary response. No mutations at any level are identified in 
these cases by NGS. “ND” stands for not detected, open circles = mutation testing not performed, filled circles = 
mutation testing is perform; open circles = mutation testing is not performed. The dotted horizontal red line = 
MMR (0.1%). Y-axis ratio = %BCR-ABL1/ABL1 on IS. 
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5.9. Tables 
Table 5.1. BCR-ABL1 TKD mutation testing in the positive and negative controls within the platform validation study. 
Sample ID Gold-standard NGS 
patient ID 
sample 
ID 
mutations 
by 
Sanger/pyro 
percentag
e 
HGVS coding 
nomenclature 
Mutations by NGS 
(≥5%) 
percentage coverage 
Mutation
s by NGS 
(<5%) 
percentag
e 
Coverag
e 
21 NEQAS F359V 98.00 c.1075T>G F359V 88.77 73823 ND ND ND 
22 NEQAS M351T 92.00 c.1052T>C M351T 84.48 77571 ND ND ND 
24 NEQAS Q252H 85.00 c.756G>T Q252H 35 22149 ND ND ND 
25 NEQAS E255K 42.00 c.763G>A E255K 47.72 46125 ND ND ND 
26 NEQAS Y253H 8.00 c.757T>C Y253H 10.3 46391 M351T 3.91 68354 
27 NEQAS F317L 40.00 c.949T>C F317L 47.26 138681 ND ND ND 
  
245 
 
28 NEQAS T315I 34.00 c.944C>T T315I 37.19 109045 ND ND ND 
23 NEQAS 
M244V;G25
0E 
55;53 
c.730A>G;c.749G
>A 
M244V;G250E;E28
2K 
43.39;42.27;22.
86 
25995;26170;581
56 
ND ND ND 
-ve control 
(1) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(2) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control (3 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(4) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(5) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(6) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(7) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(8) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(9) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(10) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(11) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(12) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control 
(13) 
non-
CML 
ND ND ND ND ND ND ND ND ND 
-ve control non- ND ND ND ND ND ND ND ND ND 
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(14) CML 
-ve control 
(38) 
CML ND ND ND ND ND ND ND ND ND 
-ve control 
(39) 
CML ND ND ND ND ND ND ND ND ND 
-ve control 
(40) 
CML ND ND ND ND ND ND ND ND ND 
-ve control 
(42) 
CML ND ND ND ND ND ND ND ND ND 
-ve control 
(43) 
CML ND ND ND ND ND ND ND ND ND 
-ve 
control(44) 
CML ND ND ND ND ND ND ND ND ND 
“ND” stands for not detected; “-ve” stands for negative; “ID” stands for identity; “TKD” stands for Tyrosine Kinase Domaine. More than one mutation in the same samples 
are separated with a semi-colon.  
 
 
Table 5.2. BCR-ABL1 TKD mutation testing in 30 samples in the validation cohort. 
ID Gold-standard NGS   
Pat
ien
t ID 
mutations by 
Sanger/pyro 
perce
ntage 
HGVS coding 
nomenclature 
Mutations by 
NGS (≥5%) 
percentage coverage 
Mutations 
by NGS 
(<5%) 
percentage Coverage comments 
1 E255K 86.00 c.763G>A E255K 93.2 15113 ND ND ND Single mutations 
on both 
platforms [5-
100%]. 100% 
concordance 
2 L387F 97.00 c.1161G>T L387F 94.93  2746 ND ND ND 
3 T315I 89.00 c.944C>T T315I 87.96 18763 ND ND ND 
4 L387F 97.00 c.1161G>T L387F 94.93 23512 ND ND ND 
5 F317L 98.00 c.949T>C F317L 97.41 22425 ND ND ND 
6 M244V 85.00 c.730A>G M244V 82.05 10872 ND ND ND 
11 T315I 41.00 c.944C>T T315I 21.3 38833 ND ND ND 
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13 E255V  84.00 c.764A>T E255V  52.71 6543 T315I 2.65 23309 
14 F359I 92.00 c.1075T>A F359I 60.38 68249 ND ND ND 
15 Y253H  40.00 c.757T>C Y253H  82.58 14741 ND ND ND 
16 T315I  97.00 c.944C>T T315I  85.77 12922 ND ND ND 
17 T315I 6.00 c.944C>T T315I 7.3 8238 ND ND ND 
19 F359V  80.00 c.1075T>G F359V  70.46 43036 T315I;E255V 3.02;1.38 
25818;144
60 
20 T315I  97.00 c.944C>T T315I  89.17 62474 ND ND ND 
36 G250E 99;15 c.749G>A G250E 89.45 40762 ND ND ND 
45 G250E 35.00 c.749G>A G250E 33.54 23174 V299A 1.81 22742 
30 L298V ND c.892CG L298V 54.44 28902 V379I 3.68 62695 >20%, missed by 
Sanger. 2 
reasons:  1) Not 
reported rather 
than not 
detected 
because not 
actionable 
mutation (L298V, 
L387M). 2) <20% 
and not one of 
the mutations 
quantified by 
pyrosequencing 
(G250E). Both 
mutations in 
sample 33 are 
mutually 
exclusive 
(polyclonal). 
18 L387M ND c.1159T>A L387M 85.37 10203 M244I 2.43 17765 
34 G250E ND c.749G>A G250E 6.99 16234 ND ND ND 
35 G250E ND c.749G>A G250E 17.31 17098 ND ND ND 
33 G250E ND c.749G>A E462K;G250E 44.4;9.31 43392;34396 ND ND ND 
7 T315I 96.00 c.944C>T T315I;F317L 28.92;7.87 16693;16874 ND ND ND single mutaions 
on SS, but 10 Y253H  95.00 c.757T>C Y253H;F317L 86.06;8.59;7. 12988;42247 ND ND ND 
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94 multiple on NGS. 
The additional 
mutation(s) 
detected by NGS 
were <20% and 
around 5% for 
the mutations 
quantified by 
pyrosequencing. 
E255K and V299L 
compound; 
E255K and F317L 
compound. P-
loop muations 
are mututally 
exclusive. 
31 F359V 88.00 c.1075T>G F359V;F359C 83.19;9.88 73098;77172 Y253H 3.42 24381 
32 E462K 30.00 c.1384G>A E462K;S446P 44.51;18.83 41513;42732 ND ND ND 
8 E255K  62.00 c.763G>A 
E255K;F317L;T31
5I 
51.35;7.23;5.
8 
7358;14578;146
29 
Y253H;K247
R;M244V;L3
87F;G250E 
3.16;3.06;3
.06;2.33;1.
8 
7217;6836;
6862;1495
3;6902 
37 Y253H;F317L 24;62 c.757T>C;c.949T>C Y253H;F317L 45.61;55.48 18505;20317 G250E 1.88 19100 Multiple matins 
on both 
platforms (same 
number of 
mutations). 
Mutations are 
[10-100]%.E255V 
and T315I 
compound; 
E255K and T315I 
compound; 
Y253H and T315I 
compound. P-
loop mutations 
are mutually 
exclusive. 
12 
E255V;E255K
;T315I 
32;19
;13 
c.764A>T;c.763G>A;
c.944C>T 
E255V;E255K;T31
5I 
30.65;17.5;1
4.12 
10323;10184;22
541 
ND ND ND 
29 
F317L;V299L;
T315I;E255K 
35;34
;8;11 
c.949T>C;c.895G>C;
c.944C>T;c.763G>A 
F317L;V299L;T31
5I;E255K 
32.71;30.35;
10.32;12 
13511;15526;13
532;17690 
ND ND ND 
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9 
M244V;Y253
H 
72;10 c.730A>G;c.757T>C 
M244V;Y253H;F3
17L;T315I;E255K 
46.7;12.21;8.
05;6.45;5.23 
9541;10044;162
77;16361;10782 
F359I 3.4 68039 
Multiple 
mutations on 
both platforms 
(more on NGS).  
The additional 
mutation(s) 
detected by NGS 
were <20% and 
around 5% for 
the mutations 
quantified by 
pyrosequencing. 
“ND” stands for not detected; “ID” stands for identity; “TKD” stands for Tyrosine Kinase Domaine. More than one mutation in the same samples are separated with a semi-
colon. 
 
 
Table 5.3. BCR-ABL1 TKD mutation testing in patients with longitude samples included in the validation cohort. 
ID Gold-standard NGS 
Pati
ent 
ID 
mutations by 
Sanger/pyro 
percen
tage 
HGVS coding 
nomenclature 
Mutations by NGS (≥5%) percentage coverage 
Mutatio
ns by 
NGS 
(<5%) 
percen
tage 
Coverag
e 
1 NT NT NT ND ND ND ND ND ND 
1 NT NT NT ND ND ND ND ND ND 
1 ND ND ND ND ND ND ND ND ND 
1 E255K 84.00 c.763G>A E255K 88.95 5115 ND ND ND 
1 E255K 86.00 c.763G>A E255K 93.2 15113 ND ND ND 
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2 NT NT NT ND ND ND ND ND ND 
2 NT NT NT L387F 13.98 15725 ND ND ND 
2 NT NT NT L387F 82.62 12856 ND ND ND 
2 NT NT NT L387F 80.37 9345 ND ND ND 
2 L387F 97.00 c.1161G>T L387F 94.93 10457 ND ND ND 
3 NT NT NT ND ND ND ND ND ND 
3 T315I 8 c.944C>T F315I 7.97 44233 ND ND ND 
3 NT NT NT F315I 56.14 53265 ND ND ND 
3 T315I 89.00 c.944C>T T315I 87.96 18763 ND ND ND 
4 NT NT NT ND ND ND ND ND ND 
4 NT NT NT ND ND ND ND ND ND 
4 NT NT NT M244V 18.39 59429 ND ND ND 
4 NT NT NT E459K 9.12 10775 ND ND ND 
4 L387F 97.00 c.1161G>T L387F 94.93 23512 ND ND ND 
5 ND ND ND ND ND ND ND ND ND 
5 ND ND ND ND ND ND ND ND ND 
5 ND ND ND ND ND ND ND ND ND 
5 ND ND ND ND ND ND Y253H 2 21360 
5 NT NT NT ND ND ND ND ND ND 
5 NT NT NT F359V 94.16 43420 ND ND ND 
5 NT NT NT F359V;F317L;F351I 41.64;10.23;3.36 19259;7598;19179 F351I 3.36 19179 
5 NT NT NT F317L 29.91 13331 ND ND ND 
5 F317L  95.00 c.949T>C F317L ;K247R 97.54;97.28 21365;9786 ND ND ND 
5 F317L 98.00 c.949T>C F317L;K247R 97.41;96.81 22425;8163 ND ND ND 
5 NT NT NT F317L;T315I;E255K 54.8;6.99;5.58 23643;23883;9891 ND ND ND 
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5 NT NT NT F317L;T315I;E255K 49.52;6.78;5.37 22822;23005;9063 
L387F;F
359V 
2.54;1.
81 
16192;4
2906 
5 NT NT NT 
F317L;Y253H;T315I;E25
5K 
37.63;10.55;6.6;5.45 23814;8897;23942;9387 
T315A;L
387F 
2.69;2.
67 
24092;1
6469 
5 ND ND ND ND ND ND ND ND ND 
6 ND ND ND ND ND ND ND ND ND 
6 ND ND ND ND ND ND ND ND ND 
6 ND ND ND ND ND ND ND ND ND 
6 NT NT NT M244V 43.66 116078 ND ND ND 
6 M244V 85 c.730A>G M244V 82.05 10872 ND ND ND 
10 NT NT NT M244V 10.14 31439 Y253H 4.4 36469 
10 Y253H  95.00 c.757T>C Y253H;F317L 86.06;8.59 12988;42247 F359I 3.4 68039 
12 NT NT NT 
E255K;Y253F;E255V;T31
5I;E459K 
30.65;17.5;14.12;12.4
5;5.71 
11414;10781;11753;249
97;8201 
M351V 
1.22;1.
11 
8455 
12 NT NT NT 
E255V;E255K;T315I;Y25
3H 
30.65;17.5;14.12;12.4
5;5.71 
15694;15446;14840;148
02 
ND ND ND 
12 
E255V;E255K;T
315I 
32;19;
13 
c.764A>T;c.763G>A;c.94
4C>T 
E255V;E255K;T315I 
30.65;17.5;14.12;12.4
5;5.71 
10323;10184;22541 ND ND ND 
16 V299L  96.00 c.895G>C V299L 40.22 21198 ND ND ND 
16 T315I;V299L 54;39 c.944C>T;c.895G>C T315I;V299L 45.75;13.81 20953;14676 ND ND ND 
16 T315I  97.00 c.944C>T T315I  85.77 12922 ND ND ND 
19 F359V  24.00 c.1075T>G F359V  25.13 27293 ND ND ND 
19 NT NT NT F359V 79.9 19954 ND ND ND 
19 F359V  80.00 c.1075T>G F359V  70.46 43036 ND ND ND 
29 NT NT NT V299L;V299L 83.71;87.39 14739;29886 ND ND ND 
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29 NT NT NT 
V299L;V299L;F317L;F31
7L;T315I 
48.42;48.19;15.04;14.
98;7.99 
29123;28680;19567;229
25;19634 
F359L 1.68 69175 
29 NT NT NT 
V299L;V299L;F317L;F31
7L;T315I 
54.16;52.06;10.06;10.
6;5.66 
13674;21905;10428;147
60;14798 
ND ND ND 
29 NT NT NT V299L;F317L 55.2;15.97 15914;12671 ND ND ND 
29 V299L;F317L 72;20 c.895G>C;c.949T>C F317L;V299L 80.83;9.13 10646;15041 
E255K;
M244T 
1.05;1.
01 
18594;1
4749 
29 NT NT NT 
V299L;V299L;F317L;F31
7L;E255K;E255K 
49.21;47.62;19.26;18.
63;10.22;9.82 
20311;27326;16157;186
76;22438;23520 
T315I 1.15 16239 
29 
F317L;V299L;T3
15I;E255K 
35;34;
8;11 
c.949T>C;c.895G>C;c.94
4C>T;c.763G>A 
F317L;V299L;T315I;E255
K 
32.71;30.35;10.32;12 
13511;15526;13532;176
90 
ND ND ND 
“ND” stands for not detected; “NT” stands for not tested; “ID” stands for identity; “TKD” stands for Tyrosine Kinase Domaine. More than one mutation in the same samples 
are separated with a semi-colon.  
 
 
Table 5.4. Internal Patient clinical characteristics and outcome in the sub-category of mutations with <5%.   
patient TKI at 
the 
time of 
TKI 
line 
notes months 
from dx 
Low-level 
mutations 
mutation_% response 
at test 
(reason to 
Best resp 
after test 
TKI at 
best 
Current 
TKI 
resp at last 
FU 
months 
between 
test and 
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the 
test 
test) response last FU 
9 IMA 
400 
mg 
1 previous IMA 
dose reduction 
due to cytopenia 
and side effects 
10 E459K 3,2 stable MR3 MR5 DASA 
100 mg  
DASA MR2 10 
25 NILO 
800 
mg  
1 - 20 F311L 1,15 stable MR2 MR3 NILO 800 
mg  
NILO MR3 13 
26 DASA 
50 mg 
2 IMA intolerance 108 F317L; M343T; 
F359V; ex7 del 
1.21;2.39;1.52 MR2/MR3 MR3 DASA 50 
mg  
DASA Haem R 
only 
9 
29 IMA 
400 
mg 
1 previous stop 
IMA for 
pregnancy 
146 D276G; ex8-9 
ins  
4.43;1.69 blast crisis none NE NE died 3 
31 DASA 
100 
mg 
2 IMA resistance 24 F317L;E450V 1.85;2.88 MR2 MR4.5 DASA 
100 mg  
BOSU  Haem Resp 
after Ph 
neg BC 
14 
47 IMA 
400 
mg 
1 stopped IMA 
due to 
pneumonitis 
5 F311L; M351R 1.24;1.6 MR2 (but 
no MR1 at 
3 months) 
MR4.5 NILO NILO  MR4.5 13 
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60 NILO 
800 
mg  
2 IMA failure at 3 
months 
25 F311L; ex7 del 1.09;4.93 MR2 MR2 NILO 800 
mg  
NILO MR2 13 
61 PONA 
30 mg  
3 IMA failure, 
previous F539V 
on NILO (at 
reduced dose 
due to 
intolerance) 
235 F311L 1,01 Haem R 
only 
Haem R 
only 
PONA 30 
mg  
PONA Haem R 
only 
13 
72 IMA 
200 
mg  
1 on Destiny trial, 
deescalating 
IMA 
112 F311L 1,06 MR3 from 
MR5 
MR3 IMA 300 
mg daily 
IMA MR3 12 
75 IMA 
300 
mg  
1 IMA intolerance 
and resistance 
3 F311L 1,07 Haem R 
only 
MR3 NILO 600 
mg 
NILO MR3 12 
82 IMA 
400 
mg 
1 on-off IMA to try 
pregnancy; lost 
MR3 on IMA; 
previous E255K 
and T315I on 
Sanger, not 
reconfirmed 
62 E255K; F317L 3.07;2.77 MR2 MR3 IMA 400 
mg 
IMA MR3 12 
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133 PONA 
15 mg 
3 IMA and DASA 
resistance, 
cytog: cryptic 
ABL1 insertion 
on BCR  
206 Ex7 del; ex8-9 
ins 
1.3;1.3 Haem R 
only 
MR1 PONA 15 
mg 
PONA MR1 6 
152 IMA 
300 
mg 
1 Liver toxicity on 
IMA 
30 F317L; T315A; 
F359L; M244V  
2.96;1.22;1.1;1.28 stable MR3 MR3 IMA 300 
mg  
IMA MR3 6 
167 IMA 
400 
mg  
1  - 132 E459G 3 stable MR3 MR3 IMA 400 
mg 
IMA MR3 4 
171 DASA 
50 mg  
1 DASA 1st line, 
continued at 
reduced dose 
due to 
intolerance 
38 D276G; ex8-9 
ins 
2.34;3.51 lost MR 4.5 MR3 DASA 80 
mg 
DASA MR3 3 
“Resr” stands for response; “FU” stands for follow-up; “Cytog” stands for cytogenetic; “haem” stands for haematological; “IMA” stands for imatinib; “DASA” stands for 
dasatinib; “MR
1
”stands for 1 log of transcript level reduction on the International Scale (IS); “MR
2
” stands for 2 log of transcript level reduction on the International Scale 
(IS); “MR
3
” stands for 3 log of transcript level reduction on the International Scale (IS) or Major Molecular Response (MMR).  
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Table 5.5. Co-existence of high-level mutation with at least 1 low-level mutation in patients with unexplained resistance to mutation-specific sensitive TKI. 
Pt number Mutation 1 % mut 1 Mutation 2 % mut 2 Mutation 3 % mut 3 Mutation 4 % mut 4 Clinical details 
22 M351T 5.66 E316G 1.17 - - - - Dasatinib resistance 
41 Y253H 34.1 F317L 3.95 Ex8-9 ins 3.4 - - Dasatinib resistance 
66 T315I 80.1 F317L 1.15 E255V 1.16 Ex8-9 ins 2 Ponatinib resistance 
98 Y253H 78 F317L 1 F359V 1.16 - - Dasatinib resistance 
136 F317L 98.5 Ex8-9 ins 1.23 - - - - Ponatinib resistance 
“Mut” stands for mutation; “EX” stands for exon; “Pt” stands for patient; “TKI” stands for Tyrosine Kinase Inhibitor. 
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Chapter VI 
 
6. Personalizing Clinical Management of 
Chronic Myeloid Leukaemia in the 
Era of Tyrosine Kinase Inhibitors by 
Enhanced Molecular Monitoring. 
 
 
6.1. Introduction 
In this chapter we sought to conclude the thesis by providing a mini-review in the current 
methodologies available for molecular testing incorporating our findings in this context 
where appropriate, in addition to discussing possible future applications to improve the 
molecular monitoring of residual disease in CML. 
6.2. Novel Methodologies for Molecular Monitoring and KD 
Mutation Testing 
6.2.1. Next Generation Sequencing (NGS) 
6.2.1.1.Definition and Advantages 
Capillary electrophoresis sequencing (CES) was introduced in the 1970s and it became the 
gold-standard platform for all sequencing application since its automation in the 1980s [1]. 
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Pyrosequencing was introduced in the 1990s. However, these methods are hampered by 
inherent limitations in throughput, scalability, speed and resolution. The demand for high-
throughput sequencing coupled with the significant reduction in the cost of sequencing by 
2007 have driven the development of next generation sequencing technologies [2]. In 
principle, the concept behind NGS technology combines those of CE and pyrosequencing, 
only functioning at a much higher throughput. The sequencing is based on the ‘sequencing 
by synthesis’ approach as opposed to the ‘chain termination’ chemistry. ‘Sequencing by 
syntheses’ utilizes advances in the fluidics technology to release certain patterns of 
nucleotide flows per sequencing cycle in order to synthesize the nascent nucleic acid 
strand. This unique combination of fluidics and chemistry enables the direct translation of 
genetic information (nucleic acid) to digital information (nucleic acid sequence), rapidly 
generating large quantities of data. 
Despite their diversity, NGS workflows comprise of 4 main steps: 1) The generation of a 
single-stranded template nucleic acid library, 2) the clonal amplification of the library, 3) 
data generation via sequencing and 4) Data analysis using a range of bioinformatics tools. 
Sample multiplexing via barcoding and/or indexing further enables the simultaneous 
investigation of large numbers of samples and targets reducing considerably time and cost. 
6.2.1.2.NGS Applications 
NGS has a very wide range of usage. Different applications include de novo sequencing 
(sequencing the genomes of organisms with unknown sequences), resequencing 
(resequence the genome of previously sequenced organisms), RNA-Seq (for global gene 
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expression, splice usage and breakpoint analysis), CHIP-Seq (for protein–DNA binding 
regions), Methyl-Seq (for bisulphite treated CpG methylation analysis), CLIP-Seq (for 
protein–RNA binding sequences), WGS (whole genome sequencing – including intronic 
and intergenic regions), WES (whole exome sequencing – coding regions only, excluding 
intronic and intergenic) and targeted sequencing (target capture via probe hybridization or 
ligation and amplicon based enrichment). Targeted sequencing with its two subtypes has 
particular importance in the context of molecular monitoring, both of which we have 
investigated in two different applications in CML clinical management as discussed in 
chapters two and five, respectively.  
Targeted sequencing combines hybridization or PCR, cloning, and sequencing in one 
advanced methodology. It allows the isolation of genes or regions of interest for 
subsequent targeted sequencing using either an oligonucleotide-based hybridization 
method or by utilizing highly multiplexed amplicon generation strategy known as 
amplicon deep sequencing or ultra-deep sequencing. The hybridization method is 
accompanied with a design using freely available online tools with high efficiency 
achieved by advances in chemistry and technology. Once isolated, the targets of interest 
are clonally amplified in-vitro and sequenced to a depth that exceeds that provided by 
Sanger sequencing by 30-10,000 fold. Dedicated informatics software pipelines then 
assemble, map and align the sequenced reads to the reference genome and perform variant 
detection. Once a sequence variation is identified as a molecular biomarker, amplicon 
deep sequencing could be used for future diagnosis, prognosis or follow-up monitoring of 
residual disease. The quantitative feature is gained by sequencing targeted regions of 
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interest at depths of hundreds or thousands of reads allowing the sensitive detection and 
quantification of rare events.  
The application of target enrichment followed by amplicon deep sequencing in minimal 
residual disease (MRD) monitoring for CML is twofold. Targeted enrichment facilitates 
the isolation of the two fusion partners, BCR and ABL1 for subsequent mapping of the 
precise fusion junction on the genomic level. Amplicon deep sequencing then can follow 
for the sensitive monitoring of the fusion sequence as a surrogate marker for response to 
therapy. This application could have a unique advantage particularly in patients with 
sustained deep molecular response marking them as eligible for therapy discontinuation 
[3], as it facilitates the monitoring of true disease burden (using DNA template) rather than 
expression (using RNA template) [3]. This approach has been successfully used for the 
detection and tracking of clonally expanded T or B cell populations in ALL and other 
physiological and pathological conditions [4-6]. Alternatively, amplicon deep sequencing 
can be replaced with a quantitative method, such as qPCR or dPCR for MRD monitoring. 
Whether or not amplicon deep sequencing can compete with the sensitivity achieved by 
quantitative PCR-based methodologies remains unresolved. At least for cost-related 
reasons, the quantitative PCR technologies remain the method of choice for such 
investigations. In chapter 2, we applied targeted NGS to isolate the two partners of the 
BCR-ABL1 fusion gene, then mapped the precise sequence at the fusion site through 
bioinformatics analysis. Using the patient specific fusion junctions as biomarkers, we 
monitored the disease burden on the genomic level using digital PCR (dPCR). Applying 
the former strategy as a proof of principle, we have demonstrated that residual disease was 
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detectable in 80% of the cases classified as negative by RT-qPCR [3]. After demonstrating 
its feasibility, the method was deployed as a bolt-on study to the DESTINY clinical trial 
for De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprycel in Chronic 
Myeloid Leukaemia patients in the UK, for further validation of its clinical utility (work in 
progress).  
In chapter 5, we applied amplicon deep sequencing for the sensitive quantification of 
BCR-ABL1 TKD mutations. Overlapping primers designed to cover the TKD within the 
fusion transcript were used to amplify the domain following a nested PCR approach to 
enrich for the fusion ABL1. Amplicons from multiple samples were barcoded and clonally 
amplified ready for sequencing. Sequencing the amplicons on a high-throughput platform 
allowed enough depth of coverage (≥2000 reads) per base to call mutations at an LoQ and 
LoD of 5% and 1%, respectively. Amplicon deep sequencing has been deployed as a 
research tool for investigating TKD mutations and their role in causing TKI resistance 
since 2009. Despite its unique advantage as a research tool, its value as a clinical 
application for the prospective testing of these mutations is yet to be demonstrated as 
discused in chapter 5. 
6.2.1.3.Platform Comparison 
NGS platforms, in general, are divided into very high-throughput (whole genome level) 
and bench-top lower throughput platforms (targeted/exome). There are several benchtop 
NGS platforms available provided mainly by three different vendors: 454 GS-Junior and 
454 Flex
+
 (Roche Applied Science, Indianapolis, IN); MiniSeq, MiSeq and NextSeq 
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(Illumina, San Diego, CA); in addition to Ion Torrent PGM and Proton (ThermoFisher 
Scientifics, Paisley, UK). Other higher throughput platforms are also available from the 
same vendors, though they are not suitable for routine diagnostic applications. Platforms 
generally vary in the following main aspects: 1) library preparation methods, 2) clonal 
amplification method before sequencing, 3) sequencing chemistry, 4) signal detection 
method, 5) read length and throughput, 6) run time and 7) cost. A detailed comparison of 
platforms in relation to the mentioned points in (table 5.1) and discussed briefly below. 
Roche 454 is massively parallelized version of pyrosequencing and was the first NGS 
platform available for commercial use [7]. The method clonally amplifies individual DNA 
template molecules attached to a nano-scale bead suspended inside an aqueous droplet 
microreactor.  The microreactors are formed through the suspension of aqueous PCR 
reagents in an oil-based matrix (emulsion PCR) [8]. Cycling through PCR temperatures 
leads to the clonal expansion of each amplicon fragment (one-fragment one-bead one-
read). The sequencing, however, is based on the pyrosequencing chemistry [9] where the 
light generated after each nucleotide incorporation to the nascent DNA is detected and 
translated to sequence read-outs. This platform has been phased out since 2015 because 
the cost of sequencing per base was not capable of competing with the other two newly 
immerging technologies discussed in the following two paragraphs.  
Similar to the 454, Ion Semiconductor sequencing or Ion Torrent sequencing also 
performs emulsion PCR for the clonal amplification of individual DNA template 
molecules and the sequencing chemistry is based on the principles of pyrosequencing. 
However, it varies in that it detects the change in the pH that accompanies hydrogen ion 
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release after nucleotide incorporation, and translates this change to a sequence read-out 
[10]. The chip on which the sequencing reaction takes place is, therefore, the smallest 
known pH meter and the first post light sequencing technology. The major benefits of ion 
semiconductor sequencing are speed and lower cost enabled by the avoidance of modified 
nucleotides and optical measurements. The main limitation of the system, however, 
similar to the 454 system, is the lower accuracy and the struggle to sequence 
homopolymeric regions greater than 5-8bps long [2]. The error type is insertion/deletion 
(InDels) with error rates of 1.7–3% compared to substitutions [11-13]. This limitation 
reflects the process in which the chemical signal is converted to a digital one where 
precision attenuates due to multiple nucleotide incorporations in a single sequencing flow. 
Another method for in-vitro clonal amplification is bridge PCR [14-15] deployed on the 
Illumina (Solexa) platform, where nucleic acid fragments are amplified on primers 
attached to a solid surface (flow cell). The sequencing chemistry on this platform is closer 
in principle to CES in that the incorporated nucleotides are labelled with different 
fluorophores and have a terminator so that one base is added at a time. The sequence 
information is obtained following the capture of the light emitted by exciting the 
fluorophore on the incorporated nucleotide. The difference is that the nucleotides are 
modified on carbon 3 to be ‘reversible terminators’, where the fluorescent labels and the 3 
terminators are removed and cleared after each sequencing cycle to allow the 
incorporation of a new nucleotide during the next cycle [16]. The dominant error type is 
base specific miscalls (substitution) (0.4%) rather than InDels and homopolymers are less 
of an issue [2, 12, 17]. The A and C bases are excited by red while G and T by green laser 
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and imaged through different filters to identify the four different nucleotides. The overlap 
of spectra makes it difficult to separate signals particularly in a GC reach sequence [12, 
18-20]. Another source for noise is the phasing and pre-phasing phenomena. Phasing is 
related to enzyme kinetics such as incomplete removal of the 3 terminators or the 
fluorophores that cause the synthesis of some strands in a cluster to lag behind.  Pre-
phasing, on the other hand, refers to the accelerated synthesis of the strands that could be 
caused by various mechanisms including inadequate flushing of the flow cell, by 
sequences in a cluster skipping an incorporation cycle or the incorporation of nucleotides 
without an effective 3 terminator. The number of affected sequences increases with each 
cycle and thus limits the overall read length [18]. 
6.2.1.4.Third Generation Sequencing (3GS) 
The third generation, single-molecule sequencing, is the latest advance with two main 
characteristics: 1) PCR is not needed before sequencing which shortens the nucleic acid 
preparation time. 2) The signal is captured in real time, i.e. is monitored and recorded 
during the enzymatic reaction of incorporating nucleotides in the complementary strand 
[1, 21]. The two marketed platforms are single molecule real-time sequencing (SMRT) by 
Pacific Biosciences (PacBio, Menlo Park, CA) and the MinIon nanopore sequencing by 
Oxford Nanopore Technologies [22]. The basic principle of SMRT sequencing is that 
bright fluorophores conjugated to the nucleotides are released upon their incorporation by 
a single polymerase fixed to a surface inside millions of zero-mode wave-guided (ZMW) 
nano-structures. The released fluorophores are laser excited and the emission signal is 
detected via confocal visualization technologies. The signal in the Oxford nanopore is 
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generated via a processive enzyme (exonuclease) attached to a biological nanopore that 
cleaves single nucleotides from a target DNA strand and passes them through the 
nanopore. As they pass, each nucleotide creates a unique electric pulse that is recorded as 
sequence information in real time [23]. Single molecule sequencing eliminates the need 
for molecular amplification and promises speed, mobility and longer amplicon length 
sequencing. Therefore, it has a unique potential for improving the accuracy and length of 
sequencing the BCR-ABL1 TKD molecules, which in turn allows for the phasing of 
multiple mutations, i.e. determining if they were within the same clone or polyclonal. 
Although promising, the data generated to date are little, and whether phasing of the 
mutations has any clinical significance remains undetermined. 
6.2.2. Digital PCR (dPCR) 
6.2.2.1.Definition and Basic Concepts 
Digital PCR is a precise analytical technique for absolute quantification of nucleic acids 
based on PCR amplification of a single template molecule without the need for a 
calibration curve [24-28]. The most common terminologies that accompany dPCR 
applications are: partitions, lambda (λ), Poisson distribution and the dynamic range of 
quantification commonly referred to as the “sweet spot” [29]. 
A partition is the fixed space within which the single molecule PCR takes place. This can 
be a small well or water-in-oil emulsion droplet of nanoliter or picoliter volumes [29]. 
Lambda represents the mean target copy numbers present per partition. It is estimated 
applying the Poisson distribution to the number of positive partitions (k) per reaction (n: 
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the total number of partitions). The number of copies per reaction can be estimated using 
λ, the reaction volume and the total number of partitions (n).  
The Poisson distribution is a special case of the binomial destitution that describes the 
probability of an event (target molecule) in a fixed partition size. Inherent assumptions are 
that 1) there is a large population (partitions) of fixed size, 2) an event, 3) only a binary 
outcome for the event is possible and 4) there is a random distribution for the event. The 
application of the Poisson distribution in dPCR corrects for the fact that a positive 
partition can contain more than one target molecule. 
The dynamic range of dPCR is defined by the number of partitions, the volume of sample 
interrogated and the original concentration of the target in the sample [30]. The application 
of the Poisson distribution enables the dynamic range to extend beyond the number of 
partitions analyzed, albeit at the cost of reduced precision at the both extremes [31-33], 
with the most accurate quantification reached when λ= 0.6-1.6 [29]. This has to be taken 
into consideration while calculating the number of partitions used to reach the desired 
sensitivity. For example, when aiming to quantify 1 copy in 100,000 molecules, at least 
62,500 will be required to reach the desired sensitivity per sample. Hence, the “sweet 
spot” of a platform is defined by the range of λ values that can be accurately quantified 
with acceptable precision.  
6.2.2.2.dPCR Advantages in CML 
Partitioning targets within a sample after performing limiting dilution allows individual 
molecule PCR where each partition contains ≥1 or no target molecule [34-37]. This, in 
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turn, dilutes the background noise decreasing the signal-to-noise ratio and therefore 
improving the chances for a rare target to be detected. The ability to perform absolute 
linear copy number quantification over the relative quantification of qPCR simplifies the 
quantification process [29, 37].  In this way, dPCR has improved measurement precision 
over qPCR [24, 31, 37-38], and this precision can be further enhanced by using duplex 
reactions as we have demonstrated in chapter 3 [3, 38]. Analytical sensitivity can be 
improved by increasing the number of individual reaction replicates. This has been aided 
by advances in nanofluidics technologies and the introduction of the emulsion based 
technologies.  
The ability to measure extremely low concentrations of a specific target molecule whilst 
being independent of a standard curve is a unique advantage of dPCR over qPCR for 
MRD monitoring in CML. In chapters 3 and 4 we have validated the E.A.C. assay on an 
RT-dPCR platform and compared the gold-standard RT-qPCR to different RT-dPCR 
platforms, in addition to comparing the latter amongst themselves. We concluded that RT-
dPCR had a similar sensitivity to RT-qPCR with a loss of linearity after the major 
molecular response (MMR) level. The loss of linearity was caused by the presence of false 
positivity defined by the number of target molecules detected in the negative and no 
template controls. We speculated that poor assay design was a major contributor to the 
false positive signals. True positive disease quantification in samples below the MMR 
level lead to a change in patients’ classification shifting the log reduction towards higher 
ratios. The change in the molecular response level can have a critical implication on 
patients’ clinical management; therefore further work is required to optimise the assay 
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before RT-dPCR could be implemented in routine testing.  In addition, we highlighted 
another equally important application for RT-dPCR in CML, which is the contribution in 
producing more accurately calibrated secondary reference materials for calibrating in-
house standard curves towards harmonizing the international scale system of reporting.   
6.2.2.3.Platform Comparison 
There are broadly two main methods for generating the partitions for a dPCR: 
prefabricated reaction wells (in a chip or plate) or droplets (water-in-oil emulsions). 
Prefabricate platforms include the BioMark
TM
 HD (Fluidigm), QS
TM
3D (ThermoFisher 
Scientific) and Constellation (Formluatrix) with the Clarity
TM
 (JN Medsys) and Naica 
Crystal dPCR (Stilla Technologies) being close to market at this time. The emulsion based 
technologies include the QX200
TM
 droplet dPCR system (BioRad
®
 Laboratories) and the 
RainDrop
®
 (RainDance
®
 Technologies).  
Digital PCR platforms differ in several points including sample and partition volumes, 
different hands-on time and costs of consumables etc. However, interrogation of a sample 
with a platform that enables a greater partitioning of the reaction (large n) are theoretically 
more sensitive and have been demonstrated experimentally [3, 39-40]. Therefore, the 
choice of instrument is application dependent taking into account several factors including 
desired sensitivity, precision, throughput and budget. More detailed comparison between 
different dPCR platforms and between dPCR versus qPCR is provided in tables 5.2 and 
5.3, respectively. In chapter 4, we demonstrated that a platform similar to the RainDance
®
, 
which allows a greater volume of sample interrogation and greater than a million partitions 
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per reaction excels, particularly in applications such as those addressing TKI therapy 
cessation. As therapy discontinuation is being investigated in CML patients with sustained 
deep molecular remission, investing in a method similar to RainDance
®
 is justifies not 
only for the potential of increasing sensitivity, but also reducing the cost of investigation 
by reducing the number of replicates required per sample.  
6.2.3. Automation of MRD Monitoring  
The use of walk-away fully automated closed systems for qPCR, such as the Cepheid 
cartridges by GeneXpert, have provided a practical alternative for low-throughput labs or 
labs in countries where assay standardization and the performance of the RT-qPCR is 
particularly challenging. The input is a PB sample where RNA extraction, RT and qPCR 
steps are automated inside the cartridge with the transcript levels reported on the IS based 
internal algorithm without the need for a standard curve [41]. Despite the limit of 
sensitivity to MMR or above, the system is reproducible and has a quick turn-around time 
[42-45]. New more sensitive cartridges that are capable of reporting results deeper than 
MMR are already being developed (personal communication with Cepheid). The cost per 
cartridge, however, remains a considerable factor that might influence wider uptake of 
these cartridges. Digital PCR coupled with an automated system similar to that provided 
by the cartridge could be a potential future development that could improve on the 
cartridge sensitivity maintaining the relatively small volume of sample interrogated. 
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6.3. Future Directions 
The work from this thesis has shown that targeted NGS coupled with dPCR is the most 
sensitive method available for monitoring residual disease in CML. The method involves 
the rapid identification of t(9;22) fusion junctions using targeted NGS followed by the 
monitoring of residual disease on a dPCR platform. The method is currently being 
validated within the UK-based DESTINY clinical trial in addition to the European 
EROSKI and HOVON trials in collaboration with the Centre for Haematology at the 
Hammersmith hospital. An interesting addition to this protocol would be the introduction 
of a stem-cell sorting step before quantifying residual disease. This addition has the 
potential of increasing sensitivity further simply by eliminating the cell populations that 
are not contributing to the disease. 
Digital and RT-dPCR allow the assignment of absolute quantities to both BCR-ABL1 
DNA and RNA targets, respectively facilitating for the first time direct comparison of 
mean expression versus cellular disease burden. In the future, therefore, it will be 
important to explore not only whether the risk of relapse following withdrawal is a feature 
of the number of residual CML cells, but also whether it relates to the degree of 
transcriptional activity in those cells. The relationship between residual oncogene DNA 
and RNA and the impact of this ratio on outcome after withdrawal also could be the 
subject for further investigation.  
The principle of using target-enrichment NGS simplifies and accelerates the 
characterisation of BCR-ABL1 fusion junctions significantly. In addition, it provides a 
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wealth of information characterising genomic sequences surrounding the fusion junctions. 
The genomic direction of each gene within the fusion-spanning reads, for example, tells 
about the involvement of small inversions in the process of fusion formation. DNA 
binding motifs at the vicinity of the fusion junctions could also be predicted 
bioinformatically. Therefore, as more data is collected, in addition to published data, it 
would be interesting to conduct such an analysis with the aim of understanding 
mechanisms involved in the occurrence of the translocation in the first place. 
In the absence of validated methods and protocols for more sensitive methods, RT-qPCR 
remains the gold-standard for MRD monitoring in CML. As RT-dPCR promises an 
improvement in quantification sensitivity and precision, we investigated the E.A.C. assay 
performance on this platform. Our investigation showed that instead of improving 
sensitivity, RT-dPCR had exposed the presence of assay-related low-level positivity which 
limited the accuracy of quantification in samples classified below MMR. Therefore, 
further investment in developing better assays designed to function on RT-dPCR platforms 
is key for the successful implementation or RT-dPCR in future clinical practice. Planning 
for external quality control schemes and inter-laboratory validation efforts are warranted 
to accompany the assay validation process. 
High-throughput sequencing of the BCR-ABL1 TKD domain remains valuable in the cases 
of firs-line TKI resistance in order to guide appropriate therapeutic intervention, 
particularly when generic imatinib becomes available in 2017. The high risk of toxicity 
associated with ponatinib restricts the drug to those with no other alternative, where the 
status of the T315I mutation plays a focal role in managing the disease.  In our prospective 
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study, testing for the TKD mutations with NGS over a year’s interval did not provide 
strong evidence for the utility of NGS as a prognostic tool for predicting relapse. 
Therefore, although useful to guide therapeutic intervention, its prognostic value remains 
undetermined. To address this question in a meaningful manner, the involvement of a 
large multi-centre study with a unified protocol would be required. Alternatively, 
deploying sensitive monitoring in large clinical trials with well-defined clinical questions 
will also be valuable. 
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6.4. Tables 
 
   
Company CE Genetic 
Ananlyzer
Platform
454 GS 
Juniour
Flex Flex+ MiSeq MiSeqDx
NextSeq 
500/550
MiniSeq Ion Torrent Ion Proton Ion S5 3500 xl 3500 Dx
Template 
Prep
emPCR emPCR emPCR
Bridge 
amplification
Bridge 
amplification
Bridge 
amplification
Bridge 
amplification
emPCR emPCR emPCR
BigDye Terminator 
PCR
BigDye Terminator 
PCR
Seq 
Chemistry
Pyrosequenci
ng
Pyrosequen
cing
Pyrosequen
cing
Seq by 
synthesis
Seq by 
synthesis
Seq by 
synthesis
Seq by 
synthesis
Semiconductor 
sequencing
Semiconductor 
sequencing
Semiconductor 
sequencing
Dideoxy chain 
termination
Dideoxy chain 
termination
BenchTop yes yes yes yes yes yes yes yes yes yes yes yes
IVD no no no no yes no no no no no no yes
First release 2009 2005 2013 2011 2013 2014 2015 2010 2014 2015
Read length 
(bp)
400 400 1000
2 x (150, 250, 
300)bp
2 x (150, 250, 
300)bp
2 x (75-150) bp 2 x (150) bp 200-400 bp 200-400 bp 200-400 bp 400-900 400-900
Time/run 
(hours)
10 10 23 24, 39, 56 h 24, 39, 56 h 15-26h/18-29h 3.5 - 8 2-4 h 2.5-4 h 30mins - 3 hours 30mins - 3 hours
Output 
data/run (M)
35 400 700
4.5-5.1, 7.5-
8.5, 13.2-15 
Gb
4.5-5.1, 7.5-
8.5, 13.2-15 
Gb
16-39 Gb/50-
120 Gb
8 Gb
10, 100, 1000Mb 
(314, 316, 318 
chips)
10 Gb
1-2, 3-8, 10-15Gb 
(520, 530, 540 chips)
1.9-84 kb 1.9-84 kb
accuracy (%) 99.99 99 99.99
Q30 of (80, 
75, 70)%
Q30 of (80, 
75, 70)%
Q30 of (80, 
75)%
Q30 of 80% Q30 of 80% 99.999 99.999
Sample input 
(ng)
application 
depenent 
application 
depenent 
application 
depenent 
application 
depenent (5-
50)ng
application 
depenent (5-
50)ng
application 
depenent (5-
50)ng
application 
depenent 
application 
depenent (10-
50)ng
application 
depenent 
application depenent ≤ 50ng ≤ 50ng
Cost per 
run/$
$1,100 $750 $225; 425; 625
Instrument 
cost/$
$108,000 $125,000 $80,490
cost/Mb $31 $0.5
$22.5;  $4.25;  
$0.63
pros
long read  
length, fast
lowest per 
base cost
Semi-conductor 
technology with 
no need for 
expensiveoptic 
scanning and 
Fluorescent 
necleotides, fast, 
borad range of 
applications.
high quality, long 
read length
cons
high cost, 
low 
hroughput, 
6 
homopolym
er limit, will 
discontinue 
by mid 
2016.
Cluster 
density is 
critical, low 
complexity 
samples 
problematic 
to sequence
high error rate in 
homopolymer 
sequencing
High cost, low 
throughput
Cost info
pros & cons
Output and read info
Roche Illumina ThermoFisher
Table 1. Comparing metrics and performance of next-generation DNA sequencers
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Table 6.3. Quantitative PCR (qPCR)  vs digital PCR (dPCR) 
RT-qPCR RT-dPCR 
Relative quantification to a reference gene or a standard 
curve. 
Absolute quantification. 
Compromised sensitivity and precession at the lower end 
of the dynamic range. 
No need for standard curve and reference genes.  
reliant on assay chemistry, efficiency, instrument 
calibration 
Independent of assay chemistry, efficiency and instrument calibration 
(somewhat, not completely). 
Competitive amplification which masks low abundance 
targets 
Single molecule amplification. 
  increased background to noise ratio 
Extensive experimental standardisation is required minimum experimental standardisation is required 
 Improved sensitivity, specificity, precision and accuracy. 
  Poisson binary statistics 
  Scalable, flexible, simple 
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Appendix 
Chapter II Appendix 
Appendix II Figures 
 
Appendix Figure 2.1. Establishing digital PCR (dPCR) quantification cycle (Cq) range and threshold. Panels 1 to 
6 show the amplification curves obtained from the Fluidigm analysis software for the positive and negative 
controls of the six genomic DNA-based assays A1 to A6, respectively. ‘+ve’ stands for positive DNA control 
extracted from each patient's high disease level sample; ‘CSC’ stands for a negative DNA control obtained from 
a healthy individual (HI); NTC stands for no-template control; Pool stands for a negative control obtained from 
pooling DNA extracted from eight chronic myeloid leukemia patients 
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Appendix Figure 2.2. 
Linearity and the 
dynamic range assessed 
for the Fluidigm 
platform using a series 
of dilutions of two 
synthetic oligos, each 
containing the fusion 
sequence of one chronic 
myeloid leukemia 
patient (A3 and A6 in 
panelsa and b, 
respectively). Linearity 
was maintained when 
four molecules per panel 
were detected, which 
equates to a λ of 0.005 
(approximately equal to 
2 copies per μL). 
Consequently, 2 copies 
per μL was defined as 
the limit of accurate 
quantification for our 
assays 
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Appendix Figure 2.3. Establishing digital RT-PCR (RT-dPCR) quantification cycle (Cq) range and threshold for 
the cDNA-based Wessex assay. The panels show the amplification curves obtained from the Fluidigm analysis 
software using: CSC, a negative DNA control obtained from a healthy individual (HI); Pool, a negative control 
obtained from pooling DNA extracted from eight chronic myeloid leukemia patients. +ve, positive DNA control 
extracted from each patient's high disease level sample; NTC, no-template control 
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Appendix Figure 2.4. Linearity 
and the dynamic range assessed 
for the Fluidigm platform using 
a series of dilutions of a 
reference material (ERM; panel 
a) produced by the European 
Commission for Reference 
Materials, in addition to an in-
house standardized plasmid 
(Wessex; panel b) containing 
the major BCR-ABL1 fusion 
transcript e13a2. Linearity was 
maintained when four 
molecules per panel were 
detected, which equates to a λ 
of 0.005 (approximately equal 
to 2 copies per μL). 
Consequently, 2 copies per μL 
was defined as the limit of 
accurate quantification for this 
assay 
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Appendix II Tables 
Appendix Table 2.1. Performance characteristics of the 6 patient-specific hydrolysis probe assays in standard curves prepared from patients' early disease samples. 
Average performance metrics were taken from multiple runs. 
Patient/assay Quantitative range Sensitivity Slope R2 Efficiency Cq Threshold DNA Conc (ng/ul) 
                  
A1 ABL1-BCR 5x 10^-4 5x 10^-4 -3.396 0.992 97.003 26.6 0.1 50 
A1 ABL1-BCR  10^-3 10^-3 -3.645 0.997 88.076 26 0.1 50 
A1 ABL1-BCR 10^-3 10^-3 -3.026 0.99 114.049 26 0.1 50 
                  
A2 BCR-ABL1 10^-4 10^-4 -3.185 0.992 106.031 27.7 0.1 50 
A2 BCR-ABL1 10^-4 10^-4 24.6 0.992 105.035 24.6 0.1 50 
A2 BCR-ABL1 5 x 10^-4 10^-4 -3.256 0.981 102.831 28 0.1 50 
A2 BCR-ABL1 10^-4 10^-4 -3.279 0.984 101.823 25.4 0.1 50 
                  
A3 BCR-ABL1 5x10^-4 5x10^-5 -3.108 0.982 109.788 24.8 0.1 50 
A3 BCR-ABL1 10^-4 5x10^-5 -3.218 0.972 104.509 22.6 0.1 50 
A3 BCR-ABL1 10^-4 10^-5 -3.47 0.988 94.171 24.4 0.1 50 
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A4 ABL1-BCR 10^-4 10^-4 -3.521 0.994 92.321 26 0.1 50 
A4 ABL1-BCR 10^-4 10^-4 -3.154 0.99 107.509 26 0.1 50 
A4 ABL1-BCR 10^-3 10^-3 -4.684 0.998 63.491 24 0.1 50 
                  
A5 BCR-ABL1 10^-3 5 x 10^-4 -3.408 0.982 96.537 24.6 0.1 50 
A5 BCR-ABL1 5 x 10^-4 10^-4 -3.384 0.987 97.477 25 0.1 50 
A5 BCR-ABL1 10^-4 5x10^-5 -3.126 0.981 108.88 26 0.1 50 
                  
A6 BCR-ABL1 10^-3 10^-4 -3.365 0.98 98.237 27 0.1 50 
A6 BCR-ABL1 5x10^-4 5x10^-5 -3.197 0.966 105.505 27 0.1 50 
A6 BCR-ABL1 5x10^-4 5x10^-4 -3.289 0.965 101.47 26 0.1 50 
 
 
 
 
 
  
 
 
292 
 
 
 
Appendix Table 2.2. Standard curve efficiency of hydrolysis probe assays following preamplification of genomic DNA 
 Patient/assay ct range slope y intercept R2 eff% 
accepted range:   (16-40) (-3.0 to -3.6)   (0.98-1) (80-110) 
 A1 ABL1-BCR 20.7-26.6 -3.01 21.817 0.996 114.868 
 A2 BCR-ABL1 15-26.8 -3.8 15.183 0.99 81.8 
 A3 BCR-ABL1 17-27.9 -3.6 16.98 0.998 88.6 
 A4 ABL1-BCR 16-26 -3.41 15.79 0.995 96.5 
 A5 BCR-ABL1 17.8-27 -3.16 17.42 0.998 107 
 A6 BCR-ABL1 17.8-24 -0.36 17.44 0.994 98.48 
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Chapter III Appendix 
Appendix III 
Figures  
 
Appendix Figure 3.1. 
E.A.C. assay 
performance on the 
QD
®
3D dPCR platform - 
limit of quantification 
(LoQ). The linearity of 
the E.A.C. assay was 
tested on the QS
®
3D 
dPCR platform for both 
targets BCR-ABL1 (a) 
and ABL1 (b). Duplex 
reactions are 
represented on the left 
panel and uniplex 
reaction on the right 
panel. Three views are 
shown: a view of the 
full range of dilutions, a 
restricted view within 
the sweet spot and a 
restricted view within 
the lower end outside 
the sweet spot. The 
dotted line represents 
the threshold for true 
positivity.  
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Appendix Figure 3.2. The relation between K,P,λ on the QS
®
3D Platform. "k" stands for the total number of 
positive partitions; "p" stands for the probability of having more than one target molecule per partition; "λ" 
stands for the mean target molecules per partition and λ= -ln(1-k/n). The yellow and orange highlights indicate 
the sweet spot range for the chip defined by the manufacturing company and the dPCR MIQE guidelines, 
respectively. 
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Appendix Figure 3.3. Platform comparison. The mean of BCR-ABL1 copies per µl of cDNA from the replicate 
chips per sample are compared on both the RT-qPCR and QS
®
3D RT-dPCR platforms. P-values are generated 
applying the non-parametric Wilcoxon Signed-Rank test. 
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Appendix Figure 3.4. Platform comparison. The mean of ABL1 copies per µl of cDNA from the replicates chips 
per sample are compared on both the RT-qPCR and QS
®
3D RT-dPCR platforms. P-values are generated applying 
the non-parametric Wilcoxon Signed-Rank test. 
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Appendix Figure 3.5. Platform comparison. The mean of BCR-ABL1 copies per µl of cDNA from the replicate 
chips per sample are compared to the BCR-ABL1 copies per µl of cDNA detected in the negative controls on the 
QS
®
3D RT-dPCR platform. P-values are generated applying the non-parametric Mann-Whitney U test.
  
 
 
298 
 
 
 
Appendix III Tables  
Appendix Table 3.1. Hydrolysis probe assay details. 
Assay transcrip
t type  
Dx/Ux gene  Primer/prob
e 
sequence RT-qPCR 
conc. (nM) 
RT-
dPCR 
conc 
(nM) 
PCR 
conditions 
Settings 
modified 
E.A.C. 
e13/e14-
a2 
Duple
x 
BCR-
ABL1 
ENF501 5'-TCCGCTGACCATCAAYAAGGA-3' 300 900 95°C x 20 sec ramp rate 100% 
        ENF561 5'-CACTCAGACCCTGAGGCTCAA-3' 300 900 45 cycles no auto 
increment 
  
        ENP541F-
MGB 
6FAM-CCCTTCAGCGGCCAGT 100 250 95°C x 3 sec *Rxn 
volume 
20ul 
      ABL1 ENF1003 5'-
TGGAGATAACACTCTAAGCATAACTAAAGG
T-3' 
150 900 60°C x 45 sec Reporter 
dye 
FAM/V
IC 
        ABL1063 5'-GATGTAGTTGCTTGGGACCCA-3' 150 900   Quencher 
dye 
MGB 
        ABL1043V-
MGB 
VIC-CATTTTTGGTTTGGGCTTC 200 250   passive 
reference 
Rox 
         or (ZEN 
ABL1 
 To be provided by Birmingham       threshold 0.12 
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ENPr1043-
TET) 
Old HH   Uniple
x 
BCR-
ABL1 
ENF-501 5'-TCCGCTGACCATCAAYAAGGA-3' 300 300 50°C x 2 min ramp rate 100% 
        ENF-561 5'-CACTCAGACCCTGAGGCTCAA-3' 300 300 95°C x 10 
min 
no auto 
increment 
  
        ENP-541 FAM-CCCTTCAGCGGCCAGTAGCATCTGA-
TAMRA 
100 100 45 cycles Rxn volume 20ul 
      ABL1 ABL-146F 5'-GATACGAAGGGAGGGTGTACCA-3' 150 900 95°C x 15 sec Reporter 
dye 
FAM/V
IC 
        ABL-240R 5'-CTCGGCCAGGGTGTTGAA-3' 150 900 60°C x 60 sec Quencher 
dye 
MGB 
        ABL-183T FAM-
TGCTTCTGATGGCAAGCTCTACGTCTCCT-
TAMRA 
200 250   passive 
reference 
Rox 
                  threshold 0.12 
Hs0000092   Uniple
x 
ABL1   TaqMan life technologies     95°C x 20 sec ramp rate 100% 
                45 cycles no auto 
increment 
  
                95°C x 3 sec Rxn volume 20ul 
  
 
 
300 
 
 
 
                60°C x 45 sec Reporter 
dye 
FAM/V
IC 
                  Quencher 
dye 
MGB 
                  passive 
reference 
Rox 
                  threshold 0.12 
modified 
E.A.C. 
  Uniple
x 
GUSB EAC_GUS_F 5'-GAAAATATGTGGTTGGAGAGCTCATT-3' 900   95°C x 20 sec ramp rate 100% 
        EAC_GUS_R 5'-CCGAGTGAAGATCCCCTTTTT-3' 900   45 cycles no auto 
increment 
  
        EAC_GUS_P FAM-ACTCTCGTCGGTGACTG 250   95°C x 3 sec Rxn volume 20ul 
                60°C x 45 sec Reporter 
dye 
FAM/V
IC 
                  Quencher 
dye 
MGB 
                  passive 
reference 
Rox 
                  threshold 0.12 
‘Dx’ stands for duplex; ‘Ux’ stands for uniplex; ‘Rxn’ stands for reaction. 
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Appendix Table 3.2. Unpaired, two-tail, one-sample, Student's t-test results table, testing the significance of difference between the measured mean target copies per 
category in duplex and uniplex and the corresponding reference values. Dilution points are prepared using the ERM reference material. 
Est 
target/chip 
Catego
ry 
Ref 
concentra
tion 
(copy/chi
p or λ) 
Mean SE (±) Degrees 
of 
Freedom 
Differenc
e (mean-
ref)(bias) 
95% 
CI_low 
95% 
CI_hi 
p-
value 
Statist
ics 
  ERM ref Relative 
uncertainty (%) 
Bias 
Absolu
te 
value 
Bias 
Relative 
uncertatin
y 
Ref 
Relat
ive 
Unce
rtaint
y 
Dupl
ex 
FA
M 
1 2 2.00 0.29 16 0.00 -0.61 0.61 1.000
0 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 0.000 0.000 0.096 
Dupl
ex 
FA
M 
2 4 3.22 0.28 16 -0.78 -1.37 -0.19 0.012
8 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 0.778 0.194 0.096 
Dupl
ex 
FA
M 
3 8 9.00 0.73 16 1.00 -0.54 2.54 0.187
8 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 1.001 0.125 0.096 
Dupl
ex 
FA
M 
4 16 16.26 1.25 14 0.26 -2.42 2.94 0.839
2 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084 0.259 0.016 0.084 
Dupl
ex 
FA
M 
5 32 32.15 1.43 14 0.15 -2.92 3.23 0.916
8 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084 0.153 0.005 0.084 
Dupl
ex 
FA
M 
6 64 69.25 1.49 14 5.25 2.07 8.44 0.003
4 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084 5.251 0.082 0.084 
Dupl
ex 
FA
M 
7 128 130.60 6.25 14 2.57 -10.84 15.98 0.687
0 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 2.573 0.020 0.097 
Dupl
ex 
FA
M 
8 256 256.00 7.50 16 0.02 -15.86 15.91 0.997
4 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 0.024 0.000 0.097 
Dupl
ex 
FA
M 
9 512 514.10 5.10 16 2.12 -8.69 12.94 0.682
5 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 2.124 0.004 0.097 
Dupl
ex 
FA
M 
10 1000 892.60 52.73 16 -107.40 -219.20 4.42 0.058
7 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 107.40
0 
0.107 0.102 
Dupl
ex 
FA
M 
11 5000 5172.0
0 
114.30 4 172.10 -145.10 489.40 0.206
4 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 172.10
0 
0.034 0.102 
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Dupl
ex 
FA
M 
12 10000 10394.
00 
240.20 4 393.80 -273.10 1061.0
0 
0.176
5 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 393.80
0 
0.039 0.102 
Dupl
ex 
FA
M 
13 15000 15612.
00 
311.60 16 612.30 -48.25 1273.0
0 
0.067
0 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 612.30
0 
0.041 0.112 
Dupl
ex 
FA
M 
14 20000 21337.
00 
336.10 16 1337.00 624.60 2049.0
0 
0.001
0 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 1337.0
00 
0.067 0.112 
Dupl
ex 
FA
M 
15 25000 23416.
00 
508.10 16 -1584.00 -
2661.00 
-507.10 0.006
6 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 1584.0
00 
0.063 0.112 
Dupl
ex 
FA
M 
16 30000 27356.
00 
1609.00 4 -2644.00 -
7112.00 
1824.0
0 
0.175
8 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 2644.0
00 
0.088 0.112 
Dupl
ex 
FA
M 
17 35000 25234.
00 
631.20 4 -9766.00 -
11519.0
0 
-
8013.0
0 
0.000
1 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 9766.0
00 
0.279 0.112 
Dupl
ex 
FA
M 
18 40000 30720.
00 
1861.00 4 -9280.00 -
14446.0
0 
-
4113.0
0 
0.007
6 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 9280.0
00 
0.232 0.112 
Dupl
ex 
FA
M 
19 45000 38709.
00 
1235.00 4 -6291.00 -
9720.00 
-
2862.0
0 
0.007
0 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 6291.0
00 
0.140 0.112 
Dupl
ex 
FA
M 
20 50000 43073.
00 
3414.00 4 -6927.00 -
16406.0
0 
2553.0
0 
0.112
4 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 6927.0
00 
0.139 0.112 
Dupl
ex 
VI
C 
1 2 1.67 0.33 4 -0.33 -1.26 0.59 0.504
0 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 0.333 0.167 0.096 
Dupl
ex 
VI
C 
2 4 4.22 0.40 16 0.22 -0.63 1.07 0.241
2 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 0.222 0.056 0.096 
Dupl
ex 
VI
C 
3 8 10.22 0.88 16 2.22 0.36 4.09 0.037
0 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 2.224 0.278 0.096 
Dupl
ex 
VI
C 
4 16 17.01 1.03 16 1.01 -1.17 3.19 0.836
4 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084 1.008 0.063 0.084 
Dupl VI 5 32 31.86 2.42 4 -0.14 -6.87 6.59 0.399 t-test Two- ERM- 3 8.400 0.084 -0.140 -0.004 0.084 
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ex C 0 tail AD623d  
Dupl
ex 
VI
C 
6 64 58.09 2.65 16 -5.91 -11.53 -0.28 0.972
0 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084 5.906 0.092 0.084 
Dupl
ex 
VI
C 
7 128 113.60 6.06 16 -14.43 -27.28 -1.59 0.633
8 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 14.430 0.113 0.097 
Dupl
ex 
VI
C 
8 256 248.30 13.11 16 -7.71 -35.50 20.08 0.318
4 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 7.707 0.030 0.097 
Dupl
ex 
VI
C 
9 512 513.30 5.47 16 1.33 -10.27 12.92 0.001
3 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 1.326 0.003 0.097 
Dupl
ex 
VI
C 
10 1000 1085.0
0 
36.95 4 84.68 -17.91 187.30 0.606
6 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 84.680 0.085 0.102 
Dupl
ex 
VI
C 
11 5000 5172.0
0 
115.30 4 171.90 -148.20 492.00 < 
0.000
1 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 171.90
0 
0.034 0.102 
Dupl
ex 
VI
C 
12 10000 10429.
00 
240.00 4 429.10 -237.40 1095.0
0 
0.140
2 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 429.10
0 
0.043 0.102 
Dupl
ex 
VI
C 
13 15000 15671.
00 
308.30 16 671.20 17.71 1325.0
0 
0.004
7 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 671.20
0 
0.045 0.112 
Dupl
ex 
VI
C 
14 20000 22094.
00 
556.90 16 2094.00 913.30 3274.0
0 
<0.00
01 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 2094.0
00 
0.105 0.112 
Dupl
ex 
VI
C 
15 25000 25169.
00 
448.40 16 168.80 -781.90 1119.0
0 
0.054
8 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 168.80
0 
0.007 0.112 
Dupl
ex 
VI
C 
16 30000 27288.
00 
1553.00 4 -2712.00 -
7024.00 
1601.0
0 
0.454
0 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 2712.0
00 
0.090 0.112 
Dupl
ex 
VI
C 
17 35000 25352.
00 
620.80 4 -9648.00 -
11372.0
0 
-
7925.0
0 
<0.00
01 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 9648.0
00 
0.276 0.112 
Dupl
ex 
VI
C 
18 40000 30781.
00 
1698.00 4 -9219.00 -
13932.0
0 
-
4506.0
0 
0.011
2 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 9219.0
00 
0.230 0.112 
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Dupl
ex 
VI
C 
19 45000 39036.
00 
1284.00 4 -5964.00 -
9530.00 
-
2399.0
0 
0.020
4 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 5964.0
00 
0.133 0.112 
Dupl
ex 
VI
C 
20 50000 43252.
00 
3492.00 4 -6748.00 -
16444.0
0 
2948.0
0 
0.162
0 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 6748.0
00 
0.135 0.112 
Unip
lex 
FA
M 
1 2 2.11 0.45 16 -0.11 0.85 -1.08 0.405
0 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 0.111 0.056 0.096 
Unip
lex 
FA
M 
2 4 5.56 0.71 16 -1.56 -0.05 -3.06 0.021
7 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 1.556 0.389 0.096 
Unip
lex 
FA
M 
3 8 9.11 0.66 16 -1.11 0.28 -2.50 0.054
6 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096 1.111 0.139 0.096 
Unip
lex 
FA
M 
4 16 17.23 1.21 16 -1.23 1.34 -3.80 0.162
3 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084 1.231 0.077 0.084 
Unip
lex 
FA
M 
5 32 32.92 0.95 16 -0.92 1.10 -2.93 0.174
6 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084 0.917 0.029 0.084 
Unip
lex 
FA
M 
6 64 56.47 4.59 4 7.53 20.28 -5.23 0.088
3 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084 7.527 0.118 0.084 
Unip
lex 
FA
M 
7 128 122.60 13.42 4 5.37 42.62 -31.88 0.354
7 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 5.370 0.042 0.097 
Unip
lex 
FA
M 
8 256 209.90 12.23 16 46.05 71.99 20.12 0.000
8 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 46.050 0.180 0.097 
Unip
lex 
FA
M 
9 512 403.70 20.37 16 108.30 151.50 65.08 < 
0.000
1 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097 108.30
0 
0.212 0.097 
Unip
lex 
FA
M 
10 1000 892.60 52.73 16 107.40 219.20 -4.42 0.029
3 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 107.40
0 
0.107 0.102 
Unip
lex 
FA
M 
11 5000 4713.0
0 
199.40 4 287.50 841.20 -266.20 0.111
4 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 287.50
0 
0.058 0.102 
Unip
lex 
FA
M 
12 10000 8948.0
0 
179.50 15 1052.00 1411.00 692.50 < 
0.000
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102 1052.0
00 
0.105 0.102 
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1 
Unip
lex 
FA
M 
13 15000 19849.
00 
1323.00 4 -4849.00 -
1176.00 
-
8522.0
0 
0.010
7 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 4849.0
00 
0.323 0.112 
Unip
lex 
FA
M 
14 20000 21633.
00 
566.10 13 -1633.00 -116.20 -
3150.0
0 
0.018
4 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 1633.0
00 
0.082 0.112 
Unip
lex 
FA
M 
15 25000 24450.
00 
1254.00 4 550.20 4032.00 -
2932.0
0 
0.341
8 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 550.20
0 
0.022 0.112 
Unip
lex 
FA
M 
16 30000 30617.
00 
1351.00 4 -616.90 3134.00 -
4368.0
0 
0.335
8 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 616.90
0 
0.021 0.112 
Unip
lex 
FA
M 
17 35000 27528.
00 
3973.00 4 7472.00 18503.0
0 
-
3559.0
0 
0.066
6 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 7472.0
00 
0.213 0.112 
Unip
lex 
FA
M 
18 40000 32738.
00 
1680.00 4 7262.00 11925.0
0 
2599.0
0 
0.006
2 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 7262.0
00 
0.182 0.112 
Unip
lex 
FA
M 
19 45000 37512.
00 
6075.00 4 7488.00 24355.0
0 
-
9380.0
0 
0.142
6 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 7488.0
00 
0.166 0.112 
Unip
lex 
FA
M 
20 50000 45125.
00 
2210.00 15 4875.00 9297.00 453.50 0.016
4 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112 4875.0
00 
0.098 0.112 
Unip
lex 
VI
C 
1 2 1.6670
0 
0.23570 16 0.333300 0.833 -0.166 0.088
2 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096   0.096 
Unip
lex 
VI
C 
2 4 4.22 0.40 16 -0.222200 0.627 -1.071 0.293
4 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096   0.096 
Unip
lex 
VI
C 
3 8 10.22 0.88 16 -2.224000 -0.360 -4.089 0.011
2 
t-test Two-
tail 
ERM-
AD623e  
2 9.560 0.096   0.096 
Unip
lex 
VI
C 
4 16 17.01 1.03 16 -1.008000 1.173 -3.188 0.170
9 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084   0.084 
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Unip
lex 
VI
C 
5 32 34.26 4.75 16 -2.258000 7.809 -12.320 0.320
4 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084   0.084 
Unip
lex 
VI
C 
6 64 58.72 2.92 15 5.279000 11.130 -0.570 0.036
8 
t-test Two-
tail 
ERM-
AD623d  
3 8.400 0.084   0.084 
Unip
lex 
VI
C 
7 128 113.60 10.04 4 14.43000
0 
42.310 -13.440 0.112
0 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097   0.097 
Unip
lex 
VI
C 
8 256 248.30 13.11 16 7.707000 35.500 -20.080 0.282
4 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097   0.097 
Unip
lex 
VI
C 
9 512 414.20 16.35 15 97.78000
0 
130.500 65.060 < 
0.000
1 
t-test Two-
tail 
ERM-
AD623c 
4 9.730 0.097   0.097 
Unip
lex 
VI
C 
10 1000 979.20 29.97 4 20.82000
0 
104.000 -62.390 0.262
8 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102   0.102 
Unip
lex 
VI
C 
11 5000 4464.0
0 
180.80 4 535.7000
00 
1038.00
0 
33.680 0.020
7 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102   0.102 
Unip
lex 
VI
C 
12 10000 8099.0
0 
209.30 16 -
7099.000
000 
-
6656.00
0 
-
7543.0
00 
< 
0.000
1 
t-test Two-
tail 
ERM-
AD623b 
5 10.19
0 
0.102   0.102 
Unip
lex 
VI
C 
13 15000 19458.
00 
660.80 4 -
4458.000
000 
-
2624.00
0 
-
6293.0
00 
0.001
3 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112   0.112 
Unip
lex 
VI
C 
14 20000 22082.
00 
1016.00 4 -
2082.000
000 
737.800 -
4901.0
00 
0.054
8 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112   0.112 
Unip
lex 
VI
C 
15 25000 25169.
00 
448.40 16 -
168.8000
00 
781.900 -
1119.0
00 
0.355
8 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112   0.112 
Unip
lex 
VI
C 
16 30000 27322.
00 
446.70 15 2678.000
000 
3572.00
0 
1784.0
00 
< 
0.000
1 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112   0.112 
Unip
lex 
VI
C 
17 35000 25299.
00 
427.70 16 9701.000
000 
10608.0
00 
8795.0
00 
< 
0.000
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112   0.112 
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1 
Unip
lex 
VI
C 
18 40000 33824.
00 
1678.00 4 6176.000
000 
10834.0
00 
1518.0
00 
0.010
6 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112   0.112 
Unip
lex 
VI
C 
19 45000 40864.
00 
1864.00 16 4136.000
000 
8087.00
0 
184.80
0 
0.020
6 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112   0.112 
Unip
lex 
VI
C 
20 50000 49080.
00 
458.00 4 920.4000
00 
2192.00
0 
-
351.10
0 
0.057
4 
t-test Two-
tail 
ERM-
AD623a  
6 11.15
0 
0.112     0.112 
Est = estimated; VIC indicates the ABL1 target; FAM indicates the BCR-ABL1 target. Red coloured numbers indicate significant p-values. 
 
 
Appendix Table 3.3. Paired, two-tail, Student's t-test results table, testing the significance of difference between the measured mean per category for both targets in 
duplex and uniplex. Dilution points are prepared using the ERM reference material. 
Est target/chip Category Ref concentration 
(copy/chip or λ) 
mean of 
difference 
SD (±) SEM (±) 95% 
CI_low 
95% CI_hi p-value Statistics   
Uniplex vs 
Duplex 
Ratio 1 2 0.1786 1.129 0.6518 -2.626 2.983 0.8098 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 2 4 0.4243 0.165 0.09527 0.01441 0.8342 0.0469 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 3 8 -0.1396 0.08625 0.0498 -0.3538 0.07471 0.1072 paired t-test Two-tail 
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Uniplex vs 
Duplex 
Ratio 4 16 0.05092 0.1322 0.07635 -0.2776 0.3794 0.5734 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 5 32 -0.1324 0.1169 0.0675 -0.4228 0.1581 0.189 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 6 64 -0.03016 0.1076 0.06214 -0.2975 0.2372 0.6754 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 7 128 0.09371 0.1914 0.1105 -0.3818 0.5692 0.4858 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 8 256 -0.1318 0.04094 0.02364 -0.2335 -0.03015 0.0307 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 9 512 -0.01404 0.2093 0.07912 -0.2077 0.1796 0.865 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 10 1000 -0.05134 0.05888 0.03399 -0.1976 0.09493 0.2701 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 11 5000 0.06232 0.1501 0.08664 -0.3105 0.4351 0.2701 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 12 10000 -0.01081 0.3896 0.1299 -0.3103 0.2887 0.9357 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 13 15000 0.02326 0.133 0.02186 -0.02108 0.06759 0.2945 paired t-test Two-tail 
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Uniplex vs 
Duplex 
Ratio 14 20000 -0.006543 0.1212 0.06999 -0.3077 0.2946 0.934 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 15 25000 -0.02275 0.06569 0.03793 -0.1859 0.1404 0.6095 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 16 30000 0.1235 0.09195 0.05308 -0.1049 0.3519 0.1455 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 17 35000 0.09281 0.2666 0.1539 -0.5696 0.7552 0.6079 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 18 40000 -0.0244 0.1191 0.06876 -0.3202 0.2714 0.7566 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 19 45000 -0.07531 0.1684 0.09723 -0.4937 0.343 0.5196 paired t-test Two-tail 
Uniplex vs 
Duplex 
Ratio 20 50000 -0.08291 0.1055 0.06089 -0.3449 0.1791 0.3064 paired t-test Two-tail 
 
 
Appendix Table 3.4. Bland-Altman ratio values between measured and reference target copy numbers per chip. 
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Est target/chip concentration 
(copy/chip) 
log 
(copy/chip) 
mean 
measured 
Bias 
(measured/ref) 
(difference for 
ratio) 
SD bias 95% CI 95% CI statistics 
Duplex FAM Est target/chip 10 0.301 6.168 0.4325 0.1436 0.151 0.7141 Ratio (measured/ref) 
Duplex FAM Est target/chip 100   43.25295 0.4315 0.02754 0.3775 0.4855 Ratio (measured/ref) 
Duplex FAM Est target/chip 1000   431.5081 0.4425 0.02209 0.3992 0.4858 Ratio (measured/ref) 
Duplex FAM Est target/chip 10000   4425.445 0.4281 0.03177 0.3659 0.4904 Ratio (measured/ref) 
Duplex FAM Est target/chip 20000   8562.52 0.4082 0.06881 0.2734 0.5431 Ratio (measured/ref) 
Duplex FAM Est target/chip 30000   12247.49 0.4586 0.0385 0.3831 0.5341 Ratio (measured/ref) 
Duplex FAM Est target/chip 40000   18343.84 0.4657 0.0584 0.3186 0.5341 Ratio (measured/ref) 
Duplex VIC Est target/chip 10   6.25141 0.6251 0.3843 -0.1281 1.378 Ratio (measured/ref) 
Duplex VIC Est target/chip 100   43.75374 0.4375 0.1338 0.1752 0.6999 Ratio (measured/ref) 
Duplex VIC Est target/chip 1000   421.0343 0.421 0.02874 0.3647 0.4774 Ratio (measured/ref) 
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Duplex VIC Est target/chip 10000   4384.648 0.4385 0.02163 0.3961 0.4809 Ratio (measured/ref) 
Duplex VIC Est target/chip 20000   8562.538 0.4281 0.02984 0.3696 0.4866 Ratio (measured/ref) 
Duplex VIC Est target/chip 30000   12249.71 0.4083 0.0688 0.2735 0.5432 Ratio (measured/ref) 
Duplex VIC Est target/chip 40000   18384.64 0.4596 0.03912 0.3829 0.5363 Ratio (measured/ref) 
Uniplex FAM Est target/chip 10   6.112296 0.6111 0.3296 -0.03483 1.257 Ratio (measured/ref) 
Uniplex FAM Est target/chip 100   47.93454 0.4794 0.07716 0.3281 0.6306 Ratio (measured/ref) 
Uniplex FAM Est target/chip 1000   452.1032 0.4521 0.02266 0.4077 0.4965 Ratio (measured/ref) 
Uniplex FAM Est target/chip 10000   4325.214 0.4325 0.02014 0.393 0.472 Ratio (measured/ref) 
Uniplex FAM Est target/chip 20000   9252.772 0.4626 0.01295 0.4373 0.488 Ratio (measured/ref) 
Uniplex FAM Est target/chip 30000   13152.29 0.4384 0.02451 0.3904 0.4864 Ratio (measured/ref) 
Uniplex FAM Est target/chip 40000   17259.23 0.4315 0.02257 0.3872 0.4757  Ratio (measured/ref) 
Uniplex VIC Est target/chip 10   5.223169 0.5222 0.3232 -0.1112 1.156 Ratio (measured/ref) 
Uniplex VIC Est target/chip 100   52.74274 0.5274 0.1546 0.2244 0.8304 Ratio (measured/ref) 
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Uniplex VIC Est target/chip 1000   469.7585 0.4698 0.05262 0.3666 0.5729 Ratio (measured/ref) 
Uniplex VIC Est target/chip 10000   4399.777 0.44 0.0515 0.339 0.5409 Ratio (measured/ref) 
Uniplex VIC Est target/chip 20000   9069.599 0.4535 0.03493 0.385 0.5219 Ratio (measured/ref) 
Uniplex VIC Est target/chip 30000   13566.36 0.4522 0.04919 0.3558 0.5486 Ratio (measured/ref) 
Uniplex VIC Est target/chip 40000   17692.31 0.4423 0.03488 0.3739 0.5107 Ratio (measured/ref) 
 
 
 
 
Appendix Table 3.5. Wilcoxon signed rank test results table, testing the significance of difference between the measured mean target copies per category using the sum 
and mean of (K) and (n). 
platform mean or 
SUM 
Est 
target/chip 
Sample 
ID 
Category Mean SD (±) SE (±) Degrees 
of 
Freedom 
95% CI p-value Statistics 
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QS3D mean Duplex FAM 20% 1 1290 1885 596.2 9 -58.56 2639 0.0587 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex FAM 10% 2 35.18 153.9 48.66 9 -74.89 145.3 0.488 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex FAM 1% 3 4.1 77.12 24.39 9 -51.07 59.27 0.8702 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex FAM 0.10% 4 34.67 77.34 24.46 9 -20.65 89.99 0.19 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex FAM 0.01% 5 13.73 5.253 1.661 9 9.969 17.48 < 0.0001 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex FAM 0.001% 6 11.77 2.51 0.7938 9 9.977 13.57 < 0.0001 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex FAM 0% 7 3.934 1.718 0.5434 9 2.705 5.163 < 0.0001 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex VIC 20% 1 -1101 5448 1723 9 -4998 2796 0.5388 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex VIC 10% 2 -678.2 3000 948.8 9 -2824 1468 0.4928 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex VIC 1% 3 1004 2271 718.2 9 -620.8 2629 0.1957 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex VIC 0.10% 4 1455 4820 1524 9 -1994 4903 0.3649 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex VIC 0.01% 5 2539 2907 919.2 9 460 4619 0.022 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex VIC 0.001% 6 1542 2995 947 9 -600.7 3684 0.138 Wilcoxon  Two-Tail, Paired 
QS3D mean Duplex VIC 0% 7 1116 2437 770.6 9 -626.8 2860 0.1813 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex FAM 20% 1 2460 7040 2226 9 -2575 7496 0.2977 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex FAM 10% 2 5.4 541.8 171.3 9 -382.2 393 0.9755 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex FAM 1% 3 11.8 231.5 73.22 9 -153.8 177.4 0.8755 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex FAM 0.10% 4 104.3 232.2 73.43 9 -61.81 270.4 0.1892 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex FAM 0.01% 5 106.3 35.56 11.25 9 80.91 131.8 < 0.0001 Wilcoxon  Two-Tail, Paired 
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QS3D SUM Duplex FAM 0.001% 6 93.43 26.82 8.481 9 74.25 112.6 < 0.0001 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex FAM 0% 7 10.9 5.175 1.636 9 7.2 14.6 < 0.0001 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex VIC 20% 1 -7936 23772 7517 9 -24942 9069 0.3186 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex VIC 10% 2 -3258 8282 2619 9 -9183 2667 0.245 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex VIC 1% 3 3012 6813 2155 9 -1862 7886 0.1956 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex VIC 0.10% 4 4364 14460 4573 9 -5981 14708 0.3649 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex VIC 0.01% 5 57931 30163 9538 9 36354 79508 0.0002 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex VIC 0.001% 6 63678 32876 10396 9 40159 87196 0.0002 Wilcoxon  Two-Tail, Paired 
QS3D SUM Duplex VIC 0% 7 2893 7621 2410 9 -2559 8345 0.2606 Wilcoxon  Two-Tail, Paired 
 
 
Appendix Table 3.6. Mann-Whitney U test results table, testing the significance of difference between the measured mean BCR-ABL1 target copies per category on the 
QS3D platform in patient samples and negative control samples using the sum and mean of (K) and (n). 
platfor
m 
mea
n or 
SUM 
Est 
target/chip 
Sampl
e ID 
Categor
y 
Mean SE (±) Degrees 
of 
Freedo
m 
differenc
e 
95% 
CI 
  p-value Statistics   
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QS3D mea
n 
Duplex FAM 20% 1 6176 1481,   6168 3058 9279 0.0003 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D mea
n 
Duplex FAM 10% 2 846.8 240.2,   839.2 334.5 1344 0.0013 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D mea
n 
Duplex FAM 1% 3 136 25.30,   128.5 75.31 181.6 < 
0.0001 
Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D mea
n 
Duplex FAM 0.10% 4 25.99 5.610,   18.44 7.249 29.63 0.0014 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D mea
n 
Duplex FAM 0.01% 5 15.03 1.676,   7.479 3.959 11 0.0002 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D mea
n 
Duplex FAM 0.001
% 
6 11.97 0.7938
, 
  4.425 2.757 6.092 < 
0.0001 
Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D mea
n 
Duplex FAM 0% 7 3.934 0.5434
, 
  -3.614 -
4.755 
-
2.472 
< 
0.0001 
Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D SUM Duplex FAM 20% 1 1711
8 
4273,   17060 8082 2603
8 
0.0004 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D SUM Duplex FAM 10% 2 2441 720.6,   2382 868.5 3896 0.002 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D SUM Duplex FAM 1% 3 408 75.89,   350 190.6 509.4 0.0001 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D SUM Duplex FAM 0.10% 4 147.8 71.45,   89.81 -
60.31 
239.9 0.1124 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D SUM Duplex FAM 0.01% 5 110.3 11.29,   52.34 28.62 76.06 0.0001 Mann-Whitney U 
test 
One-Tail, 
unpaired 
QS3D SUM Duplex FAM 0.001 6 93.93 8.481,   35.92 18.11 53.74 0.0002 Mann-Whitney U One-Tail, 
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% test unpaired 
QS3D SUM Duplex FAM 0% 7 10.9 1.636,   -47.1 -
50.54 
-
43.67 
< 
0.0001 
Mann-Whitney U 
test 
One-Tail, 
unpaired 
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Chapter IV Appendix 
Appendix IV Figures 
 
Appendix Figure 4.1. Cross-Platform comparison. The mean of BCR-ABL1 copies per µl of cDNA from the 
replicates per sample is compared on all platforms. P-values are generated applying the non-parametric 
Wilcoxon Signed-Rank test. 
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Appendix Figure 4.2. Cross-Platform comparison. The mean of ABL1 copies per µl of cDNA from the replicates 
per sample is compared on all platforms. P-values are generated applying the non-parametric Wilcoxon 
Signed-Rank test. 
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Appendix Figure 4.3. Cross-Platform comparison. The mean of BCR-ABL1 copies per µl of cDNA from the 
replicates per sample is compared to the BCR-ABL1 copies per µl of cDNA detected in the negative controls on 
the corresponding dPCR platform. P-values are generated applying the non-parametric Mann-Whitney U test. 
 
  
 
 
320 
 
 
 
 
Appendix Figure 4.4. Cross-Platform comparison. The mean of BCR-ABL1 copies per µl of cDNA from the 
replicates per sample are compared on all platforms. The threshold for true-positive quantification is 
established based on the false negative signals quantified in the negative controls. The dotted lines represent 
the threshold and is coloured according to each platform.  
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Appendix Figure 4.5. Cross-Platform comparison. The sum of BCR-ABL1 copies per µl of cDNA from the 
replicates per sample are compared on all platforms. The threshold for true-positive quantification is 
established based on the false negative signals quantified in the negative controls. The dotted lines represent 
the threshold and is coloured according to each platform.
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Appendix IV Tables 
Appendix Table 4.1. Wilcoxon signed rank test results table, testing the significance of difference between the measured mean per category for both targets using the sum 
and mean of (K) and (n) on BioRad
®
 and RainDrop
®
 dPCR platforms. 
platform mean or 
SUM 
Est target/chip Sample 
ID 
Category Mean SD (±) SE (±) Degrees 
of 
Freedom 
95% CI p-value Statistics 
BioRad mean Duplex FAM 20% 1 -2005.0000 1268.0000 400.9000 9 -2912.0000 -1099.0000 0.0007 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex FAM 10% 2 -377.2000 251.3000 79.4800 9 -557.0000 -197.4000 0.001 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex FAM 1% 3 -35.7100 77.8100 24.6100 9 -91.3800 19.9500 0.1806 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex FAM 0.10% 4 -1.7200 16.6400 5.2620 9 -13.6200 10.1800 0.7512 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex FAM 0.01% 5 0.1948 0.8166 0.2582 9 -0.3894 0.7790 0.4699 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex FAM 0.001% 6 0.3778 0.3045 0.0963 9 0.1599 0.5956 0.0035 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex FAM 0% 7 0.9445 0.6203 0.1962 9 0.5007 1.3880 0.001 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex VIC 20% 1 -12631.0000 9508.0000 3007.0000 9 -19433.0000 -5829.0000 0.0023 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex VIC 10% 2 -4351.0000 4500.0000 1423.0000 9 -7569.0000 -1132.0000 0.0136 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex VIC 1% 3 -1610.0000 5211.0000 1648.0000 9 -5338.0000 2118.0000 0.3541 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex VIC 0.10% 4 -757.3000 6676.0000 2111.0000 9 -5533.0000 4018.0000 0.7281 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex VIC 0.01% 5 -1356.0000 1884.0000 595.8000 9 -2704.0000 -8.2920 0.0489 Wilcoxon  Two-Tail, Paired 
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BioRad mean Duplex VIC 0.001% 6 35.4800 3672.0000 1161.0000 9 -2591.0000 2662.0000 0.9763 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex VIC 0% 7 2678.0000 3450.0000 1091.0000 9 209.4000 5146.0000 0.0365 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex Ratio 20% 1 0.0826 0.0753 0.0238 9 0.0288 0.1365 0.007 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex Ratio 10% 2 0.0042 0.0327 0.0103 9 -0.0191 0.0276 0.6919 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex Ratio 1% 3 -0.0018 0.0047 0.0015 9 -0.0051 0.0016 0.2578 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex Ratio 0.10% 4 0.0013 0.0042 0.0013 9 -0.0017 0.0043 0.3484 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex Ratio 0.01% 5 0.0001 0.0001 0.0000 9 0.0000 0.0002 0.0852 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex Ratio 0.001% 6 0.0001 0.0001 0.0000 9 0.0000 0.0001 0.0104 Wilcoxon  Two-Tail, Paired 
BioRad mean Duplex Ratio 0% 7 0.0002 0.0001 0.0000 9 0.0001 0.0003 0.0046 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex FAM 20% 1 -6016 3803 1203 9 -8737 -3296 0.0007 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex FAM 10% 2 -1132 754.2 238.5 9 -1671 -592.4 0.001 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex FAM 1% 3 -107.6 233.6 73.86 9 -274.7 59.43 0.179 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex FAM 0.10% 4 -4.86 50.06 15.83 9 -40.67 30.95 0.7658 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex FAM 0.01% 5 9.001 7.425 2.348 9 3.69 14.31 0.004 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex FAM 0.001% 6 4.7 2.741 0.8667 9 2.74 6.661 0.0004 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex FAM 0% 7 8.5 5.583 1.766 9 4.506 12.49 0.001 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex VIC 20% 1 -37893 28525 9020 9 -58298 -17488 0.0023 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex VIC 10% 2 -13052 13499 4269 9 -22708 -3396 0.0136 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex VIC 1% 3 -4830 15633 4944 9 -16013 6353 0.3541 Wilcoxon  Two-Tail, Paired 
  
 
 
324 
 
 
 
BioRad SUM Duplex VIC 0.10% 4 -2272 20027 6333 9 -16599 12055 0.7281 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex VIC 0.01% 5 39350 17677 5590 9 26705 51995 < 0.0001 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex VIC 0.001% 6 63551 35817 11326 9 37929 89173 0.0003 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex VIC 0% 7 50071 42444 13422 9 19708 80434 0.0047 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex Ratio 20% 1 0.08263 0.07526 0.0238 9 0.02879 0.1365 0.007 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex Ratio 10% 2 0.004228 0.03267 0.01033 9 -0.01914 0.0276 0.6919 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex Ratio 1% 3 -0.00178 0.00466 0.001474 9 -0.005114 0.001553 0.2578 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex Ratio 0.10% 4 0.001305 0.004173 0.001319 9 -0.001679 0.00429 0.3484 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex Ratio 0.01% 5 0.0000717 0.0001173 3.709E-05 9 -0.0000122 0.0001556 0.0852 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex Ratio 0.001% 6 0.00005637 5.523E-05 1.747E-05 9 0.00001686 0.00009588 0.0104 Wilcoxon  Two-Tail, Paired 
BioRad SUM Duplex Ratio 0% 7 0.0001609 0.0001358 4.294E-05 9 0.00006374 0.000258 0.0046 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex FAM 20% 1 15390 17289 5467 9 3022 27758 0.0202 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex FAM 10% 2 1872 3328 1177 9 -910.2 4655 0.1556 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex FAM 1% 3 468.9 508.3 169.4 9 78.16 859.5 0.0244 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex FAM 0.10% 4 98.9 121.6 38.45 9 11.93 185.9 0.0301 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex FAM 0.01% 5 12.5 3.274 1.035 9 10.16 14.84 < 0.0001 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex FAM 0.001% 6 12.8 7.056 2.231 9 7.752 17.85 0.0003 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex FAM 0% 7 13.1 4.483 1.418 9 9.893 16.31 < 0.0001 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex VIC 20% 1 45910 53819 17019 9 7410 84410 0.0245 Wilcoxon  Two-Tail, Paired 
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RainDrop one reaction Duplex VIC 10% 2 25292 18900 6682 9 9491 41093 0.0068 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex VIC 1% 3 42306 39271 13090 9 12120 72492 0.012 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex VIC 0.10% 4 30214 25976 8214 9 11631 48796 0.0051 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex VIC 0.01% 5 39290 26421 8355 9 20389 58190 0.0011 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex VIC 0.001% 6 49748 36303 11480 9 23778 75718 0.0019 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex VIC 0% 7 35185 35784 11316 9 9587 60783 0.0125 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex Ratio 20% 1 0.03437 0.06364 0.02012 9 -0.01115 0.07989 0.1218 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex Ratio 10% 2 -0.01303 0.03749 0.01326 9 -0.04437 0.01832 0.3585 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex Ratio 1% 3 -0.003168 0.007872 0.002624 9 -0.009219 0.002882 0.2617 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex Ratio 0.10% 4 0.001281 0.002883 0.0009117 9 -0.0007817 0.003343 0.1936 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex Ratio 0.01% 5 0.000175 0.000203 6.418E-05 9 0.0000298 0.0003202 0.0234 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex Ratio 0.001% 6 0.0001826 0.0001678 5.305E-05 9 0.00006261 0.0003026 0.0074 Wilcoxon  Two-Tail, Paired 
RainDrop one reaction Duplex Ratio 0% 7 0.0003979 0.0002081 6.582E-05 9 0.000249 0.0005468 0.0002 Wilcoxon  Two-Tail, Paired 
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Appendix Table 4.2. Mann-Whitney U test results table, testing the significance of difference between the measured mean per category for the BCR-ABL1 target on the 
BioRad
®
 and RainDrop
®
 dPCR platforms in patients' samples and negative control samples using the sum and mean of (K) and (n). 
platform mean or SUM Est target/chip Sample ID Category Mean SE (±) Degrees of 
Freedom 
Difference 95% CI p-value Statistics 
BioRad mean Duplex FAM 20% 1 2880 600.1 9 2879 1619 4140 < 0.0001 t-test One-Tail, non-Paired 
BioRad mean Duplex FAM 10% 2 434.4 140.3 9 433.5 138.8 728.1 0.0032 t-test One-Tail, non-Paired 
BioRad mean Duplex FAM 1% 3 96.19 21.5 9 95.27 50.09 140.4 0.0002 t-test One-Tail, non-Paired 
BioRad mean Duplex FAM 0.10% 4 12.88 4.043 9 11.96 3.47 20.46 0.0042 t-test One-Tail, non-Paired 
BioRad mean Duplex FAM 0.01% 5 1.495 0.2669 9 0.5781 0.01732 1.139 0.022 t-test One-Tail, non-Paired 
BioRad mean Duplex FAM 0.001% 6 0.5778 0.0963 9 -0.3389 -0.5413 -0.1366 0.0012 t-test One-Tail, non-Paired 
BioRad mean Duplex FAM 0% 7 0.9445 0.1962 9 0.02775 -0.3844 0.4399 0.4445 t-test One-Tail, non-Paired 
BioRad SUM Duplex FAM 20% 1 8641 1800 9 8638 4855 12420 < 0.0001 t-test One-Tail, non-Paired 
BioRad SUM Duplex FAM 10% 2 1303 420.8 9 1300 415.8 2184 0.0032 t-test One-Tail, non-Paired 
BioRad SUM Duplex FAM 1% 3 288.6 64.51 9 285.3 149.8 420.8 0.0002 t-test One-Tail, non-Paired 
BioRad SUM Duplex FAM 0.10% 4 38.64 12.13 9 35.37 9.892 60.85 0.0046 t-test One-Tail, non-Paired 
BioRad SUM Duplex FAM 0.01% 5 13 2.454 9 9.734 4.578 14.89 0.0005 t-test One-Tail, non-Paired 
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BioRad SUM Duplex FAM 0.001% 6 5.2 0.8667 9 1.933 0.1124 3.754 0.0193 t-test One-Tail, non-Paired 
BioRad SUM Duplex FAM 0% 7 8.5 1.766 9 5.233 1.524 8.943 0.0042 t-test One-Tail, non-Paired 
RainDrop one reaction Duplex FAM 10% 2 4706 1839 9 4700 1240 8159 0.0054 t-test One-Tail, non-Paired 
RainDrop one reaction Duplex FAM 1% 3 858.6 175.6 9 851.8 501.5 1202 < 0.0001 t-test One-Tail, non-Paired 
RainDrop one reaction Duplex FAM 0.10% 4 142.4 38.44 9 135.6 54.86 216.4 0.0012 t-test One-Tail, non-Paired 
RainDrop one reaction Duplex FAM 0.01% 5 16.5 1.352 9 9.714 6.874 12.55 < 0.0001 t-test One-Tail, non-Paired 
RainDrop one reaction Duplex FAM 0.001% 6 13.3 2.231 9 6.514 1.826 11.2 0.0046 t-test One-Tail, non-Paired 
RainDrop one reaction Duplex FAM 0% 7 13.1 1.418 9 6.314 3.336 9.293 0.0002 t-test One-Tail, non-Paired 
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Appendix Figure 5.1. Comparison of different software used for bioinformatics data analysis and visualisation. (a, b, and c) show the graphical output for the NextSeq 
(JSI) software. (a) And (b) show two different scenarios for two different p-loop polyclonal mutations where the reads carrying each of the two mutations are mutually 
exclusive. (c) Shows a deletion in exon 9 of the KD. (d, e and f) show the graphical output for the NextGene (Soft genetics) software. (d) shows an example for exon 7 
deletion in the KD, (e)  shows a polyclonal situation between two mutations V299L; F317L and (f) shows a polyclonal situation between two mutations T315I; F317L. (G and 
h) show the graphical output for the IGV open source tool. (g) Shows a zoomed-out screen-shot for the entire kinase domain with the locations of the 6 amplicons 
amplifying the domain (blue lines) and the hotspot mutational loci (grey bars), while (h) zooms in to show the polyclonal status amongst three different p-loop mutations. 
In the previous examples, cDNA is used as a template and sequenced reads are aligned to the transcript NM_005157. (i and j) show the alignment of reads to the Hg19 
human reference genome when DNA is used as a template for sequencing the KD. (i) shows how the reads that span exon-exon boundaries are split when aligned to the 
human genome due to the intronic sequences that separate the exons. This type of alignment affects total coverage or depth of sequencing in addition to losing the ability 
to distinguish clonal from polyclonal mutational statuses except when the multiple mutations occur within the same exon (j). 
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Appendix Figure 5.2. Ion Torrent PGM run summary using the 316 v2 chips for a: (a) good run and (b) failed 
run. The figure compares the alignment of sequenced reads to the reference transcript NM_005157; the 
median read length per sequenced read, the amount of total reads generated including the percentage of 
clonal reads, and the loading of the chip with live Ion Sphere Particles (ISPs). 
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Appendix V Tables 
Appendix Table 5.1. Ion Torrent KD 1st and 2nd round PCR primers. Coordinate numbers are based on Transcript 1 (ABL1-001)(NM_005157), Assembly Feb. 2009 
(GRCh37/hg19) 
1st round PCR primers (Major transcript e13a2 or e14a2) 
primer Sequence name                   
Forward 
(F)  
TTCAGAAGCTTCTCCCTGACAT    BCR /Ex13-F                   
Reverse 
(R ) 
GTACTCACAGCCCCACGGA    ABL1/Ex10-R1                   
1st round PCR primers (Minor transcript e19a2) 
Forward 
(F)  
CAACAGTCCTTCGACAGCAG  BCR/Ex1-F                   
Reverse 
(R ) 
GTACTCACAGCCCCACGGA ABL1/Ex10-R1                   
2nd round PCR primers 
Fragment Sequence size 
(bp) 
location coordinates coding sequence mRNA 
sequence 
genomic 
sequence 
PCR 
Primer  
        start end start end start  end start end pool 
F1 TGGCAAGCTCTACGTCTCCT 20 exon 3-4 
junction 
133730477 133738162 543 562 924 943 20025 27710 pool 1 
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R1 CTGCACCAGGTTAGGGTGTT 20 exon 5 133747574 133747593 881 900 1262 1281 37122 37141 pool 1 
F2 GAGGGCGTGTGGAAGAAATA 20 exon 4 133738372 133738391 772 791 1153 1172 27920 27939 pool 2 
R2 CAAGTGGTTCTCCCCTACCA 20 exon 7 133750278 133750297 1109 1128 1490 1509 39826 39845 pool 2 
F3 ACTACCTGAGGGAGTGCAACC 21 exon 6 133748313 133748333 974 994 1355 1375 37861 37881 pool 1 
R3 ATACTCCAAATGCCCAGACG 20 exon 7-8 
junction 
133750432 133750439 1263 1282 1644 1663 39980 43361 pool 1 
F4 AGCCAAGTTCCCCATCAAAT 20 exon 7 133750363 133750382 1194 1213 1575 1594 39911 39930 pool 2 
R4 CAGCTCCTTTTCCACTTCGT 20 exon 9-
10 
junction 
133755542 133755544 1511 1530 1892 1911 45090 45451 pool 2 
F5 TCTATGGTGTGTCCCCCAAC 20 exon 4 133738274 133738293 674 693 1055 1074 27822 27841 pool 1 
R5 TCTGAGTGGCCATGTACAGC 20 exon 6 133748359 133748378 1021 1039 1401 1420 37907 37926 pool 1 
F6 AACACCCTAACCTGGTGCAG 20 exon 5 133747574 133747593 881 900 1262 1281 37122 37141 pool 2 
R6 CAGTCCATTTGATGGGGAAC 20 exon 7 133750369 133750388 1200 1219 1581 1600 39917 39936 pool 2 
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Appendix Table 5.2. The coordinates for the 6 
amplicons defining the BCR-ABL1 TKD Region of 
Interest (ROI). 
Chromosome start end 
chr9 133730477 133747600 
chr9 133738391 133750297 
chr9 133748313 133750439 
chr9 133750363 133755544 
chr9 133738274 133748378 
chr9 133747574 133750388 
 
 
Appendix Table 5.3. The coordinates for the most recurrent BCR-ABL1 TKD HotSpot mutations reported in 
literature. 
Chromosome anchor coordinate variant start strand exon 
chr9 133738329 133738330 c.730A>G_p.M244V 0 + EXON4 
chr9 133738341 133738342 c.742C>G_p.L248V 0 + EXON4 
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chr9 133738348 133738349 c.749G>A_p.G250E 0 + EXON4 
chr9 133738354 133738355 c.755A>G_p.Q252R 0 + EXON4 
chr9 133738355 133738356 c.756G>T_p.Q252H 0 + EXON4 
chr9 133738356 133738357 c.757T>C_p.Y253H 0 + EXON4 
chr9 133738357 133738358 c.758A>T_p.Y253F 0 + EXON4 
chr9 133738362 133738363 c.763G>A_p.E255K 0 + EXON4 
chr9 133738363 133738364 c.764A>T_p.E255V 0 + EXON4 
chr9 133738416 133738417 c.817T>A_p.L273M 0 + EXON4 
chr9 133747519 133747520 c.827A>G_p.D276G 0 + EXON5 
chr9 133747584 133747585 c.892C>G_p.L298V 0 + EXON5 
chr9 133747587 133747588 c.895G>C_p.V299L 0 + EXON5 
chr9 133748269 133748270 c.931T>C_p.F311L 0 + EXON6 
chr9 133748282 133748283 c.943C>T_p.T315A 0 + EXON6 
chr9 133748282 133748283 c.944C>T_p.T315I 0 + EXON6 
chr9 133748287 133748288 c.949T>C_p.F317L 0 + EXON6 
chr9 133748289 133748290 c.951C>G_p.F317L 0 + EXON6 
chr9 133748366 133748367 c.1028T>C_p.M343T 0 + EXON6 
chr9 133748390 133748391 c.1052T>C_p.M351T 0 + EXON6 
chr9 133748402 133748403 c.1064A>G_p.E355G 0 + EXON6 
chr9 133748413 133748414 c.1075T>G_p.F359V 0 + EXON6 
chr9 133748413 133748414 c.1075T>A_p.F359I 0 + EXON6 
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chr9 133748414 133748415 c.1076T>G_p.F359C 0 + EXON6 
chr9 133750303 133750304 c.1135G>A_p.V379I 0 + EXON7 
chr9 133750311 133750312 c.1145T>G_p.F382L 0 + EXON7 
chr9 133750313 133750314 c.1143T>G_p.F382L 0 + EXON7 
chr9 133750329 133750330 c.1159T>A_p.L387M 0 + EXON7 
chr9 133750327 133750328 c.1161G>T_p.L387F 0 + EXON7 
chr9 133750355 133750356 c.1187A>G_p.H396R 0 + EXON7 
chr9 133753878 133753879 c.1348G>C_p.E450Q 0 + EXON8 
chr9 133753879 133753880 c.1349A>G_p.E450G 0 + EXON8 
chr9 133753879 133753880 c.1349A>T_p.E450V 0 + EXON8 
chr9 133753905 133753906 c.1375G>A_p.E459K 0 + EXON8 
chr9 133753914 133753915 c.1384G>A_p.E462K 0 + EXON8 
chr9 133753953 133753954 c.1423_1424ins35_p.C475fs*11 0 + EXON8-
9ins 
chr9 133750254 133750255 c.1086_1270del185_p.R362fs*21 0 + EXON7del 
chr9 133750254 133750255 c.1086_1157del72_p.D363_R386del24 0 + EXON7del 
chr9 133738343 133738342 c.742_822del81_p.L248_K274del27 0 + EXON4del 
chr9 133747556 133747557 c.864_917del54_p.A288_T306del18  0 + EXON5-
6del 
Appendix Table 5.4. The coordinates for the targeted regions within the 
custom designed AmpliSeq panel. 
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Chromosome anchor coordinate amplicon name gene 
chr7 50358516 50358836 AMPL7154742873 IKAROS 
chr7 50367116 50367444 AMPL7154742868 IKAROS 
chr7 50444186 50444513 AMPL7154742865 IKAROS 
chr7 50450174 50450477 AMPL7156609688 IKAROS 
chr7 50455006 50455293 AMPL7154742867 IKAROS 
chr7 50459350 50459670 AMPL7154742886 IKAROS 
chr7 50467446 50467708 AMPL7154742875 IKAROS 
chr7 50467697 50467993 AMPL7154742876 IKAROS 
chr7 50467811 50468134 AMPL7154742879 IKAROS 
chr7 50468162 50468407 AMPL7154742882 IKAROS 
chr9 5021946 5022265 AMPL7154369844 JAK2 
chr9 5029684 5030001 AMPL7154369840 JAK2 
chr9 5044306 5044616 AMPL7154369842 JAK2 
chr9 5050583 5050845 AMPL7154369847 JAK2 
chr9 5054455 5054652 AMPL7154369852 JAK2 
chr9 5054641 5054950 AMPL7154369853 JAK2 
chr9 5055641 5055956 AMPL7154369846 JAK2 
chr9 5064776 5065027 AMPL7154369832 JAK2 
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chr9 5065016 5065263 AMPL7154369833 JAK2 
chr9 5066407 5066722 AMPL7154369837 JAK2 
chr9 5066711 5067024 AMPL7154369838 JAK2 
chr9 5068936 5069256 AMPL7154369835 JAK2 
chr9 5069871 5070184 AMPL7154369848 JAK2 
chr9 5072353 5072673 AMPL7154369854 JAK2 
chr9 5073600 5073912 AMPL7154369849 JAK2 
chr9 5077267 5077566 AMPL7154369850 JAK2 
chr9 5077559 5077674 AMPL7153790171 JAK2 
chr9 5078189 5078501 AMPL7154369851 JAK2 
chr9 5080155 5080461 AMPL7154369836 JAK2 
chr9 5080486 5080764 AMPL7154369845 JAK2 
chr9 5081658 5081931 AMPL7154369843 JAK2 
chr9 5089586 5089897 AMPL7154369834 JAK2 
chr9 5090434 5090581 AMPL7152998089 JAK2 
chr9 5090621 5090944 AMPL7154369839 JAK2 
chr9 5122865 5123185 AMPL7154369831 JAK2 
chr9 5126235 5126543 AMPL7154369855 JAK2 
chr9 5126573 5126897 AMPL7154369841 JAK2 
chr9 133589596 133589923 AMPL7154441886 ABL1 
chr9 133710651 133710857 AMPL7153088113 ABL1 
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chr9 133710846 133711053 AMPL7153088109 ABL1 
chr9 133729381 133729697 AMPL7154441885 ABL1 
chr9 133730163 133730445 AMPL7154441897 ABL1 
chr9 133730434 133730543 AMPL7154441614 ABL1 
chr9 133737896 133738225 AMPL7154441898 ABL1 
chr9 133738214 133738485 AMPL7154441899 ABL1 
chr9 133747403 133747710 AMPL7154441883 ABL1 
chr9 133748196 133748520 AMPL7154441896 ABL1 
chr9 133750146 133750468 AMPL7154441895 ABL1 
chr9 133753731 133754032 AMPL7156591443 ABL1 
chr9 133755354 133755680 AMPL7154441884 ABL1 
chr9 133755780 133756107 AMPL7154441900 ABL1 
chr9 133759164 133759453 AMPL7154441887 ABL1 
chr9 133759442 133759729 AMPL7154441888 ABL1 
chr9 133759704 133760030 AMPL7154441889 ABL1 
chr9 133760019 133760344 AMPL7154441890 ABL1 
chr9 133760313 133760538 AMPL7154441891 ABL1 
chr9 133760509 133760802 AMPL7154441892 ABL1 
chr9 133760701 133760886 AMPL7156591422 ABL1 
chr9 133760875 133761149 AMPL7154441894 ABL1 
chr11 494451 494745 AMPL7159990962 RNH1 
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chr11 494726 495027 AMPL7157718531 RNH1 
chr11 495005 495158 AMPL7157718529 RNH1 
chr11 497935 498230 AMPL7157718515 RNH1 
chr11 498310 498634 AMPL7159990961 RNH1 
chr11 498682 499010 AMPL7157718522 RNH1 
chr11 498917 499235 AMPL7157718521 RNH1 
chr11 499767 500098 AMPL7157718518 RNH1 
chr11 500361 500590 AMPL7153981964 RNH1 
chr11 500501 500725 AMPL7157724013 RNH1 
chr11 501923 502245 AMPL7157718525 RNH1 
chr20 30946316 30946595 AMPL7154374813 ASXL1 
chr20 30954090 30954365 AMPL7154374817 ASXL1 
chr20 30956733 30957011 AMPL7154374816 ASXL1 
chr20 30959865 30960075 AMPL7153001877 ASXL1 
chr20 31015831 31016150 AMPL7154374843 ASXL1 
chr20 31016020 31016332 AMPL7154374837 ASXL1 
chr20 31016994 31017322 AMPL7154374819 ASXL1 
chr20 31017636 31017941 AMPL7154374841 ASXL1 
chr20 31018877 31019204 AMPL7154374803 ASXL1 
chr20 31019193 31019476 AMPL7154374805 ASXL1 
chr20 31019280 31019596 AMPL7154374802 ASXL1 
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chr20 31020575 31020895 AMPL7154374830 ASXL1 
chr20 31020889 31021212 AMPL7154374824 ASXL1 
chr20 31021192 31021501 AMPL7154374825 ASXL1 
chr20 31021490 31021725 AMPL7154374826 ASXL1 
chr20 31022037 31022358 AMPL7154374854 ASXL1 
chr20 31022286 31022586 AMPL7154374855 ASXL1 
chr20 31022585 31022850 AMPL7154374856 ASXL1 
chr20 31022839 31023158 AMPL7154374857 ASXL1 
chr20 31023147 31023447 AMPL7154374858 ASXL1 
chr20 31023436 31023763 AMPL7154374859 ASXL1 
chr20 31023751 31024050 AMPL7154374860 ASXL1 
chr20 31024039 31024330 AMPL7154374861 ASXL1 
chr20 31024319 31024648 AMPL7154374862 ASXL1 
chr20 31024638 31024965 AMPL7154374863 ASXL1 
chr20 31024955 31025231 AMPL7156624121 ASXL1 
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Appendix Table 5.5. Ion Variant Caller (IVC) settings for variant calling. 
settings Configuration Somatic_Low Stringency_custom 6 
Parameter SNP INDEL HotSpot 
Minumun Allete Frequency 0.01 0.05 0.01 
Minumun Quality                       (min variant score) 
6 6 6 
Minumun Coverage 100 100 100 
Minumun Coverage on either strand 
0 2 0 
Max strand bias 0.99 0.95 0.99 
min relarive read quality            (data auality stringency) 
6.5 
    
max common signal shift (filter unusal prediction) 
0.3 
    
Maximum reference/variant signal shift (insertions) 
0.2 
    
Maximum reference/variant signal shift (deletions)  
0.2 
    
   
  
Advanced        
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Torrent Variant Caller       
hp_max_length     8 
downsample_to_coverage     10000 
outlier_probability     0.005 
do_snp_realignment     1 
prediction_precision     1 
heavy_tailed     3 
suppress_recalibration     1 
   
  
Long Indel Assembly Settings       
kmer_len     19 
min_var_count     5 
short_suffix_match     5 
min_indel_size     4 
max_hp_length     8 
min_var_freq     0.15 
relative_strand_bias     0.8 
output_mnv     0 
   
  
FreeBayes       
allow_indels     1 
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allow_snps     1 
allow_mnps     1 
allow_complex     0 
min_mapping_qv     4 
read_mismatch_limit     11 
read_max_mismatch_fraction     1 
gen_min_alt_allele_freq     0.03 
gen_min_indel_alt_allele_freq     0.1 
gen_min_coverage     6 
 
 
Appendix Table 5.6. NextGene settings for alignment and variant calling. 
Alignment settings           
Application           
  instrument type           
    Ion Torrent       
  Application Type           
    SNP/indel discovery       
  Steps           
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    Sequence alignment       
  performance settings           
    number of cores to be used=7     
Load data           
  Sample file           
    aligned BAM file downloaded form Ion Torrent server   
  Ref file           
    NextGen preloaded file       
  output           
    browse to where you want the data stored   
  Realignment           
  
tick if you want the data realigned based on 
NestGen alignment settings 
ü 
        
Set2           
Alignment             
  Mapping quality >= 
  
 
  
 
Available when realignment is not ticked 
  Remove ambiguous alignments           
  if mapping quality >=           
  
except for the highest map quality 
alignment 
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Remove paired reads that are not properly 
paired 
  
        
  allowable mismatched bases 
1 
 
(0-2) 
 
      
  allowable ambiguous alignment 500         
  seeds  21 bases Available when realignment is ticked 
  move step 3 bases       
  allowable alignments 1000 (1-1000)       
  overall matching base percentage >= 85 %       
  detect large indels           
sample trim             
  sellect sequence range from   to     
  hide unmached ends ü         
mutation filter             
  use original ü         
  except for homozygous ü         
    SNP indels homopolymer indels   
  mutation percentage <= 1 1 1     
  SNP allele count 5 5 5     
  total coverage count 500 500 500     
  balance ratio & Frequency   0.1 0.1     
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      80 80     
file type             
  load assembled result files           
  load SAGE expression data           
  extract bases  from   to     
  new sequence coverage minimum           
  load paired reads           
  library size range from   to     
  454 sequence           
  save matched reads           
  highlight anchor sequence           
  ambiguous gain/loss           
  delete structural variation mismatch   length and   bases   
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Appendix Table 5.7. NextGene settings for converting FASTQ files into fasta file type. 
from Ion Torrent FASTQ to FASTA               
 Median score threshold 12           
 Max number of uncalled bases <= 3           
 called base number of each read >= 25           
 trim or reject read when >= 3 bases with score <= 10       
 paired read data   save as         
 Remove 5' 0 bases and 3'  0 bases   default settings 
  Keep only bases 0 to 0       
  Trim by Sequences             
 Trim by sequences in file             
  custom linker             
 
Appendix Table 5.8. JSI SeqNext settings for variant calling 
Parameter     
Read     
single/double direction analysis     
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Both directions min absolute coverage off   
Both directions min% coverage off   
analyse/ignore regions     
min abs. coverage 50 per direction 
ration read directions off   
coverage warning     
low absolute coverage warning 100   
reads include PCR primers yes   
Mutations     
min abs. coverage off per direction 
ration read directions off   
min abs. coverage 2% per direction 
Mutations sorting     
Direct other % coverage 5% per direction 
Direct homopolymer % coverage 20%   
Homopolymer     
homopolymer region size 5%   
      
Hide mutation     
all unticked     
      
Quality score     
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quality score threshold off   
ignore reads threshold off%   
low quality score coverage warning off%   
      
Trimming     
5' error rate 5%   
overlap 3 abs   
3' error rate 10%   
overlap 3 abs   
Remove ends     
5' not ticked   
block length 10   
max mismatch 0   
distance 25   
3' not ticked   
block length 10   
max mismatch 0   
distance 25   
Remove bases     
5' 0   
3' 0   
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BAM/SAM     
use BAM/SAM mapping ticked   
use BAM/SAM alignment ticked   
      
Export settings     
base calling     
genome set diploid   
unique reads only not ticked   
read processing     
skip evaluation not ticked   
max mismatches 15%   
min matching bases 50%   
keep strong consensus 50%   
comp. reads only  not ticked   
barcode at 5' and 3' not ticked   
ignore paired end info not ticked   
variation table      
warning 50%   
indel gap SNP to SNP 6   
indel gap SNP to indel 6   
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Appendix Table 5.9. BCR-ABL1 TKD mutation testing results in the sub-category of samples in the prospective group with <5% mutations only.   
ID Low-level 
mutations 
coding nomenclature percenta
ge 
coverage 
2 mrd1
42158 
F317L;M351V;ex8
-9 ins 
c.951C>G;c.1051A>G;c.764A>T;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 1.64;1.92;
10.32 
66863;67151;
65603 
7 mrd1
41743 
F311L c.931T>C 1.39 45734 
9 mrd1
44736 
E459K c.1375G>A   3.2 50692 
1
8 
mrd1
41977 
Y253F;F311L c.758A>T;c.931T>C 2.29;1.04 23989;45206 
1
9 
mrd1
44261 
M351V;ex8-9 ins c.749G>A;c.951C>G;c.749G>A;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 1.09;2 66660;36189 
2
0 
mrd1
41212 
F317L;M351T  c.951C>G;c.1052T>C 1.86;1.37 14101;38532 
  
 
 
352 
 
 
 
2
1 
mrd1
44032 
M351V;ex8-9 ins c.951C>G;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 2.96;1.72 68351;21784 
2
5 
mrd1
41975 
F311L c.931T>C 1.15 54350 
2
6 
mrd1
44723 
F317L;M343T;F35
9V;ex7 del 
c.949T>C;c.1028T>C;c.1075T>G 1.21;2.39;
1.52 
28644;55411;
13936 
2
9 
mrd1
45809 
D276G;ex8-9 ins c.827A>G;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 4.43;1.69 20825;20399 
3
1 
mrd1
40025 
F317L;E450V c.951C>G;c.1349A>T 1.85;2.88 17013;9902 
3
1 
mrd1
42602 
E450G c.1349A>G 1.65 13676 
4
3 
mrd1
43368 
Ex7 del;ex8-9 ins c.1086_1157delAGATCTTGCTGCCCGAAACTGCCTGGTAGGGGAGAACCACTTGGTGAAGGTAGCTGATTTTGGCC
TGAGCAG;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 
2.7;1.19 34642;24694 
4
4 
mrd1
44781 
F317L;F359V;ex8-
9 ins 
c.949T>C;c.1075T>G;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 1.39;4;4.1
5 
68644;75411;
43936 
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4
7 
mrd1
41608 
F311L;M351R c.931T>C;c.1052T>G 1.24;1.6 54350;66832 
5
1 
mrd1
43696 
G250R;ex8-9 ins c.748G>A;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 1.77;11.7
7 
25079;14535 
5
4 
mrd1
45878 
K247R;ex8-9 ins c.740A>G;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 5.2;1.2 17027;19013 
5
7 
mrd1
43471 
Y253H;T315I;F31
7L; 
c.757T>C;c.944C>T;c.951C>G; 1.06;1.16;
1.54 
12874;18644;
33936 
5
8 
mrd1
45319 
D276G c.827A>G 1.69 24773 
6
0 
mrd1
42295 
F311L;Ex7 del c.931T>C 1.09;4.93 33243 
6
1 
mrd1
42359 
F311L c.931T>C 1.01 62526 
6
5 
mrd1
43545 
M343V c.1027A>G 1.21 60543 
6
7 
mrd1
42380 
D276E;F311L; 
F317S 
c.818T>C;c.828C>G;c.931T>C;c.950T>C 1.8;1.16;1
.27;4.82 
66462;67407;
68906 
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7
2 
mrd1
42122 
F311L c.931T>C 1.06 22342 
7
4 
mrd1
43084 
Y253H;F359V;ex8
-9 ins 
c.757T>C;c.1075T>G;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 2.4;1.13;8
.16 
11434;33253;
22044 
7
5 
mrd1
42128 
F311L c.931T>C 1.07 56721 
7
7 
mrd1
43043 
F359V c.1075T>G 2.7 61992 
8
2 
mrd1
43960 
E255K;F317L c.763G>A;c.951C>G 3.07;2.77 30334;30771 
8
5 
mrd1
43334 
K247R;Ex7 
del;ex8-9 ins 
c.[740A>G];c.1086_1157delAGATCTTGCTGCCCGAAACTGCCTGGTAGGGGAGAACCACTTGGTGAAGGTAGCTG
ATTTTGGCCTGAGCAG;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 
2;5;2.5 11487;30898;
22116 
1
1
6 
mrd1
39972 
G250V c.749G>T 2.83 636 
1
2
2 
mrd1
40062 
F317L;E450V c.951C>G;c.1349A>T 1.46;1.07 7609;5805 
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1
2
5 
mrd1
45806 
T315A   c.943A>G 1.14 33666 
1
3
1 
mrd1
46187 
 
F359L;Y353C;M34
3V;E459G;ex8-9 
ins 
 
c.1075T>C;c.758A>G;c.1027A>G;c.1376A>G;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGA
AG 
1.11;1.91;
2.2;2.17 
67241;31648;
29036;29371 
1
3
3 
mrd1
46267 
Ex7 del;ex8-9 ins c.1086_1157delAGATCTTGCTGCCCGAAACTGCCTGGTAGGGGAGAACCACTTGGTGAAGGTAGCTGATTTTGGCC
TGAGCAG;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 
1.3;1.3 66480;52850 
1
4
0 
mrd1
46718 
F311S;ex8-9 ins c.932T>C;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 1.71;3.75 56715;43988 
1
5
2 
mrd1
47255 
F317L;T315A;F35
9L;M244V  
c.951C>G;c.943A>G;c.1075T>C;c.730A>G 2.96;1.22;
1.1;1.28 
68451;66394;
67931;27432 
1
6
2 
mrd1
47930 
E450G;ex8-9 ins c.1349A>G;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 2.44;11.7
9 
13338;14798 
1
6
4 
mrd1
48098 
K247R   c.740A>G 1.17 33869 
  
 
 
356 
 
 
 
1
6
7 
mrd1
48316 
E459G c.1376A>G 3 1379 
1
7
1 
mrd1
48526 
D276G;ex8-9 ins c.827A>G;c.1423_1424insACTTTGATAACCGTGAAGAAAGAACAAGATAGAAG 2.34;3.51 26586;1427 
 
 
Appendix Table 5.10. BCR-ABL1 TKD mutation testing results in the sub-category of samples in the prospective group with ≥ & 
< 5% mutations. 
ID protein 
nomenclature 
coding nomenclature percentage coverage 
13 mrd144266 F317L c.949T>C 72.14 52221 
14 mrd142313 D276G c.827A>G 63.93 5722 
32 mrd144352 T315I c.944C>T 27.7 27448 
32 mrd142937 T315I c.944C>T 55.2 34616 
  
 
 
357 
 
 
 
32 mrd145767 T315I c.944C>T 82.6 47005 
38 mrd144243 G250E c.749G>A 85.78 34194 
39 mrd144244 Q252H c.756G>C 41.98 23999 
40 mrd144464 F359V c.1075T>G 66.73 69697 
41 mrd142840 Y253H c.757T>C 34.1 20212 
41 mrd146971 Y253H c.757T>C 84.79 15461 
45 mrd143526 E255V c.764A>T 31.06 32834 
66 mrd147718 T315I  c.944C>T 87.84 39779 
66 mrd148416 T315I c.944C>T 87.56 947 
70 mrd143309 T315I c.944C>T 32.53 23690 
  
 
 
358 
 
 
 
82 mrd140724 E255K;T315TI c.763G>A;c.944C>T 16.36;55.18   
84 mrd144090 G250E;E462K c.749G>A;c.1384G>A 71.81;8.3 27954;30281 
89 mrd140400 V299L c.895G>T 54.35 23768 
92 mrd140154 M244V c.730A>G 84.41 16691 
95 mrd140325 E255V c.764A>T 87.99 7396 
96 mrd140394 E255K c.763G>A 27.92 8579 
108 mrd140759 T315TI c.944C>T 95.23 68817 
109 mrd140760 E255K;F317L c.763G>A;c.951C>G 31.07;61.68 47540;61302 
128 mrd146207 L387M  c.1159 T>A 94.97 14187 
130 mrd146252 E255K  c.763G>A 79.14 28248 
136 mrd146565 F317L c.951C>G 98.56 36756 
  
 
 
359 
 
 
 
15 mrd142770 V299L c.895G>T 6.1 29479 
22 mrd143609 M351T c.1052T>C 5.66 69592 
66 mrd142565 T315I c.944C>T 80.1 5713 
90 mrd140725 E255K c.763G>A 49.35 53006 
91 mrd139833 E255K c.763G>A 81.47 3821 
98 mrd139877 Y253H c.757T>C 78.01 4616 
121 mrd140723 E255V;T315I c.763G>A;c.944C>T 50.42;20.27 36683;84412 
135 mrd146543 M22V;F317L;F359V c.730A>G;c.949T>C;c.1075T>G 59.43;8.5;8.5 15365;41823;68833 
135 mrd147523 M244V;F317L;F317L   c.730A>G;c.951C>G;c.949T>C 15.83;54.3 30280;82234 
138 mrd146637 F359V c.1075T>G 96.47 67930 
  
 
 
360 
 
 
 
139 mrd146701 E255V [c.764A>T]2 6.59% 35915 
151 mrd147194 E459K  c.1375G>A 85.44 18017 
 
 
 
Appendix Table 5.11. BCR-ABL1 TKD mutation testing results in samples with multiple mutations. 
ID nomenclature perc
enta
ge 
coverag
e 
comments Low-level 
mutations 
nomenclature percentag
e 
coverage 
82 mrd
140
724 
E255K;T
315TI 
c.763G>A;c.
944C>T 
16.3
6;55.
18 
  polyclonal in the 
reads covering 
both 
    
84 mrd
144
090 
G250E;E
462K 
c.749G>A;c.
1384G>A 
71.8
1;8.3 
27954;3
0281 
      
  
 
 
361 
 
 
 
15 mrd
142
770 
V299L c.895G>T 6.1 29479   ex7 del c.1086_1157delAGATCTTGCTGCCCGAAACTGC
CTGGTAGGGGAGAACCACTTGGTGAAGGTAGCT
GATTTTGGCCTGAGCAG 
1.71 40850 
22 mrd
143
609 
M351T c.1052T>C 5.66 69592   E316G c.947A>G 1.17 66438 
13
5 
mrd
146
543 
M22V;F
317L;F3
59V 
c.730A>G;c.
949T>C;c.10
75T>G 
59.4
3;8.5
;8.5 
15365;4
1823;68
833 
both (polyclonal 
and compound in 
the reads 
covering both 
mutations) 
G250E;Y253F
;E255V;M35
1T;ex8-9 ins 
c.747G>A;c.758A>T;c.764A>G;c.1052T>C;c.142
3_1424insACTTTGATAACCGTGAAGAAAGAACA
AGATAGAAG 
1.47;1.65;
1.91;1.04;
8.4 
15818;1592
5;17360;66
290;27738 
13
5 
mrd
147
523 
M244V;
F317L;F
317L   
c.730A>G;c.
951C>G;c.9
49T>C 
15.8
3;54.
3 
30280;8
2234 
both (polyclonal 
and compound in 
the reads 
covering both 
mutations) 
E255V;ex8-9 
ins 
c.763G>A;c.1423_1424insACTTTGATAACCGTG
AAGAAAGAACAAGATAGAAG 
1.85;5.4 32585;4348
8 
  
 
 
362 
 
 
 
13
9 
mrd
146
701 
E255V [c.764A>T]2 6.59
% 
35915   T315A;F317L
;M351T;Ex7 
del 
c.943A>G;c.949T>C;c.1052T>C;c.1086_1157del
AGATCTTGCTGCCCGAAACTGCCTGGTAGGGGA
GAACCACTTGGTGAAGGTAGCTGATTTTGGCCTG
AGCAG 
2.15;3.34;
1.37;21.35 
17618;1762
3;59525;59
899 
 
 
 
Appendix Table 5.12. BCR-ABL1 TKD mutation testing results of samples in the prospective group with mutations between 5-20%.   
ID Protein 
nomencl
ature 
Coding 
nomenclature 
Mutati
on_% 
covera
ge 
com
men
ts 
low level 
mutations 
Coding nomenclature percentag
e 
coverage 
8
2 
mrd1
4072
4 
E255K;T3
15TI 
c.763G>A;c.94
4C>T 
16.36;5
5.18 
       
8
4 
mrd1
4409
0 
G250E;E4
62K 
c.749G>A;c.13
84G>A 
71.81;8.
3 
27954;
30281 
       
1
0
9 
mrd1
4076
0 
E255K;F3
17L 
c.763G>A;c.95
1C>G 
31.07;6
1.68 
47540;
61302 
       
  
 
 
363 
 
 
 
1
2
1 
mrd1
4072
3 
E255V;T3
15I 
c.763G>A;c.94
4C>T 
50.42;2
0.27 
36683;
84412 
  M351T;F359V;
ex8-9 ins 
c.1052T>C;c.1075T>G;c.1423_1424insACTTTGATA
ACCGTGAAGAAAGAACAAGATAGAAG 
2.83;1.2;1.
27 
65125 
1
3
5 
mrd1
4654
3 
M22V;F3
17L;F359
V 
c.730A>G;c.94
9T>C;c.1075T
>G 
59.43;8.
5;8.5 
15365;
41823;
68833 
  G250E;Y253F;E
255V;M351T;e
x8-9 ins 
c.747G>A;c.758A>T;c.764A>G;c.1052T>C;c.1423_
1424insACTTTGATAACCGTGAAGAAAGAACAAGAT
AGAAG 
1.47;1.65;
1.91;1.04;
8.4 
15818;15925;1
7360;66290;27
738 
1
3
5 
mrd1
4752
3 
M244V;F
317L;F31
7L   
c.730A>G;c.95
1C>G;c.949T>
C 
15.83;5
4.3 
30280;
82234 
  E255V;ex8-9 
ins 
c.763G>A;c.1423_1424insACTTTGATAACCGTGAA
GAAAGAACAAGATAGAAG 
1.85;5.4 32585;43488 
 
